Plasticité de la transmission synaptique dans l’hippocampe et excitabilité intrinsèque dans un modèle murin de la maladie d’Alzheimer by Jiang, Nan
HAL Id: tel-02362077
https://tel.archives-ouvertes.fr/tel-02362077
Submitted on 13 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Plasticity of hippocampal synaptic transmission and
intrinsic excitability in a mouse model of Alzheimer’s
disease
Nan Jiang
To cite this version:
Nan Jiang. Plasticity of hippocampal synaptic transmission and intrinsic excitability in a mouse
model of Alzheimer’s disease. Cognitive Sciences. Université de Bordeaux, 2019. English. ￿NNT :
2019BORD0137￿. ￿tel-02362077￿
	    	  
1 	  
 
 
 
THÈSE PRÉSENTÉE 
 
POUR OBTENIR LE GRADE DE 
 
 
DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX 
 
 
Mention : Sciences de la Vie et de la Santé 
 
Option : Neurosciences 
 
Par Nan JIANG 
 
Sous la direction de : Thierry AMEDEE  
 
 
 
Plasticity of hippocampal synaptic transmission and 
intrinsic excitability in a mouse model  
of Alzheimer’s disease 
 
 
 
 
 
Soutenue publiquement le 17 septembre 2019 
Membres du jury : 
 
Mme Valérie Fénelon Université de Bordeaux Présidente 
Mme Claire Rampon Directrice de Recherche CNRS Rapporteure 
   Mme Corinne Beurrier Chargée de Recherche CNRS Rapporteure 
Mr Thierry Amédée Directeur de Recherche CNRS Directeur de thèse 
 
	    	  
2 	  
 
Acknowledgements 
To study at university of Bordeaux for four years with happiness and embarrassment. 
During the past four years, I gain a lot in the lab. I am writing with an appreciative heart and 
would like to show my heartfelt gratefulness to everyone in the lab who gives help to me for 
the project. There are so many people to give thanks. 
First and foremost, I would like to wholeheartedly thank my supervisor, Dr. Thierry 
AMEDEE from IINS - UMR 5297 CNRS. Dr. Thierry AMEDEE solid knowledge, strict 
research attitude and kindly person benefit me for the research career. His encouragements 
and help that has made me independent of learning in research. Carefully discussion with me 
for the topics, hypotheses, and up to the revision of manuscript. Every part has made a great 
deal of efforts. 
In the meantime, I am also very thankful to the team leader Dr. Christophe Mulle, who 
gave me a lot guides during the four years. Discussion with him has extended my research 
views and encouraged me in the field of neuroscience. 
Here, I would like to thank Dr. Gael Barthet from the team for his fruitful discussion 
of electrophysiology study, as well as the data analysis with Dr. Christophe Blanchet. Greatly 
thank to Jeffrey Lopez-Rojas for his invaluable help with electrophysiological recordings, the 
very fruitful discussions and his constant kindness. 
I am also deeply appreciative to all the jury members:  Dr. Valérie Fénelon, Dr. Claire 
Rampon and Dr. Corinne Beurrier. For their participation to my thesis committee. 
In the four years, I had the precious friendship between Dr. Gael Barthet, and my 
colleagues Tomas Jorda, Dario Cupolillo, Ania Gonçalves and Meryl Malezieux, Pei Zhang. 
They shared with me the pleasures in the lab, a precious treasure in my life. I am very grateful 
to Dr. Severine Deforges, Noelle Grosjean, Ruth Betterton, Ashley Kees, Eva Rodrigues and 
Mariela Escande for their help during the experiments.  
A special thank goes to the IINS for providing me the opportunity to perform my 
study in a remarkable and scientific institute.  Particularly, I would like to thank all the 
	    	  
3 	  
members from IINS and all the members from BIC to have the pleasure to work together for 
part of my project. 
I would also like to thank the friends from the other lab. Dr. Lei Fan, Dr. Xiaomin 
Zhang, Yuxin Ma, Shuo Liu, Ye Xiao. They make my life in Bordeaux happier and beautiful. 
Finally, I would also like to thank my family for their support. Thanks to my parents, 
Mr. Jun Jiang and Mrs. Chunling Zhang, for many years, I have provided a warm harbor for 
my PhD. Study. Their love gives me power and warmth, and I continue to overcome 
difficulties and problems and keep going forward. The completion of my doctoral thesis will 
be the another starting point of my career.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	    	  
4 	  
 
Abstract 
Azheimer's disease (AD) is a neurodegenerative disease that is linked in its early 
stage to synaptic dysfunction and loss of synapses. Numerous clinical data obtained from 
patients but also experimental data obtained on mouse models of AD show that there is a 
sexual dimorphism evidenced by a higher amyloid plaque deposition and an early onset of 
memory disorders in female mice compared to male mice.   
In this work, we investigated the molecular and cellular alterations of AD as well as 
the associated cognitive deficits in female APP/PS1 mice, a double transgenic murine model 
of AD. In parallel we studied the alterations of hippocampal synaptic transmission and 
plasticity in the stratum moleculare, a layer in the vicinity of the dentate gyrus (DG) which 
specifically displayed a high density of amyloid plaques. We showed the presence of 
numerous amyloid plaques in the DG in a larger amount in 6 month old females compared to 
age-matched males as well as a strong activation of astrocyte and microglia glial cells. These 
molecular and cellular alterations are accompanied by hippocampo-dependent memory 
deficits (contextual fear conditioning and novel object place recognition task) from the age of 
4 months in females whereas males have no deficit until the age of 12 months.  We then 
studied the electrical properties of DG neurons, the transmission and the plasticity of the 
perforant pathway - DG neurons (PP-DG synapse) in 6 month old females mouse by 
comparing the two genotypes APP/PS1 vs wild type (WT). 
In both genotypes, DG neurons displayed two distinct populations in terms of input 
resistance and action potentials (APs) discharge pattern. In contrast, the resting membrane 
potential, the input resistance, the activation threshold and the amplitude of APs were not 
modified in APP/PS1 vs WT. The frequency of discharge of APs was increased in APP/PS1 
without shift of E-S curve which relates EPSP-slopes to the associated AP firing probability.  
Basal transmission at the PP-DG synapse was altered in the APP/PS1 mouse vs WT 
without alterations in the AMPA/NMDA ratio or the AMPA rectification index. The 
frequency of the NMDA miniature currents was increased in APP/PS1 DG neurons vs WT 
which suggests an increased number of silent synapses expressing NMDA receptors but 
devoid of AMPA receptors. The long term potentiation (LTP) of population spike amplitude 
was decreased by approximately 50% in APP/PS1 mice. The decrease in LTP observed in 
APP/PS1 was partly related to alterations in the intrinsic properties of DG neurons as 
	    	  
5 	  
evidenced by LTP-induced shifts of E-S curves, which reflects an increased excitability for 
APP/PS1 mice. 
In conclusion our results show a prominent sexual dimorphism with much earlier 
amyloid plaque deposition, neuroinflammatory glial activation in female vs male APP/PS1. In 
parallel, significant deficits in hippocampal-dependent memory are observed as well as 
alterations of synaptic transmission and plasticity at the PP-DG synapse, a key synapse of the 
integration of mnesic informations originated from the entorhinal cortex 
 
Key words: Alzheimer’s disease, Aß plaques, Lateral perforant path, PGE2, Population spikes, 
Action potential, mEPSCs 
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mPGES : Microsomal prostaglandin-E2 synthase 
PGG2: Prostaglandin G2  
PGH2: Prostaglandin H2  
PGE2: Prostaglandin E2  
PGF2a: Prostaglandin F2a 
AC: Adenylyl cyclase  
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I. Introduction 
A. Alzheimer’s disease  
Alzheimer’s disease (AD), which was first reported and described in 1906 by a clinical 
psychiatrist and neuroanatomist, Alois Alzheimer, is a progressive neurodegenerative disease 
that first display light cognitive problems such as forgetfulness. The age dependent prevalence 
of AD doubles every 5 years after aged 60 and increasing from a prevalence up to 40% of 
those aged 85 years and older (Strauss et al., 1999). The disease is more frequent among 
women than men with a ratio of 1.2 to 1.5 (Gao et al., 1998). In 2018, about 50 million people 
worldwide are suffering of dementia and 60 to 70% are due to AD (World Alzheimer Report 
2018). Each year there are roughly 7.7 million new reported dementia cases (WHO, 2016). 
The number of worldwide cases of dementia will likely rise up to 82 million by 2030 and 
could possibly reach 152 million by 2050 (World Alzheimer Report 2018). The total 
estimated worldwide cost of dementia in 2018 is US $ 1 trillion and could rise up to US $ 2 
trillion by 2030 (World Alzheimer Report 2018). Of paramount importance is the 
understanding of the pathogenesis and the developing of early diagnosis and effective therapy. 
At present, there are no possible therapeutics available for the prevention or alleviation of the 
disease progression. There are continuous efforts set up by researchers worldwide to discover 
new therapies for AD. 
a. Progression of AD 
The progression rate of AD varies considerably. Usually, patients with Alzheimer's could 
live up to 4-8 years after diagnosis, but some of them can live as long as 20 years, depending 
on multiple factors. The progression of the disease depends in part on age at diagnosis but 
also on the general health status of the person. The early stage of AD generally lasts from 2-8 
years and goes through mild cognitive impairment stage (MCI) (Petersen et al., 2009) before 
evolving to dementia (Figure 1).  
A large percentage of people diagnosed with MCI have AD as an underlying cause for 
their cognitive impairment, although other disorders also can cause MCI. The moderate stage 
lasts 2-4 years and is characterized by a more serious memory deficit including long term 
memory and the loss of the ability to operate typical activities of daily life (for example 
bathing, dressing and grooming). In the late stage of AD, individuals lose the ability to 
respond advisably and are unable to talk with others. They will also be unable to control 
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actions like sitting, standing and walking. In advanced disease, patients often become mute, 
aggressive, anxious (David et al., 2012). To study the disease, we dissertate here intricate 
cellular alterations during the disease developing, and how initial responses finally turn into 
detrimental, leading to an irreversible dysfunction of the brain.  
 
          
 
 Figure 1. The progression of AD 
The figure represents a sum of the progression of AD signs from normal cognitive to MCI and 
dementia.  
 
b. Pathologic features of AD 
The crucial neuropathological features of AD were described by Alois Alzheimer in 
1906 (Alzheimer et al., 1906). Memory deficits are the first clinical symptoms of AD (Jacobs 
et al., 1995) and have been studied using different techniques of neuroscience: at the macro 
level, there is a considerable loss of brain tissue. At the micro level, pathological hallmarks of 
AD include amyloid ß accumulation, tau phosphorylation, and synaptic neuronal loss.  
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1. Amyloid Hypothesis: APP Proteolytic Process 
The finding of aggregates of β-amyloid (Aβ) in the extracellular space of the brain in 
post-mortem pieces led to the formulation of the ‘Amyloid Hypothesis’ (Hardy et al., 1992). 
The hypothesis put forward was that the formation of Aβ plaques is the preliminary event in 
AD, eventually leading to cell death and dementia.  
However, there are evidences that are difficult to reconcile with this hypothesis. The 
primary component of plaques is the Aβ peptide, a 36– to 43–amino acid peptide derived 
from amyloid precursor protein (APP), which is cleaved by β secretase and γ 
secretase  (Hamley et al., 2012) (Figure 2). Aβ peptides can be present in aggregated 
insoluble forms including fibrils as well as soluble oligomers (Kayed et al., 2003; Koffie et al., 
2009). When Aβ is in soluble oligomer, it is generally considered as the most toxic form.  
         
 
  
Figure 2. Aβ fragments derived from APP processing 
APP processes two distinct pathways: amyloidogenic and non-amyloidogenic pathway. Serial 
actions of APP by α-secretase and γ-secretase produces sAPPα, C83, APP intracellular 
domain (AICD) and P3. There is no Aβ formed through this pathway. Serial actions of APP 
by β-secretase (BACE1) and γ-secretase produces sAPPβ, C99, AICD and Aβ40-42 (Thathiah 
and De Strooper, 2011). 
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When Aβ is aggregated in the extracellular space to form Aβ plaques, these plaques are 
surrounded by abnormal neuronal processes known as degenerating fibers or (Masliah et al., 
1993) but also by activated glial cells driving an inflammatory response (Meda et al., 1995; 
Giulian et al., 1998). It is highly likely that this inflammatory response contributes to neuronal 
damage, although there are numerous evidences that glial cells are playing a protective role 
(McGeer et al., 1995; Lucin et al., 2009). 
 
2. Hyperphosphorylation of intracellular Tau protein 
Tau is a 50- to 75-kDa protein displaying six different splice forms (Lace et al., 2007). It 
was first characterized as a microtubule-associated protein in the brain, not only synthesized 
and produced in neuron cell bodies but also expressed by glial cells.  
Under physiological conditions the function of tau is to bind to tubulin to stabilize 
microtubules (Figure 3). It is proposed that neurofibrillary pathology could contribute to 
neuronal dysfunction and strongly correlates with the clinical progression of AD (Ballatore et 
al., 2007; Noble et al., 2013). In AD, tau protein is hyperphosphorylated, leading to its 
dissociation from microtubules and has a trend to self-aggregate, forming neurofibrillary 
tangles (NFTs) in cell bodies (Grundke et al., 1986; Goedert et al., 1988; Wischik et al., 
1988; Wischik et al., 1988) which finally lead to neurodegeneration (Avila et al., 2004) 
(Figure 3). The abnormal phosphorylation also leads to the formation of both soluble and 
insoluble tau filaments (Braak et al., 1994).  
It is widely acknowledged that neuroinflammation plays a pivotal role in AD pathology 
where both Aβ plaques and NFTs co-exist with microglia and astrocytes (Heneka et al., 2010; 
Serrano et al., 2011). Finally a more general picture has emerged proposing that AD is the 
combination of Aβ and hyperphosphorylation of tau (Coello et al., 2013; Schnabel et al., 
2013).  
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Figure 3. NFTs accumulation in AD 
Mechanism of NFTs formation resulting in cognitive dysfunction by hyperphosphorylated 
Tau. 
 
3. Loss of synapses and selective neuronal cell death 
It is widely known that the neurons density is reduced in AD. The loss of neurons is 
detected by common microscopic study (Terry et al., 1981). As AD is developing, cognitive 
dysfunction becomes worse together with synapse loss and neuronal cell death. Although it is 
generally acknowledged that neuronal death happens during neurodegenerative diseases, the 
mechanism of neuronal death is often unclear. There are different mechanisms which 
contribute to neuronal death, such as necrosis, apoptosis, autophagic cell death and 
excitotoxicity (Gorman et al., 2008).  
Within the neuritic plaques, synapse loss observed in AD may occurs in still living 
neurons and leads to the neuronal death (Terry et al., 1991), which might be due to toxic roles 
of the aggregated amyloid or the soluble Aβ peptide (Podlisny et al., 1995; Selkoe et al., 
2000) (Figure 4). Moreover, there is a regionally specific loss of neurons in AD and this 
specific neuronal loss in AD differs from what is found in normal aging (West et al., 1994). 
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These results suggest that AD cannot be considered as a further step in the continuum of 
normal aging though age is certainly one of risk factors for AD.  
                                
 
 
Figure 4. Aβ and NFTs in synapses loss and neuronal death 
The appearance of AD is highlighted by the Aβ formation in the brain. Along the progression 
of the disease, tau becomes hyperphosphorylated, a procedure thought to be determined by 
Aβ and increasing dendritic tau concentrations. In AD, high concentrations of tau in the 
dendritic compartment are involved in enhanced toxic actions of Aβ at postsynaptic terminals 
and therefore could be part of a toxic pathway for synapses loss and neuronal death. 
 
4. Activated glial cells 
Activated glial cell is a prominent feature of AD neuropathological features, both with 
extracellular fibrillar Aβ and intracellular neurofibrillary tangles (Selkoe et al., 1996), which 
are closely associated with reactive microglia and astrocytes (Figure 5) (Sheng et al., 1995; 
Pozo et al., 2011). The microglia are usually inside and close to the central core of Aβ plaques, 
while the astrocytes generally wall-off the plaques with some of their processes in the vicinity 
of the amyloid central core (Bamberger et al., 2001). The kinetics to develop Aβ plaques are 
not known for sure, but it is plausible that such alterations develop over several years. The 
dialogue between microglia and astrocytes play a key role in the immune response 
surrounding the Aβ plaques. As a consequence, Aβ and activated glial cells could set up a 
harmful circle, fostering neuroinflammation and the pathology.  
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Hence, chronically activated microglia and astrocytes would become neurotoxic by 
releasing inflammatory cytokines, proteolytic enzymes, complement factors and reactive 
intermediaries. Regulation of glial activation can be impaired under sustained pro-
inflammatory conditions as found in the aged brain (Bernhardi et al., 2007). 
 
 
 
Figure 5. Activated glia cells with Aβ and NFTs  
AD are characterized by the accumulation of Aβ and tau proteins which are closely associated 
with microglial and astrocytic activation. The activation of microglia and astrocytes promotes 
a neuroinflammatory environment which likely fosters the development of AD.  
 
c. Clinical Strategies 
Clinical strategies have been focussed on four aspects of the pathology: Aβ plaques, tau 
tangles, neurodegeneration, and dementia. In spite of a considerable knowledge of genetics, 
epidemiology, neuropathological and molecular mechanisms involved in the pathology, there 
is still no effective cure for AD (Table 1).  
1. β-Amyloid-Based Therapeutics 
The existing drug development treatments specifically designed multiple Aβ based 
therapeutics. With a strong evidence supporting the amyloid hypothesis, the most likely 
targets would be the successful alteration of Aβ processing through β and γ-secretase. BACE1 
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has appeared as a likely target for the treatment of AD since it is required for the formation of 
Aβ. Few BACE1 inhibitors (Lanabecestat, LY-2811376 and Verubecestat) (Stamford et al., 
2013; Oehlrich et al., 2014; Yan et al., 2016) were tested in clinical trials, but failed to 
demonstrate positive effects.  
Other studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs) lowering 
Aβ42 without obvious totally inhibition of γ-secretase activity, and it will be important to 
explain the potential molecular mechanism of this action to increase the relative proportion of 
shorter Aβ species in vitro, such as Aβ37 and Aβ38, reduced prevalence of AD (Weggen et al., 
2001).  
Removal of Aβ have been proposed and may provide an alternative method to decrease 
Aβ oligomers for the treatment of AD (Tanzi et al., 2004; Pangalos et al., 2005). Aβ 
aggregation inhibitors also have been tested with the aim to reduce Aβ load. For example, 3-
Amino-1-propanesulfonic acid (3APS) which interacts with Aβ monomers reduces Aβ 
deposition both in transgenic mice and in humans (Aisen et al., 2006; Gervais et al., 2007).  
Antibodies raised against Aβ (Aβ -antibodies) have also been tested and some studies 
have shown that they were alleviating plaque burden and cognitive deficits (Bard et al., 2000; 
Dodart et al., 2002; Lannfelt et al., 2014). Different mechanisms could contribute to these 
results, such as the binding of Aβ -antibodies to Aβ forms (monomeric, oligomeric, and 
fibrillar) which prevent oligomerization, and increased clearance of fibrillar Aβ (Pangalos et 
al., 2005). However, clinical trials using different anti-Aβ strategies that affect the formation, 
aggregation and clearance of Aβ have all failed and be stopped in phase II of phase III. 
Therefore, substitute hypotheses are urgently needed. 
2. Tau-Based Therapeutics 
On the contrary to strategies focused on β-amyloid, tau-related strategies have received 
few attentions until recently, despite the fact that a widespread tau pathology is crucial to the 
disease. Hence different strategies targeting the tau-dependent pathogenesis are actively 
studied carried, some of them being under clinical trials (Medina et al., 2011, 2014; Li et al., 
2017).  
Attenuating hyperphosphorylation of tau through the inhibition of kinases may seem a 
tempting strategy (Churcher et al., 2006; Mazanetz et al., 2007) but the task is complicated by 
the existence of numerous tau phosphorylation sites, and the ability of multiple kinases to 
phosphorylate individual sites (Mi et al., 2006). Taking into consideration that 
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hyperphosphorylation of tau may be achieved in vivo by multiple protein kinase activities 
(Wang et al., 2007; Hanger et al., 2009; Medina et al., 2015) few protein kinases, including 
GSK-3β, MARK and CDK5, have been proposed as potential therapeutic targets (Schneider 
et al., 2008). However, the development of protein kinase inhibitors faced toxicity and 
specificity, which resulted in a "dead end" during preclinical studies. 
The idea that tau dispersed from microtubules result in abnormal microtubule (MT)-
stabilizing function has led to MT-stabilizing molecules as therapeutic target. In those MT-
stabilizing molecules, some anti-mitotic drugs such as paclitaxel or epothilone D have been 
tested in tau-overexpressing mouse models (Brunden et al., 2010).  
Tau aggregation and the various tau species formed (monomers, oligomers, fibrils) along 
the aggregation process have also been a great of interest for potential treatment. As such, 
various anti-tau immunotherapy strategies to clean pathological proteins have also been tested 
in animal models suggesting that cleaning toxic protein species could be useful to treat 
tauopathies in AD (Pedersen et al., 2015).  
3. Approaches to Inhibit Neurodegeneration 
N-Methyl-D-Aspartate receptors (NMDARs) have always get the interest of researchers 
as potential drug targets (Kemp et al., 2002; Olivares et al., 2012; Zhang et al., 2016). 
Accordingly, developed NMDA receptor antagonists must partially block the receptor and 
complete the normal functions to minimize the side effects.  
The current therapy of AD includes two types: 1. the cholinesterase inhibitors (ChEIs), 
galantamine and rivastigmine (mild to moderate AD), donepezil (mild to severe AD); 2. non-
competitive NMDA receptor antagonist memantine (moderate to severe AD). Both ChEIs and 
memantine could present beneficial effects on behavior and cognition (Patel et al., 2011; 
Deardorff et al., 2016). In the central nervous system (CNS) disease, although glutamate 
induced excitotoxicity has been thought to be affected by the NMDARs antagonist 
(Phencyclidine, ketamine, MK801 dizocilpine and memantine), due to the high affinity and 
long reside time of phencyclidine, ketamine, and MK801 on the receptor, their clinical trial 
have been stopped (Ellison, 1995). Besides, memantine shows a low affinity and is well 
accepted. Therefore, it is applied to the moderate to severe AD (Reisberg et al., 2003; Pierson 
et al., 2014; Song et al., 2018). Furthermore, another glutamate release inhibitor (riluzole), is 
in phase II clinical trial for mild AD patients (Graham et al., 2017). 
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Increasing evidences propose that neurotoxicity could be involved in the pathogenicity of 
AD (Parihar et al., 2004). Neurotoxicity may be due to the chronic inflammatory response 
through the production of cytokines, reactive oxygen species (ROS), excitatory amino acids, 
proteases and nitric oxide. The inflammatory hypothesis has been highly reported as a key 
component of the pathogenesis of AD. Hence, NSAIDs has been tested in numerous clinical 
trials (Vlad et al., 2008; Laino et al., 2009). 
The use of anti-oxidants for therapeutic as well as preventive treatments in AD has been 
questioned (Perkins et al., 1999; Masaki et al., 2000; Kim et al., 2015). A study has proposed 
that anti-oxidant by scavenging free radicals lead to the suppression of hydrogen superoxide 
and thus suppressed the Aβ burden in AD (Lim et al., 2001; Matsubara et al., 2003). 
Recently, experiments also verified the supposed role of peroxisome proliferator-
activated receptor γ (PPARγ) agonists to decrease the expression of Apolipoprotein ε4 
(APOε4) gene and showed neuroprotective effect during AD development in several mouse 
models (Bonet et al., 2016; Moutinho al., 2017; Koster et al., 2017). Several PPARγ agonists 
were tested for their role in AD, but owing to the large quantity health risks, including 
cardiovascular problems, weight gain, and fluid retention, the concept of neurodegeneration in 
AD attracts certain new therapeutic treatment for AD (Palop et al., 2006). 
4. Cognitive Enhancers 
Since 1970s-1980s, it was found that acetylcholine (ACh) production, ACh levels, and 
its receptors were extremely decreased in AD brain (Kasa et al., 1997). For many years and 
still today, there are no other clinical treaments available than acetylcholinesterase inhibitors 
(AChEIs) and memantine (non-competitive NMDA receptor antagonist). This drive other 
therapeutic strategies to be investigated such as the use of baicalein, a positive allosteric 
modulator of the GABA-A receptor, to improve cognitive dysfunctions (Zhang et al., 2013).  
In addition to AChEIs, several agonists and antagonists of the serotoninergic, indirectly 
increase cholinergic neurotransmission are also being tested for AD. 5-hydroxytryptamine  (5-
HT) receptors (5-HT1A, 5-HT2A, 5-HT2C, 5-HT4, and 5HT-6) (Pauwels et al., 2000) were 
found to be effective in animal models of AD (Butzlaff et al., 2016). 5- HT1A partial agonist 
S15535 enhanced learning and memory in mouse models of AD (Millan et al., 2004) and 5-
HT2A receptor agonists improved cognitive dysfunctions (Zhang et al., 2015). Last, a 5-HT6 
receptor antagonist, SB271036, rescued memory impairment in a mouse model of AD by 
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inhibiting γ-secretase activity and reducing astrocyte and microglia activation (Yun et al., 
2015). 
The application of pharmacological treatment discussed above have been demonstrated 
to present a direct effect on the progressive alteration of cognition (Neumann et al., 1999; 
Birks et al., 2006; Tampi et al., 2007). Although these treatments display some beneficial 
aspects, numerous patients do not respond, and these compounds do not attenuate disease 
development (Giacobini et al., 2000; Hansen et al., 2007). In this case, establishment of other 
therapeutics for this complex disease will be a main aim.  
 
Table 1 Different mechanism of therapeutic strategies in the 
treatment of Alzheimer’s disease 
Hypothesis Mechnism Strategies 
Aβ hypothesis 
Inhibition of β-
secretase 
Acylguanides (Cole et al., 2006)  
Aminobenzthiazines (May et al., 2011)  
Aminoquinazolines (Madden et al., 2010)  
OM99-2 (Ghosh et al., 2000)  
Inhibition of γ-
secretase 
LY450139 (Henley et al., 2009) 
DAPT (Morohashi et al., 2006) 
Prevention of Aβ 
aggregation 
Tramiprosate (Aisen et al., 2007) 
Clioquinol (Crouch et al., 2012) 
Colostrinin (Szaniszlo et al., 2009) 
Increase Aβ 
clearance 
Neprilysin (Shirotani et al., 2001) 
IDE (Farris et al., 2003) 
ACE (Hu et al., 2001) 
Plasmin (Melchor et al., 2003) 
Anti-Aβ 
immunotherapy 
Gantenerumab (Roche) 
Solanezumab (Eli Lilly) 
Bapineuzumab (Pfizer) 
BAN2401(Logovinsky et al., 2016; Piton et 
al., 2018) 
Tau hypothesis Inhibition of tau phosphorylation 
GSK-3β (Gao et al., 2012)   
Roscovitine (Zhang et al., 2004) 
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Anti-Tau 
immunotherapy 
ACI-35 vaccine (Janssen Pharmaceuticals) 
AADvac1 vaccine, DC8E8 antibody (Axon 
Neurosciences) 
PHF1, MC1 antibodies (Eli Lilly) 
MAb86 (Roche) 
IPN001 and IPN002 antibodies (Bristol 
Meyers Squibb) 
Neuroinflammation 
hypothesis NSAIDs 
CHF-5074 (Porrini et al., 2015) 
Azeliragon (Burstein et al., 2016) 
Oridonin (Wang et al., 2014) 
Protocatechuic (Song et al., 2014) 
Acetylpuerarin (Meng et al., 2013) 
Indomethacin (Sung et al., 2004) 
Mefenamic acid (Joo et al., 2006) 
Ibuprofen (Dam et al., 2010) 
Oxidant hypothesis Anti- Oxidant 
Piracetam (Stockburger et al., 2016) 
Gingko Biloba (Liu et al., 2015) 
Blueberries (Tan et al., 2017) 
Flavonoids (Ruan et al., 2018) 
Polyphenols (Thenmozhi et al., 2016) 
AChE/BChE 
antagonism 
Inhibition of  
AChE/BChE 
Metrifonate (Mehta et al., 2012).   
γ-carboline-phenothiazine (Makhaeva et al., 
2015) 
Phenylbenzofuran analogues (Kumar et al., 
2018) 
NMDA Rs 
antagonism 
Inhibition of 
NMDARs 
Memantine (Atri et al., 2008) 
Neramexane (Rammes, 2009) 
Ifenprodil (Costa et al.,2012) 
GABA-A Rs 
antagonism 
Modulation of  
GABAARs 
SGS742 (Bollock et al., 2005) 
Baicalein  (Zhang et al., 2013) 
PPAR-γ agonism activation of   PPAR-γ 
Pioglitazone (Sato et al., 2011) 
Peroxisome (Combs et al., 2000) 
Serotoninergic  
hypothesis 
Modulation of 
Serotoninergic 
SC-53116, ML-10302, Donecopride, RS-
67333, Prucalopride (Geldenhuys et al., 2011; 
Rochais et al., 2015) 
MS-245, SB-271046  (Geldenhuys et al., 
2011) 
PDE inhibition Inhibition of  Phosphodiesterase 
BAY60-7550(Zhu et al., 2013) 
Rolipram, ibudilast (Mizuno et al., 2004; 
Blokland et al., 2006) 
BAY 73-6691,  PF-04447943  (Prickaerts et 
al., 2017). 
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B. Neuroinflammation 
Over the last two decades, an increasing range of evidence has demonstrated that 
neuroinflammation involving the activation of glial cells played a pivotal role in the disease 
progression and pathology (Akiyama et al., 2000; Heneka and O'Banion, 2007; Heneka et al., 
2015, 2018). There are considerable evidence that cytokines generated by activated glial cells 
during neuroinflammation, i.e., tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), 
and interleukin 6 (IL-6)  (Quan et al., 1998; D’Mello et al., 2013; Thomson et al., 2014) have 
profound effects on synaptic transmission and plasticity (Pickering et al., 2007; Nistico et al., 
2013) and may underlie cognitive and behavioral alterations (Raison et al., 2006; Galic et al., 
2012; Santello and Volterra, 2012; Camara et al., 2015). 
a. Neuroinflammation in AD  
Despite the considerable corpus of data pointing out the crucial role of 
neuroinflammation in AD, it is still unclear if neuroinflammation is causative or correlative of 
the pathology (Heneka et al., 2015; Kinney et al., 2018; Chaney et al., 2018; Lin, 2018; Cao 
et al., 2018; Kumar et al., 2018). It has been suggested that Aβ deposition and NFTs activate 
microglia and increases level of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α…) (Figure 
6). These cytokines enhance APP processing via β-secretase and therefore promote Aβ 
production (Blasko et al., 2000; Tuppo et al., 2005). Rodent models overexpressing mutated 
hAPP protein have highlighted a direct connection between the level of Aβ and increased 
levels of TNF-α, IL-6, IL-12, IL-1β, and IL-1α (Patel et al., 2005).  
The inflammatory procedure in AD is promoted by the activation of microglia and 
astrocytes via pro-inflammatory molecules and associated signaling pathways, therefore 
resulting in synaptic impairment, neuronal loss, as well as the other inflammatory molecules 
produced (Perlmutter et al., 1990; McGeer et al., 1993; Aisen et al., 1997). In spite of the fact 
that, the role of Aβ as a potential molecule to induce the inflammation is not clear, the 
aggregation applies an effect through activation of caspases and transcription factors 
including NF-κB and AP-1, which prone to produce many inflammation mediators (IL-1β, 
TNF-α, and IL-6) and further β amyloid (Ho et al., 2005). Pro-inflammatory cytokines (TNF-
α and IL-1β and IL-6) act directly on the neurons and cause apoptosis.  
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Pro-inflammatory cytokines might be injurious to synapses by themselves and thus 
impair neuronal function such as long term potentiation (LTP) of synaptic transmission 
(Curran et al., 2001; Griffin et al., 2006; Hickman et al., 2008; Tachida et al., 2008; Ojala et 
al., 2008; Dugan et al., 2009; Park et al., 2010; Chakrabarty et al., 2010; Zhao et al., 2011; 
Kitazawa et al., 2011; Spooren et al., 2011; Sutinen et al., 2012;). In animals, in vivo 
(Murray et al., 1998; Vereker et al., 2000) and in vitro (Bellinger et al., 1993; Tong et al., 
2012) electrophysiological studies have demonstrated that IL-1β decreases LTP in the 
hippocampus. While IL-18 also suppresses LTP in the hippocampus, the IL-1 receptor 
antagonist (IL1RA) reverse the impairment of LTP by IL-18 (Curran et al., 2001), thus 
illustrating that IL-18 affects LTP through an IL-1 dependent pathway. Cytokines can locally 
affect synaptic transmission between glia and neuron signaling. For example, a recent study 
has shown that TNFα enhances presynaptic activity via glutamate/NMDAR by measuring the 
frequency of miniature excitatory postsynaptic currents (mEPSCs) in mouse hippocampal 
slices (Habbas et al., 2015). 
Neurons also seem to lead to the accumulation of neuroinflammatory products in AD, 
although neurons were normally thought to be passive onlookers during neuroinflammation. 
Neurons generate several molecules such as IL-1, IL-6 and TNF-α (Tchelingerian et al., 1996; 
Friedman et al., 2001). It has been demonstrated that neurons are available to work as the 
origin of complement proteins (Shen et al., 1997; Strohmeyer et al., 2000), (pentraxins, C-
reactive protein, amyloid P, prostanoids, NOS) (Yasojima et al., 2000; Heneka et al., 2001; 
Pavlov et al., 2005; Simard et al., 2006). Proinflammatory molecules produced by neurons 
may actually promote further neuroinflammatory actions and result in even more serious 
neuronal impairment as well as the pathological development of AD. 
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Figure 6. Neuroinflammation in AD  
Representation of changes induced by abnormal accumulation of Aβ in the brain. Aβ 
oligomers and plaques set up from increased amyloidogenic processing of the APP and/or 
disrupted Aβ clearance circuits. Importantly, aggregation of intracellular Aβ leads to 
hyperphosphorylation of tau at postsynaptic sites, which disturbs tau function and changes 
recruitment of crucial proteins essential for synaptic potentiation. Furthermore, the increased 
Aβ load leads to abnormal activation and dysfunction of astrocytes and microglia, resulting in 
excessive generation of different inflammatory cytokines and chemokines, and eventually 
impairment in functions. 
 
1. Microglia 
Microglia are the resident brain macrophages and are usually considered as "chef 
d'orchestre" of the brain inflammatory response during infections and disease. Microglia 
accounts for 5%–12% of all glial cells in the rodent brain and for 0.5%–16% in human brain 
(Lawson et al., 1990; Mittelbronn et al., 2001; Nicola et al., 2015).  
In the course of neurodegenerative diseases, microglia become activated and 
phagocytic, proliferates and undergoes profound morphological modifications (Ransohoff et 
al., 2009; Glass et al., 2010). However, it is still debated if these modifications are beneficial 
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or detrimental to the organism, especially in the light of the time course of the disease (Sierra 
et al., 2013). 
Microglia take also part in forming appropriate neuronal connectivity during CNS 
development by pruning supernumerary and improper synapses to reinforce the appropriate 
ones based on neuronal activity and experience (Pierre et al., 2017). Additionally, microglia 
modulate in the adult brain complicated cognitive process such as learning and memory 
(Parkhurst et al., 2013; Udeochu et al., 2016). Microglia are quiescent in resting status with 
small cell body and branching processes. Under the condition of disease, microglia turn into 
actived microglia (Stence et al., 2001). Differing to the resting status, activated microglia are 
recognized by their amoeboid procedures, release of both pro-inflammatory and anti-
inflammatory molecules, as well as phagocytic removal of apoptotic cells (Gehrmann et al., 
1995; Neumann et al., 2008). Microglia continuously scan the brain parenchyma by sending 
and retracting its processes (Nimmerjahn et al., 2005; Davalos et al., 2005; Haynes et al., 
2006; Tremblay et al., 2011) and play an important role in the plasticity of neuronal circuits.  
During the course of AD, Aβ plaques are considered by microglial cells as a danger 
signal inducing a series of morphological and functional changes. These cells are termed 
"reactive" (Bornemann et al., 2001). This innate immune reaction is considered to be 
beneficial to the organism if it settles down the danger signal. If not, microglia might topple in 
a chronically activated status leading to detrimental functions. Hence, reactive microglia 
become tightly involved in Aβ deposition via cell membrane receptors (SCARA1, CD36, 
CD14, α6β1 integrin, CD47, and Toll-like receptors) in brains from AD patients and AD 
mouse models (McGeer et al., 1987; Griffin et al., 1989; Tooyama et al., 1990; Geaghan et al., 
2009; Frenkel et al., 2013; Gold et al., 2015; Heela et al., 2017). Furthermore, the expression 
of some proliferation and inflammation markers by reactive microglia (CSF1, IL34, TGFß) 
correlate with disease severity (Alonso et al., 2016), also suggesting a pathological role of 
microglia proliferation and activation in disease progression. 
2. Astroglia 
Astrocytes are also CNS-resident glial cells and respond to pathological stimuli 
through reactive gliosis aimed at neuroprotection (Sofroniew et al., 2010; Burda et al., 2014). 
However, morphological remodeling of astrocytes may lead to cognitive deficits via reducing 
the number of synapses (Zorec et al., 2015) and might contribute to synaptic weakness and 
death. Like microglia in AD, astrocytes are surrounding Aβ plaques (Medeiros et al., 2013) 
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but interestingly, their activation precede Aβ plaque deposition in APP transgenic mice, that 
is at an early stage of the pathology (Heneka et al., 2005). 
In AD, reactive astrocytes go through several complex alterations that vary between 
brain regions and happen at early stage of the disease, even before Aβ deposition (Kummer et 
al., 2014). Reactive astrocytes are characterized by enhanced expression of glial fibrillary 
acidic protein (GFAP) and also marks of functional abnormality (Olabarria et al., 2011). In 
mice models of AD, the early response is marked by astrocytes function decline, which might 
have profound and lasting effects on synaptic function, because astrocytes are key players of 
synaptic transmission (Kang et al., 1998; Olabarria et al., 2010, 2011). Similar to microglia, 
in response to Aβ, astrocytes release pro-inflammatory cytokines, nitric oxide, and other 
cytotoxic molecules fueling therefore the neuroinflammatory process.  
3. Cytokines 
Microglia and astrocytes are the main source of pro-inflammatory cytokines in AD. 
Cytokines take part to almost every step of the neuroinflammatory process but also Aβ 
deposition. Activation of microglia is designed by cytokines. Hence, in old APP/PS1 mice (15 
months of age) the pathological accumulation of Aβ seems directly related to increased levels 
of pro-inflammatory cytokines, including TNFα, IL-6, IL-1α and IL-1ß (Patel et al., 2005). 
Interestingly, in vitro incubation of microglia with soluble Aβ1–42 increase proinflammatory 
cytokines production (Lue et al., 2001) such as IL-1β (Akama et al., 2000). High levels of the 
proinflammatory cytokine IL-1β are also found in microglial cells nearby Aβ plaques in AD 
patients.  
Intracellular caspases proteases family are central of apoptosis and inflammation. In 
the caspase's family, caspase 1 activation is required to subsequent cleavage of interleukin 1β 
and interleukin 18 into their active forms (Schroder et al., 2010; Veerdonk et al., 2011). Aβ 
can initiate NRLP3 through lysosomal impairment in microglia (Halle et al., 2008). Increased 
active caspase 1 levels are found in AD brains and APP/PS1 mice. In addition, APP/PS1 mice 
lacking of NLRP3 or caspase 1 are mainly prevented from spatial memory impairment, 
hippocampal synaptic plasticity loss and related behavioural dysfunction associated with AD 
(Heneka et al., 2013). Lacking of NLRP3 or caspase 1 in APP/PS1 mice appeared to change 
microglial from a proinflammatory type to an anti-inflammatory type (Heneka et al., 2013). 
Even more, activation of microglia with different proinflammatory factors resulted activation 
of apoptotic caspase 8 and caspase 3 as well as caspase 7. Caspase 3 activation regulates NF-
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κB activity through PKCδ and increases the levels of neurotoxic proinflammatory factors, 
such as IL-1β, TNFα. Inhibition of these caspases prevented microglia activation and 
neurotoxicity (Fricker et al., 2013). Pharmacological investigations to inhibit activated 
caspases have been described to reasonable play neuroprotective roles in AD mouse models 
(Rohn et al., 2009; Biscaro et al., 2012). 
Under the head injury condition, IL-1β could promote Aβ deposition by increasing the 
expression of β-APP (Goldgaber et al., 1989; Forloni et al., 1992) through the βAPP promoter. 
(Buxbaum et al., 1992; Mrak et al., 1995). On the contrary, proinflammatory signalling 
pathways can be shown in APP/PS1 mouse model where transgenic expressed IL-1β in 
APP/PS1 mice resulted in strong neuroinflammation but decreased Aβ plaque pathology 
(Shaftel et al., 2007; Ghosh et al., 2013).  
IL-12 and IL-23, two pro-inflammatory cytokines, are produced by leucocytes and 
microglia in mouse models of AD (Berg et al., 2012), and their inhibition via the common 
subunit (p40) subsequently attenuate AD-like pathology and reverse cognitive deficits (Berg 
et al., 2012; Tan et al., 2014). An increase of CSF levels of the proinflammatory cytokine 
TNFα together with a concomitant decrease of the anti-inflammatory cytokine TGFβ has been 
reported in patients with mild cognitive impairment at risk to develop AD (Tarkowski et al., 
2003) highlighting the detrimental role of neuroinflammation in the pathogenesis of AD.  
4. Prostaglandins E2 
Prostaglandin E2 (PGE2) plays pivotal functions in neuroinflammation. PGE2 is 
produced from arachidonic acid by the microsomal prostaglandin-E2 synthase (mPGES) and 
by two rate-limiting enzymes, Cox-1 and Cox-2 (Smith et al., 1991) which are expressed by 
hippocampal neurons (Yasojima et al., 1999), astrocytes and microglia (Nieves et al., 2012) 
(Figure 7). Whereas Cox-1 is constitutively expressed, Cox-2 and mPGES are strongly 
activated by and during neuroinflammation (Nieves et al., 2012).  
PGE2 plays an important role in the pathophysiology of AD. It is present at high 
concentration in the course of the disease and by fostering the production of others 
inflammatory molecules (TNF-α, IL 1β, ROS, nitrite) may lead to neuronal death (Gehrmann 
et al., 1995; Montine et al., 1999; Aloisi et al., 2001; Combrinck et al., 2006; WEI et al., 
2010; Shi et al., 2012). Study also proposes that PGE2 promotes Aβ generation in a mouse 
model (Hoshino et al., 2009). PGE2 can bind to four different subtypes of G-protein-coupled 
receptors (EP1-4) which regulate adenylyl cyclase (AC) activity and/or phosphoinositol 
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turnover and intracellular calcium mobilization (Breyer et al., 2001). Depending on which 
subtype of receptor it is acting, PGE2 may have opposite effects on neuroinflammation. 
Activation of EP1 receptor triggers an increase of the concentration of intracellular Ca2+, 
whereas activation of the EP2/EP4 receptors are linked to increased levels of intracellular 
cAMP via Gs (Honda et al., 1993; Bastien et al., 1994; Nishigaki et al., 1995). Conversely, 
EP3 receptor couples negatively to cAMP generation via Gi (Breyer et al., 1994, 2001).  
Consistent with data of both favorable and toxic results of COX activity, more and 
more study shows both beneficial and toxic effects for EP receptors (Andreasson et al., 2010; 
Johansson et al., 2015). 
 
 
 
 
Figure 7. Prostaglandin synthesis 
PGE2 is mainly produced by two rate-limiting enzymes: Cox-1 and Cox-2. Cellular actions of 
PGE2 are performed via G protein coupled receptors family named EP1-EP4. EP1 is coupled 
to calcium mobilization. EP2 and EP4 activation increased cAMP levels, while EP3 activation 
can lead to a decrease of cAMP levels. By inhibiting PGE2 synthesis with nonsteroidal anti-
inflammatory drugs (NSAIDs) or particular EP antagonists, neuroinflammation can be 
alleviated.  
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1) EP1 receptor 
EP1 receptor is expressed in the hippocampus (Kawano et al. 2006). It is coupled to 
Gαq, and its activation leads to an increase in intracellular Ca2+ concentration. The role of 
EP1 receptor in neurodegenerative disease is still not clear but it may play a role in AD as its 
genetic deletion in APP/PS1 mice attenuated memory loss induced by ischemic insult and 
reduced the Aβ plaque load (Zhen et al., 2012). 
2) EP2 receptor 
By contrast, the role of EP2 receptor has been well assessed in neurodegenerative 
models. EP2 receptor is positively coupled via Gs to the generation of cAMP and is densely 
expressed in pyramidal neurons of hippocampus where it modulates synaptic transmission 
(Sang et al., 2005). The genetic deletion of EP2 in APP/PS1 mice leads to reduced brain lipid 
oxidation and decreased Aβ levels, possible via decreased the activity of BACE-1 (Tamagno 
et al., 2002; Liang et al., 2005). EP2 receptor is a key mediator of the microglial response to 
Aβ. The blockade of microglial EP2 receptor inhibits the ability of microglia to engulf Aβ 
(Shie et al., 2005) possibly through the blockade of the expression of CD36, a key player in 
Aβ phagocytosis by microglia (Li et al., 2015). The specific genetic deletion of microglial 
EP2 receptors in APP/PS1 mice induces alterations in growth factor levels, working memory 
and synaptic density (Johansson et al., 2015). 
3) EP3 receptor 
 EP3 receptor is coupled to G proteins through a Gi/o subunit (Hatae et al., 2002) 
which negatively regulates AC activity. In APP/PS1 mice, PGE2-EP3 signaling pathway is 
associated with the neuroinflammatory response to Aβ and its genetic deletion reduced 
proinflammatory gene expression, IL-1β and TNFα production and oxidative stress (Shi et al., 
2012). More recently we have shown that PGE2-EP3 pathway was responsible for the 
impairment of hippocampal presynaptic long term plasticity at the Mf/CA3 synapse in aged 
APP/PS1 mice and that impairment was fully reversed by the specific blockade of EP3 
receptor (Maingret et al., 2017).  
4) EP4 receptor 
EP4 receptor is positively coupled via Gs to the generation of cAMP and expressed in 
neurons at low levels (Li et al., 2008). EP4 receptor may provide neuroprotection in AD 
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models and hypoxic damage (Liang et al., 2011). In agreement to neuroprotective action, the 
stimulation of EP4 receptors in cultured microglia decreases the response to LPS (Minami et 
al., 2008; Shi et al., 2010) and its selective genetic deletion in microglia extends 
neuroinflammatory status (Shi et al., 2010). The stimulation of EP4 receptors in primary 
culture of microglia reduces levels of Aβ42 - induced inflammatory factors (TNFα, IL-12, 
iNOS, Cox-2) and conditional deletion of microglial EP4 receptors in APP/PS1 mice 
conversely increased inflammatory gene expression, oxidative protein modification and Aβ 
plaques load in brain at early stages of pathology (Woodling et al., 2014). All together, these 
results highlight an anti-inflammatory and neuroprotective role of microglial EP4 signaling 
pathway in AD mice model. 
b. Nonsteroidal anti-inflammatory drugs (NSAIDs) 
Numerous epidemiological studies have shown that chronic intake of NSAIDs reduced 
the prevalence of AD (McGeer et al., 2007). Then clinical trials revealed that NSAIDs, when 
given to asymptomatic patients, reduced AD incidence whereas they have deletarious effects 
on AD pathogenesis in its later stages (Szekely et al., 2010; Breitner et al., 2011; Wang et al., 
2015; Zhu et al., 2018; Kinney et al., 2018). 
NSAIDs inhibit cyclooxygenase activity by blocking Cox-1 and Cox-2 (Kaufmann et 
al., 1997; Vlad et al., 2008). Although NSAIDs are likely to be the safest drug option for AD, 
meta-analysis of different cohorts using NSAIDs on short, intermediate and long term 
treatment yielded no conclusive results (Etminan et al., 2003).  
 The chronic intake of NSAIDs by patients treated for inflammatory pathologies for 
more than 24 months clearly reduced the prevalence (40 to 70 %) of AD (Stewart et al., 1997; 
Veld et al., 2001; Lindsay et al., 2002; McGeer et al., 2007) whereas most of the clinical trials 
looking at the effects of NSAIDs on AD's patients failed to show positive results or even 
yielded deletarious side effects mostly on the gastrointestinal tractus (McGeer et al., 2007).  
In an effort to reduce side effects, Cox-2 specific inhibitors (nimesulide: Aisen et al., 2003; 
rofecoxib: Aisen et al., 2003, Thal et al., 2005; celecoxib: Soininen et al., 2007; Lyketsos et 
al., 2007) have been tested but also failed to demonstrate beneficial effects on AD's patients. 
A subset of NSAIDs known as "selective Aβ42 - lowering agents" (SALAs) which modify γ- 
secretase cleavage away from Aβ42 to Aβ40 and Aβ38 also failed to reduce AD risk (Szekely et 
al., 2008).  
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From all these studies it seems that effects of NSAIDs on neuroinflammation may be 
beneficial in the very early stages of AD but may become detrimental for later stages and 
even worsen the clinical symptoms (Breitner et al., 2011; Leoutsakos et al., 2012). 
C. Synaptic dysfunction  
The human brain comprises about 86 billion neurons and supposedly ten times more 
glial cells (Herculano-Houzel, 2009). This unique network processes and transfers messages 
in the form of chemical and electrical signals (Figure 8). Transmission between neurons 
happens at special junctions named synapses. Synaptic development and connectivity is 
crucial to maintain neuronal network activity and normal brain functions. It is now widely 
accepted that processing but also storage of the information within the brain involves 
structural and functional synaptic plasticity. This plasticity is considered to be the foundation 
of learning and memory in the brain (for review see Malenka & Bear, 2004) and has awarded 
the Nobel Prize in Physiology or Medicine in 2000 to Eric Kandel. When it comes to 
pathology, it is doubtless that the improper loss of synapses and/or dysfunction in neuronal 
transmission can be the cause of various psychiatric and neurologic diseases, such as mental 
retardation (Pfeiffer et al., 2009), schizophrenia (Stephan et al., 2006), Parkinson’s disease 
(Calabresi et al., 2006), autism (Sudhof et al., 2008), AD (Selkoe et al., 2002), compulsive 
behavior (Welch et al., 2007), and addiction (Kauer et al., 2007). 
 
a. Intrinsic and synaptic plasticities  
1. Intrinsic plasticity 
Passive and active membrane properties are related to ionic channels expressed at the 
plasma membrane. Resting membrane potential (RMP), membrane resistance (Rin) and the 
voltage threshold and/or the minimal current intensity (also termed rheobase) needed to 
generate action potentials (APs) are considered as passive membrane properties. Frequency of 
spike activity, i.e. discharge of APs, firing pattern i.e. frequency and/or spike frequency 
adaptation are considered as active membrane properties. Any modification of these non-
synaptic intrinsic membrane properties will change neuronal activity and likely modify circuit 
properties (Santos et al., 2010). 
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Figure 8. Synaptic transmission 
Information from one neuron is transferred to another neuron through a minute gap termed 
synapse. At the synapse, electrical signals are changed into chemical signals so as to cross the 
gap. While on the other side, the signal turns back into electrical signals again. One neuron 
could connect to thousand other neurons. 
 
As such, Ca2+ influx occuring during APs triggers Ca2+ release (CICR) from 
intracellular stores mediated by the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) via the 
activation of ryanodine receptor (RyR) channels (Berridge, 1998, 2002). Interestingly, in early 
stages of AD, increased RyR mediated Ca2+ signaling has been reported to affect small 
conductance calcium activated potassium (SK) channels through a decreased expression of 
FK506 binding protein that related to RyR2 activity (Gant et al., 2014, 2015). This could 
result in a decline of neuronal excitability. Intracellular Ca2+ rise also activates large 
conductance potassium (BK) channels, which can modulate AP firing by accelerating the 
membrane repolarization (Stutzmann et al. 2006; Chakroborty et al., 2009; Chakroborty et al., 
2012) and lead also to a decline of neuronal excitability. 
Consequently, alteration of neuronal firing properties might induce functional deficits 
in the early stages of AD (Rowan et al., 2005; Trommer et al., 2005; Cuevas et al., 2011; 
Palmer and Good, 2011).  
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2. Long term synaptic plasticity 
Long term synaptic plasticity is an activity-dependent ability of a synapse to display a 
strengthened or weakened activity over time, on minutes to hours. The idea of synaptic 
plasticity and its involvement in learning was first proposed by Ramon y Cajal, who reported 
that the amount of neurons in the brain did not seem to change noticeably during lifetime 
(Cajal, 1894; Jones, 1994). The major forms of synaptic plasticity are long-term potentiation 
(LTP) and long-term depression (LTD), which may happen at either excitatory or inhibitory 
synapses, through presynaptic and/or postsynaptic mechanisms. Both mechanisms of 
plasticities are believed to be associated with information storage and consequently in 
learning and memory as well as other physiological procedures.  
 
       
Figure 9. Signaling in LTD and LTP 
Activation of NMDA receptor, inducing potentiation or depression of synaptic transmission. 
The levels of intracellular Ca2+ approached by the activation of NMDA receptors have an 
important role in characterization of long term potentiation (LTP) or long-term depression 
(LTD) (Lisman et al., 1989; Lisman et al., 1994). Based on the fact that, weak activation of 
the NMDA receptor (left) would induce low concentration increases of Ca2+, leading to the 
activation of calcineurin (CaN) over CaMKII, leading to LTD. Conversely, strong activation 
of the NMDA receptor (right) would increase Ca2+ levels enough to activate CaMKII and 
PKC, leading to the generation of LTP. It was suggested that the activation of calcium 
sensitive adenylyl cyclases by strong activation of NMDA receptor would result in the 
activation of cAMP dependent protein kinase (PKA).  
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Classical LTP is dependent the activation of post-synaptic NMDA receptors and the 
insertion of new AMPA receptors, whereas classical LTD would be the result of the activation 
of NMDA receptors, AMPA receptors as well as kainate receptors and metabotropic 
glutamate receptors (mGluRs) (Collingridge et al., 2009; Granger et al., 2014) (Figure 9). 
Changes in both LTP and LTD have been considered to be involved in AD (Wang et al., 
2002; Shankar et al., 2008; Li et al., 2009).  
1) Long-term potentiation (LTP) 
LTP is a long lasting enhancement in the strength of synaptic transmission involving 
either presynaptic or postsynaptic mechanisms or both, was first reported in rabbit 
hippocampus (Bliss and Gardner-Medwin, 1973).  
LTP has been involved in a number of physiological events such as the building of 
new dendritic spines, increments in perforated postsynaptic densities (collecting more 
presynaptic input), and triggers an enlargement of spine heads (Harreveld and Fifkova, 1975; 
Savatic et al., 1999; Nagërl et al., 2004; Bosch and Hayashi, 2012). Hence, LTP alterations in 
the hippocampus in AD mice models have been extensively studied. LTP comprises two 
phases: early and late. The early phase depends upon protein kinase activation leading to the 
phosphorylation of synaptic AMPA receptors, enhanced activity, insertion of new AMPA 
receptors into the postsynaptic density leading to the enhancement of synaptic transmission. 
In the late phase, raised calcium levels at the postsynaptic side and constant activation of 
kinases (PKC, PKMzeta, and CamKIIa) trigger the activation of transcription factors, such as 
CREB. In vitro, the exogenous application of Aß triggers an impairment of LTP (Chen et al., 
2000; Li et al., 2011; Jo et al., 2011; Varga et al., 2015) but genetic deletion or treatment with 
blocking antibody showed that endogenous Aß is necessary for hippocampal LTP in vivo 
(Puzzo et al., 2011). This study together with other reports (Puzzo et al., 2008; Osta and 
Alberini, 2009), suggest that endogenous low levels of Aß do have a physiological function in 
synaptic plasticity.  
LTP is also impaired in tau mutant mice (Fa et al., 2016; Gelman et al., 2018). These 
alterations were observed in old mice, likely the result of high levels of accumulated tau 
(Chong et al., 2011; Sydow et al., 2011). Moreover, similar age-dependent results on LTP 
were also reported in mutant mice overexpressing normal human tau (Polydoro et al., 2009). 
Whereas tau acts on LTP by itself or downstream of Aß or even in concert with Aß is still 
debated (Jones et al., 2014). 
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2) Long-term depression (LTD) 
LTD is a long lasting decline of synaptic strength. It may occur by several ways, which 
not surprisingly have opposite effects to those observed in LTP, including internalization of 
AMPA receptors (Dudek and Bear, 1992; Massey and Bashir, 2007; Collingridge et al., 2010), 
and calcineurin activation (Mulkey et al., 1993; Li et al., 2010).  
LTD is believed to be important for the clearing of old memories and in circumstances 
requiring behavioral adaptability (Collingridge et al., 2010). This "forgetting" feature of LTD 
could be disrupted during AD causing memory problems (Jones et al., 2014). As for LTP, the 
molecular mechanisms of LTD which could be targeted by AD are poorly unknown. 
Interestingly, Aβ induces AMPA and NMDA receptors internalization through the same 
calcineurin-mediated pathways involved in LTD (Wang et al., 2004; Snyder et al., 2005; 
Hsieh et al., 2006; Koffie et al., 2011).  
Knockout mice for tau at the CA1 region of hippocampus show impairment of LTD 
(Kimura et al., 2014) suggesting an important role of tau in synaptic transmission. Besides, 
mutation of tau was found to be connected with glutamate signaling as well as excitotoxicity 
in vivo, further proposing a role for tau in modulation of synaptic transmission (Hunsberger et 
al., 2015). 
3. Short term synaptic plasticity  
Short term plasticity (STP) takes place on milliseconds to few seconds scale (Zucker 
and Regehr, 2002; Abbott and Regehr, 2004). At some synapses, a decrease of 
neurotransmitter release contributes to short term depression by decreasing the release 
probability or reducing the readily releasable pool of vesicles (Eccles et al., 1941; Feng et al., 
1941) (Figure 10). At other synapses, increases of neurotransmitter release probability (Katz 
et al., 1968) contribute to short term depression by saturating of local calcium buffer (Felmy 
et al., 2003; Blatow et al., 2003) or increasing of calcium concentration at the presynaptic 
terminal (Kamiya et al., 1994; Atluri et al., 1996; Sippy et al., 2003).  
STP plasticity such as post-tetanic potentiation (PTP) and paired pulse facilitation 
(PPF) play essential roles in long-term memory formation and hence, STP impairments cause 
long lasting memory formation deficits (Silva et al., 1996). Consistent long-term memory 
activity relies on Ca2+ mediated STP to convert short term to long term memory and set up 
synapse specificity (Frey et al., 1997; Redondo et al., 2011). 
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STP is not a trivial synaptic mechanism but seems instead to be a property to keep the 
balance between excitation and inhibition. Depending on the type of STP triggered at a 
particular synapse, it will shape the transferred information which suggests that the same 
presynaptic site may carry different information to distinct postsynaptic cells (Markram et al., 
1998). In this case, short-term facilitation and depression carry information in both low and 
high frequencies range (Fuhrmann et al., 2002). These studies highlight the crucial roles of 
STP in information processing and strongly suggest the physiological relevance of STP in 
different cognitive tasks as for example, decision making or working memory (Shyu et al., 
2009; Deng et al., 2011). 
 
 
 
Figure 10. Short term synaptic plasticity 
Presynaptic mechanisms of short term plasticity. Schematic graphs demonstrate possible 
mechanisms of facilitation and depression.  
 
The characteristics of postsynaptic receptors could be also involved in short term 
plasticity. When exposed to neurotransmitter, the desensitization of postsynaptic receptors 
could lead to a decrease synaptic activity upon repeated activation (Trussell et al., 1993; Jones 
et al., 1996; Chen et al., 2002; Sun et al., 2002; Friedman et al., 2003; Wadiche et al., 2001; 
Foster et al., 2002; Harrison et al., 2003). 
In early AD stage, a number of synaptic pathophysiological mechanisms induced by 
ryanodine receptors (RyR) of excessive Ca2+ have been reported, such as an enhanced 
frequency of spontaneous synaptic potentials, decreased PPF ratio as well as increase of 
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synaptic depression (Chakroborty et al., 2009, 2012; Briggs et al., 2013). Published studies 
have demonstrated that sizeable vesicle depletion happens at high release probability synapses, 
which has been illustrated in several studies of AD mice (Goussakov et al., 2010; Scimemi et 
al., 2012). For example, at excitatory CA3/CA1 synapses of mouse hippocampus, several 
functional Ca2+ channels may be located in the active zone at variable sites. This location 
results in a far and wide distribution of release probability through the vesicles at the active 
zone, and the depletion of the vesicles adjacent to Ca2+ channels can contribute to the Ca2+ 
dependent STP at these synapses. 
4. Activity-dependent modulation of population spike (PS) 
plasticity 
Population spike (PS) which can be recorded with extracellular electrodes is a 
composite response built by the extracellular summation of action currents during 
synchronous APs firing. With appropriate external stimulation, it is possible to trigger a 
potentiation of the PS which gives rise to an increase in the PS amplitude.  
Noteworthy, at the LPP-DG synapse, the PS amplitude is comparatively larger than 
the amplitude of the excitatory postsynaptic potential (EPSP) (Bliss et al., 1973; Andersen et 
al., 1980; Yanagihashi et al., 1992). In theory, an increase of the PS amplitude goes along 
with an increase of the field EPSP (fEPSP). Nonetheless, this close relation between PS and 
EPSP may varies while LTP is induced by tetanic stimulation. The potentiation of PS is 
relatively greater than the EPSP. This suggests that the potentiation mechanism underlying 
spikes is to some extent independent from the synaptic potentiation (Bliss et al., 1973; 
Mozzachiodi et al., 2010). Therefore, the increase in PS amplitude is not sensus stricto the 
exact equivalent of an increase in EPSP which is synaptic in essence. In other words, the 
mechanisms of an increase of PS amplitude may rely both on synaptic and non-synaptic 
mechanisms whereas an increase in the EPSP reflects synaptic mechanisms.  
The "non-synaptic" part of PS potentiation has been observed in different brain 
regions with different LTP protocols (Abraham et al., 1987; Noriega et al., 1989). It shows an 
enhancement of the intrinsic excitability in the postsynaptic neurons via modulation of voltage 
Na+ channels but also other channels (Ca2+ channels, K+ channels) (Taube and Schwartzkroin, 
1988; Wathey et al., 1992; Bernard et al., 1995; Xu et al., 2005; Fink and O’Dell, 2009).  
In some cases, alterations in intrinsic excitability without obvious changes in synaptic 
strengh, i.e. LTP or LTD, have been reported. In the CA1 hippocampus, high frequency 
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stimulation potentiates EPSPs, but this potentiation in neither a prerequisite for, nor a 
correlation of a potentiation of PS amplitude (Taube and Schwartzkroin, 1988). Short trains 
(2-3 s) of Schaffer collateral fiber stimulation delivered at 5 Hz induce increase in the 
excitability of CA1 neurons in the absence of synaptic potentiation (Fink and O’Dell, 2009).  
Furthermore, both EPSP and PS plasticities were found related to the activity of 
NMDARs (Jester et al., 1995; Lu et al., 2000). Remarkably, non-synaptic changes can 
promote synaptic modulations (Byrne et al., 1987) such as depolarization of the resting 
membrane potential, could promote the induction of synaptic plasticity which is necessary for 
memory storage (Crow et al., 1980; Mozzachiodi et al., 2008). Generally, these results show 
that neuronal activity can be modified respectively in different sections within the same cell 
(Losonczy et al., 2008) and reveal therefore that modulation of neuronal activity are more 
intricate than previously thought.  
5. Miniature excitatory postsynaptic currents (mEPSCs) 
Miniature excitatory postsynaptic current (mEPSC) is due to the spontaneous release 
of a single vesicle into the synapse in the absence of the occurence of APs as they are 
recorded in the presence of TTX. Synaptic plasticity mechanisms modifying neuronal activity 
can be studied at the level of mEPSCs (Bekkers et al., 1990; Turrigiano et al., 1998; O’Brien 
et al., 1998; Watt et al., 2000) which the frequency and the amplitude are related to pre and 
postsynaptic loci of action respectively (Prange et al., 1999; Ling et al., 2006). 
The increase in mEPSCs frequency depends on calcium influx but not on the 
activation of voltage-dependent Ca2+ channels (Gray et al., 1996; Capogna, et al., 1996; 
Sharma et al., 2003). mEPSCs frequency changes are often associated to changes in the 
transmitter release probability (Scholz et al., 1992; Debanne et al. 1996; Prange et al., 1999; 
Sharma et al., 2003), but mEPSCs frequency can change without having an effect on the 
transmitter release (Eliot et al., 1994; Yoshihara et al., 1999; Béïque et al., 2003). Hence, the 
increase of docked vesicles number can lead to an increase of mEPSC frequency (Tyler et al., 
2001; Murthy et al., 2001; Lauri et al., 2003) but also the increase of the number of functional 
release sites, i.e. via the unmasking of "silent synapses" into functional ones (Isaac et al., 
1995; Liao et al., 1995; Durand et al., 1996; Liao et al., 2001).  
Changes in mEPSCs amplitude are considered to reflect postsynaptic mechanisms. 
Unless if the quantal size of a vesicle is modified, the modification of mEPSCs amplitude is 
believed to reflect a change in the receptor number (Turrigiano et al., 1998; Watt et al., 2000; 
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Ling et al., 2006). But it is also possible that increases or decreases in the glutamate content 
of synaptic vesicles lead to the change in mEPSC amplitude. (Watt et al., 2000; Liu et al., 
1999; McAllister et al., 2000). Although there is no direct study supporting alterations in 
glutamate content in vesicles, there is direct study for alterations of sensitivity in postsynaptic 
receptors (Turrigiano et al., 1998; Lissin et al., 1998; O’Brien et al., 1998). 
Numerous data report that soluble Aβ increases neuronal activity (Bausch et al., 2006; 
Busche et al, 2012). Aβ1-40 triggers an increase in the frequency of mEPSCs together with 
firing activity (Cuevas et al., 2011).  Pharmacologically study to identify synaptic activity 
indicated that the activity of NMDA mediated mEPSCs was obviously increased, implying 
enhanced excitation and synaptic plasticity (Berberich et al., 2007; Hoe et al., 2009).  
b. Synaptic dysfunction in AD 
1. Synaptic activity and Aβ homeostasis 
AD, at least in its early stage is considered to involve synaptic dysfunction before 
synaptic and neuronal loss (Selkoe et al., 2002; Jacobsen et al., 2006; Sheng et al., 2012). In 
good agreement, spatial and contextual learning and memory deficits reported in a mouse 
model of AD appear prior to Aβ plaques and tau pathology (Billings et al., 2005). Therefore, 
it is no surprise that synapses appear as a major therapeutical target to at least alleviate the 
burden of the disease and possibly maintain cognitive and functional abilities. Furthermore, 
the brain location of Aβ plaques and tau tangles, the two main molecular hallmarks of AD, 
allows to link morphologic alterations to cognitive impairments such as learning and memory 
with synaptic dysfunction.  
It is well known that Aβ peptide, lead to morpholo-functional alterations and 
numerous harmful effects on neurons (Strooper et al., 2016). Aβ oligomers directly promote 
neuronal apoptosis via cell-surface receptors (TRAIL, TNF-related apoptosis-inducing ligand 
death death receptors 4 and 5) (Fossati et al., 2012). Furthermore, the long-term buildup of 
toxic Aβ species triggers DNA damage, injury of cellular organelles and dysregulation of 
intracellular calcium level — all of them leading to cell death (Kayed et al., 2013). Although 
Aβ under certain conditions can bring rapid impairment of synaptic plasticity (Cullen et al., 
1997; Lambert et al., 1998; Shankar et al., 2008) as well as changes of dendritic spine 
morphology and nerve terminals of dendritic spines (Rönicke et al., 2011) within hours, it 
takes years for Aβ accumulation to have noticeable and deleterious effects.  
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There are numerous data supporting synaptic pathological effects of Aβ (Hsia et al., 
1999; Mucke et al., 2000; Walsh et al., 2002; Kamenetz et al., 2003; Lacor et al., 2007).  
Depending on its extracellular concentration, Aβ may have opposite effects: low 
concentrations (100-200 pM) facilitate excitatory activity and may are involved in memory 
formation (Walsh et al., 2007; Puzzo et al., 2008, 2011; Osta and Alberini, 2009) while higher 
levels (>40 nM) suppress it (Yankner et al., 1990). As Aβ depresses synapses and impairs 
synaptic plasticity (Hsieh et al., 2006; Shankar et al., 2008), the activity-dependent Aβ 
accumulation (Cirrito et al., 2005) could be considered as a feedback mechanism protecting 
against synaptic hyperactivation and excitotoxicity (Kamenetz et al., 2003). 
 In early stages of AD, in addition to the increased expression of RyR, its function is 
regulated by PS1 and/or PS2 (Shilling et al. 2014; Prete et al. 2014). PS is known to interact 
with proteins of the neurotransmitter release machinery and its genetic deletion impairs 
synaptic plasticity (Barthet et al., 2018). At postsynaptic level, intracellular Ca2+ rise is 
enlarged by RyR-mediated CICR in dendritic spines which is required for the initiation of 
long term synaptic plasticity (Rossi et al., 2008; Goussakov et al., 2010; Briggs et al., 2016). 
In summary, further investigations on physiological functions of Aβ will be most wanted to 
decipher new targets at which possible AD therapeutics could be performed. 
1) Aβ-induced presynaptic dysfunction 
Vesicles which are released within the synapse are present at presynaptic terminals 
and their release is controled by a constellation of proteins (Jin et al., 2008). In AD, Aβ 
accumulates at presynaptic terminals (Ye et al., 2017) and not surprisingly may impair 
presynaptic mechanisms. In addition, Aβ oligomers co-localize with voltage-gated calcium 
channels to stimulate presynaptic calcium influx increasing therefore the release probability of 
neurotransmitter, leading to an unusually high level of glutamate in the extracellular space 
(Moreira et al., 2011). Aβ oligomers can also damage axonal transport (Decker et al., 2010). 
The mechanisms by which Aβ disturbs axonal transport of calcium influx through NMDA 
receptors activation, resulting in cytosolic calcium upregulation as well as the activation of 
calcineurin. GSK-3β dependent activation of calcineurin setup a new link between toxic Aβ 
and AD pathology (Pigino et al., 2009; Decker et al., 2010; Ramser, et al., 2013; Gan & 
Silverman, 2015). A recent study has shown that the axonal binding of Aβ oligomers was 
leading to neuronal degeneration (Baleriola et al., 2014).  
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Synaptic vesicles are the key players that pass on synaptic signals and Aβ could affect 
the key procedures of vesicle cycling, including trafficking, release, and recycling (Ovsepian 
et al., 2018). Additionally, Aβ may damage vesicle recycling by lowering the recycling pool 
and increasing the resting pool (Park et al., 2013).  
2) Aβ-induced postsynaptic dysfunction 
Aβ oligomers interact with the postsynaptic side to alter the structure, the composition, 
and the function of the synapse (Koffie et al., 2009). The activity of Aβ oligomers at 
postsynaptic sites can be mediated via their interaction with membrane molecules, eventually 
leading to synaptotoxicity.  
NMDA and AMPA receptors are the main ionotropic glutamate receptors expressed 
by postsynaptic excitatory synapses (Scheefhals & MacGillavry, 2018). The activation of 
NMDA receptor promotes calcium influx and triggers intracellular signaling pathways such as 
calcineurin-mediated Ca2+ signaling and Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) (Scheefhals & MacGillavry, 2018). Consequently, evoking dysregulation of 
intracellular signaling cascades may induce the disruption of neuronal transport in primary 
neurons (Rui et al., 2006; Decker et al., 2010). Similarly, the removal of AMPA receptors 
from excitatory synapses can be induced by increased Aβ levels, which result in dendritic 
spines loss and synaptic depression (Chang et al., 2006; Hsieh et al., 2006; Molina et al., 
2011; Guntupalli et al., 2016).  
Metabotropic glutamate receptors 5 (mGluR5) play a key role in modulating 
transmission at glutamatergic synapses and NMDA receptor-dependent synaptic plasticity 
(Harney et al., 2006) (Figure 11). In addition, mGluR5 seem essential in Aβ-induced 
synaptotoxicity and could be a possible therapeutical target for AD (Kumar et al., 2015). Aβ 
induces the clustering and the overstabilization of mGluR5 at the postsynaptic side and thus 
may lead to early synaptic failure (Renner et al., 2010). 
2. Synaptic activity and tau homeostasis 
Tau is present at synapses in both physiological and pathological conditions (Pooler et 
al., 2014). Normal tau is detected at both pre and postsynaptic terminales in control humains 
brains but a hyperphosphorylated form of tau (pS396/pS404) is found in AD synaptosomes, a 
key location to mediate proteotoxicity which disrupts synapses in AD (Tai et al., 2012) 
(Figure 11). 
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Figure 11. Aβ and Tau pathology in AD 
Aβ may be transported to the synapse by apoE4 and binds to postsynaptic receptors, leads to 
an increase in calcium levels, activation of CaN, caspase-3 and downstream synaptic 
receptors internalization. Tau has also been implicated in synapse dysfunction induced by Aβ, 
and phosphorylated forms of tau (pTau) are transported "through" synaptic activity. However, 
which forms of pTau are transferred and how they are transported remains unknown.  
 
Numerous publications have demonstrated that when administrated to extracellular 
cultured neuronal cells, tau oligomers promoted tau neuronal uptake and enhanced 
intracellular calcium levels (Gomez-Ramos A et al., 2008). In mice, in vivo application of tau 
oligomers induces mitochondrial and synaptic dysfunction (Berger et al., 2007; Reeves et al., 
2011).  
Strikingly, synaptic activity induced in mouse cultured cortical neurons promoted tau 
phosphorylation, translocation of endogenous tau from the dendritic shaft to spines whereas 
the addition of Aβ oligomers induced mislocalization of tau into the spines at rest i.e. without 
synaptic activation, and blocked the activity-dependent enrichment of tau within spines 
(Frandemiche et al., 2014).  
The abnormal synaptic localization of tau and the disruption of the activity-dependent 
enrichment of tau within spines by Aβ oligomers could play a role in the progression of the 
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pathology (Hoover et al., 2010; Roberson et al., 2011; Tai et al., 2012). Furthermore, synaptic 
activity and Aβ likely promote tau-phosphorylation on different sites (Frandemiche et al., 
2014) leading to different forms of phosphorylated tau (toxic vs non-toxic) which may have 
different impact on synaptic transmission and plasticity.  
1) Tau-induced presynaptic dysfunction 
In the course of AD, hyperphosphorylation of tau leads to its dissociation from 
microtubules, followed by diminished cytoskeletal solidity and impaired axonal transport 
(Wagner et al., 1996; Patrick et al., 1999). Additionally, extracellular tau oligomers can be 
taken up by neurons, accumulated within axons and dysregulate axonal transport (Wu et al., 
2013; Swanson et al., 2017). pTau binds to synaptic vesicles via its N-terminal domain and 
synaptogyrin-3 (a transmembrane vesicle protein) and interferes with presynaptic synaptic 
vesicles (SV) mobilization and release rate as well as down regulation of neurotransmission. 
(Zhou et al., 2017; McInnes et al., 2018). Accumulation of presynaptic pTau triggers a 
transient increase of spontaneous neurotransmitter release mediated by intracellular calcium 
release. This is followed by SV exocytosis block, leading to consistent synaptic transmission 
failure owing to the consequent toxicity activities (Moreno et al., 2011, 2016).  
In an inducible mouse model expressing pro-aggregant tau, a severe depletion of 
synaptic vesicles pool was observed together with an impaired LTD (Decker et al., 2015) and 
the accute addition of recombinant human tau oligomers produced the impairment of LTP (Fà 
et al., 2016).  
2) Tau-induced postsynaptic dysfunction 
The accumulation of tau into dendritic spines leads to the decreased expression of both 
NMDA and AMPA receptors, induced impaired excitatory synaptic transmission and memory 
deficits (Hoover et al., 2010; Xia et al., 2015; Kim et al., 2016; Yin et al., 2016; Zhao et al., 
2016). Lack of tau in tau-/- mutant mice disrupts the postsynaptic Src kinase Fyn localization 
resulting in the reduction of NMDA receptor phosphorylation and in fine protection against 
Aβ-induced excitotoxicity (Ittner et al., 2010; Roberson et al., 2011). In contrast to the Aβ 
toxicity mediated by phosphorylated tau protein, at least in the early stage of the disease, site-
specific phosphorylation of tau mediated by p38 MAPKinase inhibits Aβ toxicity (Ittner et al., 
2016).   
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c. Synaptic dysfunction at hippocampus 
Following entorhinal cortex, hippocampus is one of the earliest affected brain region 
in AD (Arriagada et al., 1992). AD pathological lesions and neuronal loss are observed in 
multiple regions including hippocampus as well as trans-entorhinal and entorhinal cortices 
(Hyman et al., 1984, 1990; Geddes, 1985; Isla et al., 1996; Kordower et al., 2001). The 
hippocampus is part of the limbic system, and plays important roles in the consolidation of 
information from short-term memory to long-term memory, and in spatial memory that 
enables navigation in rodents. As such, it is generally acknowledged that memory deficits in 
AD involve synaptic dysfunction and synaptic plasticity impairments in the hippocampus 
(Selkoe, 2002; Morrison and Baxter, 2012).  
The hippocampus (Figure 12) has a general shape of a seahorse and therefore was 
named after by the Venetian anatomist Julius Caesar Aranzi (1587). It comprises the dentate 
gyrus (DG) formed by a condensed layer of granule cells bodies making a v-shape and a ram's 
horn (Cornu Ammonis) comprising CA4 (in humans), CA3, CA2 and CA1. The CA fields 
present densely packed pyramidal neurons (Hyman, 1987; Cajal, 1901; Lorente, 1934). The 
main input to the hippocampus is the entorhinal cortex (EC) through perforant pathway (PP). 
This pathway generates mostly from layers II and III of EC. Cells from layer II project to DG 
and CA3, while layer III neurons project to CA1 and the subiculum. Axons from granule cells 
of DG which project to CA3 pyramidal neurons are named mossy fibers. CA3 pyramidal 
neurons mainly project to CA1 via Schaffer collaterals (Amaral and Witter, 1989). These two 
routes, EC → CA1 and EC → DG → CA3 → CA1, drive CA1 activity and CA1 pyramidal 
neurons projects back into deep layer of EC (Figure 12). 
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Figure 12. Synaptic circuits in hippocampus 
The cartoon illustrates the hippocampal morphology and circuitry. The graph below shows the 
hippocampal connectivity. The classical excitatory pathway (EC–DG–CA3–CA1–EC) is 
illustrated by solid arrows. The layer II neurons in EC project to the DG via perforant 
pathway (PP), including the lateral perforant pathway (LPP) and medial perforant pathway 
(MPP). DG projects to CA3 pyramidal neurons through mossy fibres (Mf). CA3 pyramidal 
neurons pass on the information to CA1 pyramidal neurons via Schaffer collaterals. CA1 
pyramidal neurons projects back into deep layer of EC. CA3 pyramidal neurons receive also 
projections from EC layer II neurons through the PP. CA1 pyramidal neurons receive direct 
input from EC layer III via the temporoammonic pathway (TA). The DG cells also project to 
the mossy cells in the hilus and interneurons, which project to excitatory and inhibitory 
pathways, respectively, then back to the granule cells (adapted from Deng et al., 2010) 
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1. Perforant path (PP)/Dentate Gyrus (DG) synapses 
The major excitatory input to DG is the perforant path (PP) made of glutamatergic 
projections, which form functional connections during the 3rd week of development (Esposito 
et al., 2005; Ge et al., 2006; Zhao et al., 2006; Toni et al., 2007). In the 4th week, the strength 
of excitatory afferents enhances greatly whereas the membrane input resistance is still high, 
an intrinsic property of immature neurons (Mongiat et al., 2009). According to this, immature 
granule cells (GCs) are much easier to fire AP than mature neurons (Ge et al., 2007) and 
therefore intrinsic properties of GCs may highly affect the memory encoding procedure (Rolls 
and Kesner, 2006). 
The perforant path consists of two subfields: the medial perforant path (MPP) and the 
lateral perforant path (LPP) (McNaughton, 1980). The MPP initiates from medial EC and 
projects to the middle third of the molecular cell layer, while the LPP initiates from the lateral 
EC and projects to the outmost third of the molecular cell layer. The excitatory input from 
both MPP and LPP onto GCs have different properties of short-term and long-term plasticity 
(McNaughton et al., 1980; Bramham et al., 1991; Colino et al., 1993; Patten et al., 2015). The 
MPP processes spatio-temporal informations involving NMDAR-dependent plasticity 
whereas the LPP processes novel object information through opiate receptor dependent 
plasticity (Hargreaves et al., 2005; Hunsaker et al., 2007, 2013) (Figure 13). 
Both MPP and LPP take glutamate as main neurotransmitter (White et al., 1977; 
Mathisen, 1981), but present different pharmacological and physiological features such as L-
2-amino-4-phosphonobutyric acid (L-AP4) acting through the inhibition of voltage-dependent 
calcium channels (VDCCs) and/or potassium currents, leading to the suppression of glutamate 
release (Forsythe and Clements, 1990). L-AP4 contributes to a significant larger depressive 
effect on the excitatory postsynaptic potential (EPSP) evoked by LPP than by MPP 
stimulation (Koerner and Cotman, 1981), while baclofen has the opposite effect (Lanthom 
and Cotman, 1981). Carbachol acting through postsynaptic sites, more likely suppresses MPP 
EPSP (Kahle and Cotman, 1989), and antagonists of NMDA receptor (D- (-)-2-amino-5-
phosphonovaleric acid, D-APV and 3-[( + )-2-carboxypiperazin-4-yl]-propyl-l-phosphonic 
acid, CPP) have been shown to decrease the late part of the MPP EPSP whereas with the LPP 
EPSP is unchanged (Dahl et al., 1990). Short term synaptic plasticity events such as PPF and 
PTP also vary between LPP and MPP (McNaughton, 1980).  
When it comes to AD, both pathological tau and amyloid collaboratively increases 
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cytotoxicity leading to PP degeneration. Aβ oligomer were demonstrated to be transported 
from cell bodies in the entorhinal cortex to the PP, and partly from the posterior parietal 
cortex (Morales et al., 2012; Bero et al., 2012).   
Most interestingly, tau pathology seems confined initially to PP (Sierra et al., 2000; 
Calignon et al., 2012; Liu et al., 2012; Polydoro et al., 2014). These data strongly support the 
concept of a ‘‘spread’’ of the pathology following the perforant pathway. Furthermore, PP 
projection to DG is specifically vulnerable in terms of synaptic plasticity in AD murine 
models (Palop et al., 2007).  
 
 
 
 
 
               
 
 
 
 
Figure13. Synaptic circuits of PP/DG in hippocampus 
The schematic shows the arrangement of afferent inputs to the molecular layer of the DG. 
Inputs from lateral perforant path (LPP), medial perforant path (MPP) connect the outer, 
middle molecular layer, respectively. Hippocampal granule cells bodies (yellow) located at 
the dentate granule cell body layer (DG).  
 
2. Mossy fibre (Mf) /CA3 synapses 
Since the first classified of CA3 region in the hippocampus (Lorente, 1934), there has 
been more and more interest in the different CA3 neuron characteristics. Intrinsic functional 
connectivity in CA3 is a network of highly structured connection (Willshaw et al., 1969; Marr 
et al., 1971; Hopfield et al., 1982; McNaughton et al., 1987; Treves et al., 1994; Bennett et al., 
1994; Lisman et al., 1999; Rolls et al., 2013). CA3 circuits display extensive excitatory 
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interconnections between CA3 pyramidal cells (PCs) through associational and commissural 
fibres (for review see Rebola et al., 2017) but also connections to inhibitory neurons (Lorente, 
1934). This region is as likely as involved in forming spatial representations and episodic 
memories of initial acquisition stages (Scoville and Milner, 1957; O’Keefe and Nadel, 1978; 
Kesner and Rolls, 2015). 
CA3 region receives inputs from the entorhinal cortex either directly via the PP or 
from DG through mossy fibres (Mfs) (Amaral and Witter, 1989). Mf form giant boutons (5–8 
µm in diameter) that have an average of 20 release sites per bouton. The Mf/CA3 pathway 
acts as a filter that transforms complex coded signals to specific hippocampal information, 
required for memory encoding. This procedure really depends on the firing pattern of DG 
granule cells (GCs) and leads to more positive stimulus performance in the CA3 region 
(Leutgeb et al., 2007).  
Pattern separation and pattern completion are often considered as associated with DG 
and CA3 region, respectively, with the DG granule cell and Mf setting the pathway to CA3 
(Figure 14). However, CA3 pyramidal cells also send ‘back’ to DG (Scharfman et al., 2007). 
The projection from CA3 to DG might have an effect on the circuits in the DG and CA3 
(Penttonen et al., 1997; Lisman et al., 2005), and this pathway might contribute to the 
information process. A study in the computational model showed that this backprojection has 
an important role in the ability of the computational model to present pattern separation and 
completion (Myers et al., 2011). In the hippocampus, only CA3 contains recurrent pathway: 
more than 95% of input to CA3 region is from CA3 recurrent connections. These associated 
fibers might promote the pattern completion (Guzowski et al., 2004). 
Importantly, Mf-CA3 synapses present a wide range of short term plasticity 
(frequency facilitation, paired-pulse facilitation, post-tetanic potentiation) but also presynaptic 
LTP and LTD that are depending on NMDAR activation (Nicoll and Schmitz, 2005; Rebola 
et al., 2017). Furthermore, NMDARs contribute to LTP characterized by a selective 
enhancement of NMDA receptor-mediated transmission which requires coactivation of 
NMDA and mGlu5 receptors and a postsynaptic calcium rise at Mf-CA3 synapses (Kwon and 
Castillo, 2008).  
Up to now, most of the studies in AD mouse models have been done at the 
archetypical CA3-CA1 synapse which is characterized by a canonical postsynaptic LTP. On 
the opposite, few studies have investigated Mf-CA3 synapses alterations in AD (Witton et al., 
2010; Marchetti and Marie, 2011; Wilke et al., 2014; Silva et al., 2016; Maingret et al., 2017). 
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In APP/PS1 mice at 6 months of age, postsynaptic LTP of associative/commissural (A/C) 
inputs to CA3 pyramidal cells was totally impaired (Silva et al., 2016) whereas the 
presynaptic LTP at the Mf-CA3 synapse was unaffected (Maingret et al., 2017). Interestingly, 
APP/PS1 mice at 6 months of age displayed altered fear conditionning (Kilgore et al., 2010).  
Aβ-overproducing Tg2576 mouse display impairement of short term frequency 
facilitation and absence of NMDAR independent LTP at the Mf pathway (Witton et al., 2010). 
On the contrary, tau oligomers lead to presynaptic and postsynaptic morphological changes 
(toxic function) at the Mf linked to the CA3 region in mutant human tau mice (Decker et al., 
2015). 
 
               
 
 
Figure 14. Synaptic circuit of Mf/CA3 in hippocampus 
Mossy fibre (Mf) projection contains axons of the DG granule cells in the hippocampus. 
 
3. Schaffer collaterals (SC)/CA1 synapses 
CA3 are important for the fast combination different information and pattern 
completion, while CA1 may be helpful in identifying a new event or a new context (Lisman et 
al., 2001; Kumaran et al., 2007). In the hippocampus, CA1 receives projections from CA3 
through Schaffer collaterals (SC) (Li et al., 1994) (Figure 15).  Different layers of entorhinal 
cortex (EC) transport vary kinds of information to the CA3 and CA1 regions (Sargolini et al., 
2006). This has lead to detailed physiological studies of these regions in the hippocampus. 
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Figure 15. Synaptic circuit of CA3/CA1 in hippocampus 
Sites of termination of axons of CA1 and CA3 pyramidal cells 
Regional differences in firing patterns corresponding to different environmental 
factors have been found (Lee et al., 2004; Leutgeb et al., 2004, 2005; Vazdarjanova and 
Guzowski, 2004; Dragoi and Buzsaki, 2006; Lee and Knierim, 2007; Leutgeb and Leutgeb, 
2007; Alvernhe et al., 2008). When testing rat in a spatial environment, both CA1 and CA3 
neurons are selectively firing when the animal moves to particular places in the environment. 
These ‘place cells’ are thought to set as parts of a cognitive map in the environment (O’Keefe 
et al., 1978) or representations of places where significant events happen (Eichenbaum, 1999, 
2004). Thus, investigations of age-related alterations in the firing patterns of place cells 
maybe informative of disruptions of memory procedure in aged hippocampus. Spatial 
information processed by place cells is changed in aged rats in several studies (Rosenzweig et 
al., 2003). Particularly, many studies have indicated that CA3 and CA1 place cells of aged 
rats could not form new spatial or task information quickly (Tanila et al., 1997; Oler et al., 
2000; Wilson et al., 2003, 2004, 2005). 
In the hippocampus, synaptic plasticity dysfunction of AD has been demonstrated by 
the application of Aβ peptides and strongly inhibits LTP induction at Schaffer collateral/CA1 
synapses (Chen et al., 2000). This result is also complementary to an early in vivo study 
showing impaired maintenance of CA1 - LTP in rats injected i.c.v. with Aβ1–40 or Aβ1–42 
(Cullen et al., 1997). Another study illustrates that basic synaptic transmission was disrupted 
at SC/CA1 synapse in htau mouse with an age dependent mode (Polydoro et al., 2009). Only 
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aged htau mice displayed an alteration in PPR that is symptom of a decreased glutamate 
release probability. Aged htau mice display cognitive impairment in hippocampal related 
behavioral tasks, and changes in basic synaptic function. Additionally, HFS failed to induce 
LTP in aged htau mice. Together these results suggest that tau pathology may underlie age-
dependent learning impairment via disruption of synaptic function. 
II. Study objectives 
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by 
early cognitive deficits linked to synaptic dysfunction (Selkoe, 2002; Jacobsen et al., 2006; 
Sheng et al., 2012). Numerous evidences show that neuroinflammation plays a key role in the 
pathogenesis of AD (Haruhiko et al., 2000; Rojo et al., 2008) and most importantly, 
neuroinflammatory molecules like prostanoids and cytokines are well known to modulate 
synaptic transmission and plasticity (Sang et al., 2006; Yang et al., 2008; Riazi et al., 2015). 
Multiple epidemiological studies have revealed that chronic intake of nonsteroidal anti-
inflammatory drugs (NSAIDs) reduced considerably the prevalence of AD (McGeer and 
McGeer, 2007) and clinical trials have shown that when given to asymptomatic patients, 
NSAIDs reduced AD incidence (Breitner et al., 2011). Among the proinflammatory 
molecules generated during AD, prostaglandin E2 (PGE2) plays a pivotal role ( Yang et al., 
2008). PGE2 is produced from arachidonic acid by two rate limiting enzymes, Cox-1 and 
Cox-2 and binds with four main subtypes of receptors, that is EP1, EP2, EP3, and EP4 
(Breyer et al., 2001). In a previous study we demonstrated that the presynaptic long-term 
potentiation (LTP) at hippocampal Mf-CA3 synapse was impaired in APP/PS1 males due to 
the engagement of a PGE2-EP3 signaling pathway (Maingret et al., 2017). Mf-CA3 synapse is 
characterized by prominent presynaptic short term plasticity such as paired-pulse facilitation 
(PPF), frequency facilitation (FF), and presynaptic long-term plasticity (LTP). LTP has been 
described to be involved in the novel memory fast encoding (Kesner et al., 2007), a procedure 
particularly affected in AD.  
 Among different major risk factors for developing the disease revealed by 
epidemiological and genetic studies (for review see Hickman et al., 2016), surprisingly sex, 
which is one of the major risk, has received relatively little attention so far. However, there is 
a prominent sexual dimorphism in the human pathology, with a much higher prevalence (two 
to three times) of AD-related cognitive decline and greater AD neuropathology (Buckwalter 
et al., 1993; Letenneur et al., 1994; Henderson and Buckwalter, 1994; Brayne et al., 1995; 
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Fratiglioni et al., 1997; Andersen et al., 1999; Ruitenberg et al., 2001; Corder et al., 2004; 
Barnes et al., 2005; Sinforiani et al., 2010) in women compared to men. Remarquably, this 
sexual dimorphism is also found in mouse models of AD with females displaying precocious 
and stronger memory deficits (King et al., 1999; Clinton et al., 2007; Pistell et al., 2008; 
Carroll et al., 2010) as well as higher levels of Aβ accumulation in the brain (APP23: 
Sturchler-Pierrat and Staufenbiel, 2000; 3xTg-AD: Carroll et al., 2010), than males. In 
APP/PS1 mice, Aβ deposition could be detected at 6 months, leading to a massive load of Aβ 
plaques in the hippocampus and cortex by 9 months (Jankowsky et al., 2004) further 
increased at 12 months (Garcia-Alloza et al., 2006). Higher levels of insoluble Aβ42 and Aβ 
plaque load are observed in females compared to age-matched males (Wang et al., 2003; 
Taniuchi et al., 2007; Gallagher et al., 2013) but also earlier deficits in several hippocampal-
dependent spatial memory tasks (Taniuchi et al., 2007; Gallagher et al., 2013; Richetin et al., 
2017). Amyloid-β peptides (Aβ) are one of the most important hallmark in AD pathogenesis 
(Robin Roychaudhuri et al., 2009). Neuroinflammation in AD is reported to be associated 
with Aβ, likely leading to microglia and astrocytes activation (Frozza et al., 2013). Strikingly 
in vitro and in vivo studies have reported that neuronal electrical activity was enhanced in the 
vicinity of Aβ plaques (Busche et al., 2012; Busche & Konnerth, 2016). Female transgenic 
mice displayed both earlier memory deficits and more severe Aβ plaques deposition 
compared to age-matched males (Richetin et al., 2017; Yang et al., 2018). Therefore, we first 
investigated presynaptic LTP at Mf-CA3 synapses in APP/PS1 female mice at 4 and 6 months, 
an age for which behavioural impairments are already present. Unexpectedly, we did not 
observe any difference between WT and APP/PS1 female mice. Then we chose to study 
synaptic transmission and plasticity in a region which is highly enriched with Aβ plaques, the 
stratum moleculare in the vicinity of the dentate gyrus. This region receives axonal 
projections from entorhinal cortex via the perforant pathway (PP) which convey spatial 
informations (Deng et al., 2010) and make synapses onto DG granule cells. PP projections 
carry to DG granule cells cortical inputs responsible for pattern separation and spatial 
information and memory encoding (Hyman et al., 1986; Bennet et al., 2016). The PP is 
divided into two parts: the lateral perforant pathway (LPP) and the medial perforant pathway 
(MPP). MPP and LPP display different properties in term of synaptic plasticity (Petersen et 
al., 2013) allowing to distinguish between LPP and MPP. In this study, we investigated 
whether abundant Aβ deposition in female APP/PS1 mice shows alerations of behaviours, 
neuron intrinsic properties and basal transmissions, as well as LTP at LPP/DG area. 
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III. Results 
Plasticity of synaptic transmission and intrinsic excitability in the dentate gyrus is altered 
in a mouse model of Alzheimer’s disease 
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Summary 
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disease 
characterized by molecular and cellular alterations accompanied by cognitive disorders and 
likeky related to deficits in synaptic transmission and plasticity in the hippocampus. Strikingly, 
AD displays a sexual dimorphism with a higher prevalence and stronger AD neuropathology 
and related cognitive decline in women. This dimorphism has been poorly investigated in 
transgenic mouse models of the disease. We report here that females APP/PS1, a double 
transgenic mouse model of AD, displayed much earlier Aβ plaques load than males in the 
stratum moleculare of the dentate gyrus in parallel with prominent neuroinflammatory 
activation of astrocytes and microglia. These cellular alterations were accompanied by strong 
deficits in spatial memory in APP/PS1 females when males were spared until 12 months of 
age. Interestingly, both non-synaptic and synaptic alterations at the PP-DG circuit were 
observed in APP/PS1 female mice at 6 months of age. All together our data bring new 
insights in gender-specific molecular, cellular and functional alterations in a mouse model of 
AD. 
 
Keywords 
sexual dimorphism, hippocampus, dentate gyrus, glial cells, neuroinflammation, Alzheimer's 
disease, synaptic plasticity, perforant pathway 
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Highlights 
* Neuroinflammation develops faster and stronger in APP/PS1 females than males 
* Hippocampal-dependent memory is impaired early on in APP/PS1 females but not in males 
* Basal synaptic transmission at the lateral perforant path - DG synapse is altered in APP/PS1 
female mice 
* Firing activity of type 1 DG granule cells is increased in APP/PS1 mice 
* Firing properties of DG granule cells are differentially affected by synaptic potentiation in 
WT vs APP/PS1 mice 
 
Introduction 
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disease which is 
responsible for more than 70 % of dementia in the elderly population worldwide (in "2018 
Alzheimer's disease fact and figures", 2018). AD is characterized by histopathological 
hallmarks, i.e. the extracellular deposit of Aβ plaques mostly in the cortex and the 
hippocampus and the intraneuronal accumulation of fibrillary tangles of hyperphosphorylated 
Tau (Querfurth and LaFerla, 2010). These molecular events are associated with profound 
structural changes in the brain such as the shrinkage of the cortex, the enlargement of 
ventricules and the severe atrophy of the hippocampus.  
Despite tremendous efforts both targeted at basic and clinical studies over the last three 
decades, there is still neither a treatment or a cure for AD nor efficient treatments to alleviate 
the symptoms. Nevertheless, at least in its early stage, AD is thought to affect synaptic 
circuits through alterations of synaptic transmission and plasticity, especially in the entorhinal 
cortex-hippocampal circuitry (for review see Selkoe, 2002; Spires-Jones and Hyman, 2014).  
Impairment of synaptic transmission and plasticity has been extensively studied over the last 
20 years using transgenic mouse model of AD (for review see Marchetti and Marie, 2011). 
These studies have revealed that soluble Aβ and numerous inflammatory molecules produced 
by the activation of glial cells contributed to the pathophysiology of the disease and its 
progression (Akiyama et al., 2000; Heneka and O'Banion, 2007; Heneka et al., 2015). 
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Epidemiological and genetic studies point to major risk factors for developing the disease (age, 
susceptibility genes, diabetes of type 2, obesity) (for review see Hickman et al., 2016) but 
surprisingly sex, which is one of the major risk, has received relatively little attention so far. 
In amyloidogenic mouse models of AD, female mice display precocious and stronger memory 
deficits (Carroll et al., 2010; Clinton et al., 2007; King et al., 1999; Pistell et al., 2008) as 
well as higher levels of Aβ accumulation in the brain (APP23: Sturchler-Pierrat and 
Staufenbiel, 2000; 3xTg-AD: Carroll et al., 2010), than males. In APP/PS1 female mice, 
higher levels of insoluble Aβ42 and Aβ plaque load are observed compared to age-matched 
males (Wang et al., 2003; Taniuchi et al., 2007; Gallagher et al., 2013). Paralleling these 
events, age-related deficits in several hippocampal-dependent spatial memory tasks have been 
reported in APP/PS1 male mice (Jankowsky et al., 2004; Puoliväli et al., 2002; Savonenko et 
al., 2005) but occuring earlier in females (8-9 months), an age for which males are spared 
(Gallagher et al., 2013; Taniuchi et al., 2007; Richetin et al., 2017).  
This sexual dimorphism is of high interest as it is also found in the human pathology, with a 
much higher prevalence (two to three times) of AD-related cognitive decline and greater AD 
neuropathology (Buckwalter et al., 1993; Letenneur et al., 1994; Henderson and Buckwalter, 
1994; Brayne et al., 1995; Fratiglioni et al., 1997; Andersen et al., 1999; Ruitenberg et al. 
2001; Corder et al., 2004; Barnes et al., 2005; Sinforiani et al., 2010) in women compared to 
men. 
In the present work we have compared the hippocampal progression of Aβ plaque deposition 
in male and female APP/PS1 mice at 3, 6 and 9 months of age in relation to the 
neuroinflammatory status. We focussed on the dentate gyrus (DG), a key region of the 
excitatory trisynaptic hippocampal pathway which receives axonal projections from the 
entorhinal cortex and conveys non-spatial as well as spatial informations (Deng et al., 2010). 
We then studied hippocampus-dependent spatial memory using two different one-trial 
behavioral paradigms, i.e., contextual fear conditioning (CFC) and novel object place 
recognition task (NORT) in both gender at different age. We then studied if and how the 
intrinsic properties of DG granule cells and the properties of synaptic transmission and 
plasticity at the perforant pathway - DG circuit were altered in APP/PS1 female mice at 6 
months of age.  
The main findings of our study are plural: APP/PS1 females display earlier Aβ plaques load 
than males in the stratum moleculare of the DG that are paralleled by neuroinflammatory 
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activation of glial cells. These hippocampal molecular and cellular alterations are 
accompanied by strong memory impairments in female but not male mice even in old animals 
(12 months of age). We show that APP/PS1 female mice at 6 months of age displayed 
alterations in intrinsic excitability in DG cells, as well as synaptic alterations at the PP-DG 
circuit.   
 
Material and Methods 
Ethical approval 
Animal anesthesia and euthanasia were carried out in accordance with the Animal Protection 
of ethical standards and the French legislation concerning animal experimentation and were 
approved by the University of Bordeaux / CNRS Animal care and Use Committee 
(authorization #2573). All efforts to improve the animal welfare and to minimize animals 
suffering were made.  
Animals 
The animals used in this study were males and females APPswe695/PS1ΔE9 termed APP/PS1 
obtained from Jackson Laboratory (Bar Harbor, ME, USA) and their wild-type (WT) 
littermates (C57BL6/J). Briefly, the APP/PS1 mice express a chimeric mouse/human amyloid 
precursor protein APPswe (mouse APP695 harboring a human Aβ domain and mutations 
K595N and M596L linked to a Swedish familial AD) and a human presenilin 1 mutated in 
familial AD (PS1ΔE9; deletion of exon 9). These bigenic mice were created by co-injection 
of both transgenes allowing for a co-segregation of the transgenes as a single locus 
(Jankowsky et al., 2004). Mice were generated in our animal facility from double-transgenic 
APP/PS1 males mated with C57BL/6J females. Transgenic mice (APP/PS1) and age-matched 
non-transgenic littermates (WT) were allowed free access to food and water and maintained in 
a 12 hours’ dark-light cycle. Mice were genotyped and systematically regenotyped after each 
experiments (Transcriptomics Platform, Neurocentre Magendie, Bordeaux, France). For all 
experiments, females have been used without consideration to their estrous cycle. 
Acute hippocampal slices 
In accordance with Animal Protection Association of ethical standards and the French 
legislation, APP/PS1 and WT mice at 6 months were deeply anaesthetized with a mix of 
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ketamine (80 mg/kg; i.p) and xylazine (16 mg/kg; i.p) and then intracardially perfused for 2-3 
minutes with a protective solution at 4°C containing the following (in mM): 2.5 KCl, 1.25 
NaH2PO4, 0.5 CaCl2, 7 MgCl2, 20 glucose, 26 NaHCO3, 76 sucrose, 3 pyruvic acid, 5 Na 
ascorbate, equilibrated with 95% 02 and 5% CO2 (300-310 mOsm). When the solution coming 
out of the heart was free of blood, the mouse was sacrificed by decapitation and the brain was 
quickly removed from the skull and stored in the same solution. The isolated brain was glued 
onto the stage of a vibratome (VT 1200S, Leica Microsystems, Nussloch, Germany) and 
parasagittal hippocampal slices (320 µm) were cut in the protective solution for which sodium 
chloride was replaced by sucrose, and then incubated at 33°C for 10-20 min in a resting 
solution containing the following (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 
MgCl2, 20 glucose, 26 NaHCO3, 5 Na ascorbate equilibrated with 95% 02 and 5% CO2 (300-
310 mOsm). Slices were thereafter maintained at room temperature in the same solution until 
required. Unless stated otherwise, all experiments have been done on 6 months old female 
mice.  
Electrophysiological studies on acute hippocampal slices 
For recording, slices were transferred into a recording chamber where they were submerged 
and continuously perfused with an oxygenated (95% 02 and 5% CO2) extracellular solution at 
32-34°C. Whole-cell patch clamp recordings (3-4 MΩ electrodes, -70 mV holding potential) 
were made from dentate gyrus (DG) granule cells visualized by infrared video-microscopy. 
For field recordings, electrodes of about 2 MΩ were used.  
Patch clamp electrodes were pulled out from borosilicate glass (GF 150 F-10) and filled with 
an internal solution containing the following (in mM): 140 CsCH3SO3, 2 MgCl2, 4 NaCl, 
5 phospho-creatine, 2 Na2ATP, 0.2 EGTA, 10 HEPES, and 0.33 GTP adjusted with CsOH 
(300 mOsm, pH 7.3). In some experiments a K+ based internal solution containing (in mM) 
was used: 115 KC6H11O7, 10 KCl2, 0.2 EGTA, 0.02, CaCl2 10 HEPES, 15 phospho-creatine, 
4 MgATP and 0.3 NaGTP adjusted with KOH (300 mOsm, pH 7.3). Bicuculline (10 µM) was 
added to the bath to inhibit γ-Aminobutyric acid-A (GABA-A) receptors. Voltage-clamp 
recordings were performed on DG granule cells identified with a differential interference 
contrast microscope (Eclipse FN-1, Nikon, Champigny sur Marne, France) equipped with an 
infrared camera (VX 44, Till Photonics, Gräfelfing, Germany) using an Axopatch-200B 
amplifier (Axon Instruments, Sunnyvale, CA, USA). Signals were filtered at 2 kHz and 
digitized at 5 kHz via a DigiData 1322A interface (Axon instruments). Series resistance (10-
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20 MΩ) was monitored during the recording using a −10 mV hyperpolarizing voltage step of 
50 ms length occurring at the beginning of each recording.  
To monitor the access resistance during the recording time, a hyperpolarizing voltage step (-5 
mV, 10 ms) was applied at the beginning of each sweep and DG granule cells were rejected if 
more than a 20% change occurred during the experiment. DG granule cells with a holding 
current exceeding 250 pA at a holding potential of -70 mV were also rejected. Data were 
collected and analysed using pClamp software 9.2 (Axon Instruments). For extracellular 
recordings, because of the possibility of crosstalk between mossy cell fibers (MCFs) and the 
more proximal medial perforant path (MPP) we focused our study on lateral perforant path 
(LPP) transmission. To stimulate selectively the LPP, a stimulating glass electrode (1 - 2 µm 
tip diameter) filled with extracellular recording solution was placed in the outer molecular 
layer of the DG (>100 µm away from the granule cell layer) as close to the hippocampal 
fissure as possible. In addition to the location of the stimulating electrode, we characterized 
the LPP on its ability to exhibit paired-pulse facilitation (Fig. 4C) while the MPP does not 
(Fig. 4C). Signals were recorded using an Axopatch-200B amplifier (Axon Instruments, 
Sunnyvale, CA, USA), filtered at 20 kHz and digitally sampled at 50 kHz. All experiments 
were performed in the presence of bicuculline (10 µM) to block GABA-A receptors. Input-
output curves were collected by varying stimulation strength from 0 to 200 µA in 50 µA 
intervals. For subsequent experiments on basal transmission and synaptic plasticities, the 
stimulus strength was set to a level that produced about 30% of the maximal responses. The 
LTP-induction protocol consisted of 3 bursts of 100 stimuli at 100 Hz with a 10 s interburst 
interval (HFS).  
E-S curve, which relates EPSP slopes to the associated action potential probability, was 
generated by measuring slopes during the first 2 ms (reflecting mainly the fast component of 
AMPA-receptor synaptic transmission) and sorted in 0.5mV/ms bins to the associated action 
potential probability. The AP firing probability was calculated for each bin and the EC50 value 
(the value of the EPSP-slope that elicits an AP with 50 % of probability) was calculated in 
each cell.  
EPSP amplitude/slope ratio histograms before and after HFS were generated as follows: at the 
start of the experiment, for each cell the amplitude of sub-threshold EPSPs (i.e. not triggering 
APs) was measured in current-clamp mode (the membrane potential was set to around -70 
mV), and plotted vs the EPSP slope. Then a linear regression was fitted yielding a slope value. 
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The cell was rejected if the goodness of fit, Sy.x, which quantifies the scatter of the data points 
around the best fit line was < 1.5. After this, the cell was switched to voltage-clamp mode and 
held at -70 mV. A baseline was recorded for 5 min and then the HFS protocol (3 bursts of 100 
stimuli at 100 Hz with a 10 s interburst interval) was applied followed by a period of 20 min. 
Then the cell was returned back to current-clamp mode (set around - 70 mV) and a new EPSP 
amplitude/slope ratio histogram was generated. 
Immunohistological staining and analysis 
WT and APP/PS1 male and female mice at 3, 6 and 9 months of age were anesthetized with 
intraperitoneal administration of pentobarbital (50 mg/kg body weight) and were fixed by 
transcardial perfusion with buffered saline and 50 ml of 4% paraformaldehyde (PFA). Brains 
were removed, postfixed in 4% PFA overnight and cut into 40 µm-thick frontal sections on a 
vibratome. Sections were collected into PBS 0.1M and stored at + 4°C until the staining 
protocol. After a thorough wash in TBST (Tris Buffer Sodium: 0.0384 M Trisma Base -
0.1263 M NaCl pH: 7.4 + 0.1 % Tween 20), free-floating sections were incubated with TBST 
- 10% Normal Goat Serum - 0.3% Triton X-100, for 1 hour at room temperature. Then 
sections were incubated with primary antibody in TBST - 3.5% Normal Donkey Serum 
overnight at 4°C (chicken anti - glial fibrillary acidic protein (GFAP): 1/1000 USBiologicals; 
rabbit anti - ionized calcium-binding adapter molecule Iba-1: 1/5000 Wako. Aβ plaques were 
stained either using Methoxy-X04 (a derivative of Congo red, 50 µM, Tocris) or mouse anti-
Aß1-16: 1/150 (Millipore).  
After washes in TBST, sections were incubated with secondary antibodies for 1 hour (Goat 
anti-chicken Alexa 647, anti-mouse Alexa 555 and anti-rabbit Alexa 488: 1/500, Invitrogen). 
Slices were finally washed and mounted in mounting medium (Fluoromount + DAPI, 
SouthernBiotech). Slices were imaged using the up-right widefield microscope Leica 
DM5000 (Leica Microsystems, Nanterre, France) using objectives HC PL Fluotar 20X NA 
0.5. Fluorescence excitation was performed by a LED SOLA Light (Lumencor, Beaverton, 
USA). Images were obtained by the resolutive cameras CoolSnap HQ2 (Photometrics, Tucson, 
USA) and a cooled QICAM (QImaging, Surrey, Canada). A galvanometric stage (Leica 
Microsystems) allowed the z stack reconstructions. The mosaics were made using a motorized 
stage Scan (Märzhäuser, Wetzlar, Germany). This system was controlled by MetaMorph 
software (Molecular Devices, Sunnyvale, USA). Analyses were performed with Image J 
software (National Institutes of Health, New York, USA) on the maximum intensity 
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fluorescence projections of the 3D mosaics.  
Behavioral studies: Contextual fear conditioning (CFC) 
Mice were housed individually. Prior to the test, mice were handled 2 minutes per day during 
5 days. At day 0, single-trial contextual fear conditioning was performed by placing mice into 
a conditioning chamber (context A) where they were allowed to explore for 150 secondes 
after which they received a mild electric footshock (2s, 0.7 mA) and were removed 28 
secondes after the shock. The conditioning chamber was housed in a sound attenuated box 
with the four interior walls wearing a checkerboard pattern. The conditioning cage (17 cm 
wide, 17 cm deep and 25 cm high) was made of clear plexiglas and the floor consisted of a 
shock grid. Between each animal the cage was cleaned with 70% ethanol solution. At day 1, 
mice were reexposed to the conditioning context A then to a new context (context B) during 
180 secondes for each. For the neutral context B, the chamber was housed in an identical box 
but cues made of round and stars pattern on a white background were placed around a 
rounded instead of a squared plexiglas cage. The floor grid was covered by plexiglas and 
bedding. The light was dimmed compared to context A and the cage was cleaned with 1% 
acetic acid between animals. Contextual fear memory retention was studied by measuring the 
freezing response in context A and context B.  Automatic freezing was detected with the help 
of a software (Any-Maze, Ugo Basile, Gemonio, Italy).  
Behavioral studies: Object Location Task (OLT) 
Prior to the test, mice were handled 2 minutes per day during 5 days and habituated to the 
openfield (45 cm wide, 45 cm deep and 40 cm high) the day before the experiment during 20 
minutes, in the absence of objects. The total covered distance was measured by video-tracking 
(Noldus-Ethovision, Nantes, France). The day of testing, mice were first placed for 10 
minutes (habituation phase) in the arena where two identical plastic bricks were located 15 cm 
away from the walls in adjacent quadrants (A and C or B and D). Brick exploration was 
defined as exploration with the nose directing toward it within 2 cm. Absence of preference 
with one of the two bricks was checked during the habituation phase. After a delay of 30 
minutes, mice were reexposed to the arena in which one of the two bricks was moved (for 
exemple from quadrant B to quadrant A or from quadrant D to quadrant C) in order to create a 
new spatial combination and mice were allowed to explore for again 10 minutes. The time 
spent exploring the bricks in the novel and familiar locations was measured during the first 5 
minutes as mice have tendancy to loose novelty detection behavior after few minutes (Cès et 
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al., 2018). The discrimination ratio was determined by the percentage of the time spent 
exploring the displaced brick over the time spent exploring both bricks. 
Enzyme immunoassay determination of PGE2 
The concentration of PGE2 was quantified both in WT and APP/PS1 at 3, 6 and 9 months of 
age. After anesthesia induction by intraperitoneal administration of pentobarbital (50 mg/kg 
body weight), the hippocampus was rapidly dissected and immediately frozen into liquid 
nitrogen. The concentration of PGE2 present in the hippocampus was quantified with a 
specific PGE2 competitive EIA kit (ACETM EIA kit, Cayman Chemical, Ann Arbor, MI, 
USA) following the procedures detailed in the instructions. The detection limit of this EIA kit 
was 15 pg ⁄ mL (80% B ⁄ Bo). Absorbance was measured at 415 nm by a microplate reader 
model 680 (Bio-Rad, Marnes-la-Coquette, France). 
Statistical analysis 
In order to minimize biases as much as possible, experimenters were kept blind to the 
genotype of the mice until analysis was completed. Values are presented as mean ± SEM of n 
experiments. Statistical analyses were performed with Prism 7.0 (GraphPad Software, La 
Jolla, CA, USA). Unless stated otherwise, a Student’s t- test for 2 groups and a one-way 
ANOVA with Bonferonni’s test for more than two groups were used for statistical 
comparison. Data distributions were analysed using the Kolmogorov-Smirnov test; for 
miniature events the distribution curve was calculated for each cell and all cells averaged per 
condition to create a single curve. The p -values given are two-tailed and were considered 
significant if p<0.05.  
Drugs 
Bicuculline, D-2-amino-5-phosphonopentanoate (D-AP5), LCCG-1, CGP55845 and 
Methoxy-X04 were obtained from Tocris. TTX, PGE2, D-serine and PF-04418948 were 
obtained from Sigma-Aldrich. NBQX was obtained from HelloBio. ONO compounds were a 
generous gift from ONO Pharmaceuticals Co Ltd (Japan). 
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Results 
Aβ  plaques and neuroinflammation develops faster in APP/PS1 females than males 
Males and females WT and APP/PS1 mice at 3, 6 and 9 months of age were compared in 
terms of number of Aβ plaques and glial activation (Fig. 1). While there are only very few 
and small Aβ plaques in APP/PS1 male at 9 months of age, there is a heavy load of Aβ 
plaques in APP/PS1 female at the same age (Fig. 1A). Strikingly, Aβ plaques are not 
uniformely distributed throughout the hippocampus but are clearly concentrated in the stratum 
moleculare (delineated by the white dotted-line) of the DG. At a higher magnification (lower 
panel), Aβ plaques appear either associated with a dense core commonly referred as 
"compact" dense-core plaques or diffuse without a dense core known as "cotton wool plaque" 
(Le et al., 2001). Compact plaques are formed by a dense amyloid core (anti- Aβ1-16, white 
signal) surrounded by a spider web of microglia (Iba-1, green signal) walled off by activated 
astrocytes (GFAP, red signal). Cotton wool plaques are larger structures devoid of a dense 
amyloid core but nevetheless surrounded by activated microglia and astrocytes. There is a 
progressive increase in the number of Aβ plaques in APP/PS1 males and females (Fig. 1B) 
starting at 3 months of age with significantly more Aβ plaques in females (3 months: male: 
0.04±0.03, n=44; female: 1.89±0.66, n=29, ** p<0.01; 6 months: male: 4.87±0.79, n=47; 
female: 8.48±0.77, n=56, ** p<0.01; 9 months: male: 10.14±1.42, n=37; female: 21.53±2.91, 
n=29, *** p<0.001).  
To further evaluate the neuroinflammatory status at different age, gender and genotype, 
double immunostaining of microglia (Iba-1) and astrocytes (GFAP) were performed. As 
shown in Fig. 1C, in WT females at 6 months of age, astrocytes displayed elongated bodies 
with long and thin processes whether in APP/PS females at the same age, astrocytes displayed 
rounded cell bodies with shortened and enlarged processes, a morphological hallmark of 
activated astrocytes (Wilhelmsson et al., 2006; for review see Schiweck et al., 2018). 
Microglia also displayed a typical phenotype of reactive cells (Nimmerjahn et al., 2005) 
shifting from a quiescent morphology to an activated status with enlargement of cell bodies 
and shorter and thicker processes (Fig. 1D).  
These data provide clear evidence that deposits of Aβ plaques and glial activation occur faster 
and stronger in APP/PS1 females vs males and are in good agreement with previous studies 
reporting higher level of Aβ plaques load (Taniuchi et al., 2007; Gallagher et al., 2013; 
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Sierksma et al., 2013) and abundant hypertrophic astrocytes in the DG (Richetin et al., 2017) 
in APP/PS1 females compared to age-matched males.  
Hippocampal-dependent memory is impaired in APP/PS1 females but not in males 
Hippocampal-dependent memory was tested in APP/PS1 males and females of 3 to 12 months 
of age and their age-matched WT littermates using two different one-trial behavioral 
paradigms: contextual fear conditioning (CFC) and object location task (OLT).   
Contextual fear conditioning is a hippocampal-dependent task which results in a robust long 
lasting memory for a rodent (Phillips and Ledoux, 1992). Our protocol (Fig. 2A) was 
designed to yield approximately 40-50% freezing in the retrieval test (Fig. 2B). In context A, 
APP/PS1 males at 4 months of age showed levels of freezing nearly identical to age-matched 
WT littermates indicating no memory deficits (WTcontext A: 36.78±10.6 %, n=8; APP/PS1context 
A: 37.76±8.34%, n=8, p=0.942) (Fig. 2B). In contrast, a prononced memory deficit was 
observed in APP/PS1 females at the same age (WTcontext A: 37.43±7.02 %, n=14; 
APP/PS1context A: 15.2±4.79%, n=9, * p<0.05) (Fig. 2B). When placed in a neutral context B, 
WT and APP/PS1 males displayed very similar low levels of freezing (WTcontext B: 
11.56±3.18 %, n=8; APP/PS1context B: 13.93±3.51%, n=8, p=0.624) and WT females 
significantly freezed longer that APP/PS1 (female WTcontext B: 11.57±3.06 %, n=14; female 
APP/PS1context B: 3.19±0.97%, n=9, * p<0.05).  
At 6 months of age, APP/PS1 males still displayed no memory deficit (WTcontext A: 
46.59±4.94%, n=12; APP/PS1context A: 37.99±6.36%, n=10, p=0.291) whereas APP/PS1 
females showed memory deficit as expected (WTcontext A: 50.23±5.09%, n=15; APP/PS1context 
A: 30.77±6.78%, n=10, *p<0.05) (Fig. 2C). The lack of behavioral deficit in this task was 
even observed in 12 months old male mice (WTcontext A: 49.48±7.3 %, n=7; APP/PS1context A: 
50.47±7.47%, n=11, p=0.929) (Fig. 2D).  
Importantly, mice for both genotype and gender at any age displayed low levels of freezing 
(data not shown) during the 150 s period before the footshock at the time of training (females 
4 months:  WT:0.97±0.24%, n=14; APP/PS1:0.97±0.48%, n=9, p=0.997; males 4 months: 
WT:7.22±3.59%, n=9; APP/PS1:5.25±1.32, n=8, p=0.678; females 6 months: 
WT:5.62±1.44%, n=15; APP/PS1:3.01±0.84%, n=10, p=0.186; males 6 months:  
WT:1.70±0.46 %, n=12; APP/PS1:0.48±0.21%, n=10, *p<0.05; males 12 months: 
WT:4.16±1.92%, n=7; APP/PS1:5.73±1.14%, n=11, p=0.462). Such amounts of exploratory 
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activity were good evidence for a lack of significant anxiety-related behavior in our 
experimental conditions. 
Next, APP/PS1 males and females of 3, 4 and 6 months of age and their age-matched WT 
littermates were subjected to OLT (Fig. 3A). Following the 30 minutes’ retention period, WT 
female mice spent more time exploring the novel location of the object than the familiar one 
at all age, so that the discrimination ratio was significantly different from 50% (3 months: 
65.41±3.99%, n=14, **p<0.01; 4 months: 66.34±3.76%, n=16, ***p<0.001; 6 months: 
66.25±2.9%, n=15, **p<0.01; Fig 3B).  
In contrast and as early as 3 months of age, APP/PS1 female did not explore the novel 
location of the object significantly more than the fixed one (3 months:  44.17±4.66, n=15, 
p=0.232; 4 months: 51.6±4.91%, n=10, p=0.752; 6 months: 47.76±2.32%, n=13, p=0.354; Fig 
3B) indicating therefore that they were impaired in this task at a fairly young age. Our data 
provide clear evidence that whatever the age, APP/PS1 mice never explored more than WT 
mice the novel location of the object.  
All together, these data clearly show that memory deficits displayed by APP/PS1 mice and 
tested by CFC and NORT appear much earlier in females than males. These memory deficits 
parallel the prominent increase in neuroinflammatory markers, i.e. Aβ plaques load, astrocytic 
and microglial activation ahead of few months in females compared to age-matched males.  
Basal synaptic transmission at the lateral perforant path - DG synapse is altered in 
APP/PS1 female mice 
Because the Aβ plaques appeared earlier and were more abundant in the stratum moleculare 
of the DG in female mice, we set out to characterize the basic properties of the lateral 
perforant path (LPP) input which make synaptic contact to granule cells of the DG in this 
layer. The DG receives information from layer 2 of the entorhinal cortex via a bundle of 
axons, the perforant path which is subdivided into the LPP that is assumed to convey novel 
contextual information whereas spatial information appears to be conveyed by fibres of the 
medial perforant path (MPP) (Hunsaker et al., 2007).  
The stimulating electrode was placed in the outer one-third molecular layer of the DG 
suprapyramidal blade and the recording electrode was located either in the DG granule cell 
layer for patch-clamp recordings as shown in Fig. 4A, or near the crest of the suprapyramidal 
blade for field recordings. In this way, we achieved reliable and selective activation of LPP 
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projections to the DG. To activate selectively MPP, the electrode was carefully positioned in 
the middle molecular layer, that is at a distance < 100 µm from the DG granule cell layer. 
Increasing stimulus intensity (0 - 200 pA; 0.1 ms at 0.1 Hz) of the LPP triggered population 
spike the amplitude of which was plotted against stimulus intensity (Fig. 4B). Input-output 
relationships for stimulus intensity vs population spike amplitude were significantly different 
between genotypes, APP/PS1 female mice at 6 months of age always displaying a smaller 
population spike amplitude compared to the aged-matched WT female (Fig. 4B). LPP was 
also discriminated from MPP using a paired-pulse protocol (McNaughton, 1980; Wang and 
Lambert, 2003; Petersen et al., 2013) which results in the facilitation of the second pulse 
when the LPP is stimulated but either no facilitation or even a depression of the second pulse 
when the MPP is stimulated (Fig. 4C). Stimuli were delivered at a low intensity, that is at 25-
30% maximum pop spike amplitude to minimize as much as possible current spreading to the 
adjacent pathway but also to avoid paired-pulse facilitation of the MPP which is reported for 
higher stimulus intensity (Petersen et al., 2013). The two pulses were separated by 50 to 100 
ms inter-pulse interval. Both genotypes exhibited a facilitation for the LPP but not for the 
MPP (Fig. 4C).  
The difference in the input-output relationships between the two genotypes suggest a 
decreased excitability of DG cells in APP/PS1 female mice compared to WT. We next 
examined the relative amplitude of synaptic currents mediated by AMPA and NMDA 
receptors in DG granule cells of APP/PS1 and WT female mice at 6 months of age. AMPA 
currents were recorded using the whole-cell configuration of the patch clamp technique in 
voltage-clamp mode at a holding potential of -70 mV, a potential at which NMDA currents 
were virtually absent due to the Mg2+ voltage-dependent block (Kupper et al., 1998). NMDA 
currents were isolated at a holding potential of +40 mV in the presence of 50 µM NBQX to 
block AMPA and kainate currents. We found no difference in AMPA/NMDA ratio between 
WT (2.82 ± 0.45, n=10) and APP/PS1 mice (2.35 ± 0.39, n=9; p=0.452, Fig. 4D). 
Furthermore, the AMPA rectification index, a proxy to investigate for possible change of 
AMPA receptor function did not significantly differ between both genotypes (WT:0.51 ± 0.06, 
n=10; APP/PS1:0.49 ± 0.08, n=9; p=0.794, Fig. 4E) suggesting no major alteration in AMPA 
receptor function in APP/PS1 female mice.  
We then recorded spontaneous AMPA and NMDA miniature excitatory postsynaptic currents 
(mEPSCs) from DG cells to investigate if they were altered in APP/PS1 compared to WT 
mice. AMPA mEPSCs (mAMPA) were recorded at a holding membrane potential of −70 mV 
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in the presence of 0.5 µM TTX to block action potentials and 10 µM bicuculline to block 
mIPSCs due to GABA-A receptors. For NMDA mEPSCs (mNMDA), recordings were made 
in nominal Mg2+ free solution with 50 µM D-serine (co-agonist of the NMDA receptor, 
Mothet et al., 2000) and in the presence of 10 µM NBQX to block AMPA receptors. Synaptic 
activity was recorded for 15 minutes and all events occuring during this period were counted 
for both amplitude and frequency analysis.  
The average mean frequency of mAMPA currents was similar between both genotype (WT: 
14.00 ± 2.50 events/min, n=16; APP/PS1: 18.50 ± 2.91 events/min, n=15, p=0.249). In 
contrast, the frequency of NMDA currents was significantly larger in APP/PS1 mice (17.12 ± 
1.29 events/min, n=14) when compared to WT (4.60 ± 0.43 events/min, n=13; *** p<0.001) 
(Fig. 5A).  
The average mean amplitude of mAMPA (WT: 8.19 ± 0.27 pA, n=15; APP/PS1: 9.22 ± 0.51 
pA, n=15, p=0.088) and of mNMDA (WT: 15.50 ± 0.94 pA, n=15; APP/PS1: 17.55 ± 1.09 
pA, n=14, p=0.166) currents were similar between both genotype (Fig. 5A).  
No significant differences were observed for the mean 10-90% rise time and the time constant 
(Tau) of the decay between genotypes for both mAMPA and mNMDA currents. The mean 
rise time of mAMPA and mNMDA currents was 0.65 ± 0.07 msec (n=15) and 0.77 ± 0.08 
msec (n=15) respectively for WT mice and 0.93 ± 0.13 msec (n=14) and 0.69 ± 0.05 msec 
(n=14) respectively for APP/PS1 mice (Fig. 5B). The decay of the currents was 
monoexponential with a Tau of 6.22 ± 0.35 msec (n=15) for WT mAMPA and 4.92 ± 0.21 
msec (n=14) for APP/PS1 mAMPA (Fig. 5B). For mNMDA, Tau was 15.27 ± 2.01 msec 
(n=15) for WT and 19.06 ± 1.68 msec (n=14) for APP/PS1 (Fig. 5B).  
The cumulative probability analysis of mAMPA amplitudes showed a significant difference 
between WT and APP/PS1 mice (KS test, *** p>0.0001; 2556 events of 16 cells for WT and 
3884 events of 15 cells for APP/PS1 mice) (Fig. 5C) whereas the amplitude distribution 
histogram was not statistically different between genotypes (paired t test, p=0.126) (Fig. 5C). 
The cumulative probability analysis of mNMDA amplitudes also showed a significant 
difference between WT and APP/PS1 mice (KS test, *** p>0.0001; 861 events of 15 cells for 
WT and 3461 events of 14 cells for APP/PS1 mice) but also the amplitude distribution 
histogram (paired t test, * p<0.05) (Fig. 5C).  
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In summary these results show a decreased basal transmission and an increased frequency of 
mNMDA currents for APP/PS1 vs WT mice.  
The firing activity of type 1 DG granule cells is increased in APP/PS1 mice 
Adult DG granule cells have been reported to be composed of a continuum of newly born and 
mature neurons reflecting their dynamic integration in the DG throughout the entire life of the 
organism (Aimone et al., 2011; Nakashiba et al., 2012). These two populations of DG 
neurons display different intrinsic properties, such as input resistance (Rin) and firing patterns, 
which have been used as specific hallmarks of the degree of maturation and integration in the 
circuitry. This prompted us to ask whether intrinsic properties of DG cells were differentially 
affected by Aβ pathology in APP/PS1 mice model. Whole-cell patch clamp recordings were 
carried out in DG cells from 6 months-old WT and APP/PS1 mice. Figure 6A shows 
representative electrotonus and action potentials (APs) in a DG granule cell from a WT mouse 
in response to short (200 µs) depolarizing current step injections (10 µA increments) in 
current-clamp mode at a membrane potential close to -70 mV. We did not observe significant 
differences between WT and APP/PS1 mice for input resistance (Rin), total amplitude of AP, 
amplitude of the overshoot, time to peak of the AP, time to reach the half-maximal amplitude 
(t50), threshold potential (Table 1). The resting membrane potential of DG granule cells was 
on average slightly more hyperpolarized in APP/PS1 mice compared to WT mice (-72.7 ± 0.9, 
n=23; -75.4 ± 0.7, n=15 respectively, * p<0.05, Table 1). 
The E-S curve (relates EPSP-slopes to the associated AP firing probability) was generated by 
applying increasing stimuli to span the all range, i.e. from a sub-threshold EPSP evoking no 
action potential to an EPSP evoking an action potential with 100% probability. There were no 
significant differences between genotypes in the E-S curves with a EC50 value of 5.96±0.38 
(n=15) for WT and 5.85±0.39 (n=15) for APP/PS1; p=0.849 (Fig. 6A). 
In order to discriminate the putative two types of DG cells, we then applied long current steps 
(250 ms) of 10 pA increments from -20 pA up to 200 pA to evoke trains of APs. As shown in 
Fig. 6B, DG granule cells could be divided into two distinct categories, termed type 1 and 
type 2 according to Nenov et al (2015). Type 1 DG cells exhibited spikes starting from a 
moderate intensity, increasing in frequency following steps increments (Fig. 6B). At current 
steps of high intensity (>120 pA), type 1 DG cells lacked sustained firing, APs became 
progressively smaller in amplitude and ceased before the end of the current step (Fig. 6B). In 
contrast, type 2 DG cells fired throughout all the current step without failure and exhibited 
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firing frequencies linearly proportional to the intensity of the current step, i.e. the maximum 
number of APs was always observed for the highest current intensity (Fig. 6B; Fig. 6C). 
Whatever the intensity of the current steps, WT DG cells significantly fired fewer spikes that 
APP/PS1 DG cells for both type 1 and type 2 (Fig. 6C; *** p<0.0001, two-way ANOVA). 
WT type 1 DG cells had a high Rin (368±20 MΩ, n=14) whereas WT type 2 DG cells had a 
significant lower Rin (279±19 MΩ, n=16, ** p=0.0033) (Table 2). In APP/PS1 mice, type 1 
DG cells had a Rin of 368±16 MΩ (n=17) and type 2 DG cells a Rin of 294±18 MΩ (n=14, ** 
p=0.0048) (Table 2). The proportion of type 1 vs type 2 DG granule cells was 46.7 % vs 
53.3 % in WT mice (n = 30) and not significantely modified in APP/PS1 mice (54.8 % vs 
45.2 %, n = 31, p=0.366, Chi-square = 0.815, Chi-squared test). Type 1 and type 2 Rin were 
not significantly different with respect to the genotype (p=0.993 and p=0.562 respectively) 
(Table 2). 
To gain further information on ionic mechanisms that may underlie different spiking patterns 
between type 1 and type 2 DG cells according to genotype, we studied the first three 
interspike intervals (Fig. 6D). The first spike interval was 15.9±1.6 ms (n=13) in WT type 1 
DG cells and was significantly smaller in APP/PS1 type 1 DG cells (10.4±0.8, n=17, ** 
p<0.01) whereas it was not different significantly between WT and APP/PS1 mice for type 2 
DG cells (12.5±1.2, n=17 and 9.6±0.7, n=14 respectively, p=0.069). Both the second and the 
third spike intervals confirmed the same pattern with an increased spike frequency for 
APP/PS1 vs WT type 1 cells (second spike interval: WT: 20.5±2.1 ms, n=13 and APP/PS1: 
13.3±1, n=17, ** p<0.01; third spike interval: WT: 23.9±2.2 ms, n=13 and APP/PS1: 17.±1.5, 
n=16, * p<0.05)  whereas it was not different between WT and APP/PS1 type 2 cells (second 
spike interval: WT: 16.4±1.5 ms, n=17 and APP/PS1: 13.5±1.2 ms, n=14, p=0.154; third 
spike interval: WT: 18.9±1.4 ms, n=17 and APP/PS1: 18.2±1.9, n=14, p=0.773) (Fig. 6D). 
We also examined the last three interspike intervals in type 2 DG cells, as they were spiking 
throughout all the current step without failure, to search for possible differences, with respect 
to the genotype, in spike frequency adaptation, i.e. a reduction of the firing rate to a stimulus 
of constant intensity. Whatever the interval, i.e. the third, the second or the first, they were no 
differences between both genotype (third spike interval: WT: 31.6±1.7 ms, n=15 and 
APP/PS1: 28.9±1.1 ms, n=14, p=0.206; second spike interval: WT: 30.3±1.5 ms, n=17 and 
APP/PS1: 31.6±1.4 ms, n=14, p=0.551; first spike interval: WT: 34.5±1.4 ms, n=17 and 
APP/PS1: 33.3±1.8 ms, n=14, p=0.623) (Fig. 6E).   
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In summary these results show a selective increase in firing activity for type 1 DG granule 
cells (supposedly less mature; Mongiat et al., 2009, Spampanato et al., 2012, van Praag et al., 
2002, Nenov et al. 2015) in APP/PS1 mice and no change of intrinsic excitability in type 2 
DG cells. 
The firing properties of DG granule cells are differentially affected by synaptic 
potentiation in WT vs APP/PS1 mice 
 It has been recently reported that the intrinsic excitability of DG granule cells was highly 
plastic and modulated by synaptic potentiation (Lopez-Rojas et al., 2015). Interestingly, the 
intrinsic firing properties of DG granule cells were affected in a single transgenic mouse 
model of AD (Nenov et al., 2015).   
At the LPP-DG synapse, long-term potentiation (LTP) of excitatory transmission is induced 
by high-frequency stimulation (HFS). As shown in Fig. 7A, HFS (3 bursts of 100 stimuli at 
100 Hz with a 10-second interburst interval) triggered a robust and long-lasting potentiation 
(LTP) of the population spike amplitude (PSA) in WT female mice (187±14%, n=17) which 
was completely blocked by 50 µM AP-V (n=9). This LTP was reduced by half in APP/PS1 
female mice (146±8%, n=16, * p<0.05) (Fig 7. A, D). The levels reached for LTP in age-
matched WT male mice (150±9%, n=15, * p<0.05) were similar to those observed in 
APP/PS1 female mice (Fig 7. A, D).  
We also examined if the probability of discharge of the postsynaptic DG granule cells in 
response to excitatory synaptic stimulation was differentially affected in WT vs APP/PS1 
mice. HFS induced a large shift to the left of the EPSP-to-Spike (E-S) potentiation curves (Fig. 
7B) in both genotypes although with a larger amplitude for APP/PS1 mice (EC50 WT: 
5.96±0.38, n=15, EC50 WTafter HFS: 4.51±0.41, n=11, * p<0.05; EC50 APP/PS1: 5.85±0.39, 
n=15, EC50 APP/PS1after HFS: 3.92±0.27, n=10, ** p<0.01). These results show that HFS 
induces long lasting changes in intrinsic plasticity of DG granule cells. The shift to the left 
indicates an increase of excitability in DG cells induced by LTP, i.e. to a smaller EPSP slope 
corresponds a higher AP firing probability (Fig. 7B).  
 
Then we looked to the relation between the EPSP amplitude and the EPSP slope for 
subthreshold EPSPs (i.e. not triggering APs) before and after HFS. We found a significant 
increase in the EPSP amplitude/slope ratio for APP/PS1 mice (APP/PS1: 4.55±0.18, n=15; 
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APP/PS1after HFS: 6.08±0.31, n=11, *** p<0.001) but not for WT mice (WT: 4.90±0.30, n=15; 
WTafter HFS: 5.70±0.33, n=12, p=0.08) (Fig. 7C).  
PGE2-signaling pathway is not involved in the impairment of LTP at the LPP-DG 
synapse  
In a previous work, we reported that PGE2 acting on EP3 receptors impaired Mf-CA3 LTP in 
WT male mice and that the involvement of an inflammatory PGE2-EP3 signaling pathway 
was responsible for the impairment of the LTP in aged APP/PS1 male mice (Maingret et al., 
2017). In the present work, the LTP of PSA is significantly impaired by half in APP/PS1 
female (WT: 187±14%, n=17; APP/PS1: 146±8%, n=16, * p<0.05) (Fig 7A,7D). This 
prompted us to investigate the effects of exogenous PGE2 and/or specific agonists and 
antagonists of different EP subtypes receptors on the LTP of PSA both in WT and in 
APP/PS1 female mice.  
When adding 10 µM PGE2, we did not observe any significant impairment of LTP in WT 
female mice (WT: 187±14%, n=17; WT+PGE2: 161±15%, n=17, p=0.2). Neither a specific 
EP2 receptor agonist (ONO-AE1-259-01, 1µM) nor a EP2 receptor antagonist (PF-04418948, 
10 µM) or a EP3 receptor antagonist (ONO-AE3-240, 1 µM) significantly altered LTP 
(WT+ONO-AE1-259-01: 160±12%, n=17; WT+PGE2+PF-04418948: 169±16%, n=16; 
WT+PGE2+ONO-AE3-240: 154±8%, n=16) (Fig. 7D). These results ruled out the 
involvement of either PGE2-EP2 or PGE2-EP3 signaling pathway acting of LTP at the LPP-
DG synapse in WT female mice.   
Then we searched if the impairment of LTP observed in APP/PS1 was possibly related to 
PGE2. Neither PF-04418948 (10 µM) nor ONO-AE3-240 (1 µM) rescued LTP 
(APP/PS1+PF-04418948: 140±8%, n=17, p=0.619; APP/PS1+ ONO-AE3-240: 147±11%, 
n=17, p=0.191) (Fig. 7D) which ruled out any significant involvement of inflammatory PGE2-
EP2 or PGE2-EP3 signaling pathway in APP/PS1 female mice acting on LTP. These 
somewhat unexpected results with respect to the precocious neuroinflammatory status of 
APP/PS1 female mice led us to quantified PGE2 within the hippocampus at different ages for 
both genotypes. No significant difference in PGE2 levels was observed between WT and 
APP/PS1 female mice at any age (3 months: WT: 17.9±2.06 pg/mg, n=13; APP/PS1: 
13.07±1.31 pg/mg, n=12; p=0.073; 6 months: WT: 18.98±4.31 pg/mg, n=10; APP/PS1: 
19.31±4.02 pg/mg, n=10; p=0.705; 9 months: WT: 12.44±1.41 pg/mg, n=12; APP/PS1: 
12.57±1.36 pg/mg, n=11; p=0.951) (Fig. 7E).  
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Discussion 
Our findings show prominent sex-differences in the development of Aβ plaques load and glial 
activation in a transgenic mouse model of AD. The molecular and cellular alterations 
observed in the DG of APP/PS1 female mice paralleled functional deficits revealed by 
hippocampal-dependent memory tasks. Most interestingly, these alterations are concomittant 
with modifications of the plasticity of synaptic transmission and intrinsic excitability in the 
perforant path to DG granule cells circuitry, a key region of the integration of mnesic 
informations originated from the entorhinal cortex which display a high density of Aβ plaques. 
Sex-differences in Aβ load and glial activation in the DG region  
Our results clearly show that Aβ load starts much earlier in APP/PS1 females as compared to 
age-matched APP/PS1 males. Whatever the age, Aβ plaques burden was always significantly 
higher in females vs males.  
According to Jankowsky et al (2004), APP/PS1 mice display a high ratio Aβ 42/ Aβ40  which 
accelerates Aβ aggregation into Aβ plaques starting around 6 months of age. APP/PS1 
females at 8-9 months of age display roughly twice as many Aβ plaques in the hippocampus 
and two to three times higher levels of Aβ42 (Gallagher et al., 2013; Taniuchi et al., 2007) 
than age-matched males. This sex-difference prolongs during aging and is still present in 
APP/PS1 up to 17 months of age (Wang et al., 2003). 
The physiological basis underlying this sexual dimorphism is still elusive but few potential 
mechanisms have been proposed to support it such as the increased expression of BACE-1 in 
APP/PS1 females leading to an enhanced production of Aβ (Gallagher et al., 2013), a 
modified proliferation of hippocampal progenitors (Tanuichi et al., 2007) yielding less DG 
adult-born neurons with a reduced life expectancy in  APP/PS1 females (Richetin et al., 2017) 
but also an increased activation of glial cells (microglia, Tanuichi et al., 2007; astrocytes, 
Richetin et al., 2017). Obviously, the putative influence of sex hormones has also been 
investigated. In vitro estrogen has been shown to be neuroprotective against Aβ through its 
ability to decrease lipid peroxidation (Behl et al., 1995; Gridley et al., 1997). Estrogen 
supplementation has been reported to delay the onset in AD and to reduce its prevalence in 
woman (Henderson et al., 2000) but further trials suggested that estrogen supplementation 
might have no effect on the course of the disease in elderly woman (Fillit, 2002; Cholerton et 
al., 2002).  
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There is considerable evidence that neuroinflammation is a major component of AD 
(Akiyama et al., 2000; Heneka and O'Banion, 2007; Heneka et al., 2015) contributing to its 
progression and its pathogenicity. Furthermore, and relevant to sex-differences, it has been 
suggested that the differential vulnerability to AD between man and woman could be 
mediated by a sex-specific systemic inflammatory response in early AD (Varma et al., 2016). 
The cellular players of neuroinflammation i.e. microglia, the resident immune-competent 
brain cells, and astrocytes release a plethora of inflammatory molecules such as pro-
inflammatory cytokines, prostanoids, nitric oxide and other cytotoxic molecules when 
activated. The agenda of glial activation in the course of AD is still a matter of debate, but it is 
doubtless that Aβ is a potent neuroinflammatory molecule which activates glial cells and 
thereby exacerbates the neuroinflammatory response (Heneka et al., 2015). In the present 
work, hallmarks of activated glial cells were evidenced in APP/PS1 females and appeared 
much earlier than in age-matched APP/PS1 males. In APP/PS1 females, abundant 
hypertrophic astrocytes (see Schiweck et al., 2018) and ameboïd microglia were densely 
expressed in the stratum moleculare of the DG, a region affected early by the spatiotemporal 
progression of the disease (Hurtado et al., 2010). Activated glial cells were distributed in the 
stratum moleculare and densely packed around Aβ aggregates to form Aβ plaques.  
Sex-differences in hippocampal-dependent memory tasks  
Our results show that APP/PS1 females exhibit much earlier spatial memory impairments 
than age-matched males. In order to relate hippocampal Aβ load and neuroinflammatory glial 
activation, we chose to compare mnemonic performances of APP/PS1 females and males in 
two behavioral tasks (contextual fear conditioning and object location task) testing 
hippocampal-dependent memory. APP/PS1 females were impaired as early as 4 months of 
age, i.e. an age for which there are only very few Aβ plaques, whereas age-matched males 
were spared. Remarquably, APP/PS1 males displayed unaltered CFC behavior until at least 
12 months of age, despite a noticeable hippocampal Aβ plaques load (Maingret et al., 2017). 
As noticed by Richetin et al (2017) and strenghened by our study, it suggests that 
hippocampal-dependent memory deficits were not directly linked to Aβ plaques but more 
likely to the presence of Aβ peptides. Interestingly, it has also been suggested that impaired 
synaptic integration of disabled adult-born neurons related to the neuroinflammatory 
activation of astrocytes in APP/PS1 females could be involved in those hippocampal-
dependent memory deficits (Richetin et al., 2017).  
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Electrophysiological properties of type 1 and type 2 DG granule cells in WT and APP/PS1 
mice 
Our results show, supported by previous studies, that granule cells in the DG can be 
segregated into two distinct populations i.e. type 1 and type 2, with different intrinsic 
properties, based on Rin and firing patterns (Schmidt-Hieber et al., 2004; Mongiat et al., 2009; 
Nenov et al., 2015). Type 1 DG cells are considered to be young neurons whereas type 2 cells 
correspond to more mature cells (van Praag et al., 2002; Mongiat et al., 2009; Spampanato et 
al., 2012). Remarquably, the proportion of type 1 and type 2 was not affected by the genotype 
in contrast to what was reported by Nenov et al (2015). Type 1 DG cells had a high Rin and 
did not fire APs throughout the entire duration of the current step whether type 2 DG cells has 
a low Rin but fired APs without failure during the 250 ms current step. Notably, we observed 
no differences in Rin due to genotype whereas Nenov et al (2015) reported a significant 
difference of Rin for type 2 DG cells between WT and single transgenic Tg2576 mice.  
We have no firm explanation for these discrepancies but they might be related to differences 
between Nenov's data and ours. First, in our study, we were using only female mice whether 
male and female were used indifferently in Nenov's study. Second the transgenic mouse 
model was different (single transgenic Tg2576 for Nenov et al., 2015; double transgenic 
APP/PS1 in our work) and last the age was also different (9 months old mice for Nenov et al., 
2015; 6 months old mice in our work). Interestingly, Nenov et al (2015) suggested that 
differences observed in WT vs Tg2576 DG cells could be due to a decrease in proliferation, 
survival, maturation or integration of newborn DG neurons within DG. If true, the younger 
age of our mice (6 months vs 9 months in Nenov's study) could blunt differences due to these 
mechanisms. Worthy of note, the estrous cycle is known to alter hippocampal spinogenesis 
and spine densities (Gould et al., 1990; Hara et al., 2015) and adult-born DG cells in 
APP/PS1 female mice at older age than in the present study (i.e. 7-9 months of age) display 
severely impaired dendritic spine density contributing to reduced survival rate (Richetin et al., 
2015). 
 
Differences in the plasticity of intrinsic excitability in DG granule cells between WT and 
APP/PS1 female mice 
Whatever the intensity of the current steps, APP/PS1 DG cells fired significantly more spikes 
than WT DG cells for both type 1 and type 2 hence revealing an increased excitability of DG 
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cells in APP/PS1 female mice. An increased excitability, although not statistically significant, 
was also reported for Tg2576 type 2 DG cells (Nenov et al., 2015). To caracterize further the 
firing pattern, we examined both the instantaneous firing frequency by measuring the 
interspike interval (ISI) during the first three intervals and the spike frequency adaptation by 
measuring ISI for the last three intervals for type 1 and type 2 DG cells. Type 1 APP/PS1 DG 
cells showed a significant reduction in ISI during the first three intervals compared to WT but 
not for type 2. No differences in spike frequency adaptation was observed for type 2 DG cells 
between genotypes.  
The distinct firing patterns of type 1 and type 2 DG cells imply a diversity of underlying 
voltage-dependent ion channels and their different contribution may be related to the observed 
changes in firing frequency in APP/PS1 DG cells. Hence, a decreased expression of somatic 
Na+ channels produced an increase of the instantaneous spiking frequency in PS/APP double 
transgenic mice (Brown et al., 2011). Related synaptic mechanims may also impact neuronal 
excitability such as a relative decrease in GABAergic tonus reported in cortical neurons from 
APP23/PS45 double transgenic mice (Busche et al, 2008) but unlikely to be involved in our 
experimental conditions always in the presence of bicuculline. 
Synaptic plasticity and intrinsic excitability in DG granule cells of WT vs APP/PS1 females 
The difference in the input-output relationships between WT and APP/PS1 at the LPP-DG 
synapse lead us to investigate if the synaptic content in AMPA and NMDA receptors were 
affected by the genotype. Both the AMPA/NMDA ratio and the AMPA rectification index 
were similar between genotypes suggesting neither major change in NMDA receptor activity 
nor in AMPA receptor function. Strikingly, the frequency of NMDA minis but not AMPA 
minis was increased in APP/PS1 DG granule cells. The most reasonable explanation for this 
increased frequency of NMDA minis would be an increased number of silent synapses 
expressing NMDA receptors in APP/PS1 DG granule cells but devoid of functional AMPA 
receptors. Remarquably, an increase in hippocampal silent synapses in transgenic mouse 
models of AD, by removal and/or internalization of AMPA receptors, has been previously 
reported (Hsieh et al., 2006; Price et al., 2014, reviewed in Chater and Goda, 2014), although 
in our conditions we found no decrease in AMPA receptor mediated synaptic transmission. 
Our data show a strong impairment of HFS-induced potentiation of the population spike 
amplitude in APP/PS1 female mice, when compared to aged-matched WT female mice. Thus 
it is important to unravel the intermingled relationships between synaptic plasticity and 
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plasticity of intrinsic excitability of DG granule cells to decipher how they might impact each 
other. The LTP protocol induced a prominent modulation of the E-S curve linking EPSPs 
slope to the probability of firing an action potential. HFS elicited significant shifts to the left 
for both genotype with a larger shift for APP/PS1 vs WT female mice.   
Taken together, these results indicated that synaptic potentialisation elicited changes in 
intrinsic excitability of DG granule cells with a larger increase for APP/PS1 vs WT. Strikingly, 
the increase in CA1 neuronal activity induced by Aβ oligomers impaired by half the 
potentialisation of population spike amplitude (Lei et al., 2016).  
Interestingly, we did not observe any significant changes in the threshold for action potentials 
and only a fairly minor change (less than 3 mV) in the resting membrane potentials that could 
account for excitability changes. However, we observed a significant difference in the EPSP 
amplitude/slope ratio before and after HFS for APP/PS1 but not WT DG cells. As EPSP slope 
was measured during the first two milliseconds which reflects mainly the AMPA component 
of synaptic transmission, these data suggested that changes in dendritic processing of synaptic 
input in APP/PS1 DG cells could account for excitability changes. Interestingly, changes in 
intrinsic excitability of DG cells have been recently attributed to the modulation of dendritic 
A-type potassium channels (Lopez-Rojas et al., 2016) and dendritic hyperexcitability induced 
by Kv4.2 deficiencies in the hippocampal CA1 region was reported in a single transgenic 
(hAPP) mouse model of AD (Hall et al., 2015). 
Prostanoïds and LTP impairment in APP/PS1 females 
In a previous work, we reported that PGE2-EP3 signaling pathway was impairing 
hippocampal presynaptic LTP at the mossy fiber - CA3 synapse in aged APP/PS1 males 
(Maingret et al., 2017). In the present work, neither PGE2-EP2/EP4 nor PGE2-EP3 pathways 
were involved in the impairment of PSA-LTP at LPP-DG synapses. Furthermore, in contrast 
with our previous study (Maingret et al., 2017), hippocampal levels of PGE2 were not 
increased with time in APP/PS1 vs WT females. Interestingly, deficiency of estrogen 
augments PGE2 levels in ovariectomized female rats (Wang et al., 2014) which suggests that 
female sex hormones exert a tonic brake on PGE2 levels and might explain why PGE2 levels 
were not altered in APP/PS1 vs WT females.  
In conclusion, neuroinflammatory hallmarks of AD are more precocious in double transgenic 
female mouse model of AD when compared to age-matched males. These histopathological 
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alterations are concomittant of strong and specific impairment of hippocampal-dependent 
memory task together with non-synaptic and synaptic modifications at the hippocampal PP-
DG circuitry.  Hence, our results are clear evidence that 1 - results originated from studies 
using males and females together must be taken with extreme caution as males and females 
clearly behave differently, 2 - depending on the hippocampal region and on the gender, 
mechanisms responsible for LTP impairment are different and 3 - more studies aiming at 
deciphering mechanisms on mouse models of AD in females are most wanted.  
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Figure 1: APP/PS1 mice display hippocampal Aβ plaques and glial activation earlier in female than 
male. A. Representative micrographs of a hippocampus in WT and APP/PS1 male vs female at 9 
months of age. Slices were double stained for nuclei with 4',6-diamidino-2-phenylindole (DAPI, blue 
signal) and for Aβ plaques with 2,5-Bis(2-(4-hydroxyphenyl)vinyl) anisole (methoxy-X04, red signal). 
Note the heavy load of Aβ plaques in the stratum moleculare (delineated by the white dotted-line 
located above the stratum granulare) of the DG of female mice. Bar scale = 250 µm. Lower panel, 
representative micrograph of Aß plaques (anti- Aß1-16 antibody, white signal) surrounded by activated 
astrocytes (GFAP, red signal) and microglia (Iba-1, green signal). Bar scale = 10 µm. B. Bar graphs 
represents the number of Aβ plaques in the DG stratum moleculare (as shown in A) at different ages 
for male and female mice. Note the significant higher deposit of Aβ plaques for APP/PS1 female vs 
male mice at all age. (* p<0.05; ** p<0.01; *** p<0.001). C. Magnification of a representative DG 
stratum moleculare region of WT and APP/PS1 female mice. Note the morphological changes in 
GFAP positive cells (astrocytes) in APP/PS1 (red star and green triangle) vs WT female mice (blue 
triangle).   D. Magnification of a representative DG stratum moleculare region of WT and APP/PS1 
female mice. Note the morphological changes in Iba-1 positive cells (microglia) in APP/PS1 (red star 
and green triangle) vs WT female mice (blue triangle).  
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Figure 2: APP/PS1 female mice develop contextual memory deficits earlier than male. A. At 
day 0, WT and APP/PS1 male and female mice (4, 6, 12 months) were placed in a training 
chamber (context A) where they received an electric footshock (2s, 0.75 mA). At day 1, mice 
were reexposed to the conditioning context A then to an entirely new, therefore neutral, 
context (context B). Freezing percentage was calculated for each animal. B. At 4 months of 
age, when compared to WT mice, APP/PS1 female mice show impairment of contextual fear 
conditioning when reexposed to context A whereas APP/PS1 male mice does not. C. At 6 
months of age, APP/PS1 male mice does not still show impaired contextual fear conditioning. 
D. At 12 months of age, APP/PS1 male mice still do not display impaired contextual fear 
conditioning. (* p<0.05; ** p<0.01; *** p<0.001) 
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Figure 3: APP/PS1 female mice show impaired object location task. A. During the 
habituation phase (10 min), mice are allowed to explore an open field arena with two identical 
objects. During the retention phase (30 min) mice were placed back to their home cage. 
During the test phase, the location of one object is changed and the time spent exploring the 
two objects was assessed. B. As early as 3 months of age, APP/PS female mice show 
impaired object place recognition. Discrimination ratio = time spent to explore the displaced 
object / total time spent to explore both objects. (* p<0.05; ** p<0.01; *** p<0.001) 
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Figure 4: Electrophysiological characterization of the lateral perforant path (LPP) inputs to 
the hippocampal dentate gyrus (DG). A. Diagram shows the positions of the stimulating 
electrode (located in the outer DG molecular layer) and of the recording electrode (either onto 
a DG cell for patch-clamp recordings or near the crest of the suprapyramidal blade for field 
recordings). B. Input-output relationship between the population spike amplitude (PS 
amplitude) and the stimulus intensity. For each intensity, WT (black circles) and APP/PS1 
(white circles) relationship were significantly different (50 µA: WT=0.68±0.12; 
APP/PS1=0.40±0.07, 100 µA: WT=1.79±0.19; APP/PS1=1.14±0.10, 150 µA: 
WT=2.54±0.22; APP/PS1=1.71±0.17, 200 µA: WT=2.85±0.26; APP/PS1=2.14 ±0.16, 
p<0.0001, 2-way ANOVA). C. Electrophysiological dissection of the LPP and medial 
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perforant path (MPP) by paired-pulse experiments. Whatever the gender, the paired-pulse 
ratio was significantly higher than 1 (facilitation) for the LPP, whereas it was lower than 1 for 
the MPP. D. Representative traces from whole-cell patch clamp experiments showing AMPA-
receptor- and NMDA-receptor evoked currents (in the presence of 50 µM NBQX) in DG cells. 
Histogram showing the AMPA to NMDA ratio for WT and APP/PS1 mice (WT:2.82±0.45, 
n=10; APP/PS1:2,35±0.39, n=9, p=0.452). E. Representative traces from whole-cell patch 
clamp experiments showing AMPA-receptor evoked currents from -70 and +40 mV in DG 
cells. Histogram showing the AMPA rectification index (AMPA RI) of DG cells for WT and 
APP/PS1 mice (WT:0.51±0.06, n=10; APP/PS1:0.49±0.08, n=9, p=0.794). 
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Figure 5:  AMPA-receptor and NMDA-receptor mediated mEPSCs in DG cells. A. 
Superimposed representative traces of AMPA and NMDA mEPSCs (AMPA traces are the 
average of 2556 and 3884 mEPSCs events for WT and APP/PS1 respectively; NMDA traces 
are the average of 861 and 3461 mEPSCs events for WT and APP/PS1 respectively). DG cells 
were held at a holding potential of -70 mV in the presence of bicuculline (10 µM), NBQX (10 
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µM) and TTX (0.5 µM) and recorded for 15 minutes. NMDA mEPSCs were recorded in 
nominal free Mg2+ aCSF, 4 mM Ca2+ and D serine (50 µM). The average frequency of 
NMDA mEPSCs was significantly increased for APP/PS1 mice vs WT mice (WT: 4.60±0.43, 
n=13; APP/PS1: 17.12±1.29, n=14, *** p<0.001), whereas the amplitude was not (WT: 
15.46±0.94, n=15; APP/PS1: 17.55±1.09, n=14, p=0.166). Neither the frequency (WT: 
14.00±2.50, n=16; APP/PS1: 18.50±2.91, n=15, p=0.249) nor the amplitude (WT: 8.19±0.27, 
n=15; APP/PS1: 9.22±0.51, n=15, p=0.088) of AMPA mEPSCs were different. B. Kinetic 
analysis of AMPA and NMDA mEPSCs. Normalized AMPA and NMDA mEPSCs were 
superimposed for both genotypes. The rise time (10-90%) and decay time (Tau) were similar 
for AMPA mEPSCs between both genotypes (Rise time AMPA: WT 0.81±0.04, n=15; 
APP/PS1 0.88±0.04, n=15, p=0.238; Tau AMPA: WT 6.67±0.34, n=16; APP/PS1 6.00±0.25, 
n=15, p=0.130). Rise time and Tau were also similar for NMDA mEPSCs between both 
genotypes (Rise time: WT 1.22±0.12, n=13; APP/PS1 1.04±0.07, n=14, p=0.237; Tau: WT 
27.86±2.39, n=13; APP/PS1 24.94±1.34, n=14, p=0.287). C. Cumulative probability analysis 
of AMPA and NMDA mEPSCs amplitude. The cumulative fraction for AMPA and NMDA 
mEPSCs amplitudes were significantly different between genotypes (AMPA, KS test, *** 
p>0.0001; 2556 events of 16 cells for WT [black curve] and 3884 events of 15 cells for 
APP/PS1 [red curve] mice; NMDA, KS test, *** p>0.0001; 861 events of 15 cells for WT 
[black curve] and 3461 events of 14 cells for APP/PS1 mice [red curve]). The distribution 
histogram (insets) was not statistically different between genotypes for AMPA mEPSCs 
amplitude (paired t test, p=0.126) and different between genotypes for NMDA mEPSCs 
amplitude (paired t test, * p<0.05).  
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Figure 6:  Characterization of firing properties of DG granule cells. A. Representative action 
potentials (APs) elicited in response to 0.2 ms depolarizing current steps with 10 µA 
increments in a DG granule cell from WT mouse. For each genotype (WT, black circles; 
APP/PS1, red circles) EPSP-slope values were calculated for the first two milliseconds and 
plotted versus the probability to fire action potentials. No shift in the E-S curves was observed 
between both genotype (WT: EC50=5.97, Hill slope=0.37; APP/PS1: EC50=5.98, Hill 
slope=0.39). B. Representative trains of APs elicited by long depolarizing current steps (250 
ms) of increasing intensity in a WT DG cell.  Whatever the genotype, type 1 and type 2 cells 
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were not significantly distributed (Type 1: WT = 46.7 %, n=14, APP/PS1 = 54.8 %, n=17; 
Type 2: WT = 53.3 %, n=16, APP/PS1 = 45.2 %, n=14; p=0.366). C. Input-output curves for 
type 1 and type 2 DG cells. The number of spikes elicited in response to 250 ms-long 
depolarizing current steps with 10 pA increments was significantly higher in APP/PS1 vs WT 
DG cells for both type 1 and type 2 (type 1: WT, black circles; APP/PS1, open circles, *** 
p<0.0001, 2-way ANOVA; type 2: WT, black squares, APP/PS1, open squares, *** p<0.0001, 
2-way ANOVA). Whatever the genotype the number of spikes elicited in response to 250 ms-
long depolarizing current steps with 10 pA increments increased linearly for type 2 but 
reached a plateau for type 1. D. Interspike interval (ISI) plotted as a function of the first three 
intervals. ISI was significantly higher for type 1 (black circles) cells from WT mice compared 
to APP/PS1 mice (type 1, white circles) (* p<0.05; ** p<0.01) but not for type 2 (black and 
white squares, p=0.102; p=0.132 respectively). E. Spike frequency adaptation estimated by 
the interspike interval (ISI) for the last three intervals. No differences between genotypes 
were observed for any ISI. 
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Figure 7: Population spike amplitude potentiation in DG granule cells. A. Left panel shows 
representative traces of population spike amplitude (PSA) before and after HFS. Potentiation 
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of PSA was induced by 3 bursts of 100 stimuli at 100 Hz with a 10-second interburst interval 
(HFS). Light grey traces are individual traces and black traces are the averaged traces of 60 
sweeps before and after HFS. Right panel shows time course of potentiation of PSA (WT 
black circles, APP/PS1 red circles, WT male mice blue circles). Potentiation of PSA was 
completely blocked by AP-V (50 µM, light grey circles) (n=9). B. E-S curves before and after 
HFS. Shifts to the left of E-S curves before and after HFS were significant for both genotype 
(WT: -1.45±0.57 mV/ms, * p=0.018; APP/PS1: -1.93±0.53 mV/ms, ** p= 0.0014) but larger 
for APP/S1 vs WT. A significant EC50 shift in the E-S relation was induced by HFS for both 
WT (WT: 5.96±0.38, n=15, WTafter HFS: 4.51±0.41, n=11, * p<0.05) and APP/PS1 (APP/PS1: 
5.85±0.39, n=15, APP/PS1after HFS: 3.92±0.27, n=10, ** p<0.01) although with a larger 
amplitude for the APP/PS1 genotype. C. EPSP amplitude/slope ratio before and after synaptic 
potentiation induced by high frequency stimulation (HFS). The amplitude/slope ratio was not 
different between WT and APP/PS1 mice before (WT: 4.90±0.30, n=15; APP/PS1: 4.55±0.18, 
n=15, p=0.332) or after synaptic potentiation induced by HFS (WTafter HFS: 5.72±0.33, n=12; 
APP/PS1after HFS: 6.08±0.31, n=11, p=0.406) whereas it was significantly increased by HFS in 
APP/PS1 mice (APP/PS1: 4.55±0.18, n=15; APP/PS1after HFS: 6.08±0.31, n=11, *** p<0.001) 
but not for WT (WT: 4.90±0.30, n=15; WTafter HFS: 5.72±0.33, n=12, p=0.332). D. Bar graph 
represents average of normalized PSA between 50 and 60 minutes after HFS protocol in 
different conditions (WT: 187±14%, n=17; APP/PS1: 146±8%, n=16; WTmale: 150±9, n=15; 
WT+PGE2 (10µM): 161±15%, n=17; WT+EP2 agonist (ONO-AE1-259-01, 1µM): 160±12%, 
n=17; WT+PGE2 (10 µM) +EP2 antagonist (PF, 10 µM): 169±16%, n=16; APP/PS1+EP2 
antagonist (PF, 10 µM): 140±8%, n=17. * p<0.05, t test with Welch's correction.  E. Bar 
graph represents levels of PGE2 in whole hippocampus in WT and APP/PS1 female mice at 
different ages. Note the lack of significant differences of levels of PGE2 whatever the 
genotype or the age (3 months: WT: 17.90±2.06 pg/mg, n=13; APP/PS1:13.07±1.31 pg/mg, 
n=12, p=0.073, 6 months: WT: 18.98±4.31 pg/mg, n=10; APP/PS1: 19.31±4.02 pg/mg, n=10, 
p=0.705, 9 months: WT: 12.44±1.40 pg/mg, n=12; APP/PS1: 12.57±1.36 pg/mg, n=11, 
p=0.951). 
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   Amplitude	  	  (mV)	   Overshoot	  	  (mV)	   Peak	  time	  	  (ms)	   RMP	  	  (mV)	  	   AP	  threshold	  (mV)	   t50	  (ms)	   Rin	  (MΩ)	  WT	  	   132.2	  ±	  2.1	  (12)	   62.5	  ±	  2.1	  (12)	   2.4	  ±	  0.1	  (12)	   -­‐72.7	  ±	  0.9	  (23)	   -­‐33.2	  ±	  2.7	  (10)	   1.76	  ±	  0.09	  (12)	   323	  ±	  15	  (32)	  APP/PS1	  	   125.4	  ±	  2.8	  (13)	   55.7	  ±	  2.7	  (13)	   2.4	  ±	  0.1	  (13)	   -­‐75.4	  ±	  0.7	  (15)	   -­‐32.1	  ±	  2.2	  (10)	   1.74	  ±	  0.09	  (13)	   335	  ±	  14	  (31)	  
 
Table 1. Comparison between action potentials properties in DG granule cells from WT and 
APP/PS1 female mice. Data are mean ± SEM. Values between brackets are n values. p values 
were obtained with Student's t-test (amplitude: p=0.070; overshoot: p=0.064; peak time: 
p=0.885; RMP: * p<0.05; AP threshold: p=0.764; t50: p=0.848; Rin: p=0.552). RMP: resting 
membrane potential. t50: time to get half amplitude of AP. Rin: input resistance 	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Table 2. Comparison of action potentials properties of type 1 and type 2 DG granule cells 
between WT and APP/PS1 female mice. Data are mean ± SEM. Values between brackets are 
n values. p values were obtained with Student's t-test. ADP: after depolarisation. AHP: after 
hyperpolarisation. Ithr: AP current threshold (minimal current intensity inducing an AP) 	  	  	  	  	  	  	  	  	  	  
	  
	   	  	  	  	  	  	  	  	  	  	  WT	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  APP/PS1	  
Type	  1	   p	  (I	  vs	  II)	   Type	  2	  
p	  (Type	  1	  
WT	  vs	  
APP/PS1)	  
Type	  1	   p	  (I	  vs	  II)	   Type	  2	  
p	  (Type	  2	  
WT	  vs	  
APP/PS1)	  
1st	  AP	  
latency	  
(ms)	  
160	  ±	  9.1	  
(13)	   0.178	  
177.4	  ±	  8.5	  	  
(17)	  
0.809	  
	  
163	  ±	  8.2	  	  
(17)	   0.746	  
158.4	  ±	  12.1	  	  
(14)	  
0.198	  
	  
ADP	  	  
(mV)	  
8.2	  ±	  0.7	  
(13)	   0.244	  
9.5	  ±	  0.8	  
	  (16)	  
0.217	  
	  
9.4	  ±	  0.7	  
	  (17)	   0.824	  
9.7	  ±	  0.8	  
	  (14)	  
0.897	  
	  
fast	  
AHP	  	  
(mV)	  
18	  ±	  0.9	  
(13)	   0.086	  
15.3	  ±	  1.1	  	  
(17)	  
0.525	  
	  
17.2	  ±	  0.8	  	  
(17)	  
0.018	  
*	  
14.4	  ±	  0.8	  	  
(14)	  
0.561	  
	  
slow	  
AHP	  	  
(mV)	  
10.3	  ±	  1	  
(13)	   0.209	  
8.6	  ±	  0.9	  
	  (16)	  
0.318	  
	  
9.2	  ±	  0.7	  
	  (17)	   0.343	  
8.2	  ±	  0.7	  
	  (12)	  
0.764	  
	  
Ithr	  (pA)	  
53.1	  ±	  3.4	  
(13)	   0.493	  
58.2	  ±	  5.9	  	  
(17)	  
0.001	  
**	  
37.1	  ±	  2.9	  	  
(17)	   0.078	  
44.3	  ±	  2.5	  	  
(14)	  
0.053	  
	  
RIn	  
(MΩ)	  
368	  ±	  20	  
(14)	  
0.003	  
**	  
279	  ±	  19	  
	  (16)	  
0.993	  
	  
368	  ±	  16	  
	  (17)	  
0.004	  
**	  
294	  ±	  17	  
	  (14)	  
0.562	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Supplements 
This part is presenting results which have not been embedded in the manuscript for 
publication. 
A. Contextual Fear Conditioning in old male mice (18 months) 
As demonstrated by our results, APP/PS1 males were spared at least up to 12 months of 
age. We decided to investigate if males were still spared at even older ages, i.e. 18 months, 
and tested the ability of WT and APP/PS1 male mice at 18 months of age to discriminate 
between two highly similar contexts, context A vs context B, or between two very different 
contexts, context A vs context C. When testing the two highly similar contexts (A vs B), WT 
and APP/PS1 did not show differences in freezing percentages between context A vs context 
B (WT: Fcontext A: day 1, 65.64 ± 5.89%, n=28; day 2, 70.41 ± 6.38%, n=27; day 3, 71.21 ± 
4.91%, n=27; day 4, 81.24 ± 3.37%, n=27; day 5, 79.58 ± 3.69%, n=27; day 6, 72.53 ± 4.40%, 
n=27; day 7, 77.51 ± 3.62%, n=27; Fcontext B: day 1, 50.66 ± 5.73%, n=28; day 2, 77.92 ± 
4.55%, n=27; day 3, 78.33 ± 3.47%, n=27; day 4, 75.55 ± 3.79%, n=27; day 5, 75.17 ± 4.6%, 
n=27; day 6, 71.59 ± 4.15%, n=27; day 7, 70.64 ± 5.08%, n=27; APP/PS1: Fcontext A: day 1, 
57.78 ± 6.19%, n=28; day 2, 80.25 ± 3.97%, n=26; day 3, 87.00 ± 2.15%, n=25; day 4, 86.41 
± 2.11%, n=26; day 5, 85.95 ± 2.62%, n=26; day 6, 83.55 ± 2.68%, n=26; day 7, 84.17 ± 
3.52%, n=27; Fcontext B: day 1, 52.98 ± 6.11%, n=28; day 2, 81.95 ± 4.26%, n=27; day 3, 89.85 
± 3.45%, n=24; day 4, 86.12 ± 3.53%, n=25; day 5, 89.60 ± 2.31%, n=25; day 6, 87.86 ± 
3.34%, n=26; day 7, 82.54 ± 4.42%, n=27) (Fig. 1A, 1B). When testing the two very different 
contexts (A vs C), WT and APP/PS1 did discriminate equally well (WT: Fcontext A: 68.77 ± 
3.52%, n=13; Fcontext C: 4.10 ± 1.10%, n=11; *** p<0.0001; APP/PS1: Fcontext A: 72.91 ± 
4.84%, n=14; Fcontext C: 25.91 ± 6.02%, n=14, *** p<0.0001) (Fig. 1C, 1D). These results 
indicated a lack of context fear generalization in old male mice.  
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Figure 1:  Contextual fear conditioning in 18 months old males 
A. Experimental design for context A and context B. B. Similar freezing behavior of WT 
(black) and APP/PS1 (blue) mice in two highly similar contexts (context A and context B). C. 
CFC box. D. Contextual discrimination of WT (black) and APP/PS1 (blue) mice in very 
different contexts (context A and context C). *** p < 0.0001 
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B. APP/PS1 female mice do not present impaired presynaptic 
LTP at Mf-CA3 synapses 
In a previous study we reported that presynaptic LTP at hippocampal MF/CA3 synapses 
was impaired in APP/PS1 males (Maingret et al., 2017). We then investigated if the 
presynaptic LTP at Mf-CA3 synapses was also impaired in APP/PS1 female mice by 
recording fEPSPs. fEPSPs were evoked by minimal stimulation intensity at low frequency 
(0.1 Hz). The fEPSP slope is taken as a proxy to measure the excitatory drive to CA3 neurons.  
Basal fEPSP slope were measured as 99.99 ±3.75 % for WT female mice and 99.99 ± 
3.75 % for APP/PS1 female mice at 4 months and were not significantly different. Long term 
synaptic potentiation (LTP) was triggered by high frequency tetanic stimulation (HFS, 3 x 
100 Hz, every 10 s). The relative change in the fEPSP slope was 168.8 ± 13.59 % (n=8) of 
baseline during 30-40 min after HFS for WT and 154.3 ± 17.4 % (n=8, p > 0.05; Fig. 2A) for 
APP/PS1. The total blockade of fEPSPs by mGluR agonist LCCG-1 confirmed the recording 
of Mf-CA3 synaptic transmission (Fig. 2A).  
Then we questioned whether LTP was altered in female mice at 6 months, an age for 
which both molecular and cellular hallmarks of AD were present, together with behavioral 
deficits. LTP was 163.8 ± 6.3 % (n=8) for WT and 148.78 ± 5.52 % (n=8, p > 0.05) for 
APP/PS1 (Fig. 2B).  
Therefore, Mf-CA3 synaptic plasticity was not impaired in APP/PS1 female mice at 4 
and 6 months of age despite prominent AD's alterations.  
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Figure 2: Presynaptic LTP at MF-CA3 synapses  
A. Representative traces of WT and APP/PS1 female mice and time course of fEPSPs 
recorded in CA3 pyramidal neurons with low frequency (0.1 Hz) stimulation of Mf before 
(dotted line) and after HFS (solid line) in WT mice (black) and APP/PS1 mice (blue) at 4 
months. Slope of fEPSPs were normalized as percentage of average baseline fEPSPs slope. 
Each point is an average of 6 subsequent fEPSPs. Scale bar is 10 ms for horizontal line and 1 
mV for vertical line. Histograms show averaged relative fEPSPs slope recorded between 30 
and 40 minutes (WT: 168.8 ± 13.59 %, n = 8; APP/PS1: 154.3 ± 17.4 %, n = 8; ns). B. 
Representative traces of WT and APP/PS1 female mice and time course of fEPSPs recorded 
in CA3 pyramidal neurons at 6 months. Histograms show averaged relative fEPSPs slope 
recorded between 30 and 40 minutes (WT: 163.8 ± 6.3 %, n = 8; APP/PS1: 148.78 ± 5.52 %, 
n = 8; ns). 
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C. Impaired LTP of population spikes in APP/PS1 mice at 
LPP/DG synapses 
Then we investigated if synaptic potentiation was affected in APP/PS1 female mice at 
an other synapse. We chose to investigate the lateral perforant pathway - DG synapse because 
of its location in the stratum moleculare of the DG, a region displaying a massive load of Aβ 
plaques at 6 months of age. To do so, we measured the population spike amplitude (PSA), 
which reflects APs discharge, between the upper positive deflection and the lower negative 
deflection (Fig. 3A). The basal stimulation intensity was chosen to evoke 25-30% of maximal 
PSA. This allowed us to compare the response of neurons in DG to the same excitatory drive 
before and after HFS (Fig. 3A). The relative potentiation of PSA was 186.6 ± 14.33 % (n=17) 
for WT and significantly impaired in APP/PS1 (146.5 ± 8.52 %, n=16, * p < 0.05; Fig. 3B). 
Interestingly, LTP in WT male mice was significantly lower than in age-matched WT female 
mice (male: 149.8 ± 9.39 %, n=15; female: 186.6 ± 14.33 %, n=17, * p < 0.05). LTP was 
purely NMDA-dependent as completely blocked by AP-V (Fig. 3B). 
 
  
 
 
 
 
 
 
 
Figure 3: Population spike amplitude potentiation at LPP/DG synapses 
A. Left panel shows representative traces of population spike amplitude (PSA) before and 
after HFS. Potentiation of PSA was induced by 3 bursts of 100 stimuli at 100 Hz with a 10-
second inter burst interval (HFS). B. Middle panel shows time course of potentiation of PSA 
at 6 months (WT females, black circles; APP/PS1 females, blue circles; WT males, orange 
circles). Potentiation of PSA was completely blocked by AP-V (50 µM, solid black spot) 
(n=9). Bar graph represents average of normalized PSA between 40 and 50 minutes after HFS 
protocol in different conditions (WT: 186.6 ± 14.33%, n=17; APP/PS1: 146.5 ± 8.52 %, n=16, 
* p < 0.05). 
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D. PGE2 and LTP at LPP-DG synapses 
a. PGE2  
PGE2 is a key neuroinflammatory molecule and of particular interest in AD studies 
(McGeer and McGeer, 2007). Having shown that PGE2 impaired synaptic plasticity at the Mf-
CA3 synapse (Maingret et al., 2017), we investigated the effects of PGE2 at LPP-DG synapse 
during the process of the neuroinflammation in APP/PS1 female mice.  
Bath application of PGE2 (10 µM) had no effect on synaptic basal transmission in WT 
female mice at LPP-DG synapses (baseline: 99.9 ± 1.77%, n=8; PGE2: 99.58 ± 1.04%, n=8, p 
> 0.05; Fig. 4). These data indicated that exogenous application of PGE2 did not affect basal 
transmission (Fig. 4 B). 
  
 
 
Figure 4: PGE2 has no effect on basal transmission 
A. Averaged traces of baseline (black) and application of PGE2 (green). B. Representative 
time course of PS recorded in DG granule cells in response to 0.1 Hz stimulation of LPP in 
baseline (black circles) and after the application of PGE2 (10µM, green circles). PS amplitude 
was normalized as percentage of average baseline of PS amplitude. Each dot corresponds to 
average of 6 consecutive PS amplitude recorded. PGE2 (10µM) was performed after 10 mins 
of baseline and PS were acquired for 20 minutes. Scale bar is 10 ms for horizontal line and 1 
mV for vertical line. Bar graph represent average amplitude of PS recorded between 10 and 
20 minutes (baseline: 99.9 ± 1.77%, n=8; PGE2: 99.58 ± 1.04%, n=8; p > 0.05). 
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b. EP4 receptor 
NB: the putative involvement of EP2 and EP3 receptors is presented in III. Results 
section. Last we investigated the putative involvment of EP4 receptor. Pre-incubation of 
10µM ONO-AE1-329, a selective EP4 receptor agonist, had neither an effect on LTP in WT 
(WT: 186.6 ± 14.33 %, n=17; WT + PGE2: 161.7 ± 15.41%, n=17; WT + ONO-AE1-329: 
149.2 ± 13.72 %, n=14; p > 0.05) (Fig. 5A, 5B) nor ONO-AE2-227, a selective EP4 receptor 
antagonist, rescued impaired LTP in APP/PS1 mice (APP/PS1: 146.5 ± 8.52 %, n=16; 
APP/PS1 + ONO-AE2-227, 166.8 ± 9.2 %, n=10; p > 0.05) (Fig. 5A, 5B). 
 
 
Figure 5: EP4 receptor has no effect at LPP-DG synapse 
A. Average time course of LPP-DG LTP in WT and APP/PS1 female mice at 6 months. PSA 
LTP was induced by 3 bursts at 100 Hz with a 10s interburst interval. B. Bar graph represents 
average of normalized PSA between 40 and 50 minutes after the HFS protocol (WT: 186.6 ± 
14.33 %, n=17; WT + PGE2: 161.7 ± 15.41 %, n=17; WT + ONO-AE1-329: 149.2 ± 13.72 %, 
n=14; APP/PS1: 146.5 ± 8.52 %, n=16; APP/PS1 + ONO-AE2-227, 166.8 ± 9.2 %, n=10).  
 
E. APs number in APP/PS1 vs WT female mice 
At the maximal current intensity (200 pA) and for a 250 ms step, we studied the 
number of spikes during the first and the last 50 ms of the step (Fig. 6A). During the first 50 
ms, type I DG cells (WT: 2.92 ± 0.21, n=13; APP/PS1: 3.70 ± 0.20, n=17; * p < 0.05) but not 
type II DG cells (WT: 2.94 ± 0.24, n=17; APP/PS1: 3.50 ± 0.20, n=14) showed a significant 
increase of spikes number in APP/PS1 vs WT mice (Fig. 6B). For the last 50 ms, both type I 
and type II DG cells did not show significant spikes number between WT and APP/PS1 mice 
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(type I WT: 0.53 ± 0.14, n=13; type I APP/PS1: 1 ± 0.24, n=17; type II WT: 1.23 ± 0.13, 
n=17; type II APP/PS1: 1.57 ± 0.17, n=14) (Fig. 6C). However, WT type II DG cells 
significantly fired more spikes than type I DG cells (Type I: 0.53 ± 0.14, n=13; Type II: 1.23 
± 0.13, n=17; ** p < 0.05) (Fig. 6C).  
                
         
 
 
Figure 6: Increased spikes number in APP-PS1 mice 
A.	  Spikes evoked in response to 250 ms prolonged depolarizing current at 200 pA. B and C: 
Spikes firing number for the first and last 50 ms (Type I, solid: WT: 2.92 ± 0.21, n=13; 
APP/PS1: 3.70 ± 0.20, n=17; * p < 0.05. WT: Type I: 0.53 ± 0.14, n=13; Type II, circle: 1.23 
± 0.13, n=17; ** p < 0.05). 
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IV. Discussion - Conclusion 
Gender Differences in LTP of population spike amplitude (PSA) 
The physiological basis underlying gender differences is still elusive, but it is known 
for a long time that estrogen modulates neuronal cell activity in the hippocampus (Teyler et 
al., 1980; Foy and Teyler, 1983; Wong and Moss, 1992). As such, the significant larger 
increase in LTP in WT female mice vs male mice could be related to estrogen levels.  
Interestingly, in female rats, a large LTP was observed during proestrus when estrogen was 
expressed at a high level (Warren et al., 1995). Furthermore, HFS did not induce LTP in 
males as large as in females when estrogen levels were low. In ovariectomized rats, 
administration of 17-β-estradiol promoted induction of LTP, showing that estrogen could 
indeed modulates LTP (Cordoba et al. 1997). Our results showed that WT female mice 
displayed significantly larger LTP when compared to males. Because all experiments have 
been done without consideration of the estrous cycle, we cannot conclude on a possible effect 
of estrogen but such effect is plausible and may deserve further investigation. 
Aβ impaired LTP at LPP-DG synapse 
In APP/PS1 female mice, DG region displayed a massive load of Aβ plaques when 
compared to other hippocampal regions. Entorhinal cortex is the main input to hippocampus 
via DG for new memory encoding, and mostly prone to dysfunction in early AD. Evidences 
suggest that Aβ may affect neuronal activity (Cirrito et al., 2005) and affect LTP (Wang et al., 
2004; Gong et al., 2006; Ahmed et al., 2010). Our results showed the partial impairment of 
LTP in APP/PS1 female mice of 6 months of age at LPP-DG synapses. Many factors could 
contribute to this impairment, a decrease in the probability of transmitter release, a decrease in 
the reliability or the strength of individual synapses, a decrease in the number of functional 
synapses or receptors.  
PGE2 
PGE2 is of particular interest because its level is increased in the CSF of AD patients 
(Montine et al., 1999; Combrinck et al., 2006). PGE2 can bind to four subtypes of receptors 
(EP1-4) which are all expressed in the hippocampus and its effects may vary accordingly. 
PGE2 is produced mostly from COX-2 signaling pathway (Brock et al., 1999; Vidensky et al., 
2003; Chen and Bazan, 2005) and it is an important modulator of hippocampal synaptic 
transmission and plasticity (Bazan, 2001; Chen et al., 2002; Chen and Bazan, 2005).  
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Here we show that PGE2 via the activation of EP3 receptors inhibits a presynaptic 
form of LTP at Mf-CA3 synapse whereas it had no effects on LTP at LPP-DG synapse 
whatever the subtype of EP receptor. Furthermore, to our surprise, hippocampal levels of 
PGE2 were not increased with time in APP/PS1 females vs WT females.   
Aβ and intrinsic excitability 
Series of studies show that Aβ accumulation and abnormal excitatory neuronal activity 
are associated (Buckner et al., 2005; Mintun et al., 2006; Seeley et al., 2009; Sperling et al., 
2009) but the molecular mechanisms are still illdefined.  
It has been demonstrated that over activation of NMDA receptor has a crucial effect 
on increased excitability, which is thought to play a key role in AD. More specifically, Aβ 
oligomers has been illustrated to enhance NMDA receptor mediated currents in rat DG (Wu et 
al., 1995) and to enhance NMDA receptor mediated hippocampal neuronal firing in vivo 
(Molnár et al., 2004). The interaction of Aβ oligomers with NMDA receptor promotes a Ca2+ 
influx (Felice et al., 2007) which induces an increase of intracellular calcium stocks and in 
turn the activation of ryanodine receptor (RyR) mediated Ca2+ induced Ca2+ release (CICR) 
from endoplasmic reticulum stores (Lima et al., 2011). Ultimately, this lead to persistant 
neuronal depolarization and the activation of synaptotoxic calcium associated pathways 
(Ferreira and Klein, 2011).   
 In conclusion, the amyloid hypothesis of AD postulates that accumulation of Aβ in the 
brain is the primary influence driving AD pathogenesis (Selkoe et al., 2000; Cirrito et al., 
2005; Hu et al., 2018). The formation of Aβ is the result of cellular process via successive 
enzymatic cuts of APP by β-secretase and γ-secretase (Querfurth et al., 2010). In the present 
work we have highlighted the presence of Aβ plaques in the hippocampus in both APP/PS1 
male and female mice and demonstrated that the deposition was occuring earlier and heavier 
in female mice than in age-matched male mice.   
Numerous publications have reported that Aβ was inducing synaptic dysfunction 
through changes of neuronal intrinsic excitability in AD brain (Zhang and Linden, 2003). 
Hence, application of soluble Aβ to cultured neurons (Cuevas et al., 2011), brain slices 
(Minkeviciene et al., 2009; Varga et al., 2014; Ren et al., 2014) or in vivo (Orbán et al., 2010; 
Busche et al., 2012), induced neuronal hyperexcitability in the hippocampus. These data are 
consistent with some AD mouse models for which increased Aβ levels are involved in altered 
neuronal activity, spontaneous activity and hyperexcitability activity (Palop et al., 2007; 
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Palop and Mucke, 2010; Brown et al., 2011; Kerrigan et al., 2014). Alterations of synaptic 
activity is considered as an early event leading to cognitive deficits appearing in the course of 
AD (Mesulam et al., 1999; Srivareerat et al., 2009, 2011; Alkadhi et al., 2010, 2011). 
In the hippocampus, DG granule cells are susceptible to AD pathology (A.T. Dao et 
al., 2016). Following these findings, our data showed that in the DG area, the depostion of Aβ 
plaques paralleled a decreased excitability of APP/PS1 female DG granule cells detected 
shown by the input/output (I/O) relationships. Hippocampal LTP is generally accepted to be 
an important molecular mechanism related to learning and memory processes (Abraham et al., 
2003; Malenka et al., 2004). It has been proposed that depression of basal synaptic 
transmission and LTP reported in mouse models of AD could be related to the activation of 
presynaptic Ca2+ activated K+ channels, which modifies in turn excitability and transmitter 
release (Ye et al., 2010).  
The present study showed an increased intrinsic excitability and LTP impairment at 
LPP/DG synapse in a mouse model of AD. Although increased excitability activity and its 
cellular and functional consequences are typically reported in mouse models of AD, the 
mechanisms of Aβ-induced neuronal hyperexcitability remain to be clarified. Neuronal brain 
activity is also tightly controlled via a balance between excitation and inhibition 
neurotransmission and an imbalance may lead to hyperexcitability. NMDARs play an 
essential role in the hyperexcitability, which is also considered to be a potential target of AD.  
Abnormal firing activity can seriously weaken or impair LTP in vitro (Schubert et al., 
2005; Salmani et al., 2011). Interestingly, LTP and increased excitability activity may 
crossover. Therefore, attenuating excessive neuronal excitability activity could reverse HFS 
induced LTP impairment (Albensi et al., 2007). According to these reports, administration of 
levetiracetam prevented aberrant network activity in hAPP mice and restored learning and 
memory function (Sanchez et al., 2012) and had similar actions in patients with mild 
cognitive impairments (MCI) that have significant brain Aβ deposition (Bakker et al., 2012). 
Collectively, our data show that Aβ-induced excessive excitatory activity in the hippocampus 
may have a crucial role in the development of early synaptic functional deficits in AD. 
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V. Perspectives  
 
 Although gender differences have been reported for many years, our understanding of 
the potential bases underlying these differences is relatively poor Joseph et al., 1978; 
Williams et al., 1990; Roof et al., 1993; Gresack and Frick, 2003; Clinton et al., 2007; 
Richetin et al., 2017). Clearly, more research is needed to investigate the etiology of sex 
differences in memory and synaptic functions.  
 
 Our studies may help to clarify that Aβ may affect hippocampal-dependent memory 
task and neuronal activity in a sex dimorphic manner. These findings could have significant 
benefits for a differential preventive treatment of the human pathology (Claxton et al., 2013; 
Zissimopoulos et al., 2017; Ferretti et al., 2018). The complex network of gender differences 
should be taken into account when designing models for disease prevention and diagnosis as 
well.  
  
 To further address Aβ effects on neuronal activity, it would be necessary to evaluate it 
taking into consideration distances between recorded neuron and Aβ plaques (Busche et al., 
2008; Ovsepian et al., 2016). In this respect, Ab form is an important issue (oligomers vs 
plaques) as soluble Aβ oligomers are described to impact more severely synaptic and 
cognitive dysfunction than plaques (Selkoe et al., 2008; Shankar et al., 2008; Mucke and 
Selkoe, 2012). Therefore, it will be relevant to assay Aβ40/Aβ42 levels in hippocampal 
homogenates from APP/PS1 females vs males and to compare them to the number of Ab 
plaques.  
 
 Although the putative effects of Aβ on LTD have not been studied in the present work, 
it is known that Ab may facilitate LTD (Snyder et al., 2005; Li et al., 2009; Chen et al., 2013) 
by involving mGluR, p38MAPK and caspase-3 activities. Strikingly, same Ab - activated 
intracellular signaling pathways are involved in the blockade of hippocampal LTP (Wang et 
al., 2004) which suggests that a crossover pathway could reinforce Ab induced LTP 
impairments (reviewed in Mucke and Selkoe, 2012).  
 
 Whereas we have evaluated how the intrinsic properties of type 1 and type 2 DG cells 
were affected in APP/PS1 female mice, we have not investigated if the impaired LTP was 
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different depending on the subtype of DG cells. This is an important issue as type 1 and type 2 
are signatures of the degree of maturation and circuitry integration of DG cells which can be 
differentially impacted by the pathology.  
 
 So far, almost all clinical trials have failed and the number of AD patients is 
continuously growing. Therefore, there is an urgent need for new studies. Deciphering 
relationships between Aβ-associated aberrant excitatory neuronal activity and cognitive 
deficits in AD could present valuable insights into the mechanisms of early stages of AD to 
lead to new therapeutic methods.  
  
Indeed, disruptions of the balance between excitatory and inhibitory activity are likely 
involved in the early processes of cognitive deficits in AD (Palop et al., 2007; Leonard and 
McNamara, 2007). Here, we focused only on excitatory inputs onto granule cells in the DG 
but it would be necessary to study inhibitory activity that was also reported to be associated 
with impairments of both short and long term plasticity in DG (Palop et al., 2007). As such, 
prominent increases of neuronal activity in hippocampal networks may possibly coexist with 
altered glutamatergic transmission in our mouse model of AD and the complex relationships 
between excitatory and inhibitory activity need to be further clarified. 
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VI. Annexes 	  
PGE2-EP3 signaling pathway impairs hippocampal presynaptic 
long-term plasticity in a mouse model of Alzheimer’s disease 
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ABSTRACT: Alzheimer’s disease (AD) is a progressive neurodegenerative disease 
characterized by early cognitive deficits linked to synaptic dysfunction and loss. Considerable 
evidence suggests that neuroinflammation contributes to AD. Prostaglandin E2 (PGE2), a key 
neuroinflammatory molecule, modulates hippocampal synaptic transmission and plasticity. 
We investigated the effect of PGE2 on synaptic transmission and presynaptic plasticity at 
synapses between mossy fibers from the dentate gyrus and CA3 pyramidal cells (Mf-CA3 
synapse). These synapses are involved in mnemonic processes and consequently may be of 
relevance for AD. We provide evidence that although PGE2 had no effect both on either basal 
transmission or short-term plasticity, it strongly impaired presynaptic Mf-CA3 long-term 
potentiation (LTP) by acting on PGE2 receptor 3 (EP3) receptors. During aging, hippocampal 
levels of PGE2 markedly increased in the APP/PS1 mouse model of AD and impaired 
specifically presynaptic LTP via a PGE2-EP3 signaling pathway. In summary, the building up 
of PGE2 during the progression of AD leads to specific impairment of hippocampal 
presynaptic plasticity and highlights EP3 receptors as a potential target to alleviate cognitive 
deficits in AD.                                                                    
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Introduction 
Alzheimer’s disease (AD) is a progressive and 
devastating neurodegenerative disease characterized 
by deficits in learning and memory processes. There 
is considerable evidence that neuroinflammation 
involving the activation of glial cells contributes to 
the disease progression and pathology (Akiyama et 
al., 2000; Heneka and O’Banion, 2007). As such, 
epidemiological studies have revealed that chronic 
intake of nonsteroidal anti-inflammatory drugs 
(NSAIDs) reduced the prevalence of AD (McGeer 
and McGeer, 2007). Furthermore, clinical trials have 
revealed that NSAIDs, when given to asymptomatic 
patients, reduce AD incidence, whereas they have 
adverse effect on AD pathogenesis in its later stages 
(Breitner et al., 2011).  
When activated in neuroinflammatory 
conditions, glia release a plethora of 
neuroinflammatory molecules such as inflammatory 
cytokines, chemokines, and prostanoids 
(Eikelenboom et al., 1994). The prostanoid 
prostaglandin E2 (PGE2) plays pivotal functions in 
inflammation (Bos et al., 2004). PGE2 is produced 
from arachidonic acid by the microsomal 
prostaglandin-E2 synthase (mPGES) and by 2 rate-
limiting enzymes, Cox-1 and Cox-2 (Smith et 
al.,1991), which are expressed by hippocampal 
neurons (Yasojima et al., 1999), astrocytes and 
microglia (Font-Nieves et al., 2012). Although Cox-1 
is constitutively expressed, Cox-2 and mPGES are 
strongly activated by and during neuroinflammation 
(Font-Nieves et al., 2012). PGE2 can bind to 4 
different subtypes of G-proteinecoupled receptors 
(EP1-4), which regulate adenylyl cyclase (AC) 
activity and/or phosphoinositol turnover and 
intracellular calcium mobilization (Breyer et al., 
2001). 
PGE2 plays an important role in the 
pathophysiology of AD. It is a primary target of 
NSAIDs, and its level is elevated together with the 
expression of Cox-2 in the brain of AD patients 
(Kitamura et al.,1999; Montine et al.,1999; Yasojima 
et al.,1999). Both in vitro and in vivo, PGE2 
stimulates amyloid beta (Aß) production by 
microglial cells, astrocytes, and neurons (Hoshino et 
al., 2007). Selective inhibition of Cox-2 by NS398 
acutely prevents the Aß-induced impairment of long-
term potentiation (LTP) of a-amino-3-hydroxy-5-
methyl-4isoxazolepropionic acid receptorsemediated 
synaptic transmission at CA3-CA1 synapses 
(Kotilinek et al., 2008). Exogenous addition of PGE2 
did not impair by itself LTP inwild-type mice but 
preventedthe ability of NS398 to restore LTP 
impairment induced by synthetic Aß suggesting 
complex interactions between PGE2, Aß, and 
postsynaptic forms of LTP (Kotilinek et al., 2008). 
AD, at least in its early stage, is thought to 
involve synaptic dysfunction and loss (Jacobsen et 
al., 2006; Selkoe, 2002; Sheng et al., 2012). 
Connections between the dentate gyrus (DG) and the 
hippocampal CA3 region through mossy fiber (Mf) 
synapses have been proposed to participate in the 
rapid encoding of novel memory (Kesner, 2007), a 
mnemonic process particularly affected in AD 
conditions. Mf synapses onto CA3 pyramidal cells 
display a wide dynamic range of presynaptic 
plasticity, including prominent shortterm plasticity 
and a form of LTP that is independent of N-methylD-
aspartate (NMDA) receptors (Henze et al., 2002; 
Salin et al., 1996). Alterations in Mf synaptic 
function in the context of AD have only been studied 
in senescent (24- to 25-month old) Tg2576 mice that 
is long after a massive load of amyloid plaques 
(Witton et al., 2010). 
Here we thus studied Mf-CA3 synaptic function 
in the APPswe/ PS1ΔE9 (APP/PS1) mouse model of 
AD in relation with PGE2. APP/ PS1 mice are 
characterized by an over-production of Aß protein 
leading to a noticeable load of amyloid plaques 
around 12 months of age (Jankowsky et al., 2004) 
and display synaptic dysfunction (Volianskis et al., 
2010) and learning deficits (Lagadec et al., 2012; 
Reiserer et al., 2007). We report that acute 
application of PGE2 impairs presynaptic Mf-LTP in 
young mice through activation of EP3 receptors. In 
APP/PS1 mice, presynaptic Mf-LTP was noticeably 
impaired at 12 months of age in parallel with a 
building up of endogeneous levels of PGE2 in the 
hippocampus. Mf-LTP could be fully rescued by 
blockade of EP3 receptors. Considering the diverse 
physiological roles of PGE2, directly targeting the 
EP3 receptor may prove to be a more specific 
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therapeutical strategy in AD than the global 
inhibition of prostaglandins by NSAIDs. 
Materials and methods 
2.1. Ethical approval 
Animal anesthesia and euthanasia procedures 
were carried out in accordance with the Animal 
Protection Association of ethical standards and the 
French legislation concerning animal 
experimentation and were approved by the 
University of Bordeaux/CNRS Animal Care and Use 
Committee (#55). 
2.2. Animals 
The animals used in this study were male 
APP/PS1 mice obtained from Jackson Laboratory 
(Bar Harbor, ME, USA) and their wild-type (WT) 
littermates (C57BL6/J). The APP/PS1 mice express a 
chimeric mouse/human amyloid precursor protein 
APPswe (mouse APP695 harboring a human Aß 
domain and mutations K595N and M596L linked to 
Swedish familial AD) and a human presenilin 1 
mutated in familial AD (PS1ΔE9; deletion of exon 9). 
These bigenic mice were created by co-injection of 
both trangenes allowing for a co-segregation of the 
transgenes as a single locus (Jankowsky et al., 2004). 
Mice were allowed free access to food and water and 
maintained in a 12 hours darkelight cycle. Mice were 
genotyped and systematically regenotyped after each 
experiment using transcript-specific primers (Table 
S1). 
2.3. Acute hippocampal slices 
C57BL6/J mice (P19-P21) were sacrificed by 
cervical dislocation. The brain was quickly removed 
from the skull and chilled in ice-cold low-calcium 
artificial CSF containing the following (in mM): 87 
NaCl, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgCl2, 
10 glucose, 25 NaHCO3 and 75 sucrose with pH 7.4 
adjusted by saturating with carbogen (95% O2 and 
5% CO2), and an osmolarity of 300-310 mOsm. 
Isolated brains were glued onto the stage of a 
vibratome (VT 1200S, Leica Microsystems, 
Nussloch, Germany), and parasagittal hippocampal 
slices (320 µm) were cut. Slices were then 
transferred in an extracellular solution containing the 
following (in mM): 129 NaCl, 2.5 KCl, 1.25 
NaH2PO4, 2 CaCl2, 1 MgCl2, 11 glucose, 25 
NaHCO3 equilibrated with 95% O2 and 5% CO2 (310-
320 mOsm) for 30 minutes at 33 °C and thereafter 
maintained at room temperature until required. 
Because of the well-documented difficulty in 
preparing healthy acute brain slices from mature 
adult rodents and in accordance with Animal 
Protection Association of ethical standards and the 
French legislation, APP/PS1 and WT mice at 6, 9, 
and 12 months were deeply anesthetized with a mix 
of ketamine (80 mg/kg; intraperitoneal) and xylazine 
(16 mg/kg; intraperitoneal) and then intracardially 
perfused for 2-3 minutes with a protective solution at 
4°C containing the following (in mM): 2 KCl, 1.25 
NaH2PO4, 0.4 CaCl2, 8 MgCl2, 22 glucose, 26 
NaHCO3, 200 sucrose, 2.8 pyruvic acid, 0.4 ascorbic 
acid, equilibrated with 95% O2 and 5% CO2 (310-320 
mOsm). When the solution coming out of the heart 
was free of blood, the mouse was sacrificed by 
decapitation, and the brain was quickly removed 
from the skull and stored in the same solution. 
Parasagittal brain slices (320 µm) were cut in the 
protective solution for which sodium chloride was 
replaced by sucrose, and then incubated at 33 C for 
30 minutes in a resting solution containing the 
following (in mM): 103 NaCl, 2 KCl, 1.25 NaH2PO4, 
0.27 CaCl2, 8 MgCl2, 22 glucose, 26 NaHCO3, 0.4 
ascorbic acid equilibrated with 95% O2, and 5% CO2 
(300-310 mOsm). Slices were thereafter maintained 
at room temperature in the same solution until 
required. 
2.4. Electrophysiological studies on acute 
hippocampal slices 
For recording, slices were transferred into a 
recording chamber where they were submerged and 
continuously perfused with an oxygenated (95% O2 
and 5% CO2) extracellular solution at 32 °C-34 °C. 
Whole-cell patch clamp recordings (3-4 MΩ 
electrodes, 70 mV holding potential) were made 
from hippocampal CA3 pyramidal neurons 
visualized by infrared videomicroscopy. Patch clamp 
electrodes were pulled out from borosilicate glass 
(GF 150 F-10) and filled with an internal solution 
containing the following (in mM): 140 CsCH3SO3, 2 
MgCl2, 4 NaCl, 5 phospho-creatine, 2 Na2ATP, 0.2 
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EGTA, 10 HEPES, and 0.33 GTP (pH 7.3) adjusted 
with CsOH. Bicuculline (10 µM) was added to the 
bath to inhibit g-aminobutyric acid-A receptors. 
Voltage-clamp recordings were performed on CA3 
pyramidal neurons identified with a differential 
interference contrast microscope (Eclipse FN-1, 
Nikon, Champigny sur Marne, France) equipped 
with an infrared camera (VX 44, Till Photonics, 
Gräfelfing, Germany) using an Axopatch-200B 
amplifier (Axon Instruments, Sunnyvale, CA, USA). 
Signals were filtered at 2 kHz and digitized at 5 kHz 
via a DigiData 1322A interface (Axon Instruments). 
Series resistance (10-20 MΩ) was monitored during 
the recording using a 10 mV hyperpolarizing voltage 
step of 50 ms length occurring at the beginning of 
each recording. Neurons were rejected if more than a 
20% change in series resistance occurred during the 
experiment. Neurons with a holding current 
exceeding 300 pA at a holding potential of -70 mV 
were also rejected. Data were collected and analyzed 
using pClamp software 9.2 (Axon Instruments). 
Mf-CA3 excitatory postsynaptic currents 
(EPSCs) were evoked by minimal intensity 
stimulation (Marchal and Mulle, 2004). A glass 
microelectrode (~1 µm tip diameter) was placed in 
the hilus of the DG to stimulate Mfs. The baseline 
stimulation frequency for all experiments was 0.1 Hz. 
Mf synaptic currents were identified according to the 
following criteria: robust low-frequency facilitation 
(ratio 1/0.1 Hz), low release probability at 0.1 Hz, 
rapid rise times of individual EPSC ((~1 ms), and 
EPSCs decays free of secondary peaks that may 
indicate the presence of polysynaptic contamination. 
The group II mGluR agonist (2S,1’S,2’S)-2-
(Carboxycyclopropyl) glycine (LCCG)-1 (10 µM) 
was applied routinely to confirm that Mfs were 
actually stimulated. Extracellular recordings were 
made from the stratum lucidum using glass 
electrodes (1-2 MΩ) filled with extracellular solution. 
Field excitatory postsynaptic potentials (fEPSPs) 
were evoked in response to electrical stimuli applied 
via another glass electrode (1-2 MΩ) filled with 
extracellular solution placed in the hilus of the DG. 
Signals were low-pass filtered at 20 kHz and 
digitally sampled at 50 kHz. All experiments were 
performed in the presence of D-AP5 (50 µM) to 
block NMDA receptor activity, bicuculline (10 µM), 
and (2S)-3-(([1S]-1-[3,4-dichlorophenyl]ethyl) 
amino-2 hydroxypropyl)(phenylmethyl)phosphinic 
acid hydrochloride (CGP) (3 µM) to block, 
respectively, g-aminobutyric acid-A and -B receptors. 
Inputeoutput curves were collected by varying 
stimulation strength from 40 µA to 120 µA in 40 µA 
intervals. For subsequent experiments on basal 
transmission and synaptic plasticities, the stimulus 
strength was set to a level that produced 50% of the 
maximal responses. 
2.5. Tissue processing and laser capture 
microdissection 
C57/Bl6J mice (Jackson Laboratory, Bar Harbor, 
ME, USA) at P21 were anesthetized with 
intraperitoneal administration of pentobarbital (50 
mg/kg body weight), and the brain was removed and 
rapidly frozen in heptane and stored at -80 °C until 
sectioning. For slicing, the frozen brain was mounted 
onto a chuck with Tissue-Tek O.C.T compound 
(Sakura Finetek France, Villeneuve-d’Ascq, France) 
and placed in a Leica CM3050S cryostat (Leica 
Microsystems, Wetzlar, Germany) for 20 minutes to 
equilibrate with the chamber temperature of 20 °C. 
Then, 60-µm-thick sections of the hippocampus 
region were cut and placed on polyethylene 
naphthalate (PEN) Membrane Frame slides (Carl 
Zeiss, Munich, Germany) under RNAase-free 
conditions. Then, the slides were immediately placed 
on dry ice and stained on the same day using cresyl 
violet. Briefly, slides were transferred from dry ice 
into ice-cold 95% ethanol for 40 seconds and 
incubated in 75% ethanol for 30 seconds and in 50% 
ethanol for 30 seconds. Specimens were briefly 
stained in 1% cresyl violet solution. Tissue sections 
were dehydrated through 50% ethanol (30 seconds), 
75% ethanol (30 seconds), 95% ethanol (30 seconds), 
followed by two 40 seconds incubations in 
anhydrous 100% ethanol. Slides were dried for 5 
minutes at room temperature. Immediately after 
dehydratation, laser capture microdissection (LCM) 
was performed using a P.A.L.M. MicroBeam 
microdissection system Version 4.8 equipped with a 
P.A.L.M. RoboSoftware (P.A.L.M. Microlaser 
Technologies AG, Bernried, Germany). 
Microdissection was performed at 5X magnification. 
Samples were collected in adhesives caps (P.A.L.M. 
Microlaser Technologies AG, Bernried, Germany). 
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2.6. RNA isolation, reverse transcription, and 
quantitative PCR 
To limit RNA degradation during isolation, samples 
were collected for up to 30 minutes per slide, after 
which the LCM caps were placed on a sterile 
microcentrifuge tube containing 350 µL of lysis 
buffer. The samples were stored at -80 °C until 
extraction was done. Total RNA was extracted from 
microdissected tissues, i.e., CA3 and DG, using the 
RNeasy micro Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol and eluted 
with 14 µL of RNAse-free water. The concentration 
of RNA was determined using Nanodrop 1000 and 
the integrity of RNA was determined using RNA 
6000 Pico Kit and Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA). The RNA 
quality was assessed according to the RNA integrity 
number. A RNA integrity number threshold value of 
7 was fixed, and samples below this value were 
discarded. 0.2 µg of total RNA was reverse 
transcribed to cDNA using RevertAid Premium 
Reverse Transcriptase (Fermentas) and primed with 
oligo-dT primers (Fermentas) and random primers 
(Fermentas). Quantitative polymerase chain reaction 
(q-PCR) was performed using a LightCycler 480 
Real-Time PCR System (Roche, Meylan, France). q-
PCR reactions were done in duplicate for each 
sample, using transcript-specific primers (Table S2), 
cDNA (4 ng), and LightCycler 480 SYBR Green I 
Master (Roche) in a final volume of 10µL. The PCR 
data were exported and analyzed with Gene 
Expression Analysis Software Environment 
developed at the Neurocentre Magendie. For the 
determination of the reference gene, the geNorm 
method was used (Bustin et al., 2009). Relative 
expression analysis was corrected for PCR efficiency 
and normalized against the houskeeping gene 
succinate dehydrogenase complex subunit A (Sdha). 
The relative level of expression was calculated using 
the comparative (2 -ΔΔCT) method (Livak and 
Schmittgen, 2001).	  
2.7. Immunohistological staining and analysis 
WT and APP/PS1 mice at 6, 9, and 12 months 
of age were anesthetized with intraperitoneal 
administration of pentobarbital (50 mg/kg body 
weight) and were fixed by transcardial perfusion with 
buffered saline and 50 mL of 4% paraformaldehyde 
(PFA). Brains were removed, postfixed in 4% PFA 
overnight, and cut into 40 um-thick frontal sections 
on a vibratome. Sections were collected into PBS 0.1 
M and stored at 4 °C until the staining protocol. 
After a thorough wash in TBST (tris buffer sodium: 
0.0384-M trisma base 0.1263-M NaCl, pH: 7.4 þ 
0.1% Tween 20), free-floating sections were 
incubated with TBST-10% Normal Goat 
Serume0.3% Triton X-100, for 1 hour at room 
temperature. Then sections were incubated with 
primary antibody in TBST-3.5% Normal Donkey 
Serum overnight at 4 °C (chicken antieglial fibrillary 
acidic protein (GFAP): 1/1000 USBiologicals; rabbit 
antieionized calcium-binding adapter molecule (Iba)-
1: 1/5000 Wako; mouse anti-Aß1-16: 1/150 Millipore). 
After washes in TBST, sections were incubated with 
secondary antibodies for 1 hour (Goat anti-chicken 
Alexa 647, anti-mouse Alexa 555, and anti-rabbit 
Alexa 488: 1/500, Invitrogen). Slices were finally 
washed and mounted in mounting medium 
(Fluoromount + DAPI, SouthernBiotech). Slices 
were imaged using the up-right widefield microscope 
Leica DM5000 (Leica Microsystems, Nanterre, 
France) using objectives HC PL Fluotar 20X NA 0.5. 
Fluorescence excitation was performed by a LED 
SOLA Light (Lumencor, Beaverton, USA). Images 
were obtained by the resolutive cameras CoolSnap 
HQ2 (Photometrics, Tucson, USA) and a cooled 
QICAM (QImaging, Surrey, Canada). A 
galvanometric stage (Leica Microsystems) allowed 
the z stack reconstructions. The mosaics were made 
using a motorized stage Scan (Märzhäuser, Wetzlar, 
Germany). This system was controlled by 
MetaMorph software (Molecular Devices, Sunnyvale, 
USA). Analyses were performed with Image J 
software (National Institutes of Health, New York, 
USA) on the maximum intensity fluorescence 
projections of the 3D mosaics. The distribution of 
GFAP positive cells (number of astrocytes per mm2), 
GFAP labelling, and Iba-1 positive cells (number of 
microglia per mm2) were represented as box plot for 
which the top of each box indicates the 75th quartile 
(Q3), the bottom indicates the 25th quartile (Q1), and 
the bar inside the box is the median (Q2). The 
whiskers extend out to the most extreme data point 
that is at most 1.5 times the interquartile range above 
the third quartile (Q3 + 1.5 x [Q3- Q1]) or below the 
first quartile (Q3 - 1.5 x [Q3 - Q1]). 
	    	  
117 	  
2.8. Enzyme immunoassay determination of PGE2 
The concentration of PGE2 was quantified 
both in WT and APP/PS1 at 6, 9,12, and 15 months 
of age. After anesthesia induction by intraperitoneal 
administration of pentobarbital (50 mg/kg body 
weight), the hippocampus was rapidly dissected and 
immediately frozen into liquid nitrogen. The 
concentration of PGE2 present in the hippocampus 
was quantified with a specific PGE2 competitive EIA 
kit (ACETM EIA kit, Cayman Chemical, Ann Arbor, 
MI, USA) following the procedures detailed in the 
instructions. The detection limit of this EIA kit was 
15 pg/mL (80% B/Bo). Absorbance was measured at 
415 nm by a microplate reader model 680 (Bio-Rad, 
Marnes-la-Coquette, France). 
2.9. Statistical analysis 
To eliminate bias, experimenters were kept 
blind to the genotype of the mice until all analysis 
was completed. Values are presented as mean 
standard error of the mean of n experiments. Unless 
stated otherwise, a Student t test for 2 groups and a 
1-way analysis of variance with Bonferonni’s test for 
more than 2 groups were used for statistical 
comparison. The p-values given are 2-tailed and 
were considered significant if p < 0.05. Statistical 
analysis was performed with Prism 5.0 (GraphPad 
Software, La Jolla, CA, USA). 
2.10. Drugs 
LCCG-1, bicuculline, D-2-amino-5 
phosphonopentanoate (D-AP5), and CGP55845 were 
obtained from Tocris biosciences. Sulprostone, PGE2, 
and forskolin were obtained from SigmaeAldrich. 
ONO compounds were a generous gift from ONO 
Pharmaceuticals Co Ltd (Japan). 
Results 
3.1. PGE2 impairs presynaptic long-term potentiation 
at MfeCA3 synapses  
We tested the effects of PGE2 on Mf-EPSCs 
recorded from CA3 pyramidal cells of P19-P21 wild-
type mice using the whole-cell voltage clamp mode 
of the patch clamp technique (Fig. 1A). Mf-EPSCs 
evoked by minimal intensity stimulation at low 
frequency (0.1 Hz) were not affected by bath 
application of 1-10 µM PGE2 (Fig. 1B). Mf-CA3 
synapses display prominent forms of presynaptic 
short-term plasticity (Nicoll and Schmitz, 2005), 
including paired-pulse facilitation (PPF: 2 
stimulations separated by 10-200 ms), and frequency 
facilitation (FF: switching from 0.1 Hz to >1 Hz 
tonic stimulation). PGE2 (10 µM) neither affected the 
pronounced PPF (Fig. 1C) nor FF (Fig. 1D). Last, we 
investigated possible effects of PGE2 on post-tetanic 
potentiation, another form of presynaptic short-term 
plasticity triggered by a single train of 100 stimuli at 
100 Hz and characterized by a robust increase in Mf-
EPSCs amplitude lasting several minutes. As shown 
in Fig. 1E, PGE2 (10 µM) did not affect post-tetanic 
potentiation. 
Altogether, exogenous application of PGE2 
affected neither basal synaptic transmission nor 
different forms of presynaptic short-term plasticity at 
Mf-CA3 synapses in young (P19-P21) mice. We then 
investigated whether PGE2 affected LTP of Mf-
EPSCs (Mf-LTP), a presynaptic form of plasticity 
which is independent of NMDA receptors (Nicoll 
and Schmitz, 2005). In the control condition, a high- 
frequency stimulus (HFS: 3 trains of 100 stimuli at 
100 Hz) triggered presynaptic Mf-LTP as measured 
by the mean amplitude of Mf-EPSCs recorded 30-40 
minutes after HFS (Fig. 1F). Bath application of 10-
µM PGE2 starting 10 minutes before HFS fully 
prevented Mf-LTP (Fig. 1F). In contrast, when 
applied after the induction of Mf-LTP (PGE2 AI), 
PGE2 had no effect (Fig. 2A, right panel). These 
results indicate that PGE2 impairs the induction of 
Mf-LTP but not its maintenance. 
3.2. PGE2 impairs Mf-LTP by acting on EP3 
receptors 
PGE2 can bind to 4 subtypes of G-
proteinecoupled receptors, namely EP1, EP2, EP3, 
and EP4 (Breyer et al., 2001). Markedly, the 
expression of messenger RNAs (mRNAs) coding for 
EP2 and EP3 receptors has been reported in mouse 
and rat hippocampus (Zhu et al., 2005). Thus, we 
investigated which subtype of PGE2 receptor was 
involved in the impairment of Mf-LTP. Sulprostone 
(10 µM), a potent EP3 receptor agonist (Coleman et 
al., 1987) fully prevented Mf-LTP, exactly 
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mimicking the effect of PGE2 (Fig. 2A). In contrast, 
ONO-AE1-259-01 (1 µM), a specific EP2 receptor 
agonist (Mori et al., 2009) had no effect on Mf-LTP 
(142 ± 26, n = 5; p = 0.903; Fig. 2A). ONO-AE3-240, 
a specific EP3 receptor antagonist fully prevented the 
impairment of LTP induced by PGE2 (Fig. 2A, left 
panel). Altogether these results are strong evidence 
that the EP3 receptor is solely responsible for the 
impairment of LTP. The lack of effect of the EP2 
agonist rules out the involvement of the EP4 receptor 
since it is coupled to the same intracellular signaling 
pathway as EP2. Finally, because it is coupled to 
phosphatidylinositol-calcium second messenger 
system, the EP1 receptor does not regulate AC 
activity and therefore is unlikely to be involved in 
presynaptic plasticity at Mf-CA3 synapses. Therefore, 
we focused on EP3 receptors in the rest of the study. 
3.3. Mechanisms of action of EP3 receptors at Mf-
CA3 synapses 
EP3 receptors are coupled to G proteins 
through a Gi/o subunit (Hatae et al., 2002) which 
negatively regulates AC activity. Presynaptic 3’,5’-
cyclic adenosine monophosphate (cAMP) is crucial 
for the regulation of presynaptic mechanisms at Mf-
CA3 synapses; presynaptic receptors coupled to Gs 
subunits, such as the 5-hydroxytryptamine 4 receptor 
(5-HT4) (Kobayashi et al., 2008) or dopamine 
receptor 1 (D1) (Kobayashi et al., 2012) potentiate 
Mf-CA3 synaptic transmission. To test the 
hypothesis that PGE2 negatively modulates AC 
activity through the activation of EP3 receptors, we 
investigated the effect of sulprostone on a moderate 
increase of AC activity induced by forskolin (2.5 
µM). Forskolin progressively increased Mf-EPSC 
amplitude (Fig. 2B) and sulprostone (10 µM) 
markedly reduced this potentiation (Fig. 2C). 
Both the reduction of forskolin-induced 
potentiation of synaptic transmission and the action 
on presynaptic Mf-LTP by PGE2 are consistent with 
a presynaptic locus of action for PGE2. Unfortunately, 
there is currently no suitable antibody to ascertain a 
presynaptic localization of the EP3 receptor in Mf 
terminals by immunocytochemistry. Commercially 
available antibodies for EP3 receptors lead to a 
strong background staining in brain sections in both 
EP3+/+ and EP3-/- mice (data not shown), which 
precluded any relevant conclusion (see also Shi et al., 
2012). We thus investigated the expression of mRNA 
coding for EP3 receptors (EP3 mRNA) using LCM 
of hippocampal neurons from the CA3 region and 
from the granule cell layer of the DG in brain slices 
followed by quantitative real-time reverse 
transcriptased quantitative polymerase chain reaction 
(RT-qPCR). Slices were first stained with cresyl 
violet to visualize better CA3 and DG regions (Fig. 
3A). Gene expression level of Ptger3, which codes 
for the EP3 receptor, was normalized to the 
housekeeping gene succinate dehydrogenase subunit 
A (Sdha) and mRNA expression was presented 
relative to that in the CA3 region of P19-P21 mice. 
RTqPCR indicated the expression of EP3 mRNA by 
DG granule cells (mean threshold cycle [Ct]: 31.54 ± 
0.15, n = 3) further supporting the localization of the 
EP3 receptor in Mfs. EP3 mRNA was also expressed, 
although at a much lower level, in the pyramidal cell 
layer of CA3 (mean Ct: 32.74 ± 0.55, n = 3), and the 
relative expression of EP3 mRNA was 2 fold in DG 
as compared to CA3 (2.1 fold 0.3, n = 3; p < 0.05) 
(Fig. 3B). Altogether, these results strongly suggest 
that PGE2 acting on presynaptic EP3 receptors 
controls the modulation of Mf-CA3 synaptic 
transmission by cAMP.  
3.4. Neuroinflammatory status of wild type versus 
APP/PS1 mice 
It is well established that at the clinical 
diagnosis stage, AD brains display extracellular 
deposits of Aß plaques accompanied by a prominent 
inflammatory reaction characterized by periplaque 
microgliosis and astrogliosis (Akiyama et al., 2000). 
We characterized the neuroinflammatory status of 
the hippocampus in WT and APP/PS1 mice at 
different ages (6, 9, and 12 months of age). Aß 
plaques were stained by an antibody raised against 
Aß1-16. Until 9 months of age, Aß plaques were 
barely detectable in the hippocampus of APP/PS1 
mice. At 12 months of age, Aß plaques were virtually 
absent in WT mice (Fig. 4A), whereas they were 
abundant in APP/PS1 mice (per hippocampus, WT: 
0.3 ± 0.5 plaques; APP/PS1: 21 ± 5 plaques, n = 4, p 
< 0.001; Fig. 4B). Strikingly, Aß plaques appeared to 
be nonuniformly distributed throughout the 
hippocampus but rather concentrated in the stratum 
lacunosum moleculare and the molecular layer of the 
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Fig. 1. PGE2 impairs presynaptic long-term potentiation at Mf-CA3 synapses. (A) Diagram shows the positions of the stimulating 
electrode (located in the mossy fiber tract) and of the recording electrode (CA3 neuron, whole-cell configuration of the patch 
clamp technique). (B) Representative time course of EPSCs recorded in CA3 pyramidal neurons (P19-P21) in response to low 
frequency (0.1 Hz) stimulation of mossy fiber in control conditions (black circles) and in the presence of PGE2 (10 µM; white 
circles). Note that EPSCs were evoked by minimal intensity stimulation (100 ms, 5-15 mA). EPSCs amplitude was normalized as 
percentage of average baseline EPSCs amplitude. Each dot corresponds to average of 5 consecutive EPSCs recorded for 8 cells. 
PGE2 (10 mM) was added after 10 minutes of baseline, and EPSCs were recorded for the following 30 minutes. The complete 
inhibition of EPSCs by group II mGluR agonist LCCG-1 (10 µM) confirmed that they were Mf-EPSCs. Bar graph represents 
average amplitude of EPSCs recorded between 10 and 20 minutes (control: 69.6 ± 5.6 pA, n = 8; PGE2: 64.1 10.1 pA, n = 8; p = 
0.28). (C) Average of 30 traces (left) illustrating paired-pulse facilitation (PPF) at 40 ms of Mf-EPSCs in control condition or in 
presence of PGE2 (10 mM). Bar graph represents average paired pulse ratio at 40 ms interstimulus interval (control: 348 ± 23%, n 
= 12; PGE2: 400 ± 28%, n =12, p = 0.17). (D) Average of 50 traces (left) illustrating frequency facilitation (FF) of Mf-EPSCs 
when increasing the simulation frequency from 0.1 Hz to 1 Hz in control condition or in presence of PGE2 (10 µM). Bar graphs of 
mean FF from 0.1 Hz to 1 Hz (control: 554 ± 34%, n = 12; PGE2: 613 ± 76%, n = 12, p = 0.096) (E). Representative time course 
of post-tetanic potentiation induced by simulation at 100 Hz during 1second. Bar graph represents average of normalized EPSCs 
during the 5 first minutes following the tetanic stimulation (control: 346 ± 48 %, n = 8; PGE2: 322 ± 55 %, n = 7, p = 0.742). (F) 
Time course of the effect of PGE2 (10 µM) on mossy fiber presynaptic LTP. Mf-LTP was induced by 3 bursts of 100 stimuli at 
100 Hz with a 10-second interburst interval (HFS). PGE2 was bath applied 10 minutes before HFS. Note the complete prevention 
of LTP induced by PGE2 (10 µM). Each dot corresponds to average of 6 consecutive EPSCs recorded for n cells. Data are 
presented as mean standard error of the mean. Abbreviations: DG, dentate gyrus; EPSCs, excitatory postsynaptic currents; LTP, 
long-term potentiation; Mf, mossy fiber; PGE2, prostaglandin E2; PP, perforant pathway; SC, shaffer collaterals. 
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Fig. 2. PGE2 impairs Mf-LTP by acting on EP3 receptors. (A) Left panel: ONO-AE3-240 (1 µM) (light gray symbols) rescued 
impairment by PGE2 of presynaptic Mf-LTP. Right panel: Bar graph represents average of normalized EPSCs between 30 and 40 
minutes after the HFS protocol in different conditions (PGE2 AI stands for PGE2 after induction) (control: 137 ± 18%, n = 10; 
PGE2: 83 ± 7%, n= 11; **p < 0.01; PGE2 AI: 136 ± 12%, n = 5, *p < 0.05; sulprostone: 86 ± 11%, n = 7, *p < 0.05; ONO-AE1-
259-01: 142 ± 26%, n = 5; ONO-AE3-240: 159 ± 18%, n = 5; **p < 0.01 vs. sulprostone and ***p < 0.001 vs. PGE2; ONO-AE3-
240 + PGE2: 134 ± 6%, n = 5). Note that when applied after the induction of LTP, PGE2 had no effect. Note that sulprostone (EP3 
receptor agonist) fully mimicked PGE2 induced blockade of LTP, and ONO-AE3-240 fully prevented the blockade of LTP 
induced by PGE2. ONO-AE1-259-01 (1 µM; EP2 receptor agonist) had no effect on LTP. (B) Time course of Mf-EPSCs 
potentiation induced by bath application of forskolin (2.5 µM) in control condition and in presence of sulprostone (10 µM). Mf-
EPSCs were averaged every minute and normalized to the mean amplitude of the 10 minutes preceding bath application of 
forskolin. Representative currents (averages of 60 EPSCs) recorded between 20 and 30 minutes after forskolin application 
illustrating the effect of sulprostone on forskolin-induced potentiation of Mf-EPSCs. (C) Bar graph represents the effect of 
sulprostone on forskolin-induced potentiation of Mf-EPSCs (control: 198 ± 18%, n = 9; sulprostone: 128 ± 13%, n = 6, *p < 
0.05). The complete inhibition of EPSCs by group II mGluR agonist LCCG-1 (10 µM) in A, B, and C confirmed that they were 
Mf-EPSCs. Data are presented as mean standard error of the mean. Abbreviations: EPSCs, excitatory postsynaptic currents; HFS, 
high-frequency stimulus; PGE2, prostaglandin E2. 
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Fig. 3. EP3 receptor expression in dentate gyrus (DG) and CA3 pyramidal layer. (A) Laser capture microdissection (LCM) of DG 
and CA3 neurons. Hippocampii were stained with cresyl violet. Upper panel: intact hippocampus before LCM. Left lower panel: 
LCM captured CA3 neuronal layer. Right lower panel: LCM captured DG. Bar = 300 mm. (B) Quantitative real-time polymerase 
chain reaction of hippocampal EP3 receptor mRNA derived from wild-type mice (P21) in DG and CA3 pyramidal layer. Bar 
graph illustrates the increase of expression in DG compared to CA3 pyramidal layer (2.1 fold 0.3, n = 3, per group; *p < 0.05). 
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Fig. 4. Neuroinflammatory status in APP/PS1 mice. (A) Representative micrograph of a hippocampus in a WT mouse (12 months 
of age) double stained for nuclei with 40,6-diamidino-2-phenylindole (DAPI) and for Aß plaques (anti-Aß1-16 antibody). No Ab 
plaques were detected. Bar scale = 250 mm. (B) Representative micrograph of a hippocampus in a APP/PS1 mouse (12 months of 
age). Note the presence of Ab plaques (white signal) mainly distributed in the stratum lacunosum moleculare and the molecular 
layer (ML) of the DG. Bar scale = 250 mm. Right panel: close up of an Ab plaque (white signal) surrounded by glial cells. Note 
the large cell bodies with short and thick processes of astrocytes (GFAP, red signal) in the vicinity of the plaque. Microglia (Iba-1, 
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green signal) walling off the plaque displayed round cell bodies with retracted processes. Bar scale = 10 mm. (C) Magnification 
of representative hippocampal area in the CA3 region (stratum lucidum and part of stratum radiatum) of WT and APP/PS1 mice 
(12 months of age). Note the increase in the number of GFAP positive cells (astrocytes, red signal) in APP/PS1 versus WT mice. 
Nuclei are stained with DAPI (blue signal). Bar scale = 10 mm. (D) Iba-1 positive cells (microglia, green signal) are more 
numerous in APP/PS1 versus WT mice. Nuclei are stained with DAPI (blue signal). Bar scale = 10 mm. (E) Box plot showing the 
distribution of GFAP positive cells (number of astrocytes per mm) in whole hippocampus and CA3 region in WT and APP/PS1 
mice. Whole hippocampus: WT: Q1 = 426, Q2 = 443, Q3 = 465; APP/PS1: Q1 = 447, Q2 =528, Q3 = 681; CA3 region: WT: Q1 
= 365, Q2 = 468, Q3 =554; APP/PS1: Q1 =559, Q2 = 720, Q3 = 829. (F) Box plot showing the distribution of GFAP labeling of 
astrocytes in whole hippocampus and CA3 region in WT and APP/PS1 mice. Whole hippocampus: WT: Q1 = 0.87, Q2 = 1.03, 
Q3 =1.15; APP/PS1: Q1 =1.11, Q2 = 1.17, Q3 = 1.60; CA3 region: WT: Q1 = 0.67, Q2 = 0.98, Q3 = 1.26; APP/PS1: Q1= 1.22, 
Q2 = 1.58, Q3 = 2.02. (G) Box plot showing the distribution of Iba-1 positive cells (number of microglia per mm2) in whole 
hippocampus and CA3 region in WT and APP/PS1 mice. Whole hippocampus: WT: Q1 = 195, Q2 = 259, Q3 = 301; APP/PS1: 
Q1 = 549, Q2 = 604, Q3 = 770; CA3 region: WT: Q1 = 176, Q2 = 202, Q3 = 272; APP/PS1: Q1 = 338, Q2 = 452, Q3 = 602. A 1-
way analysis of variance (ANOVA) followed by a KruskaleWallis post hoc test was used in D, E, and G (*p < 0.05, **p < 0.01, 
***p < 0.001). (H) Bar graph represents levels of PGE2 in whole hippocampus in WT and APP/PS1 at different ages. Note the 
significant increase of PGE2 levels at 12 and 15 months of age in APP/PS1 mice versus WT mice. (For interpretation of the 
references to color in this figure legend, the reader is referred to the Web version of this article.) 
 
PGE2 is a key neuroinflammatory molecule 
linked to AD in epidemiological studies (McGeer 
and McGeer, 2007) and in transgenic mouse models 
of AD (Kotilinek et al., 2008; Liang et al., 2005; 
Shi et al., 2012). We then quantified PGE2 within 
the hippocampus during aging for both genotypes. 
No significant difference in PGE2 levels was 
observed between WT and APP/PS1 mice (Fig. 4H) 
at ages up to 9 months (6 months: WT: 10.0 ± 1.4 
pg/mg, n = 8; APP/ PS1: 10.1± 0.84 pg/mg, n = 9; p 
= 0.957; 9 months: WT: 9.54 ± 0.98 pg/mg, n = 14; 
APP/PS1: 10.71 ± 1.51 pg/mg, n = 12; p = 0.511). 
In contrast, PGE2 levels were increased in APP/PS1 
mice compared to WT mice at 12 and 15 months of 
age (12 months: WT: 10.91± 0.9 pg/mg, n = 18; 
APP/PS1: 14.67 ± 1.36 pg/mg, n = 17; *p < 0.05; 15 
months: WT: 10.87 ± 2.38 pg/mg, n = 6; and 
APP/PS1: 17.07 ± 1.42 pg/mg, n = 13; Fig. 4H). 
Interestingly, the expression of hippocampal EP3 
mRNA was reported to increase for the same 
APP/PS1 mouse model (Shi et al., 2012). These 
results show that APP/PS1 mice displayed, together 
with the load of Aß plaques and a marked activation 
of astrocytes and microglia, increased hippocampal 
levels of PGE2. 
3.5. Presynaptic Mf-LTP is impaired in 12-month-
old APP/PS1 mice 
Since PGE2 alters synaptic plasticity at Mf-
CA3 synapses in WT mice, we investigated what 
could be the impact of increased levels of PGE2 
caused by neuroinflammation in APP/PS1 mice. 
Because of the very low rate of success in obtaining 
patch-clamp recordings from 6, 9, and 12-month-
old mice, we recorded fEPSP in the remainder of 
the study. We did not observe any differences 
between WT and APP/PS1 mice in inputeoutput 
relationships for fiber volley amplitude versus 
fEPSP slope at 6, 9 (data not shown), and 12 
months of age (Fig. 5A). Similarly, neither PPF nor 
FF was differentially affected between the 2 
genotypes (Table 1). No difference in the extent of 
Mf-LTP was observed between APP/PS1 mice and 
their WT littermates at 9 months of age (Fig. 5B). 
In contrast, presynaptic Mf-LTP was impaired in 
APP/PS1 mice at 12 months of age (Fig. 5C). 
3.6. Role of EP3 receptors in Mf-LTP deficits in 
APP/PS1 mice 
Strikingly, the alteration of Mf-LTP was 
concomitant with the increased levels of PGE2 in 
APP/PS1 mice (see Fig. 4H). We thus tested 
whether the building up of ambient PGE2 produced 
within the course of the pathology in APP/PS1 mice 
was involved in the impairment of presynaptic Mf-
LTP observed at 12 months of age. On the one hand, 
blocking EP3 receptors with ONO-AE3-240 (1 µM) 
added 30 minutes before the HFS burst rescued Mf-
LTP in APP/PS1 mice to a similar extent as Mf-
LTP in WT mice but had no effect per se on Mf-
LTP in WT mice (Fig. 5E). On the other hand, 
activating EP3 receptors with sulprostone (1 µM) 
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did not significantly impair further Mf-LTP in 
APP/PS1 mice (Fig. 5C). Last, presynaptic Mf-LTP 
was strongly impaired by PGE2 (10 µM) an effect 
faithfully mimicked by 1µM sulprostone (Fig. 5D), 
demonstrating the functionality of the PGE2-EP3 
pathway in WT littermates. 
Taken together, these results provide strong 
evidence that PGE2 acting via EP3 receptors is 
responsible for the impairment of Mf-LTP in 12-
month-old APP/PS1 mice, an age where the 
building up of endogenous PGE2 due to 
neuroinflammation, presumably reaches a critical 
level to impact EP3 receptors. 
Discussion 
Our findings demonstrate that PGE2, acting 
through the EP3 receptor subtype, inhibits 
presynaptic long-term plasticity at Mf-CA3 
synapses. We further provide evidence that in the 
APP/PS1 mouse model of AD, the PGE2-EP3 
receptor signaling pathway is responsible for the 
impairment of presynaptic LTP at Mf-CA3 
synapses by showing that the blockade of EP3 
receptors fully rescues the LTP at 12-month-old, an 
age characterized by a neuroinflammatory reaction 
and chronically elevated levels of the 
neuroinflammatory molecule PGE2. These results 
highlight EP3 receptors as a potential therapeutical 
target to alleviate synaptic dysfunction, and 
possibly also cognitive deficits associated with AD.  
4.1. PGE2 inhibits Mf-LTP by acting on EP3 
receptors likely localized presynaptically 
PGE2- and Cox-2-signaling pathways 
modulate hippocampal synaptic transmission and/or 
plasticity (Chen and Bazan, 2005; Sang et al., 2005; 
Yang et al., 2009). Depending on the concentration, 
PGE2 can either be beneficial or detrimental to 
hippocampal transmission and/or plasticity. 
Endogenous basal levels of PGE2 regulate 
membrane excitability, synaptic transmission, and 
plasticity in hippocampal CA1 pyramidal neurons 
(Chen and Bazan, 2005; Chen et al., 2002) and are 
necessary for memory acquisition (Rall et al., 2003), 
consolidation (Teather et al., 2002), and retention 
(Cowley et al., 2008; Sharifzadeh et al., 2006; 
Shaw et al., 2003). In the course of 
neuroinflammation, Cox-2 and microsomal PGE2 
synthase expression levels are increased in different 
mouse models of AD (Akitake et al., 2013; Ferretti 
et al., 2012) in parallel with impairments of 
synaptic plasticity and cognitive deficits. These data 
are coherent with a key role of PGE2, which is 
further supported by the induction of cognitive 
deficits in transgenic mice overexpressing Cox-2 in 
hippocampal neurons (Andreasson et al., 2001). 
As a part of a complex system, PGE2 can bind 
to 4 different subtypes of receptors (EP1-4). 
Depending on the subtype, the activation of EP 
receptors leads to changes in the production of 
cAMP and/or in phosphoinositol turnover and 
intracellular calcium mobilization (Breyer et al., 
2001). Our data show that ONO-AE1-259-01, a 
specific EP2 receptor agonist (Mori et al., 2009), 
had no effect on presynaptic Mf LTP, therefore 
ruling out any significant involvement of this 
receptor. Furthermore, as the EP4 receptor is 
coupled to the same intracellular signaling pathway 
as the EP2 receptor, namely the Gs-AC-cAMP 
pathway leading to an increase of cAMP production, 
our data also rule out a significant involvement of 
the EP4 receptor in PGE2-induced impairment of 
Mf LTP.  
Here we show that activation of EP3 receptors 
by either exogenous PGE2 in WT mice or 
endogenous PGE2 in APP/PS1 mice inhibits a 
presynaptic form of LTP at Mf-CA3 synapses. EP3 
receptors couple with the Gi-AC-cAMP pathway 
leading to inhibition of cAMP generation (Breyer et 
al., 2001; Irie et al., 1994). Two isoforms of AC are 
expressed by hippocampal neurons; AC1 and AC8 
(Wang et al., 2003; Xia et al., 1991). AC8 activity 
is exclusively dependent on intracellular Ca2+ 
(Nielsen et al., 1996), whereas AC1, which is 
highly expressed in DG cells (Xia et al., 1991), is 
both regulated by G proteins and intracellular Ca2+ 
(Willoughby and Cooper, 2007). Therefore, it is 
likely that only AC1 may be linked to the PGE2-
EP3esignaling pathway. Our results are consistent 
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with other studies showing that simple deletion of 
AC1 (Villacres et al., 1998) or double deletion of 
AC1/AC8 (Wang et al., 2003) do not affect basal 
properties at Mf-CA3 synapses. However, we 
observed a normalization of Mf-EPSCs amplitude 
following application of a moderate concentration 
of forskolin, an activator of AC which is known to 
enhance Mf-CA3 synaptic transmission. Hence, the 
activation of PGE2-EP3 signaling pathway does not 
directly modulate synaptic basal transmission; 
however, it may interact with pathways linked to 
AC, when previously activated. In keeping with this, 
we found that PGE2 impaired presynaptic Mf-LTP, 
an effect mimicked by sulprostone (EP3 agonist) 
and blocked by ONO-AE3-240 (EP3 antagonist), 
whereas ONO-AE1-259-01 (EP2 agonist) had no 
effect. These data provide strong evidence for an 
effect of PGE2 mediated by EP3 receptors, but not 
EP2/EP4 receptors, and indicate that PGE2 acts by 
downregulating AC activity triggered during the 
HFS bursts. Because of the impact of EP3 receptor 
activation on presynaptic mechanisms, we propose 
that EP3 receptors are localized in presynaptic 
terminals. Indeed, many lines of evidence 
coherently point at a presynaptic localization of EP3 
receptors at Mf-CA3 synapses. First, PGE2 
modulates the release of neurotransmitters by Mf 
through a EP3 receptor Gi-AC-cAMP pathway. 
Second, the PGE2-EP3 receptor signaling pathway 
specifically impairs the presynaptic form of LTP at 
Mf-CA3 synapses. Third, DG cells express mRNA 
coding for EP3 receptor. Last, the PGE2-EP3 
receptor signaling pathway regulates the 
hippocampal expression of presynaptic proteins 
such as synaptophysin, synapsin 1, SNAP-25, or 
VAMP-2 but not the expression of proteins 
belonging to the postsynaptic density (Shi et al., 
2012). However, due to the lack of a suitable 
antibody against EP3 receptors (this study; Shi et al., 
2012), we were not able to ascertain its cellular 
localization. All the data are consistent with EP3 
receptors being expressed at Mfs, but they cannot 
rule out a putative glial expression of EP3 receptors 
(Slawik, 2004). However, glial process has a 
restricted access to Mf-CA3 synaptic cleft in 
physiological conditions (Rollenhagen et al., 2007), 
which seems to preclude a major role for glial EP3 
receptor in the modulation of Mf synaptic plasticity. 
4.2. Elevation of PGE2 during AD-linked 
neuroinflammatory processes is responsible for 
impairment of synaptic plasticity at Mf-CA3 
synapses 
Most relevant to our study, PGE2-EP3 
signaling seems to be a key component in the 
progression of the pathology in the APP/PS1 mouse 
model of Alzheimer’s disease (Shi et al., 2012). The 
present finding that PGE2-EP3 negatively controls 
presynaptic Mf-LTP in WT mice prompted us to 
investigate if this plasticity was altered in APP/PS1 
mice during the course of the disease and if the 
PGE2-EP3 signaling pathway was involved. So far, 
most of the studies focussed on synaptic failure in 
mouse models of AD have not addressed whether 
and how progressive neuroinflammatory processes 
are linked with synaptic dysfunction. Here, we 
showed that presynaptic Mf-LTP was impaired in 
APP/PS1 mice starting at 12 months of age, 
whereas presynaptic short-term plasticity was not. 
Strikingly, this impairment paralleled the increase 
in hippocampal levels of PGE2 in APP/PS1 mice 
that we could detect starting at 12 months of age. 
Furthermore, EP3 receptor blockade by ONO-AE3-
240 fully rescued impaired Mf-LTP in 12-month-
old APP/PS1 mice clearly supporting a key role of 
the PGE2-EP3 signaling pathway in the 
development of synaptic dysfunction at the Mf-CA3 
synapse in neuroinflammatory processes linked to 
AD. Worthy to note, ONO-AE3-240 had no effect 
on Mf-LTP in 12-month-old WT mice suggesting 
that the amount of PGE2 produced during normal 
aging was not sufficient to activate tonically EP3 
receptors and therefore impair plasticity. 
Interestingly, a time point of 8 months in the APP/ 
PS1 mouse was proposed for the expression onset 
of inflammatory genes IL-1ß, iNOS, and TNFα, 
which is driven by an increased expression of 
hippocampal EP3 mRNA (Shi et al., 2012). In our 
study, the time course of impairment of presynaptic 
Mf-LTP correlates well with the progressive 
development of neuroinflammation characterized 
by a mild activation of microglia and astrocytes and 
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elevated levels of PGE2. Mf-CA3 synapses seem 
therefore relatively spared by the pathology in terms 
of presynaptic plasticity, at least up to 12 months of 
age. In contrast, postsynaptic long-term potentiation 
at associative/commissural CA3 synapses is 
completely abolished starting at 6 months of age in 
APP/PS1 mice (Viana da Silva et al., 2016). These 
data suggest that early learning deficits involving 
short-term working memory (Lagadec et al., 2012) 
or long-term spatial memory (Reiserer et al., 2007), 
which occur at 6-7 months of age may not involve 
presynaptic Mf-CA3 plasticity but rather may be 
related to alterations of postsynaptic plasticity at 
CA3-CA1 synapses (Volianskis et al., 2010) and/or 
CA3-CA3 synapses (Viana da Silva et al., 2016). 
4.3. Pathophysiological relevance of PGE2-EP3 
signaling at Mf-CA3 synapses in the contex of AD 
Potential alterations of Mf-CA3 synaptic 
function and plasticity in the context of AD have 
only received limited attention, despite the key role 
of DG-CA3 circuits in the encoding of new spatial 
information and complex mnemonic processes 
(Kesner, 2007). Our study demonstrates for the first 
time that presynaptic Mf-LTP is specifically altered 
through a PGE2-EP3 signaling pathway in APP/ 
PS1 mice at 12 months of age and most importantly 
can be entirely rescued by the pharmacological 
blockade of the EP3 receptor. Therefore, in addition 
to being instrumental in neuroinflammation 
processes (Shi et al., 2012), PGE2-EP3 signaling is 
also linked to synaptic alterations. Further work is 
necessary to elucidate how the engagement of the 
PGE2-EP3 signaling pathway during 
neuroinflammatory processes contributes to AD-
related cognitive deficits. Interestingly, contextual 
fear conditioning is altered in APP/PS1 mice 
(Kilgore et al., 2010), and PGE2 has been shown to 
be necessary and sufficient to induce CFC when 
injected in the dorsal hippocampus (Hein et al., 
2007). 
In conclusion, our data demonstrate that PGE2 
signaling via EP3 receptors impairs a presynaptic 
form of LTP at Mf-CA3 synapses, hence 
identifying a potential mechanism to explain 
deficits in 1-trial memory in AD (Kilgore et al., 
2010). This pathway, implicated in 
neuroinflammatory processes in the course of AD 
(Shi et al., 2012), may identify a presynaptic form 
of LTP as a new target and leads to the promising 
idea of a therapeutical targeting of EP3 receptors 
instead of an upstream global inhibition of the 
production of PGE2, which may have deleterious 
effects. 
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Fig. 5. PGE2-EP3 signaling pathway impairs Mf presynaptic plasticity in APP/PS1 mice aged 12 months. (A) Inputeoutput 
relationship between the amplitude of fiber volley and the slope of fEPSP for gradually increasing stimulation intensities in wild type 
animals (black circles) and APP/PS1 animals (white circles) at 12 months of age. Both genotypes (WT and APP/PS1) displayed 
similar inputeoutput relationships forfiber presynaptic LTP (Mf-LTP) in WT and APP/PS1 mice at 9 months of age. Mf-LTP was 
induced by 3 bursts of 100 stimuli at 100 Hzfiber volley amplitude versus fEPSP slope (WT: 0.21 mV/ms ± 0.08 mV/ms, n = 8; 
APP/PS1: 0.28 mV/ms ± 0.12 mV/ms, n = 6; p = 0.624). (B) Average time course of mossy with a 10-second interburst interval 
(HFS). There was no difference between the 2 genotypes for normalized EPSCs measured between 40 and 50 minutes (WT: 152 ± 
14%; APP/PS1: 160 ± 11%, p = 0.67, n = 5 for both conditions). (C) Average time course of Mf-LTP in WT and APP/PS1 mice aged 
12 months. Note the impairment of Mf-LTP in APP/PS1 mice (WT: 173 ± 12%, n = 15; APP/PS1: 126 ± 13%, n = 11, p < 0.001). 
Bar graph represents average of normalized slopes from fEPSPs. Sulprostone had no further significant effect on LTP reduction in 
APP/PS1 mice (APP/PS1 + sulprostone: 92 ± 26%, n = 4, p < 0.001). (D) Bar graph represents average of normalized slopes from 
fEPSPs in WT mice at 12 months of age either in the presence of PGE2 or sulprostone. Note that sulprostone or PGE2 induced similar 
decrease of LTP (WT: 173 ± 12%, n = 15; PGE2: 114 ± 5%, n = 9; sulprostone: 125 ± 12%, n = 7; p < 0.001). (E) Average time 
course of Mf-LTP illustrates the rescue of Mf-LTP in presence of ONO-AE3-240 (1 mM) in APP/PS1 mice at 12 months of age. Bar 
graph illustrates the average of fEPSPs slopes (WT: 173 ± 12%, n = 15; WT + ONO-AE3-240: 180 ± 4%, n = 7; APP/PS1: 126 ± 
13%, n = 11; APP/PS1 + ONO-AE3-240: 163 ± 17%, n = 10; p < 0.001). In these series of experiments (not shown due to the time 
scale), the complete inhibition of EPSCs by group II mGluR agonist LCCG-1 (10 mM) confirmed that they were Mf-EPSCs. ***p < 
0.001. Abbreviations: EP3, prostaglandin E2 receptor 3; fEPSP, field excitatory postsynaptic potential; HFS, high-frequency 
stimulus; Mf, mossy fiber; PGE2, prostaglandin E2. 
 
Table 1 
Short-term plasticity in WT and APP/PS1 mice at 9 and 12 months of age 
Short-term 
plasticity 
WT (9 mo) APP/PS1 (9 mo) WT (12 mo) APP/PS1 (12 mo) 
PPF 
FF 
381 ± 43% 
673 ± 100% 
369 ± 59%, p = 0.869 
484 ± 61% , p = 0.148 
383 ± 75 % 
532 ± 88 % 
       282 ± 37%, p = 0.296 
418 ± 123%,  p = 0.432 
 
For PPF, average of 30 traces at 40 ms interstimulus interval. For FF, average of 50 traces when increasing the stimulation frequency 
from 0.1 Hz to 1 Hz. Data are mean ± standard error of the mean, n = 6-8 mice per group; Student t test. Key: FF, frequency 
facilitation; PPF, paired-pulse facilitation; WT, wild-type mice. 
 
Appendix A. Supplementary data 
Supplementary data associated with this article can be found, in the online version, at 
http://dx.doi.org/10.1016/j.neurobiolaging. 2016.10.012. 
References 
Akitake, Y., Nakatani, Y., Kamei, D., Hosokawa, M., Akatsu, H., Uematsu, S., Akira, S., Kudo, S., Hara, S., 
Takahashi, M., 2013. Microsomal prostaglandin E synthase-1 is induced in Alzheimer’s disease and its 
deletion mitigates Alzheimer’s diseaselike pathology in a mouse model. J. Neurosci. Res. 91, 909-919. 
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., 
Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S.T., Hampel, H., Hull, M., Landreth, G., Lue, L.F., Mrak, 
R., Mackenzie, I.R., McGeer, P.L., O’Banion, M.K., Pachter, J., Pasinetti, G., PlataeSalaman, C., Rogers, J., 
	    	  
129 	  
Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., 
Webster, S., Wegrzyniak, B., Wenk, G., WysseCoray, T., 2000. Inflammation and Alzheimer’s disease. 
Neurobiol. Aging 21, 383-421. 
Andreasson, K.I., Savonenko, A., Vidensky, S., Goellner, J.J., Zhang, Y., Shaffer, A., Kaufmann, W.E., 
Worley, P.F., Isakson, P., Markowska, A.L., 2001. Age-dependent cognitive deficits and neuronal apoptosis in 
cyclooxygenase-2 transgenic mice. J. Neurosci. 21, 8198-8209. 
Bos, C.L., Richel, D.J., Ritsema, T., Peppelenbosch, M.P., Versteeg, H.H., 2004. Prostanoids and prostanoid 
receptors in signal transduction. Int. J. Biochem. Cell Biol. 36, 1187-1205. 
Breitner, J.C., Baker, L., Montine, T., 2011. Extended results of the Alzheimer’s disease anti-inflammatory 
prevention trial. Alzheimer Demen. 7, 402-411. 
Breyer, R.M., Bagdassarian, C.K., Myers, S.A., Breyer, M.D., 2001. Prostanoid receptors: subtypes and 
signaling. Annu. Rev. Pharmacol. Toxicol. 41, 661-690. 
Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, 
M.W., Shipley, G.L., Vandesompele, J., Wittwer, C.T., 2009. The MIQE guidelines: minimum information for 
publication of quantitative realtime PCR experiments. Clin. Chem. 55, 611-622. 
Chen, C., Bazan, N.G., 2005. Endogenous PGE2 regulates membrane excitability and synaptic transmission in 
hippocampal CA1 pyramidal neurons. J. Neurophysiol. 93, 929-941. 
Chen, C., Magee, J., Bazan, N., 2002. Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal 
long-term synaptic plasticity. J. Neurophysiol. 87, 2851-2857. 
Coleman, R.A., Kennedy, I., Sheldrick, R.L., 1987. New evidence with selective agonists and antagonists for 
the subclassification of PGE2-sensitive (EP) receptors. Adv. Prostaglandin Thromboxane Leukot. Res. 17A, 
467-470. 
Cowley, T.R., Fahey, B., O’Mara, S.M., 2008. COX-2, but not COX-1, activity is necessary for the induction 
of perforant path long-term potentiation and spatial learning in vivo. Eur. J. Neurosci. 27, 2999-3008. 
Eikelenboom, P., Zhan, S.S., van Gool, W.A., Allsop, D., 1994. Inflammatory mechanisms in Alzheimer’s 
disease. Trends Pharmacol. Sci. 15, 447-450. 
Eng, L.F., Ghirnikar, R.S., 1994. GFAP and astrogliosis. Brain Pathol. 4, 229-237. 
Eng, L.F., Yu, A.C., Lee, Y.L., 1992. Astrocytic response to injury. Prog. Brain Res. 94, 353-365. 
Ferretti, M.T., Bruno, M.A., Ducatenzeiler, A., Klein, W.L., Cuello, A.C., 2012. Intracellular Aß-oligomers 
and early inflammation in a model of Alzheimer’s disease. Neurobiol. Aging 33, 1329-1342. 
Font-Nieves, M., Sans-Fons, M.G., Gorina, R., Bonfill-Teixidor, E., Salas-Pérdomo, A., Márquez-Kisinousky, 
L., Santalucia, T., Planas, A.M., 2012. Induction of COX-2 enzyme and down-regulation of COX-1 expression 
by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J. Biol. Chem. 287, 6454-6468. 
Hatae, N., Yamaoka, K., Sugimoto, Y., Negishi, M., Ichikawa, A., 2002. Augmentation of receptor-mediated 
adenylyl cyclase activity by Gi-coupled prostaglandin receptor subtype EP3 in a Gbetagamma subunit-
independent manner. Biochem. Biophys. Res. Commun. 290, 162-168. 
	    	  
130 	  
Hein, A.M., Stutzman, D.L., Bland, S.T., Barrientos, R.M., Watkins, L.R., Rudy, J.W., Maier, S.F., 2007. 
Prostaglandins are necessary and sufficient to induce contextual fear learning impairments after interleukin-1 
beta injections into the dorsal hippocampus. Neuroscience 150, 754-763. 
Heneka, M., O’Banion, M.K., 2007. Inflammatory processes in Alzheimer’s disease. J. Neuroimmunol. 184, 
69-91. 
Henze, D., Wittner, L., Buzsáki, G., 2002. Single granule cells reliably discharge targets in the hippocampal 
CA3 network in vivo. Nat. Neurosci. 5, 790-795. 
Hoshino, T., Nakaya, T., Homan, T., Tanaka, K., Sugimoto, Y., Araki, W., Narita, M., Narumiya, S., Suzuki, 
T., Mizushima, T., 2007. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro 
and in vivo. J. Biol. Chem. 282, 32676-33288. 
Irie, A., Segi, E., Sugimoto, Y., Ichikawa, A., Negishi, M., 1994. Mouse prostaglandin E receptor EP3 subtype 
mediates calcium signals via Gi in cDNA-transfected Chinese hamster ovary cells. Biochem. Biophys. Res. 
Commun. 204, 303-309. 
Jacobsen, J.S., Wu, C.C., Redwine, J.M., Comery, T.A., Arias, R., Bowlby, M., Martone, R., Morrison, J.H., 
Pangalos, M.N., Reinhart, P.H., Bloom, F.E., 2006. Early-onset behavioral and synaptic deficits in a mouse 
model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A. 103, 5161-5166. 
Jankowsky, J.L., Fadale, D.J., Anderson, J., Xu, G.M., Gonzales, V., Jenkins, N., Copeland, N.G., Lee, M.K., 
Younkin, L.H., Wagner, S.L., Younkin, S.G., Borchelt, D.R., 2004. Mutant presenilins specifically elevate the 
levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma 
secretase. Hum. Mol. Genet. 13, 159-170. 
Kesner, R.P., 2007. Behavioral functions of the CA3 subregion of the hippocampus. Learn. Mem. 14, 771-781. 
Kilgore, M., Miller, C., Fass, D.M., Hennig, K.M., Haggarty, S.J., Sweatt, J.D., Rumbaugh, G., 2010. 
Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s 
disease. Neuropsychopharmacol 35, 870-880. 
Kitamura, Y., Shimohama, S., Koike, H., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P.J., 
Taniguchi, T., 1999. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-
gamma in Alzheimer’s disease brains. Biochem. Biophys. Res. Commun. 254, 582-586. 
Kobayashi, K., Haneda, E., Higuchi, M., Suhara, T., Suzuki, H., 2012. Chronic fluoxetine selectively 
upregulates dopamine D1-like receptors in the hippocampus. Neuropsychopharmacol 37, 1500-1508. 
Kobayashi, K., Ikeda, Y., Haneda, E., Suzuki, H., 2008. Chronic fluoxetine bidirectionally modulates 
potentiating effects of serotonin on the hippocampal mossy fiber synaptic transmission. J. Neurosci. 28, 6272-
6280. 
Kotilinek, L., Westerman, M., Wang, Q., Panizzon, K., Lim, G.P., Simonyi, A., Lesne, S., Falinska, A., 
Younkin, L.H., Younkin, S.G., Rowan, M., Cleary, J., Wallis, R.A., Sun, G.Y., Cole, G., Frautschy, S., Anwyl, 
R., Ashe, K.H., 2008. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory 
and synaptic plasticity. Brain 131, 651-664. 
	    	  
131 	  
Lagadec, S., Rotureau, L., Hémar, A., Macrez, N., Delcasso, S., Jeantet, Y., Cho, Y.H., 2012. Early temporal 
short-term memory deficits in double transgenic APP/PS1 mice. Neurobiol. Aging 33, 203-211. 
Liang, X., Wang, Q., Hand, T., Wu, L., Breyer, R.M., Montine, T.J., Andreasson, K., 2005. Deletion of the 
prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer’s 
disease. J. Neurosci. 25, 10180-10187. 
Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR 
and the 2(-Delta Delta C(T)). Methods 25, 402-408. 
Marchal, C., Mulle, C., 2004. Postnatal maturation of mossy fibre excitatory transmission in mouse CA3 
pyramidal cells: a potential role for kainate receptors. J. Physiol. 561, 27-37. 
McGeer, P.L., McGeer, E.G., 2007. NSAIDs and Alzheimer disease: epidemiological, animal model and 
clinical studies. Neurobiol. Aging 28, 639-647. 
Montine, T.J., Sidell, K.R., Crews, B.C., Markesbery, W.R., Marnett, L.J., Roberts, L.J., Morrow, J.D., 1999. 
Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495-1498. 
Mori, A., Ishii, T., Kuroki, T., Shigeta, N., Sakamoto, K., Nakahara, T., Ishii, K., 2009. The prostanoid EP(2) 
receptor agonist ONO-AE1-259-01 protects against glutamateinduced neurotoxicity in rat retina. Eur. J. 
Pharmacol. 616, 64-67. 
Nicoll, R.A., Schmitz, D., 2005. Synaptic plasticity at hippocampal mossy fibre synapses. Nat. Rev. Neurosci. 
6, 863-876. 
Nielsen, M.D., Chan, G.C., Poser, S.W., Storm, D.R., 1996. Differential regulation of type I and type VIII 
Ca2+-stimulated adenylyl cyclases by Gi-coupled receptors in vivo. J. Biol. Chem. 271, 33308-33316. 
Nimmerjahn, A., Kirchhoff, F., Helmchen, F., 2005. Resting microglial cells are highly dynamic surveillants of 
brain parenchyma in vivo. Science 308, 1314-1318. 
Rall, J.M., Mach, S.A., Dash, P.K., 2003. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates 
memory acquisition in rats. Brain Res. 968, 273-276. 
Reiserer, R.S., Harrison, F.E., Syverud, D.C., McDonald, M.P., 2007. Impaired spatial learning in the APPSwe 
+ PSEN1DeltaE9 bigenic mouse model of Alzheimer’s disease. Gen. Brain Behav. 6, 54-65. 
Rollenhagen, A., Sältzer, K., Rodriguez, E.P., Jonas, P., Frotscher, M., Lübke, J.H.R., 2007. Structural 
determinants of transmission at large hippocampal mossy fiber synapses. J. Neurosci. 27, 10434-10444. 
Salin, P.A., Scanziani, M., Malenka, R.C., Nicoll, R.A., 1996. Distinct short-term plasticity at two excitatory 
synapses in the hippocampus. Proc. Natl. Acad. Sci. U S A. 93, 13304-13309. 
Sang, N., Zhang, J., Marcheselli, V., Bazan, N.G., Chen, C., 2005. Postsynaptically synthesized prostaglandin 
E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. J. Neurosci. 25, 
9858-9870. 
Selkoe, D., 2002. Alzheimer’s disease is a synaptic failure. Science 298, 789-791. 
	    	  
132 	  
Sharifzadeh, M., Tavasoli, M., Soodi, M., Mohammadi-Eraghi, S., Ghahremani, M.H., Roghani, A., 2006. A 
time course analysis of cyclooxygenase-2 suggests a role in spatial memory retrieval in rats. Neurosci. Res. 54, 
171-179. 
Shaw, K.N., Commins, S., O’Mara, S.M., 2003. Deficits in spatial learning and synaptic plasticity induced by 
the rapid and competitive broad-spectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing 
endogenous brain-derived neurotrophic factor. Eur. J. Neurosci. 17, 2438-2746. 
Sheng, M., Sabatini, B.L., Südhof, T.C., 2012. Synapses and Alzheimer’s disease. Cold Spring Harb Perspect. 
Biol. 4, 1-18. 
Shi, J., Wang, Q., Johansson, J.U., Liang, X., Woodling, N.S., Priyam, P., Loui, T.M., Merchant, M., Breyer, 
R.M., Montine, T.J., Andreasson, K., 2012. Inflammatory prostaglandin E2 signaling in a mouse model of 
Alzheimer disease. Ann. Neurol. 72, 788-798. 
Slawik, H., 2004. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. 
Neurochem. Int. 45, 653-660. 
Smith, W.L., Marnett, L.J., DeWitt, D.L., 1991. Prostaglandin and thromboxane biosynthesis. Pharmacol. Ther. 
49, 153-179. 
Teather, L.A., Packard, M.G., Bazan, N.G., 2002. Post-training cyclooxygenase-2 (COX-2) inhibition impairs 
memory consolidation. Learn Mem. 9, 41-47. 
Viana da Silva, S., Haberl, M.G., Zhang, P., Bethge, P., Lemos, C., Gonçalves, N., Gorlewicz, A., Malezieux, 
M., Gonçalves, F.Q., Grosjean, N., Blanchet, C., Frick, A., Nägerl, U.V., Cunha, R.A., Mulle, C., 2016. Early 
synaptic deficits in the APP/PS1 mouse model of Alzheimer’s disease involve neuronal adenosine A2A 
receptors. Nat. Commun. 7, 11915. 
Villacres, E.C., Wong, S.T., Chavkin, C., Storm, D.R., 1998. Type I adenylyl cyclase mutant mice have 
impaired mossy fiber long-term potentiation. J. Neurosci. 18, 3186-3194. 
Volianskis, A., Køstner, R., Mølgaard, M., Hass, S., Jensen, M.S., 2010. Episodic memory deficits are not 
related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the 
APPswe/PS1dE9-deleted transgenic mice model of ß-amyloidosis. Neurobiol. Aging 31, 1173-1187. 
Wang, H., Pineda, V.V., Chan, G.C.K., Wong, S.T., Muglia, L.J., Storm, D.R., 2003. Type 8 adenylyl cyclase 
is targeted to excitatory synapses and required for mossy fiber long-term potentiation. J. Neurosci. 23, 9710-
9718. 
Willoughby, D., Cooper, D.M.F., 2007. Organization and Ca2+ regulation of adenylyl cyclases in cAMP 
microdomains. Physiol. Rev. 87, 965-1010. 
Witton, J., Brown, J.T., Jones, M.W., Randall, A.D., 2010. Altered synaptic plasticity in the mossy fibre 
pathway of transgenic mice expressing mutant amyloid precursor protein. Mol. Brain 3, 32. 
Xia, Z.G., Refsdal, C.D., Merchant, K.M., Dorsa, D.M., Storm, D.R., 1991. Distribution of mRNA for the 
calmodulin-sensitive adenylate cyclase in rat brain: expression in areas associated with learning and memory. 
Neuron 6, 431-443. 
	    	  
133 	  
Yang, H., Zhang, J., Breyer, R.M., Chen, C., 2009. Altered hippocampal long-term synaptic plasticity in mice 
deficient in the PGE2 EP2 receptor. J. Neurochem. 108, 295-304. 
Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L., 1999. Distribution of cyclooxygenase-1 and 
cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830, 226-236. 
Zhu, P., Genc, A., Zhang, X., Zhang, J., Bazan, N.G., Chen, C., 2005. Heterogeneous expression and 
regulation of hippocampal prostaglandin E2 receptors. J. Neurosci. Res. 81, 817-826.
	    	  
134	  	  
VII. References 
Abbott, L. and W. G. Regehr (2004). "Synaptic computation." Nature 431(7010): 796. 
Abraham, W., B. Gustafsson and H. Wigström (1987). "Long-­‐term potentiation involves 
enhanced synaptic excitation relative to synaptic inhibition in guinea-­‐pig hippocampus." The 
Journal of Physiology 394(1): 367-380. 
Abraham, W. C. and J. M. Williams (2003). "Properties and mechanisms of LTP 
maintenance." Neuroscientist 9(6): 463-474. 
Ahmed, T., S. Enam and A. Gilani (2010). "Curcuminoids enhance memory in an amyloid-
infused rat model of Alzheimer's disease." Neuroscience 169(3): 1296-1306. 
Aisen, P. S. (1997). "Inflammation and Alzheimer’s disease: mechanisms and therapeutic 
strategies." Gerontology 43(1-2): 143-149. 
Aisen, P. S., S. Gauthier, B. Vellas, R. Briand, D. Saumier, J. Laurin and D. Garceau (2007). 
"Alzhemed: a potential treatment for Alzheimer's disease." Curr Alzheimer Res 4(4): 473-478. 
Aisen, P. S., D. Saumier, R. Briand, J. Laurin, F. Gervais, P. Tremblay and D. Garceau (2006). 
"A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease." 
Neurology 67(10): 1757-1763. 
Aisen, P. S., K. A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K. L. Davis, M. R. Farlow, S. 
Jin, R. G. Thomas and L. J. Thal (2003). "Effects of rofecoxib or naproxen vs placebo on 
Alzheimer disease progression: a randomized controlled trial." Jama 289(21): 2819-2826. 
Akama, K. and L. Van Eldik (2000). "β-Amyloid stimulation of inducible nitric oxide 
synthase in astrocytes is IL-1β-and TNF-αdependent, and involves a TNF-α receptor-
associated factor-and NF kappa B-inducing kinase-dependent signaling mechanism." J Biol 
Chem 275(11): 7918. 
Akiyama, H., S. Barger, S. Barnum, B. Bradt, J. Bauer, G. M. Cole, N. R. Cooper, P. 
Eikelenboom, M. Emmerling, B. L. Fiebich, C. E. Finch, S. Frautschy, W. S. Griffin, H. 
Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I. R. Mackenzie, P. L. McGeer, M. K. 
O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, 
R. Strohmeyer, I. Tooyoma, F. L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. 
Wegrzyniak, G. Wenk and T. Wyss-Coray (2000). "Inflammation and Alzheimer's disease." 
Neurobiol Aging 21(3): 383-421. 
Albensi, B. C., D. R. Oliver, J. Toupin and G. Odero (2007). "Electrical stimulation protocols 
for hippocampal synaptic plasticity and neuronal hyper-excitability: are they effective or 
relevant?" Exp Neurol 204(1): 1-13. 
Alkadhi, K. A., K. H. Alzoubi, M. Srivareerat and T. T. Tran (2011). "Chronic psychosocial 
stress exacerbates impairment of synaptic plasticity in beta-amyloid rat model of Alzheimer's 
disease: prevention by nicotine." Curr Alzheimer Res 8(7): 718-731. 
Alkadhi, K. A., M. Srivareerat and T. T. Tran (2010). "Intensification of long-term memory 
deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease." 
Mol Cell Neurosci 45(3): 289-296. 
Aloisi, F. (2001). "Immune function of microglia." Glia 36(2): 165-179. 
Alvernhe, A., T. Van Cauter, E. Save and B. Poucet (2008). "Different CA1 and CA3 
representations of novel routes in a shortcut situation." Journal of Neuroscience 28(29): 7324-
7333. 
	    	  
135	  	  
Amaral, D. G. and M. P. Witter (1989). "The three-dimensional organization of the 
hippocampal formation: a review of anatomical data." Neuroscience 31(3): 571-591. 
Andersen, K., H. Nielsen, A. Lolk, J. Andersen, I. Becker and P. Kragh-Sørensen (1999). 
"Incidence of very mild to severe dementia and Alzheimer’s disease in Denmark: the Odense 
Study." Neurology 52(1): 85-85. 
Andersen, P., S. Sundberg, O. Sveen, J. Swann and H. Wigström (1980). "Possible 
mechanisms for long-­‐lasting potentiation of synaptic transmission in hippocampal slices from 
guinea-­‐pigs." The Journal of Physiology 302(1): 463-482. 
Andreasson, K. (2010). "Emerging roles of PGE2 receptors in models of neurological 
disease." Prostaglandins & other lipid mediators 91(3-4): 104-112. 
Aston-Jones, G., J. Rajkowski, P. Kubiak and T. Alexinsky (1994). "Locus coeruleus neurons 
in monkey are selectively activated by attended cues in a vigilance task." Journal of 
Neuroscience 14(7): 4467-4480. 
Atluri, P. P. and W. G. Regehr (1996). "Determinants of the time course of facilitation at the 
granule cell to Purkinje cell synapse." Journal of Neuroscience 16(18): 5661-5671. 
Atri, A., L. W. Shaughnessy, J. J. Locascio and J. H. Growdon (2008). "Long-term course and 
effectiveness of combination therapy in Alzheimer’s disease." Alzheimer disease and 
associated disorders 22(3): 209. 
Avila, J., M. Perez, F. Lim, A. Gomez-Ramos, F. Hernandez and J. Lucas (2004). "Tau in 
neurodegenerative diseases: tau phosphorylation and assembly." Neurotoxicity research 6(6): 
477-482. 
Bakker, A., G. L. Krauss, M. S. Albert, C. L. Speck, L. R. Jones, C. E. Stark, M. A. Yassa, S. 
S. Bassett, A. L. Shelton and M. Gallagher (2012). "Reduction of hippocampal hyperactivity 
improves cognition in amnestic mild cognitive impairment." Neuron 74(3): 467-474. 
Baleriola, J., C. A. Walker, Y. Y. Jean, J. F. Crary, C. M. Troy, P. L. Nagy and U. Hengst 
(2014). "Axonally synthesized ATF4 transmits a neurodegenerative signal across brain 
regions." Cell 158(5): 1159-1172. 
Ballatore, C., V. M.-Y. Lee and J. Q. Trojanowski (2007). "Tau-mediated neurodegeneration 
in Alzheimer's disease and related disorders." Nature Reviews Neuroscience 8(9): 663. 
Bard, F., C. Cannon, R. Barbour, R.-L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. 
Huang and K. Johnson-Wood (2000). "Peripherally administered antibodies against amyloid 
β-peptide enter the central nervous system and reduce pathology in a mouse model of 
Alzheimer disease." Nature medicine 6(8): 916. 
Barnes, L. L., R. S. Wilson, J. L. Bienias, J. A. Schneider, D. A. Evans and D. A. Bennett 
(2005). "Sex differences in the clinical manifestations of Alzheimer disease pathology." 
Archives of general psychiatry 62(6): 685-691. 
Barthet, G., T. Jorda-Siquier, J. Rumi-Masante, F. Bernadou, U. Mueller and C. Mulle (2018). 
"Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity." 
Nature communications 9(1): 4780. 
Bastien, L., N. Sawyer, R. Grygorczyk, K. M. Metters and M. Adam (1994). "Cloning, 
functional expression, and characterization of the human prostaglandin E2 receptor EP2 
subtype." Journal of Biological Chemistry 269(16): 11873-11877. 
	    	  
136	  	  
Bausch, S. B., S. He, Y. Petrova, X.-M. Wang and J. O. McNamara (2006). "Plasticity of both 
excitatory and inhibitory synapses is associated with seizures induced by removal of chronic 
blockade of activity in cultured hippocampus." Journal of neurophysiology 96(4): 2151-2167. 
Bazan, N. G. (2001). "COX-2 as a multifunctional neuronal modulator." Nature Medicine 7: 
414. 
Béïque, J. C. and R. Andrade (2003). "PSD-­‐95 regulates synaptic transmission and plasticity 
in rat cerebral cortex." The Journal of physiology 546(3): 859-867. 
Bekkers, J., G. Richerson and C. Stevens (1990). "Origin of variability in quantal size in 
cultured hippocampal neurons and hippocampal slices." Proceedings of the National 
Academy of Sciences 87(14): 5359-5362. 
Bellinger, F. P., S. Madamba and G. R. Siggins (1993). "Interleukin 1β inhibits synaptic 
strength and long-term potentiation in the rat CA1 hippocampus." Brain research 628(1-2): 
227-234. 
Bennett, I. J. and C. E. Stark (2016). "Mnemonic discrimination relates to perforant path 
integrity: an ultra-high resolution diffusion tensor imaging study." Neurobiology of learning 
and memory 129: 107-112. 
Bennett, M., W. Gibson and J. Robinson (1994). "Dynamics of the CA3 pyramidial neuron 
autoassociative memory network in the hippocampus." Philosophical Transactions of the 
Royal Society of London. Series B: Biological Sciences 343(1304): 167-187. 
Berberich, S., V. Jensen, Ø. Hvalby, P. H. Seeburg and G. Köhr (2007). "The role of 
NMDAR subtypes and charge transfer during hippocampal LTP induction." 
Neuropharmacology 52(1): 77-86. 
Berger, Z., H. Roder, A. Hanna, A. Carlson, V. Rangachari, M. Yue, Z. Wszolek, K. Ashe, J. 
Knight and D. Dickson (2007). "Accumulation of pathological tau species and memory loss in 
a conditional model of tauopathy." Journal of Neuroscience 27(14): 3650-3662. 
Bernard, C. and H. Wheal (1995). "Expression of EPSP/spike potentiation following low 
frequency and tetanic stimulation in the CA1 area of the rat hippocampus." Journal of 
Neuroscience 15(10): 6542-6551. 
Berridge, M. J. (1998). "Neuronal calcium signaling." Neuron 21(1): 13-26. 
Berridge, M. J. (2002). "The endoplasmic reticulum: a multifunctional signaling organelle." 
Cell calcium 32(5-6): 235-249. 
Billings, L. M., S. Oddo, K. N. Green, J. L. McGaugh and F. M. LaFerla (2005). 
"Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in 
transgenic mice." Neuron 45(5): 675-688. 
Birks, J. S. (2006). "Cholinesterase inhibitors for Alzheimer's disease." Cochrane database of 
systematic reviews(1). 
Biscaro, B., O. Lindvall, G. Tesco, C. T. Ekdahl and R. M. Nitsch (2012). "Inhibition of 
microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a 
transgenic mouse model for Alzheimer’s disease." Neurodegenerative Diseases 9(4): 187-198. 
Blasko, I., R. Veerhuis, M. Stampfer-Kountchev, M. Saurwein-Teissl, P. Eikelenboom and B. 
Grubeck-Loebenstein (2000). "Costimulatory effects of interferon-γ and interleukin-1β or 
tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes." 
Neurobiology of disease 7(6): 682-689. 
	    	  
137	  	  
Blatow, M., A. Caputi, N. Burnashev, H. Monyer and A. Rozov (2003). "Ca2+ buffer 
saturation underlies paired pulse facilitation in calbindin-D28k-containing terminals." Neuron 
38(1): 79-88. 
Bliss, T. V. and T. Lømo (1973). "Long-­‐lasting potentiation of synaptic transmission in the 
dentate area of the anaesthetized rabbit following stimulation of the perforant path." The 
Journal of physiology 232(2): 331-356. 
Blokland, A., R. Schreiber and J. Prickaerts (2006). "Improving memory: a role for 
phosphodiesterases." Current pharmaceutical design 12(20): 2511-2523. 
Bonet-Costa, V., V. Herranz-Perez, M. Blanco-Gandia, C. Mas-Bargues, M. Ingles, P. Garcia-
Tarraga, M. Rodriguez-Arias, J. Minarro, C. Borras and J. M. Garcia-Verdugo (2016). 
"Clearing Amyloid-β through PPAR γ/ApoE Activation by Genistein is a Treatment of 
Experimental Alzheimer’s Disease." Journal of Alzheimer's Disease 51(3): 701-711. 
Bornemann, K. D., K.-H. Wiederhold, C. Pauli, F. Ermini, M. Stalder, L. Schnell, B. Sommer, 
M. Jucker and M. Staufenbiel (2001). "Aβ-induced inflammatory processes in microglia cells 
of APP23 transgenic mice." The American journal of pathology 158(1): 63-73. 
Bosch, M. and Y. Hayashi (2012). "Structural plasticity of dendritic spines." Current opinion 
in neurobiology 22(3): 383-388. 
Braak, H., E. Braak and M. Strothjohann (1994). "Abnormally phosphorylated tau protein 
related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex 
of sheep and goat." Neuroscience letters 171(1-2): 1-4. 
Bramham, C. R., N. Milgram and B. Srebro (1991). "Activation of AP5-­‐sensitive NMDA 
receptors is not required to induce LTP of synaptic transmission in the lateral perforant path." 
European Journal of Neuroscience 3(12): 1300-1308. 
Brayne, C., C. Gill, F. A. Huppert, C. Barkley, E. Gehlhaar, D. M. Girling, D. W. O'Connor 
and E. S. Paykel (1995). "Incidence of clinically diagnosed subtypes of dementia in an elderly 
population: Cambridge Project for Later Life." The British Journal of Psychiatry 167(2): 255-
262. 
Breitner, J. C., L. D. Baker, T. J. Montine, C. L. Meinert, C. G. Lyketsos, K. H. Ashe, J. 
Brandt, S. Craft, D. E. Evans and R. C. Green (2011). "Extended results of the Alzheimer’s 
disease anti-inflammatory prevention trial." Alzheimer's & Dementia 7(4): 402-411. 
Breyer, R. M., C. K. Bagdassarian, S. A. Myers and M. D. Breyer (2001). "Prostanoid 
receptors: subtypes and signaling." Annual review of pharmacology and toxicology 41(1): 
661-690. 
Breyer, R. M., R. B. Emeson, J.-L. Tarng, M. D. Breyer, L. S. Davis, R. M. Abromson and S. 
M. Ferrenbach (1994). "Alternative splicing generates multiple isoforms of a rabbit 
prostaglandin E2 receptor." Journal of Biological Chemistry 269(8): 6163-6169. 
Briggs, C. A., C. Schneider, J. C. Richardson and G. E. Stutzmann (2013). "beta amyloid 
peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease 
mice." Neurobiology of aging 34(6): 1632-1643. 
Brito-Moreira, J., A. C Paula-Lima, T. R Bomfim, F. F Oliveira, F. J Sepulveda, F. G De 
Mello, L. G Aguayo, R. Panizzutti and S. T Ferreira (2011). "Aβ oligomers induce glutamate 
release from hippocampal neurons." Current Alzheimer Research 8(5): 552-562. 
	    	  
138	  	  
Brock, T. G., R. W. McNish and M. Peters-Golden (1999). "Arachidonic acid is preferentially 
metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2." Journal of 
Biological Chemistry 274(17): 11660-11666. 
Brown, J. T., J. Chin, S. C. Leiser, M. N. Pangalos and A. D. Randall (2011). "Altered 
intrinsic neuronal excitability and reduced Na+ currents in a mouse model of Alzheimer's 
disease." Neurobiol Aging 32(11): 2109.e2101-2114. 
Buckner, R. L., A. Z. Snyder, B. J. Shannon, G. LaRossa, R. Sachs, A. F. Fotenos, Y. I. 
Sheline, W. E. Klunk, C. A. Mathis, J. C. Morris and M. A. Mintun (2005). "Molecular, 
structural, and functional characterization of Alzheimer's disease: evidence for a relationship 
between default activity, amyloid, and memory." J Neurosci 25(34): 7709-7717. 
Buckwalter, J. G., E. Sobel, M. E. Dunn, M. M. Diz and V. W. Henderson (1993). "Gender 
differences on a brief measure of cognitive functioning in Alzheimer's disease." Archives of 
neurology 50(7): 757-760. 
Bullock, R. (2005). "SGS-742 Novartis." Current opinion in investigational drugs (London, 
England: 2000) 6(1): 108-113. 
Burda, J. E. and M. V. Sofroniew (2014). "Reactive gliosis and the multicellular response to 
CNS damage and disease." Neuron 81(2): 229-248. 
Burstein, A. H., I. Dunn, T. Soeder, M. N. Sabbagh and L. D. Altstiel (2016). "Azeliragon 
Phase 2b Survival Analysis Supports Beneficial Effects on Delaying Time to Cognitive 
Deterioration in Patients with Mild Alzheimer's Disease." Alzheimer's & Dementia: The 
Journal of the Alzheimer's Association 12(7): P352. 
Busche, M. A., X. Chen, H. A. Henning, J. Reichwald, M. Staufenbiel, B. Sakmann and A. 
Konnerth (2012). "Critical role of soluble amyloid-β for early hippocampal hyperactivity in a 
mouse model of Alzheimer’s disease." Proceedings of the National Academy of Sciences 
109(22): 8740-8745. 
Buxbaum, J. D., M. Oishi, H. I. Chen, R. Pinkas-Kramarski, E. A. Jaffe, S. E. Gandy and P. 
Greengard (1992). "Cholinergic agonists and interleukin 1 regulate processing and secretion 
of the Alzheimer beta/A4 amyloid protein precursor." Proceedings of the National Academy 
of Sciences 89(21): 10075-10078. 
Byrne, J. H. (1987). "Cellular analysis of associative learning." Physiological Reviews 67(2): 
329-439. 
Calabresi, P., B. Picconi, L. Parnetti and M. Di Filippo (2006). "A convergent model for 
cognitive dysfunctions in Parkinson's disease: the critical dopamine–acetylcholine synaptic 
balance." The Lancet Neurology 5(11): 974-983. 
Cao, W. and H. Zheng (2018). "Peripheral immune system in aging and Alzheimer’s disease." 
Molecular neurodegeneration 13(1): 51. 
Capogna, M., B. H. Gahwiler and S. M. Thompson (1996). "Calcium-independent actions of 
alpha-latrotoxin on spontaneous and evoked synaptic transmission in the hippocampus." 
Journal of Neurophysiology 76(5): 3149-3158. 
Carroll, J. C., E. R. Rosario, A. Villamagna and C. J. Pike (2010). "Continuous and cyclic 
progesterone differentially interact with estradiol in the regulation of Alzheimer-like 
pathology in female 3× Transgenic-Alzheimer’s disease mice." Endocrinology 151(6): 2713-
2722. 
	    	  
139	  	  
Chai, X., S. Wu, T. K. Murray, R. Kinley, C. V. Cella, H. Sims, N. Buckner, J. Hanmer, P. 
Davies and M. J. O'Neill (2011). "Passive immunization with anti-tau antibodies in two 
transgenic models reduction of tau pathology and delay of disease progression." Journal of 
Biological Chemistry 286(39): 34457-34467. 
Chakrabarty, P., C. Ceballos-Diaz, A. Beccard, C. Janus, D. Dickson, T. E. Golde and P. Das 
(2010). "IFN-γ promotes complement expression and attenuates amyloid plaque deposition in 
amyloid β precursor protein transgenic mice." The Journal of Immunology 184(9): 5333-5343. 
Chakroborty, S., C. Briggs, M. B. Miller, I. Goussakov, C. Schneider, J. Kim, J. Wicks, J. C. 
Richardson, V. Conklin and B. G. Cameransi (2012). "Stabilizing ER Ca2+ channel function 
as an early preventative strategy for Alzheimer’s disease." PloS one 7(12): e52056. 
Chakroborty, S., I. Goussakov, M. B. Miller and G. E. Stutzmann (2009). "Deviant ryanodine 
receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD 
mice." Journal of Neuroscience 29(30): 9458-9470. 
Chakroborty, S., J. Kim, C. Schneider, C. Jacobson, J. Molgó and G. E. Stutzmann (2012). 
"Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying 
synaptic depression in presymptomatic Alzheimer's disease mice." Journal of Neuroscience 
32(24): 8341-8353. 
Chaney, A., M. Bauer, D. Bochicchio, A. Smigova, M. Kassiou, K. E. Davies, S. R. Williams 
and H. Boutin (2018). "Longitudinal investigation of neuroinflammation and metabolite 
profiles in the APP swe× PS 1Δe9 transgenic mouse model of Alzheimer's disease." Journal 
of neurochemistry 144(3): 318-335. 
Chang, E. H., M. J. Savage, D. G. Flood, J. M. Thomas, R. B. Levy, V. Mahadomrongkul, T. 
Shirao, C. Aoki and P. T. Huerta (2006). "AMPA receptor downscaling at the onset of 
Alzheimer’s disease pathology in double knockin mice." Proceedings of the National 
Academy of Sciences 103(9): 3410-3415. 
Chavez-Noriega, L., T. Bliss and J. Halliwell (1989). "The EPSP-spike (ES) component of 
long-term potentiation in the rat hippocampal slice is modulated by GABAergic but not 
cholinergic mechanisms." Neuroscience letters 104(1-2): 58-64. 
Chen, C. and N. G. Bazan (2005). "Endogenous PGE2 regulates membrane excitability and 
synaptic transmission in hippocampal CA1 pyramidal neurons." J Neurophysiol 93(2): 929-
941. 
Chen, C., D. M. Blitz and W. G. Regehr (2002). "Contributions of receptor desensitization 
and saturation to plasticity at the retinogeniculate synapse." Neuron 33(5): 779-788. 
Chen, Q. S., B. L. Kagan, Y. Hirakura and C. W. Xie (2000). "Impairment of hippocampal 
long-­‐term potentiation by Alzheimer amyloid β-­‐peptides." Journal of neuroscience research 
60(1): 65-72. 
Chong, S.-A., I. Benilova, H. Shaban, B. De Strooper, H. Devijver, D. Moechars, W. Eberle, 
C. Bartic, F. Van Leuven and G. Callewaert (2011). "Synaptic dysfunction in hippocampus of 
transgenic mouse models of Alzheimer's disease: A multi-electrode array study." 
Neurobiology of disease 44(3): 284-291. 
Churcher, I. (2006). "Tau therapeutic strategies for the treatment of Alzheimer's disease." 
Current topics in medicinal chemistry 6(6): 579-595. 
Cirrito, J. R., K. A. Yamada, M. B. Finn, R. S. Sloviter, K. R. Bales, P. C. May, D. D. 
Schoepp, S. M. Paul, S. Mennerick and D. M. Holtzman (2005). "Synaptic activity regulates 
interstitial fluid amyloid-β levels in vivo." Neuron 48(6): 913-922. 
	    	  
140	  	  
Clinton, L. K., L. M. Billings, K. N. Green, A. Caccamo, J. Ngo, S. Oddo, J. L. McGaugh and 
F. M. LaFerla (2007). "Age-dependent sexual dimorphism in cognition and stress response in 
the 3xTg-AD mice." Neurobiology of disease 28(1): 76-82. 
Cole, D. C., E. S. Manas, J. R. Stock, J. S. Condon, L. D. Jennings, A. Aulabaugh, R. Chopra, 
R. Cowling, J. W. Ellingboe and K. Y. Fan (2006). "Acylguanidines as small-molecule β-
secretase inhibitors." Journal of medicinal chemistry 49(21): 6158-6161. 
Collingridge, G. L., S. Peineau, J. G. Howland and Y. T. Wang (2010). "Long-term 
depression in the CNS." Nature reviews neuroscience 11(7): 459. 
Combrinck, M., J. Williams, M. A. De Berardinis, D. Warden, M. Puopolo, A. D. Smith and 
L. Minghetti (2006). "Levels of CSF prostaglandin E2, cognitive decline, and survival in 
Alzheimer’s disease." Journal of Neurology, Neurosurgery & Psychiatry 77(1): 85-88. 
Combs, C. K., D. E. Johnson, J. C. Karlo, S. B. Cannady and G. E. Landreth (2000). 
"Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated 
proinflammatory responses and neurotoxicity by PPARγ agonists." Journal of Neuroscience 
20(2): 558-567. 
Corder, E. H., E. Ghebremedhin, M. G. Taylor, D. R. Thal, T. G. OHM and H. Braak (2004). 
"The biphasic relationship between regional brain senile plaque and neurofibrillary tangle 
distributions: modification by age, sex, and APOE polymorphism." Annals of the New York 
Academy of Sciences 1019(1): 24-28. 
Cordoba Montoya, D. A. and H. F. Carrer (1997). "Estrogen facilitates induction of long term 
potentiation in the hippocampus of awake rats." Brain Res 778(2): 430-438. 
Costa, R. O., P. N. Lacor, I. L. Ferreira, R. Resende, Y. P. Auberson, W. L. Klein, C. R. 
Oliveira, A. C. Rego and C. M. Pereira (2012). "Endoplasmic reticulum stress occurs 
downstream of GluN2B subunit of N-­‐methyl-­‐D-­‐aspartate receptor in mature hippocampal 
cultures treated with amyloid-­‐β oligomers." Aging cell 11(5): 823-833. 
Crouch, P. J. and K. J. Barnham (2012). "Therapeutic redistribution of metal ions to treat 
Alzheimer's disease." Acc Chem Res 45(9): 1604-1611. 
Crow, T. J. (1980). "Molecular pathology of schizophrenia: more than one disease process?" 
British medical journal 280(6207): 66. 
Cuevas, M. E., H. Haensgen, F. J. Sepúlveda, G. Zegers, J. Roa, C. Opazo and L. G. Aguayo 
(2011). "Soluble Aβ 1-40 Peptide Increases Excitatory Neurotransmission and Induces 
Epileptiform Activity in Hippocampal Neurons." Journal of Alzheimer's Disease 23(4): 673-
687. 
Cullen, W. K., Y.-H. Suh, R. Anwyl and M. J. Rowan (1997). "Block of LTP in rat 
hippocampus in vivo by β-amyloid precursor protein fragments." Neuroreport 8(15): 3213-
3217. 
Curran, B. and J. O’Connor (2001). "The pro-inflammatory cytokine interleukin-18 impairs 
long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in 
vitro." Neuroscience 108(1): 83-90. 
D'Mello, C., K. Riazi, T. Le, K. M. Stevens, A. Wang, D. M. McKay, Q. J. Pittman and M. G. 
Swain (2013). "P-Selectin-mediated monocyte–cerebral endothelium adhesive interactions 
link peripheral organ inflammation to sickness behaviors." Journal of Neuroscience 33(37): 
14878-14888. 
	    	  
141	  	  
Da Silva, S. V., M. G. Haberl, P. Zhang, P. Bethge, C. Lemos, N. Goncalves, A. Gorlewicz, 
M. Malezieux, F. Q. Goncalves and N. Grosjean (2016). "Early synaptic deficits in the 
APP/PS1 mouse model of Alzheimer’s disease involve neuronal adenosine A 2A receptors." 
Nature communications 7: 11915. 
Dao, A. T., M. A. Zagaar, A. T. Levine and K. A. Alkadhi (2016). "Comparison of the Effect 
of Exercise on Late-Phase LTP of the Dentate Gyrus and CA1 of Alzheimer's Disease 
Model." Mol Neurobiol 53(10): 6859-6868. 
Davalos, D., J. Grutzendler, G. Yang, J. V. Kim, Y. Zuo, S. Jung, D. R. Littman, M. L. Dustin 
and W.-B. Gan (2005). "ATP mediates rapid microglial response to local brain injury in 
vivo." Nature neuroscience 8(6): 752. 
David, R., E. Mulin, L. Friedman, F. Le Duff, E. Cygankiewicz, O. Deschaux, R. Garcia, J. A. 
Yesavage, P. H. Robert and J. M. Zeitzer (2012). "Decreased daytime motor activity 
associated with apathy in Alzheimer disease: an actigraphic study." The American Journal of 
Geriatric Psychiatry 20(9): 806-814. 
De Calignon, A., M. Polydoro, M. Suárez-Calvet, C. William, D. H. Adamowicz, K. J. 
Kopeikina, R. Pitstick, N. Sahara, K. H. Ashe and G. A. Carlson (2012). "Propagation of tau 
pathology in a model of early Alzheimer's disease." Neuron 73(4): 685-697. 
De Felice, F. G., P. T. Velasco, M. P. Lambert, K. Viola, S. J. Fernandez, S. T. Ferreira and 
W. L. Klein (2007). "Abeta oligomers induce neuronal oxidative stress through an N-methyl-
D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug 
memantine." J Biol Chem 282(15): 11590-11601. 
Deardorff, W. J. and G. T. Grossberg (2016). "A fixed-dose combination of memantine 
extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease." 
Drug design, development and therapy 10: 3267. 
Debanne, D., N. C. Guerineau, B. Gähwiler and S. M. Thompson (1996). "Paired-­‐pulse 
facilitation and depression at unitary synapses in rat hippocampus: quantal fluctuation affects 
subsequent release." The Journal of physiology 491(1): 163-176. 
Decker, H., K. Y. Lo, S. M. Unger, S. T. Ferreira and M. A. Silverman (2010). "Amyloid-β 
peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism 
that is mediated by glycogen synthase kinase 3β in primary cultured hippocampal neurons." 
Journal of Neuroscience 30(27): 9166-9171. 
Decker, J. M., L. Krüger, A. Sydow, S. Zhao, M. Frotscher, E. Mandelkow and E.-M. 
Mandelkow (2015). "Pro-aggregant Tau impairs mossy fiber plasticity due to structural 
changes and Ca++ dysregulation." Acta neuropathologica communications 3(1): 23. 
Del Prete, D., F. Checler and M. Chami (2014). "Ryanodine receptors: physiological function 
and deregulation in Alzheimer disease." Molecular neurodegeneration 9(1): 21. 
Deng, P.-Y., D. Sojka and V. A. Klyachko (2011). "Abnormal presynaptic short-term 
plasticity and information processing in a mouse model of fragile X syndrome." Journal of 
Neuroscience 31(30): 10971-10982. 
Deng, W., J. B. Aimone and F. H. Gage (2010). "New neurons and new memories: how does 
adult hippocampal neurogenesis affect learning and memory?" Nature reviews neuroscience 
11(5): 339. 
Doody, R. S., R. G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, K. Kieburtz, R. 
Raman, X. Sun and P. S. Aisen (2014). "Phase 3 trials of solanezumab for mild-to-moderate 
Alzheimer's disease." New England Journal of Medicine 370(4): 311-321. 
	    	  
142	  	  
Dudek, S. M. and M. F. Bear (1995). Homosynaptic long-term depression in area CA1 of 
hippocampus and effects of N-methyl-D-aspartate receptor blockade. How We Learn; How 
We Remember: Toward An Understanding Of Brain And Neural Systems: Selected Papers of 
Leon N Cooper, World Scientific: 200-204. 
Durand, G. M., Y. Kovalchuk and A. Konnerth (1996). "Long-term potentiation and 
functional synapse induction in developing hippocampus." Nature 381(6577): 71. 
Eccles, J. C., B. Katz and S. W. Kuffler (1941). "Nature of the" endplate potential" in 
curarized muscle." Journal of Neurophysiology 4(5): 362-387. 
Eichenbaum, H. (2004). "Hippocampus: cognitive processes and neural representations that 
underlie declarative memory." Neuron 44(1): 109-120. 
Eichenbaum, H., P. Dudchenko, E. Wood, M. Shapiro and H. Tanila (1999). "The 
hippocampus, memory, and place cells: is it spatial memory or a memory space?" Neuron 
23(2): 209-226. 
Eliot, L., E. Kandel and R. Hawkins (1994). "Modulation of spontaneous transmitter release 
during depression and posttetanic potentiation of Aplysia sensory-motor neuron synapses 
isolated in culture." Journal of Neuroscience 14(5): 3280-3292. 
Ellison, G. (1995). "The N-methyl-D-aspartate antagonists phencyclidine, ketamine and 
dizocilpine as both behavioral and anatomical models of the dementias." Brain Research 
Reviews 20(2): 250-267. 
Espósito, M. S., V. C. Piatti, D. A. Laplagne, N. A. Morgenstern, C. C. Ferrari, F. J. Pitossi 
and A. F. Schinder (2005). "Neuronal differentiation in the adult hippocampus recapitulates 
embryonic development." Journal of Neuroscience 25(44): 10074-10086. 
Etminan, M., S. Gill and A. Samii (2003). "Effect of non-steroidal anti-inflammatory drugs on 
risk of Alzheimer's disease: systematic review and meta-analysis of observational studies." 
Bmj 327(7407): 128. 
Fa, M., D. Puzzo, R. Piacentini, A. Staniszewski, H. Zhang, M. A. Baltrons, D. L. Puma, I. 
Chatterjee, J. Li and F. Saeed (2016). "Extracellular tau oligomers produce an immediate 
impairment of LTP and memory." Scientific reports 6: 19393. 
Farris, W., S. Mansourian, Y. Chang, L. Lindsley, E. A. Eckman, M. P. Frosch, C. B. Eckman, 
R. E. Tanzi, D. J. Selkoe and S. Guenette (2003). "Insulin-degrading enzyme regulates the 
levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular 
domain in vivo." Proc Natl Acad Sci U S A 100(7): 4162-4167. 
Felmy, F., E. Neher and R. Schneggenburger (2003). "Probing the intracellular calcium 
sensitivity of transmitter release during synaptic facilitation." Neuron 37(5): 801-811. 
Feng, T. (1941). "Studies on the neuromuscular junction. XXVI. The changes of the end-plate 
potential during and after prolonged stimulation." Chinese Journal of Physiology 16: 341-372. 
Ferreira, S. T. and W. L. Klein (2011). "The Abeta oligomer hypothesis for synapse failure 
and memory loss in Alzheimer's disease." Neurobiol Learn Mem 96(4): 529-543. 
Fink, A. E. and T. J. O'Dell (2009). "Short trains of theta frequency stimulation enhance CA1 
pyramidal neuron excitability in the absence of synaptic potentiation." Journal of 
Neuroscience 29(36): 11203-11214. 
Font-Nieves, M., M. G. Sans-Fons, R. Gorina, E. Bonfill-Teixidor, A. Salas-Pérdomo, L. 
Márquez-Kisinousky, T. Santalucia and A. M. Planas (2012). "Induction of COX-2 enzyme 
	    	  
143	  	  
and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin 
E2 production in astrocytes." Journal of Biological Chemistry 287(9): 6454-6468. 
Forloni, G., F. Demicheli, S. Giorgi, C. Bendotti and N. Angeretti (1992). "Expression of 
amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by 
interleukin-1." Molecular brain research 16(1-2): 128-134. 
Forsythe, I. and J. Clements (1990). "Presynaptic glutamate receptors depress excitatory 
monosynaptic transmission between mouse hippocampal neurones." The Journal of 
Physiology 429(1): 1-16. 
Fossati, S., J. Ghiso and A. Rostagno (2012). "TRAIL death receptors DR4 and DR5 mediate 
cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer’s Aβ." 
Cell death & disease 3(6): e321. 
Foster, K. A., A. C. Kreitzer and W. G. Regehr (2002). "Interaction of postsynaptic receptor 
saturation with presynaptic mechanisms produces a reliable synapse." Neuron 36(6): 1115-
1126. 
Foy, M. R. and T. J. Teyler (1983). "17-α-estradiol and 17-β-estradiol in hippocampus." Brain 
research bulletin 10(6): 735-739. 
Fratiglioni, L., M. Viitanen, E. von Strauss, V. Tontodonati, A. Herlitz and B. Winblad (1997). 
"Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the 
Kungsholmen Project, Stockholm." Neurology 48(1): 132-138. 
Frenkel, D., K. Wilkinson, L. Zhao, S. E. Hickman, T. K. Means, L. Puckett, D. Farfara, N. D. 
Kingery, H. L. Weiner and J. El Khoury (2013). "Scara1 deficiency impairs clearance of 
soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease 
progression." Nature communications 4: 2030. 
Frey, U. and R. G. Morris (1997). "Synaptic tagging and long-term potentiation." Nature 
385(6616): 533-536. 
Fricker, M., A. Vilalta, A. M. Tolkovsky and G. C. Brown (2013). "Caspase inhibitors protect 
neurons by enabling selective necroptosis of inflamed microglia." Journal of Biological 
Chemistry 288(13): 9145-9152. 
Friedman, W. (2001). "Cytokines regulate expression of the type 1 interleukin-1 receptor in 
rat hippocampal neurons and glia." Experimental neurology 168(1): 23-31. 
Frozza, R. L., A. Bernardi, J. B. Hoppe, A. B. Meneghetti, A. M. Battastini, A. R. Pohlmann, 
S. S. Guterres and C. Salbego (2013). "Lipid-core nanocapsules improve the effects of 
resveratrol against Aβ-induced neuroinflammation." Journal of biomedical nanotechnology 
9(12): 2086-2104. 
Fuhrmann, G., I. Segev, H. Markram and M. Tsodyks (2002). "Coding of temporal 
information by activity-dependent synapses." Journal of neurophysiology 87(1): 140-148. 
Galic, M. A., K. Riazi and Q. J. Pittman (2012). "Cytokines and brain excitability." Frontiers 
in neuroendocrinology 33(1): 116-125. 
Gallagher, J., A. Minogue and M. Lynch (2013). "Impaired performance of female APP/PS1 
mice in the Morris water maze is coupled with increased Aβ accumulation and microglial 
activation." Neurodegenerative Diseases 11(1): 33-41. 
Gan, K. J. and M. A. Silverman (2015). "Dendritic and axonal mechanisms of Ca2+ elevation 
impair BDNF transport in Aβ oligomer–treated hippocampal neurons." Molecular biology of 
the cell 26(6): 1058-1071. 
	    	  
144	  	  
Gant, J., E. Blalock, I. Kadish, N. Porter, C. Norris, O. Thibault and P. Landfield (2014). 
"FK506-binding protein 1b/12.6: a key to aging-related hippocampal Ca2+ dysregulation?" 
European journal of pharmacology 739: 74-82. 
Gant, J. C., K.-C. Chen, I. Kadish, E. M. Blalock, O. Thibault, N. M. Porter and P. W. 
Landfield (2015). "Reversal of aging-related neuronal Ca2+ dysregulation and cognitive 
impairment by delivery of a transgene encoding FK506-binding protein 12.6/1b to the 
hippocampus." Journal of Neuroscience 35(30): 10878-10887. 
Gao, C., C. Hölscher, Y. Liu and L. Li (2012). "GSK3: a key target for the development of 
novel treatments for type 2 diabetes mellitus and Alzheimer disease." Reviews in the 
Neurosciences 23(1): 1-11. 
Gao, S., H. C. Hendrie, K. S. Hall and S. Hui (1998). "The Relationships Between Age, Sex, 
and the Incidence of Dementia and Alzheimer Disease: A Meta-analysis." JAMA Psychiatry 
55(9): 809-815. 
Garcia-Alloza, M., E. M. Robbins, S. X. Zhang-Nunes, S. M. Purcell, R. A. Betensky, S. Raju, 
C. Prada, S. M. Greenberg, B. J. Bacskai and M. P. Frosch (2006). "Characterization of 
amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease." 
Neurobiology of disease 24(3): 516-524. 
Garcia-Osta, A. and C. M. Alberini (2009). "Amyloid beta mediates memory formation." 
Learning & memory 16(4): 267-272. 
García-Sierra, F., J. J. Hauw, C. Duyckaerts, C. M. Wischik, J. Luna-Muñoz and R. Mena 
(2000). "The extent of neurofibrillary pathology in perforant pathway neurons is the key 
determinant of dementia in the very old." Acta neuropathologica 100(1): 29-35. 
Ge, S., E. L. Goh, K. A. Sailor, Y. Kitabatake, G.-l. Ming and H. Song (2006). "GABA 
regulates synaptic integration of newly generated neurons in the adult brain." Nature 
439(7076): 589. 
Ge, S., C.-h. Yang, K.-s. Hsu, G.-l. Ming and H. Song (2007). "A critical period for enhanced 
synaptic plasticity in newly generated neurons of the adult brain." Neuron 54(4): 559-566. 
Geddes, J. W., D. T. Monaghan, C. W. Cotman, I. T. Lott, R. C. Kim and H. C. Chui (1985). 
"Plasticity of hippocampal circuitry in Alzheimer's disease." Science 230(4730): 1179-1181. 
Gehrmann, J., Y. Matsumoto and G. W. Kreutzberg (1995). "Microglia: intrinsic 
immuneffector cell of the brain." Brain Research Reviews 20(3): 269-287. 
Geldenhuys, W. J. and C. J. Van der Schyf (2011). "Role of serotonin in Alzheimer’s 
disease." CNS drugs 25(9): 765-781. 
Gelman, S., J. Palma, G. Tombaugh and A. Ghavami (2018). "Differences in synaptic 
dysfunction between rTg4510 and APP/PS1 mouse models of Alzheimer’s disease." Journal 
of Alzheimer's Disease 61(1): 195-208. 
Ghosh, A. K., D. Shin, D. Downs, G. Koelsch, X. Lin, J. Ermolieff and J. Tang (2000). 
"Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase)." Journal of the 
American Chemical Society 122(14): 3522-3523. 
Ghosh, S., M. D. Wu, S. S. Shaftel, S. Kyrkanides, F. M. LaFerla, J. A. Olschowka and M. K. 
O'Banion (2013). "Sustained interleukin-1β overexpression exacerbates tau pathology despite 
reduced amyloid burden in an Alzheimer's mouse model." Journal of Neuroscience 33(11): 
5053-5064. 
	    	  
145	  	  
Giacobini, E. (2000). "Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer 
disease." Alzheimer Disease & Associated Disorders 14(1): S3-S10. 
Giulian, D., L. J. Haverkamp, J. Yu, W. Karshin, D. Tom, J. Li, A. Kazanskaia, J. Kirkpatrick 
and A. E. Roher (1998). "The HHQK domain of β-amyloid provides a structural basis for the 
immunopathology of Alzheimer’s disease." Journal of Biological Chemistry 273(45): 29719-
29726. 
Glass, C. K., K. Saijo, B. Winner, M. C. Marchetto and F. H. Gage (2010). "Mechanisms 
underlying inflammation in neurodegeneration." Cell 140(6): 918-934. 
Goedert, M., C. Wischik, R. Crowther, J. Walker and A. Klug (1988). "Cloning and 
sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer 
disease: identification as the microtubule-associated protein tau." Proceedings of the National 
Academy of Sciences 85(11): 4051-4055. 
Gold, M. and J. El Khoury (2015). β-amyloid, microglia, and the inflammasome in 
Alzheimer’s disease. Seminars in immunopathology, Springer. 
Goldgaber, D., H. W. Harris, T. Hla, T. Maciag, R. J. Donnelly, J. S. Jacobsen, M. P. Vitek 
and D. C. Gajdusek (1989). "Interleukin 1 regulates synthesis of amyloid beta-protein 
precursor mRNA in human endothelial cells." Proceedings of the National Academy of 
Sciences 86(19): 7606-7610. 
Gomez-Nicola, D. and V. H. Perry (2015). "Microglial dynamics and role in the healthy and 
diseased brain: a paradigm of functional plasticity." The Neuroscientist 21(2): 169-184. 
Gomez-Ramos, A., M. Diaz-Hernandez, A. Rubio, M. Miras-Portugal and J. Avila (2008). 
"Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic 
receptors in neuronal cells." Molecular and Cellular Neuroscience 37(4): 673-681. 
Gong, B., Z. Cao, P. Zheng, O. V. Vitolo, S. Liu, A. Staniszewski, D. Moolman, H. Zhang, M. 
Shelanski and O. Arancio (2006). "Ubiquitin hydrolase Uch-L1 rescues β-amyloid-induced 
decreases in synaptic function and contextual memory." Cell 126(4): 775-788. 
Gorman, P. M., S. Kim, M. Guo, R. A. Melnyk, J. McLaurin, P. E. Fraser, J. U. Bowie and A. 
Chakrabartty (2008). "Dimerization of the transmembrane domain of amyloid precursor 
proteins and familial Alzheimer's disease mutants." BMC neuroscience 9(1): 17. 
Goussakov, I., M. B. Miller and G. E. Stutzmann (2010). "NMDA-mediated Ca2+ influx 
drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice." 
Journal of Neuroscience 30(36): 12128-12137. 
Granger, A. J. and R. A. Nicoll (2014). "Expression mechanisms underlying long-term 
potentiation: a postsynaptic view, 10 years on." Philosophical Transactions of the Royal 
Society B: Biological Sciences 369(1633): 20130136. 
Griffin, W. S., L. C. Stanley, C. Ling, L. White, V. MacLeod, L. J. Perrot, C. L. White, 3rd 
and C. Araoz (1989). "Brain interleukin 1 and S-100 immunoreactivity are elevated in Down 
syndrome and Alzheimer disease." Proc Natl Acad Sci U S A 86(19): 7611-7615. 
Griffin, W. S. T., L. Liu, Y. Li, R. E. Mrak and S. W. Barger (2006). "Interleukin-1 mediates 
Alzheimer and Lewy body pathologies." Journal of neuroinflammation 3(1): 5. 
Group, A. R. (2007). "Naproxen and celecoxib do not prevent AD in early results from a 
randomized controlled trial." Neurology 68(21): 1800-1808. 
Guntupalli, S., J. Widagdo and V. Anggono (2016). "Amyloid-β-induced dysregulation of 
AMPA receptor trafficking." Neural plasticity 2016. 
	    	  
146	  	  
Guzowski, J. F., J. J. Knierim and E. I. Moser (2004). "Ensemble dynamics of hippocampal 
regions CA3 and CA1." Neuron 44(4): 581-584. 
Habbas, S., M. Santello, D. Becker, H. Stubbe, G. Zappia, N. Liaudet, F. R. Klaus, G. Kollias, 
A. Fontana and C. R. Pryce (2015). "Neuroinflammatory TNFα impairs memory via astrocyte 
signaling." Cell 163(7): 1730-1741. 
Halle, A., V. Hornung, G. C. Petzold, C. R. Stewart, B. G. Monks, T. Reinheckel, K. A. 
Fitzgerald, E. Latz, K. J. Moore and D. T. Golenbock (2008). "The NALP3 inflammasome is 
involved in the innate immune response to amyloid-β." Nature immunology 9(8): 857. 
Hamley, I. W. (2012). "The amyloid beta peptide: a chemist’s perspective. Role in 
Alzheimer’s and fibrillization." Chemical reviews 112(10): 5147-5192. 
Hanger, D. P., B. H. Anderton and W. Noble (2009). "Tau phosphorylation: the therapeutic 
challenge for neurodegenerative disease." Trends in molecular medicine 15(3): 112-119. 
Hansen, R. A., G. Gartlehner, K. N. Lohr and D. I. Kaufer (2007). "Functional outcomes of 
drug treatment in Alzheimer’s disease." Drugs & aging 24(2): 155-167. 
Hargreaves, E. L., G. Rao, I. Lee and J. J. Knierim (2005). "Major dissociation between 
medial and lateral entorhinal input to dorsal hippocampus." science 308(5729): 1792-1794. 
Harrison, J. and C. E. Jahr (2003). "Receptor occupancy limits synaptic depression at 
climbing fiber synapses." Journal of Neuroscience 23(2): 377-383. 
Hatae, N., Y. Sugimoto and A. Ichikawa (2002). "Prostaglandin receptors: advances in the 
study of EP3 receptor signaling." The journal of biochemistry 131(6): 781-784. 
Haynes, S. E., G. Hollopeter, G. Yang, D. Kurpius, M. E. Dailey, W. B. Gan and D. Julius 
(2006). "The P2Y12 receptor regulates microglial activation by extracellular nucleotides." Nat 
Neurosci 9(12): 1512-1519. 
Henderson, V. W. and J. G. Buckwalter (1994). "Cognitive deficits of men and women with 
Alzheimer's disease." Neurology 44(1): 90-90. 
Heneka, M. T., M. J. Carson, J. El Khoury, G. E. Landreth, F. Brosseron, D. L. Feinstein, A. 
H. Jacobs, T. Wyss-Coray, J. Vitorica and R. M. Ransohoff (2015). "Neuroinflammation in 
Alzheimer's disease." The Lancet Neurology 14(4): 388-405. 
Heneka, M. T., M. P. Kummer, A. Stutz, A. Delekate, S. Schwartz, A. Vieira-Saecker, A. 
Griep, D. Axt, A. Remus and T.-C. Tzeng (2013). "NLRP3 is activated in Alzheimer’s 
disease and contributes to pathology in APP/PS1 mice." Nature 493(7434): 674. 
Heneka, M. T., G. E. Landreth and D. L. Feinstein (2001). "Role for peroxisome proliferator-­‐
activated receptor-­‐γ in Alzheimer's disease." Annals of Neurology: Official Journal of the 
American Neurological Association and the Child Neurology Society 49(2): 276-276. 
Heneka, M. T., R. M. McManus and E. Latz (2018). "Inflammasome signalling in brain 
function and neurodegenerative disease." Nature Reviews Neuroscience: 1. 
Heneka, M. T. and M. K. O'Banion (2007). "Inflammatory processes in Alzheimer's disease." 
Journal of neuroimmunology 184(1-2): 69-91. 
Heneka, M. T., M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. 
O'Banion, T. Klockgether, F. Van Leuven and G. E. Landreth (2005). "Acute treatment with 
the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels 
in APPV717I transgenic mice." Brain 128(6): 1442-1453. 
	    	  
147	  	  
Henley, D. B., P. C. May, R. A. Dean and E. R. Siemers (2009). "Development of 
semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of 
Alzheimer's disease." Expert Opin Pharmacother 10(10): 1657-1664. 
Herculano-Houzel, S. (2009). "The human brain in numbers: a linearly scaled-up primate 
brain." Frontiers in human neuroscience 3: 31. 
Hickman, R. A., A. Faustin and T. Wisniewski (2016). "Alzheimer disease and its growing 
epidemic: risk factors, biomarkers, and the urgent need for therapeutics." Neurologic clinics 
34(4): 941-953. 
Hickman, S. E., E. K. Allison and J. El Khoury (2008). "Microglial dysfunction and defective 
β-amyloid clearance pathways in aging Alzheimer's disease mice." Journal of Neuroscience 
28(33): 8354-8360. 
Ho, G. J., R. Drego, E. Hakimian and E. Masliah (2005). "Mechanisms of cell signaling and 
inflammation in Alzheimer's disease." Current Drug Targets-Inflammation & Allergy 4(2): 
247-256. 
Hoe, H.-S., Z. Fu, A. Makarova, J.-Y. Lee, C. Lu, L. Feng, A. Pajoohesh-Ganji, Y. Matsuoka, 
B. T. Hyman and M. D. Ehlers (2009). "The effects of amyloid precursor protein on 
postsynaptic composition and activity." Journal of Biological Chemistry 284(13): 8495-8506. 
Honda, A., Y. Sugimoto, T. Namba, A. Watabe, A. Irie, M. Negishi, S. Narumiya and A. 
Ichikawa (1993). "Cloning and expression of a cDNA for mouse prostaglandin E receptor 
EP2 subtype." Journal of Biological Chemistry 268(11): 7759-7762. 
Hoover, B. R., M. N. Reed, J. Su, R. D. Penrod, L. A. Kotilinek, M. K. Grant, R. Pitstick, G. 
A. Carlson, L. M. Lanier and L.-L. Yuan (2010). "Tau mislocalization to dendritic spines 
mediates synaptic dysfunction independently of neurodegeneration." Neuron 68(6): 1067-
1081. 
Hopfield, J. J. (1982). "Neural networks and physical systems with emergent collective 
computational abilities." Proceedings of the national academy of sciences 79(8): 2554-2558. 
Hoshino, T., T. Namba, M. Takehara, T. Nakaya, Y. Sugimoto, W. Araki, S. Narumiya, T. 
Suzuki and T. Mizushima (2009). "Prostaglandin E2 stimulates the production of amyloid-β 
peptides through internalization of the EP4 receptor." Journal of Biological Chemistry 
284(27): 18493-18502. 
Hsia, A. Y., E. Masliah, L. McConlogue, G.-Q. Yu, G. Tatsuno, K. Hu, D. Kholodenko, R. C. 
Malenka, R. A. Nicoll and L. Mucke (1999). "Plaque-independent disruption of neural 
circuits in Alzheimer’s disease mouse models." Proceedings of the National Academy of 
Sciences 96(6): 3228-3233. 
Hsieh, H., J. Boehm, C. Sato, T. Iwatsubo, T. Tomita, S. Sisodia and R. Malinow (2006). 
"AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss." 
Neuron 52(5): 831-843. 
Hu, J., A. Igarashi, M. Kamata and H. Nakagawa (2001). "Angiotensin-converting enzyme 
degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, 
fibril formation; and inhibits cytotoxicity." J Biol Chem 276(51): 47863-47868. 
Hu, N.-W., G. T. Corbett, S. Moore, I. Klyubin, T. T. O’Malley, D. M. Walsh, F. J. Livesey 
and M. J. Rowan (2018). "Extracellular Forms of Aβ and Tau from iPSC Models of 
Alzheimer’s Disease Disrupt Synaptic Plasticity." Cell Reports 23(7): 1932-1938. 
	    	  
148	  	  
Hunsaker, M. R., G. G. Mooy, J. S. Swift and R. P. Kesner (2007). "Dissociations of the 
medial and lateral perforant path projections into dorsal DG, CA3, and CA1 for spatial and 
nonspatial (visual object) information processing." Behavioral neuroscience 121(4): 742. 
Hunsberger, H. C., C. C. Rudy, S. R. Batten, G. A. Gerhardt and M. N. Reed (2015). "P301L 
tau expression affects glutamate release and clearance in the hippocampal trisynaptic 
pathway." Journal of neurochemistry 132(2): 169-182. 
Hyman, B., G. Van Hoesen, L. Kromer and A. Damasio (1986). "Perforant pathway changes 
and the memory impairment of Alzheimer's disease." Annals of Neurology: Official Journal 
of the American Neurological Association and the Child Neurology Society 20(4): 472-481. 
Hyman, B. T. and G. W. Van Hoesen (1987). "Neuron numbers in Alzheimer's disease: cell-
specific pathology." Neurobiology of aging 8(6): 555-556. 
Hyman, B. T., G. W. Van Hoesen, A. R. Damasio and C. L. Barnes (1984). "Alzheimer's 
disease: cell-specific pathology isolates the hippocampal formation." Science 225(4667): 
1168-1170. 
In'T Veld, B. A., A. Ruitenberg, A. Hofman, L. J. Launer, C. M. van Duijn, T. Stijnen, M. M. 
Breteler and B. H. Stricker (2001). "Nonsteroidal antiinflammatory drugs and the risk of 
Alzheimer's disease." New England Journal of Medicine 345(21): 1515-1521. 
Isaac, J. T., R. A. Nicoll and R. C. Malenka (1995). "Evidence for silent synapses: 
implications for the expression of LTP." Neuron 15(2): 427-434. 
Ittner, A., S. W. Chua, J. Bertz, A. Volkerling, J. van der Hoven, A. Gladbach, M. Przybyla, 
M. Bi, A. van Hummel and C. H. Stevens (2016). "Site-specific phosphorylation of tau 
inhibits amyloid-β toxicity in Alzheimer’s mice." Science 354(6314): 904-908. 
Jacobs, D. M., M. Sano, G. Dooneief, K. Marder, K. L. Bell and Y. Stern (1995). 
"Neuropsychological detection and characterization of preclinical Alzheimer's disease." 
Neurology 45(5): 957-962. 
Jacobsen, J. S., C.-C. Wu, J. M. Redwine, T. A. Comery, R. Arias, M. Bowlby, R. Martone, J. 
H. Morrison, M. N. Pangalos and P. H. Reinhart (2006). "Early-onset behavioral and synaptic 
deficits in a mouse model of Alzheimer's disease." Proceedings of the National Academy of 
Sciences 103(13): 5161-5166. 
Jankowsky, J. L., D. J. Fadale, J. Anderson, G. M. Xu, V. Gonzales, N. A. Jenkins, N. G. 
Copeland, M. K. Lee, L. H. Younkin and S. L. Wagner (2003). "Mutant presenilins 
specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for 
augmentation of a 42-specific γ secretase." Human molecular genetics 13(2): 159-170. 
Jester, J. M., L. W. Campbell and T. J. Sejnowski (1995). "Associative EPSP-­‐-­‐spike 
potentiation induced by pairing orthodromic and antidromic stimulation in rat hippocampal 
slices." The Journal of physiology 484(3): 689-705. 
Jin, Y. and C. C. Garner (2008). "Molecular mechanisms of presynaptic differentiation." 
Annual review of cell and developmental biology 24: 237-262. 
Johansson, J. U., N. S. Woodling, H. D. Brown, Q. Wang and K. I. Andreasson (2015). 
"Microarray analysis of the in vivo response of microglia to Aβ peptides in mice with 
conditional deletion of the prostaglandin EP2 receptor." Genomics data 5: 268-271. 
Jones, M. V. and G. L. Westbrook (1996). "The impact of receptor desensitization on fast 
synaptic transmission." Trends in neurosciences 19(3): 96-101. 
	    	  
149	  	  
Joo, Y., H.-S. Kim, R.-S. Woo, C. H. Park, K.-Y. Shin, J.-P. Lee, K.-A. Chang, S. Kim and 
Y.-H. Suh (2006). "Mefenamic acid shows neuroprotective effects and improves cognitive 
impairment in in vitro and in vivo Alzheimer's disease models." Molecular pharmacology 
69(1): 76-84. 
Kahle, J. and C. Cotman (1989). "Carbachol depresses synaptic responses in the medial but 
not the lateral perforant path." Brain research 482(1): 159-163. 
Kamenetz, F., T. Tomita, H. Hsieh, G. Seabrook, D. Borchelt, T. Iwatsubo, S. Sisodia and R. 
Malinow (2003). "APP processing and synaptic function." Neuron 37(6): 925-937. 
Kamiya, H. and R. S. Zucker (1994). "Residual Ca2+ and short-term synaptic plasticity." 
Nature 371(6498): 603. 
Kang, J., L. Jiang, S. A. Goldman and M. Nedergaard (1998). "Astrocyte-mediated 
potentiation of inhibitory synaptic transmission." Nature neuroscience 1(8): 683. 
Kása, P., Z. Rakonczay and K. Gulya (1997). "The cholinergic system in Alzheimer's 
disease." Progress in neurobiology 52(6): 511-535. 
Katz, B. and R. Miledi (1968). "The role of calcium in neuromuscular facilitation." J Physiol 
195(2): 481-492. 
Kauer, J. A. and R. C. Malenka (2007). "Synaptic plasticity and addiction." Nature reviews 
neuroscience 8(11): 844. 
Kaufmann, W. E., K. I. Andreasson, P. C. Isakson and P. F. Worley (1997). 
"Cyclooxygenases and the central nervous system." Prostaglandins 54(3): 601-624. 
Kawano, T., J. Anrather, P. Zhou, L. Park, G. Wang, K. A. Frys, A. Kunz, S. Cho, M. Orio 
and C. Iadecola (2006). "Prostaglandin E 2 EP1 receptors: downstream effectors of COX-2 
neurotoxicity." Nature medicine 12(2): 225. 
Kayed, R., E. Head, J. L. Thompson, T. M. McIntire, S. C. Milton, C. W. Cotman and C. G. 
Glabe (2003). "Common structure of soluble amyloid oligomers implies common mechanism 
of pathogenesis." Science 300(5618): 486-489. 
Kayed, R. and C. A. Lasagna-Reeves (2013). "Molecular mechanisms of amyloid oligomers 
toxicity." Journal of Alzheimer's Disease 33(s1): S67-S78. 
Kemp, J. A. and R. M. McKernan (2002). "NMDA receptor pathways as drug targets." Nature 
neuroscience 5(11s): 1039. 
Kerrigan, T. L., J. T. Brown and A. D. Randall (2014). "Characterization of altered intrinsic 
excitability in hippocampal CA1 pyramidal cells of the Abeta-overproducing PDAPP mouse." 
Neuropharmacology 79: 515-524. 
Kesner, R. P. (2007). "Behavioral functions of the CA3 subregion of the hippocampus." 
Learning & memory 14(11): 771-781. 
Kesner, R. P. and E. T. Rolls (2015). "A computational theory of hippocampal function, and 
tests of the theory: new developments." Neuroscience & Biobehavioral Reviews 48: 92-147. 
Kilgore, M., C. A. Miller, D. M. Fass, K. M. Hennig, S. J. Haggarty, J. D. Sweatt and G. 
Rumbaugh (2010). "Inhibitors of class 1 histone deacetylases reverse contextual memory 
deficits in a mouse model of Alzheimer's disease." Neuropsychopharmacology 35(4): 870. 
Kim, G. H., J. E. Kim, S. J. Rhie and S. Yoon (2015). "The role of oxidative stress in 
neurodegenerative diseases." Experimental neurobiology 24(4): 325-340. 
	    	  
150	  	  
Kim, Y., H. Choi, W. Lee, H. Park, T.-I. Kam, S.-h. Hong, J. Nah, S. Jung, B. Shin and H. 
Lee (2016). "Caspase-cleaved tau exhibits rapid memory impairment associated with tau 
oligomers in a transgenic mouse model." Neurobiology of disease 87: 19-28. 
Kimura, T., D. J. Whitcomb, J. Jo, P. Regan, T. Piers, S. Heo, C. Brown, T. Hashikawa, M. 
Murayama and H. Seok (2014). "Microtubule-associated protein tau is essential for long-term 
depression in the hippocampus." Philosophical Transactions of the Royal Society B: 
Biological Sciences 369(1633): 20130144. 
King, D. L., G. W. Arendash, F. Crawford, T. Sterk, J. Menendez and M. J. Mullan (1999). 
"Progressive and gender-dependent cognitive impairment in the APPsw transgenic mouse 
model for Alzheimer’s disease." Behavioural brain research 103(2): 145-162. 
Kinney, J. W., S. M. Bemiller, A. S. Murtishaw, A. M. Leisgang and B. T. Lamb (2018). 
"Inflammation as a central mechanism in Alzheimer's disease." Alzheimer's & Dementia: 
Translational Research & Clinical Interventions. 
Kitazawa, M., D. Cheng, M. R. Tsukamoto, M. A. Koike, P. D. Wes, V. Vasilevko, D. H. 
Cribbs and F. M. LaFerla (2011). "Blocking IL-1 signaling rescues cognition, attenuates tau 
pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease 
model." The Journal of Immunology 187(12): 6539-6549. 
Koffie, R. M., B. T. Hyman and T. L. Spires-Jones (2011). "Alzheimer's disease: synapses 
gone cold." Molecular neurodegeneration 6(1): 63. 
Koffie, R. M., M. Meyer-Luehmann, T. Hashimoto, K. W. Adams, M. L. Mielke, M. Garcia-
Alloza, K. D. Micheva, S. J. Smith, M. L. Kim and V. M. Lee (2009). "Oligomeric amyloid β 
associates with postsynaptic densities and correlates with excitatory synapse loss near senile 
plaques." Proceedings of the National Academy of Sciences 106(10): 4012-4017. 
Kordower, J. H., Y. Chu, G. T. Stebbins, S. T. DeKosky, E. J. Cochran, D. Bennett and E. J. 
Mufson (2001). "Loss and atrophy of layer II entorhinal cortex neurons in elderly people with 
mild cognitive impairment." Annals of Neurology: Official Journal of the American 
Neurological Association and the Child Neurology Society 49(2): 202-213. 
Kumar, A., D. K. Dhull and P. S. Mishra (2015). "Therapeutic potential of mGluR5 targeting 
in Alzheimer's disease." Frontiers in neuroscience 9: 215. 
Kumar, A., F. Pintus, A. Di Petrillo, R. Medda, P. Caria, M. J. Matos, D. Viña, E. Pieroni, F. 
Delogu and B. Era (2018). "Novel 2-pheynlbenzofuran derivatives as selective 
butyrylcholinesterase inhibitors for Alzheimer’s disease." Scientific reports 8(1): 4424. 
Kumar, K., A. Kumar, R. M. Keegan and R. Deshmukh (2018). "Recent advances in the 
neurobiology and neuropharmacology of Alzheimer’s disease." Biomedicine & 
pharmacotherapy 98: 297-307. 
Kummer, M. P., T. Hammerschmidt, A. Martinez, D. Terwel, G. Eichele, A. Witten, S. Figura, 
M. Stoll, S. Schwartz and H.-C. Pape (2014). "Ear2 deletion causes early memory and 
learning deficits in APP/PS1 mice." Journal of Neuroscience 34(26): 8845-8854. 
Kwon, H.-B. and P. E. Castillo (2008). "Long-term potentiation selectively expressed by 
NMDA receptors at hippocampal mossy fiber synapses." Neuron 57(1): 108-120. 
Lace, G. L., S. B. Wharton and P. G. Ince (2007). "A brief history of tau: the evolving view of 
the microtubule-associated protein tau in neurodegenerative diseases." Clinical 
neuropathology 26(2): 43. 
	    	  
151	  	  
Lacor, P. N., M. C. Buniel, P. W. Furlow, A. S. Clemente, P. T. Velasco, M. Wood, K. L. 
Viola and W. L. Klein (2007). "Aβ oligomer-induced aberrations in synapse composition, 
shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease." 
Journal of Neuroscience 27(4): 796-807. 
LAINO, C. (2009). "In follow-up analysis of clinical trial, NSAIDs seem to preserve 
cognitive function in patients with healthy brains." Neurology Today 9(18): 21-22. 
Lannfelt, L., C. Möller, H. Basun, G. Osswald, D. Sehlin, A. Satlin, V. Logovinsky and P. 
Gellerfors (2014). "Perspectives on future Alzheimer therapies: amyloid-β protofibrils-a new 
target for immunotherapy with BAN2401 in Alzheimer’s disease." Alzheimer's research & 
therapy 6(2): 16. 
Lasagna-Reeves, C. A., D. L. Castillo-Carranza, U. Sengupta, A. L. Clos, G. R. Jackson and 
R. Kayed (2011). "Tau oligomers impair memory and induce synaptic and mitochondrial 
dysfunction in wild-type mice." Molecular neurodegeneration 6(1): 39. 
Lauri, S. E., K. Lamsa, I. Pavlov, R. Riekki, B. E. Johnson, E. Molnar, H. Rauvala and T. 
Taira (2003). "Activity blockade increases the number of functional synapses in the 
hippocampus of newborn rats." Molecular and Cellular Neuroscience 22(1): 107-117. 
Lawson, L., V. Perry, P. Dri and S. Gordon (1990). "Heterogeneity in the distribution and 
morphology of microglia in the normal adult mouse brain." Neuroscience 39(1): 151-170. 
Lee, I. and J. J. Knierim (2007). "The relationship between the field-shifting phenomenon and 
representational coherence of place cells in CA1 and CA3 in a cue-altered environment." 
Learning & Memory 14(11): 807-815. 
Lee, I., D. Yoganarasimha, G. Rao and J. J. Knierim (2004). "Comparison of population 
coherence of place cells in hippocampal subfields CA1 and CA3." Nature 430(6998): 456. 
Leoutsakos, J. M. S., B. O. Muthen, J. C. Breitner, C. G. Lyketsos and A. R. Team (2012). 
"Effects of non-­‐steroidal anti-­‐inflammatory drug treatments on cognitive decline vary by 
phase of pre-­‐clinical Alzheimer disease: findings from the randomized controlled Alzheimer's 
Disease Anti-­‐inflammatory Prevention Trial." International journal of geriatric psychiatry 
27(4): 364-374. 
Letenneur, L., D. Commenges, J.-F. Dartigues and P. Barberger-Gateau (1994). "Incidence of 
dementia and Alzheimer's disease in elderly community residents of south-western France." 
International journal of epidemiology 23(6): 1256-1261. 
Leutgeb, J. K., S. Leutgeb, M.-B. Moser and E. I. Moser (2007). "Pattern separation in the 
dentate gyrus and CA3 of the hippocampus." science 315(5814): 961-966. 
Leutgeb, S. and J. K. Leutgeb (2007). "Pattern separation, pattern completion, and new 
neuronal codes within a continuous CA3 map." Learning & memory 14(11): 745-757. 
Leutgeb, S., J. K. Leutgeb, C. A. Barnes, E. I. Moser, B. L. McNaughton and M.-B. Moser 
(2005). "Independent codes for spatial and episodic memory in hippocampal neuronal 
ensembles." Science 309(5734): 619-623. 
Leutgeb, S., J. K. Leutgeb, A. Treves, M.-B. Moser and E. I. Moser (2004). "Distinct 
ensemble codes in hippocampal areas CA3 and CA1." Science 305(5688): 1295-1298. 
Li, C. and J. Götz (2017). "Tau-based therapies in neurodegeneration: opportunities and 
challenges." Nature Reviews Drug Discovery 16(12): 863. 
	    	  
152	  	  
Li, J., X. Liang, Q. Wang, R. M. Breyer, L. McCullough and K. Andreasson (2008). 
"Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral 
ischemia." Neuroscience letters 438(2): 210-215. 
Li, S., S. Hong, N. E. Shepardson, D. M. Walsh, G. M. Shankar and D. Selkoe (2009). 
"Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by 
disrupting neuronal glutamate uptake." Neuron 62(6): 788-801. 
Li, S., M. Jin, T. Koeglsperger, N. E. Shepardson, G. M. Shankar and D. J. Selkoe (2011). 
"Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving 
excessive activation of extrasynaptic NR2B-containing NMDA receptors." Journal of 
Neuroscience 31(18): 6627-6638. 
Li, X., E. Melief, N. Postupna, K. S. Montine, C. D. Keene and T. J. Montine (2015). 
"Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates 
microglial Aβ42 phagocytosis." The American journal of pathology 185(1): 230-239. 
Li, X. G., P. Somogyi, A. Ylinen and G. Buzsáki (1994). "The hippocampal CA3 network: an 
in vivo intracellular labeling study." Journal of comparative neurology 339(2): 181-208. 
Li, Z., J. Jo, J.-M. Jia, S.-C. Lo, D. J. Whitcomb, S. Jiao, K. Cho and M. Sheng (2010). 
"Caspase-3 activation via mitochondria is required for long-term depression and AMPA 
receptor internalization." Cell 141(5): 859-871. 
Liang, X., L. Lin, N. S. Woodling, Q. Wang, C. Anacker, T. Pan, M. Merchant and K. 
Andreasson (2011). "Signaling via the prostaglandin E 2 receptor EP4 exerts neuronal and 
vascular protection in a mouse model of cerebral ischemia." The Journal of clinical 
investigation 121(11): 4362-4371. 
Liang, X., Q. Wang, T. Hand, L. Wu, R. M. Breyer, T. J. Montine and K. Andreasson (2005). 
"Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden 
in a model of Alzheimer's disease." Journal of Neuroscience 25(44): 10180-10187. 
Liao, D., N. A. Hessler and R. Malinow (1995). "Activation of postsynaptically silent 
synapses during pairing-induced LTP in CA1 region of hippocampal slice." Nature 
375(6530): 400. 
Liao, D., R. H. Scannevin and R. Huganir (2001). "Activation of silent synapses by rapid 
activity-dependent synaptic recruitment of AMPA receptors." Journal of Neuroscience 
21(16): 6008-6017. 
Lin, L., L. J. Zheng and L. J. Zhang (2018). "Neuroinflammation, Gut Microbiome, and 
Alzheimer’s Disease." Molecular neurobiology 55(11): 8243-8250. 
Lindsay, J., D. Laurin, R. Verreault, R. Hébert, B. Helliwell, G. B. Hill and I. McDowell 
(2002). "Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study 
of Health and Aging." American journal of epidemiology 156(5): 445-453. 
Ling, D. S., L. S. Benardo and T. C. Sacktor (2006). "Protein kinase Mζ enhances excitatory 
synaptic transmission by increasing the number of active postsynaptic AMPA receptors." 
Hippocampus 16(5): 443-452. 
Lisman, J. (1989). "A mechanism for the Hebb and the anti-Hebb processes underlying 
learning and memory." Proc Natl Acad Sci U S A 86(23): 9574-9578. 
Lisman, J. (1994). "The CaM kinase II hypothesis for the storage of synaptic memory." 
Trends in neurosciences 17(10): 406-412. 
	    	  
153	  	  
Lisman, J. E., L. M. Talamini and A. Raffone (2005). "Recall of memory sequences by 
interaction of the dentate and CA3: a revised model of the phase precession." Neural 
Networks 18(9): 1191-1201. 
Lissin, D. V., S. N. Gomperts, R. C. Carroll, C. W. Christine, D. Kalman, M. Kitamura, S. 
Hardy, R. A. Nicoll, R. C. Malenka and M. Von Zastrow (1998). "Activity differentially 
regulates the surface expression of synaptic AMPA and NMDA glutamate receptors." 
Proceedings of the National Academy of Sciences 95(12): 7097-7102. 
Liu, G., S. Choi and R. W. Tsien (1999). "Variability of neurotransmitter concentration and 
nonsaturation of postsynaptic AMPA receptors at synapses in hippocampal cultures and 
slices." Neuron 22(2): 395-409. 
Liu, X., W. Hao, Y. Qin, Y. Decker, X. Wang, M. Burkart, K. Schoetz, M. D. Menger, K. 
Fassbender and Y. Liu (2015). "Long-term treatment with Ginkgo biloba extract EGb 761 
improves symptoms and pathology in a transgenic mouse model of Alzheimer’s disease." 
Brain, behavior, and immunity 46: 121-131. 
Logovinsky, V., A. Satlin, R. Lai, C. Swanson, J. Kaplow, G. Osswald, H. Basun and L. 
Lannfelt (2016). "Safety and tolerability of BAN2401-a clinical study in Alzheimer’s disease 
with a protofibril selective Aβ antibody." Alzheimer's research & therapy 8(1): 14. 
Lorente de Nó, R. (1934). "Studies on the structure of the cerebral cortex. II. Continuation of 
the study of the ammonic system." Journal für Psychologie und Neurologie. 
Losonczy, A., J. K. Makara and J. C. Magee (2008). "Compartmentalized dendritic plasticity 
and input feature storage in neurons." Nature 452(7186): 436. 
lou Camara, M., F. Corrigan, E. J. Jaehne, M. C. Jawahar, H. Anscomb and B. T. Baune 
(2015). "Effects of centrally administered etanercept on behavior, microglia, and astrocytes in 
mice following a peripheral immune challenge." Neuropsychopharmacology 40(2): 502. 
Lu, W.-Y., M. F. Jackson, D. Bai, B. A. Orser and J. F. MacDonald (2000). "In CA1 
pyramidal neurons of the hippocampus protein kinase C regulates calcium-dependent 
inactivation of NMDA receptors." Journal of Neuroscience 20(12): 4452-4461. 
Lucin, K. M. and T. Wyss-Coray (2009). "Immune activation in brain aging and 
neurodegeneration: too much or too little?" Neuron 64(1): 110-122. 
Lue, L. F., R. Rydel, E. F. Brigham, L. B. Yang, H. Hampel, G. M. Murphy Jr, L. Brachova, 
S. D. Yan, D. G. Walker and Y. Shen (2001). "Inflammatory repertoire of Alzheimer's disease 
and nondemented elderly microglia in vitro." Glia 35(1): 72-79. 
Madden, J., J. R. Dod, R. Godemann, J. Kraemer, M. Smith, M. Biniszkiewicz, D. J. Hallett, J. 
Barker, J. D. Dyekjaer and T. Hesterkamp (2010). "Fragment-based discovery and 
optimization of BACE1 inhibitors." Bioorganic & medicinal chemistry letters 20(17): 5329-
5333. 
Maingret, V., G. Barthet, S. Deforges, N. Jiang, C. Mulle and T. Amédée (2017). "PGE2-EP3 
signaling pathway impairs hippocampal presynaptic long-term plasticity in a mouse model of 
Alzheimer's disease." Neurobiology of aging 50: 13-24. 
Makhaeva, G. F., S. V. Lushchekina, N. P. Boltneva, V. B. Sokolov, V. V. Grigoriev, O. G. 
Serebryakova, E. A. Vikhareva, A. Y. Aksinenko, G. E. Barreto and G. Aliev (2015). 
"Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of 
butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease." Scientific 
reports 5: 13164. 
	    	  
154	  	  
Malenka, R. C. and M. F. Bear (2004). "LTP and LTD: an embarrassment of riches." Neuron 
44(1): 5-21. 
Maletic-Savatic, M., R. Malinow and K. Svoboda (1999). "Rapid dendritic morphogenesis in 
CA1 hippocampal dendrites induced by synaptic activity." Science 283(5409): 1923-1927. 
Marchetti, C. and H. Marie (2011). "Hippocampal synaptic plasticity in Alzheimer’s disease: 
what have we learned so far from transgenic models?" Reviews in the Neurosciences 22(4): 
373-402. 
Markram, H., D. Pikus, A. Gupta and M. Tsodyks (1998). "Potential for multiple mechanisms, 
phenomena and algorithms for synaptic plasticity at single synapses." Neuropharmacology 
37(4-5): 489-500. 
Marr, D. (1971). "Simple memory: a theory for archicortex." Philos Trans R Soc Lond B Biol 
Sci 262(841): 23-81. 
Masaki, K., K. Losonczy, G. Izmirlian, D. Foley, G. Ross, H. Petrovitch, R. Havlik and L. 
White (2000). "Association of vitamin E and C supplement use with cognitive function and 
dementia in elderly men." Neurology 54(6): 1265-1272. 
Masliah, E., M. Mallory, T. Deerinck, R. Deteresa, S. Lamont, A. Miller, R. D. Terry, B. 
Carragher and M. Ellisman (1993). "Re-evaluation of the structural organization of neuritic 
plaques in Alzheimer's disease." Journal of Neuropathology & Experimental Neurology 
52(6): 619-632. 
Massey, P. V. and Z. I. Bashir (2007). "Long-term depression: multiple forms and 
implications for brain function." Trends in neurosciences 30(4): 176-184. 
Matsubara, E., T. Bryant-­‐Thomas, J. Pacheco Quinto, T. L. Henry, B. Poeggeler, D. Herbert, 
F. Cruz-­‐Sanchez, Y. J. Chyan, M. A. Smith and G. Perry (2003). "Melatonin increases 
survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's 
disease." Journal of neurochemistry 85(5): 1101-1108. 
May, P. C., R. A. Dean, S. L. Lowe, F. Martenyi, S. M. Sheehan, L. N. Boggs, S. A. Monk, B. 
M. Mathes, D. J. Mergott and B. M. Watson (2011). "Robust central reduction of amyloid-β 
in humans with an orally available, non-peptidic β-secretase inhibitor." Journal of 
Neuroscience 31(46): 16507-16516. 
McAllister, A. K. and C. F. Stevens (2000). "Nonsaturation of AMPA and NMDA receptors 
at hippocampal synapses." Proceedings of the National Academy of Sciences 97(11): 6173-
6178. 
McGeer, P. L., S. Itagaki, H. Tago and E. G. McGeer (1987). "Reactive microglia in patients 
with senile dementia of the Alzheimer type are positive for the histocompatibility 
glycoprotein HLA-DR." Neurosci Lett 79(1-2): 195-200. 
McGeer, P. L., T. Kawamata, D. G. Walker, H. Akiyama, I. Tooyama and E. G. McGeer 
(1993). "Microglia in degenerative neurological disease." Glia 7(1): 84-92. 
McGeer, P. L. and E. G. McGeer (1995). "The inflammatory response system of brain: 
implications for therapy of Alzheimer and other neurodegenerative diseases." Brain Research 
Reviews 21(2): 195-218. 
McGeer, P. L. and E. G. McGeer (2007). "NSAIDs and Alzheimer disease: epidemiological, 
animal model and clinical studies." Neurobiology of aging 28(5): 639-647. 
	    	  
155	  	  
McInnes, J., K. Wierda, A. Snellinx, L. Bounti, Y.-C. Wang, I.-C. Stancu, N. Apóstolo, K. 
Gevaert, I. Dewachter and T. L. Spires-Jones (2018). "Synaptogyrin-3 mediates presynaptic 
dysfunction induced by tau." Neuron 97(4): 823-835. e828. 
McNaughton, B. (1980). "Evidence for two physiologically distinct perforant pathways to the 
fascia dentata." Brain research 199(1): 1-19. 
McNaughton, B. L. and R. G. Morris (1987). "Hippocampal synaptic enhancement and 
information storage within a distributed memory system." Trends in neurosciences 10(10): 
408-415. 
Medeiros, R. and F. M. LaFerla (2013). "Astrocytes: conductors of the Alzheimer disease 
neuroinflammatory symphony." Experimental neurology 239: 133-138. 
Medina, M. and J. Avila (2014). "New perspectives on the role of tau in Alzheimer's disease. 
Implications for therapy." Biochemical pharmacology 88(4): 540-547. 
Medina, M. and J. Avila (2015). "Further understanding of tau phosphorylation: implications 
for therapy." Expert review of neurotherapeutics 15(1): 115-122. 
Medina, M., J. J. Garrido and F. G. Wandosell (2011). "Modulation of GSK-3 as a therapeutic 
strategy on tau pathologies." Frontiers in molecular neuroscience 4: 24. 
Mehta, M., A. Adem and M. Sabbagh (2012). "New acetylcholinesterase inhibitors for 
Alzheimer's disease." International Journal of Alzheimer’s disease 2012. 
Melchor, J. P., R. Pawlak and S. Strickland (2003). "The tissue plasminogen activator-
plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits 
Abeta-induced neurodegeneration." J Neurosci 23(26): 8867-8871. 
Meng, Q., F. Lou, W. Hou, M. Liu, H. Guo and X. Zhang (2013). "Acetylpuerarin reduces 
inflammation and improves memory function in a rat model of Alzheimer's disease induced 
by Aβ1-42." Die Pharmazie-An International Journal of Pharmaceutical Sciences 68(11): 904-
908. 
Mesulam, M. M. (1999). "Neuroplasticity failure in Alzheimer's disease: bridging the gap 
between plaques and tangles." Neuron 24(3): 521-529. 
Mi, K. and G. V. Johnson (2006). "The role of tau phosphorylation in the pathogenesis of 
Alzheimer's disease." Current Alzheimer Research 3(5): 449-463. 
Millan, M. J. (2004). "The role of monoamines in the actions of established and “novel” 
antidepressant agents: a critical review." European journal of pharmacology 500(1-3): 371-
384. 
Miñano-Molina, A. J., J. España, E. Martín, B. Barneda-Zahonero, R. Fadó, M. Solé, R. 
Trullás, C. A. Saura and J. Rodríguez-Alvarez (2011). "Soluble oligomers of amyloid-β 
peptide disrupt membrane trafficking of α-amino-3-hydroxy-5-methylisoxazole-4-propionic 
acid receptor contributing to early synapse dysfunction." Journal of Biological Chemistry 
286(31): 27311-27321. 
Minkeviciene, R., S. Rheims, M. B. Dobszay, M. Zilberter, J. Hartikainen, L. Fulop, B. Penke, 
Y. Zilberter, T. Harkany, A. Pitkanen and H. Tanila (2009). "Amyloid beta-induced neuronal 
hyperexcitability triggers progressive epilepsy." J Neurosci 29(11): 3453-3462. 
Mintun, M. A., G. N. Larossa, Y. I. Sheline, C. S. Dence, S. Y. Lee, R. H. Mach, W. E. Klunk, 
C. A. Mathis, S. T. DeKosky and J. C. Morris (2006). "[11C]PIB in a nondemented 
population: potential antecedent marker of Alzheimer disease." Neurology 67(3): 446-452. 
	    	  
156	  	  
Mittelbronn, M., K. Dietz, H. Schluesener and R. Meyermann (2001). "Local distribution of 
microglia in the normal adult human central nervous system differs by up to one order of 
magnitude." Acta neuropathologica 101(3): 249-255. 
Molnar, Z., K. Soos, I. Lengyel, B. Penke, V. Szegedi and D. Budai (2004). "Enhancement of 
NMDA responses by beta-amyloid peptides in the hippocampus in vivo." Neuroreport 15(10): 
1649-1652. 
Mongiat, L. A., M. S. Espósito, G. Lombardi and A. F. Schinder (2009). "Reliable activation 
of immature neurons in the adult hippocampus." PloS one 4(4): e5320. 
Montine, T., M. Beal, M. Cudkowicz, H. O’donnell, R. Margolin, L. McFarland, A. Bachrach, 
W. Zackert, L. Roberts and J. Morrow (1999). "Increased CSF F2-isoprostane concentration 
in probable AD." Neurology 52(3): 562-562. 
Montine, T., K. Sidell, B. Crews, W. Markesbery, L. Marnett, L. Roberts and J. Morrow 
(1999). "Elevated CSF prostaglandin E2 levels in patients with probable AD." Neurology 
53(7): 1495-1495. 
Moreno, H., S. Choi, E. Yu, J. Brusco, J. Avila, J. Moreira, M. Sugimori and R. R. Llinás 
(2011). "Blocking effects of human tau on squid giant synapse transmission and its prevention 
by T-817 MA." Frontiers in synaptic neuroscience 3: 3. 
Moreno, H., G. Morfini, L. Buitrago, G. Ujlaki, S. Choi, E. Yu, J. E. Moreira, J. Avila, S. 
Brady and H. Pant (2016). "Tau pathology-mediated presynaptic dysfunction." Neuroscience 
325: 30-38. 
Morohashi, Y., T. Kan, Y. Tominari, H. Fuwa, Y. Okamura, N. Watanabe, C. Sato, H. 
Natsugari, T. Fukuyama and T. Iwatsubo (2006). "C-terminal fragment of presenilin is the 
molecular target of a dipeptidic γ-secretase-specific inhibitor DAPT (N-[N-(3, 5-
difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester)." Journal of Biological Chemistry 
281(21): 14670-14676. 
Morrison, J. H. and M. G. Baxter (2012). "The ageing cortical synapse: hallmarks and 
implications for cognitive decline." Nature Reviews Neuroscience 13(4): 240. 
Moutinho, M. and G. E. Landreth (2017). "Therapeutic potential of nuclear receptor agonists 
in Alzheimer’s disease." Journal of lipid research 58(10): 1937-1949. 
Mozzachiodi, R. and J. H. Byrne (2010). "More than synaptic plasticity: role of nonsynaptic 
plasticity in learning and memory." Trends in neurosciences 33(1): 17-26. 
Mozzachiodi, R., F. D. Lorenzetti, D. A. Baxter and J. H. Byrne (2008). "Changes in neuronal 
excitability serve as a mechanism of long-term memory for operant conditioning." Nature 
neuroscience 11(10): 1146. 
Mrak, R. E., J. G. Sheng and W. S. T. Griffin (1995). "Glial cytokines in Alzheimer's disease: 
review and pathogenic implications." Human pathology 26(8): 816-823. 
Mucke, L., E. Masliah, G.-Q. Yu, M. Mallory, E. M. Rockenstein, G. Tatsuno, K. Hu, D. 
Kholodenko, K. Johnson-Wood and L. McConlogue (2000). "High-level neuronal expression 
of Aβ1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity 
without plaque formation." Journal of Neuroscience 20(11): 4050-4058. 
Mulkey, R. M., C. E. Herron and R. C. Malenka (1993). "An essential role for protein 
phosphatases in hippocampal long-term depression." Science 261(5124): 1051-1055. 
	    	  
157	  	  
Murray, C. A. and M. A. Lynch (1998). "Evidence that increased hippocampal expression of 
the cytokine interleukin-1β is a common trigger for age-and stress-induced impairments in 
long-term potentiation." Journal of Neuroscience 18(8): 2974-2981. 
Murthy, V. N., T. Schikorski, C. F. Stevens and Y. Zhu (2001). "Inactivity produces increases 
in neurotransmitter release and synapse size." Neuron 32(4): 673-682. 
Myers, C. E. and H. E. Scharfman (2011). "Pattern separation in the dentate gyrus: a role for 
the CA3 backprojection." Hippocampus 21(11): 1190-1215. 
Nägerl, U. V., N. Eberhorn, S. B. Cambridge and T. Bonhoeffer (2004). "Bidirectional 
activity-dependent morphological plasticity in hippocampal neurons." Neuron 44(5): 759-767. 
Neumann, H., M. Kotter and R. Franklin (2008). "Debris clearance by microglia: an essential 
link between degeneration and regeneration." Brain 132(2): 288-295. 
Neumann, P., R. Hermann, K. Kuntz, S. Araki, S. Duff, J. Leon, P. Berenbaum, P. Goldman, 
L. Williams and M. Weinstein (1999). "Cost-effectiveness of donepezil in the treatment of 
mild or moderate Alzheimer’s disease." Neurology 52(6): 1138-1138. 
Nicoll, R. A. and D. Schmitz (2005). "Synaptic plasticity at hippocampal mossy fibre 
synapses." Nature Reviews Neuroscience 6(11): 863. 
Nimmerjahn, A., F. Kirchhoff and F. Helmchen (2005). "Resting microglial cells are highly 
dynamic surveillants of brain parenchyma in vivo." Science 308(5726): 1314-1318. 
Nishigaki, N., M. Negishi, A. Honda, Y. Sugimoto, T. Namba, S. Narumiya and A. Ichikawa 
(1995). "Identification of prostaglandin E receptor ‘EP2’cloned from mastocytoma cells as 
EP4 subtype." FEBS letters 364(3): 339-341. 
Nisticò, R., D. Mango, G. Mandolesi, S. Piccinin, N. Berretta, M. Pignatelli, M. Feligioni, A. 
Musella, A. Gentile and F. Mori (2013). "Inflammation subverts hippocampal synaptic 
plasticity in experimental multiple sclerosis." PloS one 8(1): e54666. 
Noble, W., D. P. Hanger, C. C. Miller and S. Lovestone (2013). "The importance of tau 
phosphorylation for neurodegenerative diseases." Frontiers in neurology 4: 83. 
Novak, P., R. Schmidt, E. Kontsekova, B. Kovacech, T. Smolek, S. Katina, L. Fialova, M. 
Prcina, V. Parrak and P. Dal-Bianco (2018). "FUNDAMANT: An interventional 72-week 
phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology 
in Alzheimer’s disease." Alzheimer's research & therapy 10(1): 108. 
O'Keefe, J. and D. Conway (1978). "Hippocampal place units in the freely moving rat: why 
they fire where they fire." Experimental brain research 31(4): 573-590. 
O'Keefe J and Nadel L (1978). "The	  Hippocampus	  as	  a	  Cognitive	  Map." Oxford	  University	  Press.  
O’Brien, R. J., S. Kamboj, M. D. Ehlers, K. R. Rosen, G. D. Fischbach and R. L. Huganir 
(1998). "Activity-dependent modulation of synaptic AMPA receptor accumulation." Neuron 
21(5): 1067-1078. 
Oehlrich, D., H. Prokopcova and H. J. Gijsen (2014). "The evolution of amidine-based brain 
penetrant BACE1 inhibitors." Bioorganic & medicinal chemistry letters 24(9): 2033-2045. 
Ojala, J. O., E. M. Sutinen, A. Salminen and T. Pirttilä (2008). "Interleukin-18 increases 
expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells." 
Journal of neuroimmunology 205(1-2): 86-93. 
	    	  
158	  	  
Olabarria, M., H. N. Noristani, A. Verkhratsky and J. J. Rodríguez (2010). "Concomitant 
astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease." 
Glia 58(7): 831-838. 
Olabarria, M., H. N. Noristani, A. Verkhratsky and J. J. Rodríguez (2011). "Age-dependent 
decrease in glutamine synthetase expression in the hippocampal astroglia of the triple 
transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic 
transmission?" Molecular neurodegeneration 6(1): 55. 
Oler, J. A. and E. J. Markus (2000). "Age-­‐related deficits in the ability to encode contextual 
change: A place cell analysis." Hippocampus 10(3): 338-350. 
Olmos-Alonso, A., S. T. Schetters, S. Sri, K. Askew, R. Mancuso, M. Vargas-Caballero, C. 
Holscher, V. H. Perry and D. Gomez-Nicola (2016). "Pharmacological targeting of CSF1R 
inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology." 
Brain 139(3): 891-907. 
Orban, G., K. Volgyi, G. Juhasz, B. Penke, K. A. Kekesi, J. Kardos and A. Czurko (2010). 
"Different electrophysiological actions of 24- and 72-hour aggregated amyloid-beta oligomers 
on hippocampal field population spike in both anesthetized and awake rats." Brain Res 1354: 
227-235. 
Ovsepian, S. V., V. B. O'Leary, L. Zaborszky, V. Ntziachristos and J. O. Dolly (2018). 
"Synaptic vesicle cycle and amyloid β: biting the hand that feeds." Alzheimer's & Dementia 
14(4): 502-513. 
Palmer, A. and M. Good (2011). Hippocampal synaptic activity, pattern separation and 
episodic-like memory: implications for mouse models of Alzheimer's disease pathology, 
Portland Press Limited. 
Palop, J. J., J. Chin, E. D. Roberson, J. Wang, M. T. Thwin, N. Bien-Ly, J. Yoo, K. O. Ho, 
G.-Q. Yu and A. Kreitzer (2007). "Aberrant excitatory neuronal activity and compensatory 
remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease." 
Neuron 55(5): 697-711. 
Palop, J. J., L. Mucke and E. D. Roberson (2011). "Quantifying biomarkers of cognitive 
dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: 
depletion of calcium-dependent proteins and inhibitory hippocampal remodeling." Methods 
Mol Biol 670: 245-262. 
Pangalos, M., S. Jacobsen and P. Reinhart (2005). Disease modifying strategies for the 
treatment of Alzheimer's disease targeted at modulating levels of the β-amyloid peptide, 
Portland Press Limited. 
Parihar, M. and T. Hemnani (2004). "Experimental excitotoxicity provokes oxidative damage 
in mice brain and attenuation by extract of Asparagus racemosus." Journal of Neural 
Transmission 111(1): 1-12. 
Park, K. M. and W. J. Bowers (2010). "Tumor necrosis factor-alpha mediated signaling in 
neuronal homeostasis and dysfunction." Cellular signalling 22(7): 977-983. 
Parkhurst, C. N., G. Yang, I. Ninan, J. N. Savas, J. R. Yates III, J. J. Lafaille, B. L. 
Hempstead, D. R. Littman and W.-B. Gan (2013). "Microglia promote learning-dependent 
synapse formation through brain-derived neurotrophic factor." Cell 155(7): 1596-1609. 
Patel, L. and G. T. Grossberg (2011). "Combination therapy for Alzheimer’s disease." Drugs 
& aging 28(7): 539-546. 
	    	  
159	  	  
Patel, N. S., D. Paris, V. Mathura, A. N. Quadros, F. C. Crawford and M. J. Mullan (2005). 
"Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of 
Alzheimer's disease." Journal of neuroinflammation 2(1): 9. 
Patrick, G. N., L. Zukerberg, M. Nikolic, S. de La Monte, P. Dikkes and L.-H. Tsai (1999). 
"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration." 
Nature 402(6762): 615. 
Patten, A. R., S. Y. Yau, C. J. Fontaine, A. Meconi, R. C. Wortman and B. R. Christie (2015). 
"The benefits of exercise on structural and functional plasticity in the rodent hippocampus of 
different disease models." Brain Plasticity 1(1): 97-127. 
Paula-Lima, A. C., T. Adasme, C. SanMartin, A. Sebollela, C. Hetz, M. A. Carrasco, S. T. 
Ferreira and C. Hidalgo (2011). "Amyloid beta-peptide oligomers stimulate RyR-mediated 
Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent 
RyR-mediated dendritic spine remodeling produced by BDNF." Antioxid Redox Signal 14(7): 
1209-1223. 
Pauwels, P. J. (2000). "Diverse signalling by 5-hydroxytryptamine (5-HT) receptors." 
Biochemical pharmacology 60(12): 1743-1750. 
Pavlov, V. A. and K. J. Tracey (2005). "The cholinergic anti-inflammatory pathway." Brain, 
behavior, and immunity 19(6): 493-499. 
Pedersen, J. T. and E. M. Sigurdsson (2015). "Tau immunotherapy for Alzheimer's disease." 
Trends in molecular medicine 21(6): 394-402. 
Penttonen, M., A. Kamondi, A. Sik, L. Acsády and G. Buzsáki (1997). "Feed-­‐forward and 
feed-­‐back activation of the dentate gyrus in vivo during dentate spikes and sharp wave 
bursts." Hippocampus 7(4): 437-450. 
Perkins, A. J., H. C. Hendrie, C. M. Callahan, S. Gao, F. W. Unverzagt, Y. Xu, K. S. Hall and 
S. L. Hui (1999). "Association of antioxidants with memory in a multiethnic elderly sample 
using the Third National Health and Nutrition Examination Survey." American journal of 
epidemiology 150(1): 37-44. 
Perlmutter, L. S. and H. C. Chui (1990). "Microangiopathy, the vascular basement membrane 
and Alzheimer's disease: a review." Brain research bulletin 24(5): 677-686. 
Petersen, R., F. Moradpour, B. Eadie, J. Shin, T. Kannangara, K. Delaney and B. Christie 
(2013). "Electrophysiological identification of medial and lateral perforant path inputs to the 
dentate gyrus." Neuroscience 252: 154-168. 
Petersen, R. C. (2009). "Early diagnosis of Alzheimer's disease: is MCI too late?" Current 
Alzheimer Research 6(4): 324-330. 
Pfeiffer, B. E. and K. M. Huber (2009). "The state of synapses in fragile X syndrome." The 
Neuroscientist 15(5): 549-567. 
Pickering, M. and J. J. O’Connor (2007). "Pro-inflammatory cytokines and their effects in the 
dentate gyrus." Progress in brain research 163: 339-354. 
Pierre, W. C., P. L. Smith, I. Londono, S. Chemtob, C. Mallard and G. A. Lodygensky (2017). 
"Neonatal microglia: the cornerstone of brain fate." Brain, behavior, and immunity 59: 333-
345. 
Pigino, G., G. Morfini, Y. Atagi, A. Deshpande, C. Yu, L. Jungbauer, M. LaDu, J. Busciglio 
and S. Brady (2009). "Disruption of fast axonal transport is a pathogenic mechanism for 
	    	  
160	  	  
intraneuronal amyloid beta." Proceedings of the National Academy of Sciences 106(14): 
5907-5912. 
Pistell, P. J., M. Zhu and D. K. Ingram (2008). "Acquisition of conditioned taste aversion is 
impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer’s disease." 
Neuroscience 152(3): 594-600. 
Piton, M., C. Hirtz, C. Desmetz, J. Milhau, A. D. Lajoix, K. Bennys, S. Lehmann and A. 
Gabelle (2018). "Alzheimer’s disease: advances in drug development." Journal of Alzheimer's 
Disease(Preprint): 1-11. 
Podlisny, M. B., B. L. Ostaszewski, S. L. Squazzo, E. H. Koo, R. E. Rydell, D. B. Teplow and 
D. J. Selkoe (1995). "Aggregation of secreted amyloid-protein into sodium dodecyl sulfate-
stable oligomers in cell culture." Journal of Biological Chemistry 270(16): 9564-9570. 
Polydoro, M., C. M. Acker, K. Duff, P. E. Castillo and P. Davies (2009). "Age-dependent 
impairment of cognitive and synaptic function in the htau mouse model of tau pathology." J 
Neurosci 29(34): 10741-10749. 
Polydoro, M., V. I. Dzhala, A. M. Pooler, S. B. Nicholls, A. P. McKinney, L. Sanchez, R. 
Pitstick, G. A. Carlson, K. J. Staley and T. L. Spires-Jones (2014). "Soluble pathological tau 
in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer’s disease model." 
Acta neuropathologica 127(2): 257-270. 
Pooler, A. M., W. Noble and D. P. Hanger (2014). "A role for tau at the synapse in 
Alzheimer's disease pathogenesis." Neuropharmacology 76: 1-8. 
Porrini, V., A. Lanzillotta, C. Branca, M. Benarese, E. Parrella, L. Lorenzini, L. Calzà, R. 
Flaibani, P. Spano and B. Imbimbo (2015). "CHF5074 (CSP-1103) induces microglia 
alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-
amyloid." Neuroscience 302: 112-120. 
Prange, O. and T. H. Murphy (1999). "Correlation of miniature synaptic activity and evoked 
release probability in cultures of cortical neurons." Journal of Neuroscience 19(15): 6427-
6438. 
Prickaerts, J., P. R. Heckman and A. Blokland (2017). "Investigational phosphodiesterase 
inhibitors in phase I and phase II clinical trials for Alzheimer’s disease." Expert opinion on 
investigational drugs 26(9): 1033-1048. 
Puzzo, D., L. Privitera, M. Fa', A. Staniszewski, G. Hashimoto, F. Aziz, M. Sakurai, E. M. 
Ribe, C. M. Troy and M. Mercken (2011). "Endogenous amyloid-­‐β is necessary for 
hippocampal synaptic plasticity and memory." Annals of neurology 69(5): 819-830. 
Puzzo, D., L. Privitera, E. Leznik, M. Fà, A. Staniszewski, A. Palmeri and O. Arancio (2008). 
"Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus." 
Journal of Neuroscience 28(53): 14537-14545. 
Quan, N., M. Whiteside and M. Herkenham (1998). "Time course and localization patterns of 
interleukin-1β messenger RNA expression in brain and pituitary after peripheral 
administration of lipopolysaccharide." Neuroscience 83(1): 281-293. 
Querfurth, H. W. and F. M. LaFerla (2010). "Alzheimer's disease." N Engl J Med 362(4): 
329-344. 
Raison, C. L., L. Capuron and A. H. Miller (2006). "Cytokines sing the blues: inflammation 
and the pathogenesis of depression." Trends in immunology 27(1): 24-31. 
	    	  
161	  	  
Rammes, G. (2009). "Neramexane: a moderate-affinity NMDA receptor channel blocker: new 
prospects and indications." Expert review of clinical pharmacology 2(3): 231-238. 
Ramón y Cajal, S. (1894). "The Croonian lecture.—La fine structure des centres nerveux." 
Proceedings of the Royal Society of London 55(331-335): 444-468. 
Ramser, E. M., K. J. Gan, H. Decker, E. Y. Fan, M. M. Suzuki, S. T. Ferreira and M. A. 
Silverman (2013). "Amyloid-β oligomers induce tau-independent disruption of BDNF axonal 
transport via calcineurin activation in cultured hippocampal neurons." Molecular biology of 
the cell 24(16): 2494-2505. 
Ransohoff, R. M. and V. H. Perry (2009). "Microglial physiology: unique stimuli, specialized 
responses." Annual review of immunology 27: 119-145. 
Rebola, N., M. Carta and C. Mulle (2017). "Operation and plasticity of hippocampal CA3 
circuits: implications for memory encoding." Nature Reviews Neuroscience 18(4): 208. 
Redondo, R. L. and R. G. Morris (2011). "Making memories last: the synaptic tagging and 
capture hypothesis." Nature Reviews Neuroscience 12(1): 17. 
Reed-Geaghan, E. G., J. C. Savage, A. G. Hise and G. E. Landreth (2009). "CD14 and toll-
like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation." Journal 
of Neuroscience 29(38): 11982-11992. 
Reisberg, B., R. Doody, A. Stöffler, F. Schmitt, S. Ferris and H. J. Möbius (2003). 
"Memantine in moderate-to-severe Alzheimer's disease." New England Journal of Medicine 
348(14): 1333-1341. 
Ren, S. C., P. Z. Chen, H. H. Jiang, Z. Mi, F. Xu, B. Hu, J. Zhang and Z. R. Zhu (2014). 
"Persistent sodium currents contribute to Abeta1-42-induced hyperexcitation of hippocampal 
CA1 pyramidal neurons." Neurosci Lett 580: 62-67. 
Renner, M., P. N. Lacor, P. T. Velasco, J. Xu, A. Contractor, W. L. Klein and A. Triller 
(2010). "Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for 
mGluR5." Neuron 66(5): 739-754. 
Riazi, K., M. A. Galic, A. C. Kentner, A. Y. Reid, K. A. Sharkey and Q. J. Pittman (2015). 
"Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the 
hippocampus during peripheral inflammation." Journal of Neuroscience 35(12): 4942-4952. 
Richetin, K., P. Petsophonsakul, L. Roybon, B. P. Guiard and C. Rampon (2017). 
"Differential alteration of hippocampal function and plasticity in females and males of the 
APPxPS1 mouse model of Alzheimer's disease." Neurobiology of aging 57: 220-231. 
Roberson, E. D., B. Halabisky, J. W. Yoo, J. Yao, J. Chin, F. Yan, T. Wu, P. Hamto, N. 
Devidze and G.-Q. Yu (2011). "Amyloid-β/Fyn–induced synaptic, network, and cognitive 
impairments depend on tau levels in multiple mouse models of Alzheimer's disease." Journal 
of Neuroscience 31(2): 700-711. 
Rochais, C., C. d. Lecoutey, F. Gaven, P. Giannoni, K. Hamidouche, D. Hedou, E. Dubost, D. 
Genest, S. Yahiaoui and T. Freret (2015). "Novel multitarget-directed ligands (MTDLs) with 
acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist 
activities as potential agents against Alzheimer’s disease: the design of donecopride." Journal 
of medicinal chemistry 58(7): 3172-3187. 
Rohn, T. T., P. Kokoulina, C. R. Eaton and W. W. Poon (2009). "Caspase activation in 
transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase 
inhibitor, Q-VD-OPh." International journal of clinical and experimental medicine 2(4): 300. 
	    	  
162	  	  
Rojo, L. E., J. A. Fernandez, A. A. Maccioni, J. M. Jimenez and R. B. Maccioni (2008). 
"Neuroinflammation: implications for the pathogenesis and molecular diagnosis of 
Alzheimer's disease." Arch Med Res 39(1): 1-16. 
Rolls, E. (2013). "A quantitative theory of the functions of the hippocampal CA3 network in 
memory." Frontiers in cellular neuroscience 7: 98. 
Rolls, E. T. and R. P. Kesner (2006). "A computational theory of hippocampal function, and 
empirical tests of the theory." Progress in neurobiology 79(1): 1-48. 
Rossi, L., S. Mazzitelli, M. Arciello, C. Capo and G. Rotilio (2008). "Benefits from dietary 
polyphenols for brain aging and Alzheimer’s disease." Neurochemical research 33(12): 2390-
2400. 
Rowan, M., I. Klyubin, Q. Wang and R. Anwyl (2005). Synaptic plasticity disruption by 
amyloid β protein: modulation by potential Alzheimer's disease modifying therapies, Portland 
Press Limited. 
Roychaudhuri, R., M. Yang, M. M. Hoshi and D. B. Teplow (2009). "Amyloid β-protein 
assembly and Alzheimer disease." Journal of Biological Chemistry 284(8): 4749-4753. 
Ruan, Q., J. Ruan, W. Zhang, F. Qian and Z. Yu (2018). "Targeting NAD+ degradation: The 
therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty." 
Pharmacological research 128: 345-358. 
Ruitenberg, A., S. Kalmijn, M. De Ridder, W. Redekop, F. van Harskamp, A. Hofman, L. 
Launer and M. Breteler (2001). "Prognosis of Alzheimer’s disease: the Rotterdam Study." 
Neuroepidemiology 20(3): 188-195. 
Rutten, K., C. Lieben, L. Smits and A. Blokland (2007). "The PDE4 inhibitor rolipram 
reverses object memory impairment induced by acute tryptophan depletion in the rat." 
Psychopharmacology 192(2): 275-282. 
Rutten, K., J. Prickaerts and A. Blokland (2006). "Rolipram reverses scopolamine-induced 
and time-dependent memory deficits in object recognition by different mechanisms of action." 
Neurobiology of learning and memory 85(2): 132-138. 
Salmani, M. E., Y. Fathollahi, J. Mirnajafizadeh and S. Semnanian (2011). "Epileptogenic 
insult alters endogenous adenosine control on long-term changes in synaptic strength by theta 
pattern stimulation in hippocampus area CA1." Synapse 65(3): 189-197. 
Sanchez, P. E., L. Zhu, L. Verret, K. A. Vossel, A. G. Orr, J. R. Cirrito, N. Devidze, K. Ho, G. 
Q. Yu, J. J. Palop and L. Mucke (2012). "Levetiracetam suppresses neuronal network 
dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model." 
Proc Natl Acad Sci U S A 109(42): E2895-2903. 
Sang, N., J. Zhang, V. Marcheselli, N. G. Bazan and C. Chen (2005). "Postsynaptically 
synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a 
presynaptic PGE2 EP2 receptor." Journal of Neuroscience 25(43): 9858-9870. 
Santello, M. and A. Volterra (2012). "TNFα in synaptic function: switching gears." Trends in 
neurosciences 35(10): 638-647. 
Santos, S. F., N. Pierrot and J.-N. Octave (2010). "Network excitability dysfunction in 
Alzheimer's disease: insights from in vitro and in vivo models." Reviews in the neurosciences 
21(3): 153-172. 
	    	  
163	  	  
Sargolini, F., M. Fyhn, T. Hafting, B. L. McNaughton, M. P. Witter, M.-B. Moser and E. I. 
Moser (2006). "Conjunctive representation of position, direction, and velocity in entorhinal 
cortex." Science 312(5774): 758-762. 
Sarlus, H. and M. T. Heneka (2017). "Microglia in Alzheimer’s disease." The Journal of 
clinical investigation 127(9): 3240-3249. 
Sato, T., H. Hanyu, K. Hirao, H. Kanetaka, H. Sakurai and T. Iwamoto (2011). "Efficacy of 
PPAR-γ agonist pioglitazone in mild Alzheimer disease." Neurobiology of aging 32(9): 1626-
1633. 
Scharfman, H. E. (2007). "The CA3 “backprojection” to the dentate gyrus." Progress in brain 
research 163: 627-637. 
Schneider, A. and E. Mandelkow (2008). "Tau-based treatment strategies in 
neurodegenerative diseases." Neurotherapeutics 5(3): 443-457. 
Scholz, K. P. and R. J. Miller (1992). "Inhibition of quantal transmitter release in the absence 
of calcium influx by a G protein-linked adenosine receptor at hippocampal synapses." Neuron 
8(6): 1139-1150. 
Schroder, K. and J. Tschopp (2010). "The inflammasomes." cell 140(6): 821-832. 
Schroeder, S. K., A. Joly-Amado, M. N. Gordon and D. Morgan (2016). "Tau-directed 
immunotherapy: a promising strategy for treating Alzheimer’s disease and other tauopathies." 
Journal of neuroimmune pharmacology 11(1): 9-25. 
Schubert, M., H. Siegmund, H. C. Pape and D. Albrecht (2005). "Kindling-induced changes 
in plasticity of the rat amygdala and hippocampus." Learn Mem 12(5): 520-526. 
Scimemi, A. and J. S. Diamond (2012). "The number and organization of Ca2+ channels in 
the active zone shapes neurotransmitter release from Schaffer collateral synapses." Journal of 
Neuroscience 32(50): 18157-18176. 
Scoville, W. B. and B. Milner (1957). "Loss of recent memory after bilateral hippocampal 
lesions." Journal of neurology, neurosurgery, and psychiatry 20(1): 11. 
Seeley, W. W., R. K. Crawford, J. Zhou, B. L. Miller and M. D. Greicius (2009). 
"Neurodegenerative diseases target large-scale human brain networks." Neuron 62(1): 42-52. 
Selkoe, D. J. (2000). "Toward a comprehensive theory for Alzheimer's disease. Hypothesis: 
Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-­‐
protein." Annals of the New York Academy of Sciences 924(1): 17-25. 
Selkoe, D. J. (2002). "Alzheimer's disease is a synaptic failure." Science 298(5594): 789-791. 
Serrano-Pozo, A., M. P. Frosch, E. Masliah and B. T. Hyman (2011). "Neuropathological 
alterations in Alzheimer disease." Cold Spring Harbor perspectives in medicine 1(1): a006189. 
Serrano-Pozo, A., M. L. Mielke, T. Gómez-Isla, R. A. Betensky, J. H. Growdon, M. P. Frosch 
and B. T. Hyman (2011). "Reactive glia not only associates with plaques but also parallels 
tangles in Alzheimer's disease." The American journal of pathology 179(3): 1373-1384. 
Shaftel, S. S., S. Kyrkanides, J. A. Olschowka, H. M. Jen-nie, R. E. Johnson and M. K. 
O’Banion (2007). "Sustained hippocampal IL-1β overexpression mediates chronic 
neuroinflammation and ameliorates Alzheimer plaque pathology." The Journal of clinical 
investigation 117(6): 1595-1604. 
Shankar, G. M., B. L. Bloodgood, M. Townsend, D. M. Walsh, D. J. Selkoe and B. L. 
Sabatini (2007). "Natural oligomers of the Alzheimer amyloid-beta protein induce reversible 
	    	  
164	  	  
synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling 
pathway." J Neurosci 27(11): 2866-2875. 
Shankar, G. M., S. Li, T. H. Mehta, A. Garcia-Munoz, N. E. Shepardson, I. Smith, F. M. Brett, 
M. A. Farrell, M. J. Rowan and C. A. Lemere (2008). "Amyloid-β protein dimers isolated 
directly from Alzheimer's brains impair synaptic plasticity and memory." Nature medicine 
14(8): 837. 
Sharma, G. and S. Vijayaraghavan (2003). "Modulation of presynaptic store calcium induces 
release of glutamate and postsynaptic firing." neuron 38(6): 929-939. 
Shen, Y., R. Li, E. G. McGeer and P. L. McGeer (1997). "Neuronal expression of mRNAs for 
complement proteins of the classical pathway in Alzheimer brain." Brain research 769(2): 
391-395. 
Sheng, M., B. L. Sabatini and T. C. Sudhof (2012). "Synapses and Alzheimer's disease." Cold 
Spring Harb Perspect Biol 4(5). 
Sheng, W. S., S. Hu, F. H. Kravitz, P. K. Peterson and C. C. Chao (1995). "Tumor necrosis 
factor alpha upregulates human microglial cell production of interleukin-10 in vitro." Clin. 
Diagn. Lab. Immunol. 2(5): 604-608. 
Shi, C.-S., K. Shenderov, N.-N. Huang, J. Kabat, M. Abu-Asab, K. A. Fitzgerald, A. Sher and 
J. H. Kehrl (2012). "Activation of autophagy by inflammatory signals limits IL-1β production 
by targeting ubiquitinated inflammasomes for destruction." Nature immunology 13(3): 255. 
Shi, J., J. Johansson, N. S. Woodling, Q. Wang, T. J. Montine and K. Andreasson (2010). 
"The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain 
innate immunity." The Journal of Immunology 184(12): 7207-7218. 
Shi, J., Q. Wang, J. U. Johansson, X. Liang, N. S. Woodling, P. Priyam, T. M. Loui, M. 
Merchant, R. M. Breyer and T. J. Montine (2012). "Inflammatory prostaglandin E2 signaling 
in a mouse model of Alzheimer disease." Annals of neurology 72(5): 788-798. 
Shie, F. S., K. S. Montine, R. M. Breyer and T. J. Montine (2005). "Microglial EP2 as a New 
Target to Increase Amyloid β Phagocytosis and Decrease Amyloid β-­‐Induced Damage to 
Neurons." Brain pathology 15(2): 134-138. 
Shilling, D., M. Müller, H. Takano, D.-O. D. Mak, T. Abel, D. A. Coulter and J. K. Foskett 
(2014). "Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-
linked familial Alzheimer's disease pathogenesis." Journal of Neuroscience 34(20): 6910-
6923. 
Shirotani, K., S. Tsubuki, N. Iwata, Y. Takaki, W. Harigaya, K. Maruyama, S. Kiryu-Seo, H. 
Kiyama, H. Iwata, T. Tomita, T. Iwatsubo and T. C. Saido (2001). "Neprilysin degrades both 
amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and 
phosphoramidon-sensitive endopeptidases." J Biol Chem 276(24): 21895-21901. 
Shyu, B.-C. and B. A. Vogt (2009). "Short-term synaptic plasticity in the nociceptive 
thalamic-anterior cingulate pathway." Molecular pain 5(1): 51. 
Sierra, A., O. Abiega, A. Shahraz and H. Neumann (2013). "Janus-faced microglia: beneficial 
and detrimental consequences of microglial phagocytosis." Frontiers in cellular neuroscience 
7: 6. 
Silva, A. J., T. W. Rosahl, P. F. Chapman, Z. Marowitz, E. Friedman, P. W. Frankland, V. 
Cestari, D. Cioffi, T. C. Südhof and R. Bourtchuladze (1996). "Impaired learning in mice with 
abnormal short-lived plasticity." Current Biology 6(11): 1509-1518. 
	    	  
165	  	  
Simard, A. R., D. Soulet, G. Gowing, J.-P. Julien and S. Rivest (2006). "Bone marrow-
derived microglia play a critical role in restricting senile plaque formation in Alzheimer's 
disease." Neuron 49(4): 489-502. 
Sinforiani, E., A. Citterio, C. Zucchella, G. Bono, S. Corbetta, P. Merlo and M. Mauri (2010). 
"Impact of gender differences on the outcome of Alzheimer’s disease." Dementia and 
Geriatric Cognitive Disorders 30(2): 147-154. 
Sippy, T., A. Cruz-Martín, A. Jeromin and F. E. Schweizer (2003). "Acute changes in short-
term plasticity at synapses with elevated levels of neuronal calcium sensor-1." Nature 
neuroscience 6(10): 1031. 
Smith, W. L., L. J. Marnett and D. L. DeWitt (1991). "Prostaglandin and thromboxane 
biosynthesis." Pharmacology & therapeutics 49(3): 153-179. 
Snyder, E. M., Y. Nong, C. G. Almeida, S. Paul, T. Moran, E. Y. Choi, A. C. Nairn, M. W. 
Salter, P. J. Lombroso and G. K. Gouras (2005). "Regulation of NMDA receptor trafficking 
by amyloid-β." Nature neuroscience 8(8): 1051. 
Sofroniew, M. V. and H. V. Vinters (2010). "Astrocytes: biology and pathology." Acta 
neuropathologica 119(1): 7-35. 
Soininen, H., C. West, J. Robbins and L. Niculescu (2007). "Long-term efficacy and safety of 
celecoxib in Alzheimer’s disease." Dementia and geriatric cognitive disorders 23(1): 8-21. 
Song, X., M. Ø. Jensen, V. Jogini, R. A. Stein, C.-H. Lee, H. S. Mchaourab, D. E. Shaw and 
E. Gouaux (2018). "Mechanism of NMDA receptor channel block by MK-801 and 
memantine." Nature 556(7702): 515. 
Song, Y., T. Cui, N. Xie, X. Zhang, Z. Qian and J. Liu (2014). "Protocatechuic acid improves 
cognitive deficits and attenuates amyloid deposits, inflammatory response in aged AβPP/PS1 
double transgenic mice." International Immunopharmacology 20(1): 276-281. 
Sperling, R. A., P. S. Laviolette, K. O'Keefe, J. O'Brien, D. M. Rentz, M. Pihlajamaki, G. 
Marshall, B. T. Hyman, D. J. Selkoe, T. Hedden, R. L. Buckner, J. A. Becker and K. A. 
Johnson (2009). "Amyloid deposition is associated with impaired default network function in 
older persons without dementia." Neuron 63(2): 178-188. 
Spires-Jones, T. L. and B. T. Hyman (2014). "The intersection of amyloid beta and tau at 
synapses in Alzheimer’s disease." Neuron 82(4): 756-771. 
Srivareerat, M., T. T. Tran, K. H. Alzoubi and K. A. Alkadhi (2009). "Chronic psychosocial 
stress exacerbates impairment of cognition and long-term potentiation in beta-amyloid rat 
model of Alzheimer's disease." Biol Psychiatry 65(11): 918-926. 
Srivareerat, M., T. T. Tran, S. Salim, A. M. Aleisa and K. A. Alkadhi (2011). "Chronic 
nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment 
in Abeta rat model of Alzheimer's disease." Neurobiol Aging 32(5): 834-844. 
Stamford, A. and C. Strickland (2013). "Inhibitors of BACE for treating Alzheimer's disease: 
a fragment-based drug discovery story." Current opinion in chemical biology 17(3): 320-328. 
Stence, N., M. Waite and M. E. Dailey (2001). "Dynamics of microglial activation: A 
confocal time-­‐lapse analysis in hippocampal slices." Glia 33(3): 256-266. 
Stephan, K. E., T. Baldeweg and K. J. Friston (2006). "Synaptic plasticity and dysconnection 
in schizophrenia." Biological psychiatry 59(10): 929-939. 
	    	  
166	  	  
Stewart, W. F., C. Kawas, M. Corrada and E. J. Metter (1997). "Risk of Alzheimer's disease 
and duration of NSAID use." Neurology 48(3): 626-632. 
Stockburger, C., D. Miano, T. Pallas, K. Friedland and W. E. Müller (2016). "Enhanced 
neuroplasticity by the metabolic enhancer piracetam associated with improved mitochondrial 
dynamics and altered permeability transition pore function." Neural plasticity 2016. 
Storm-Mathisen, J. (1981). "Glutamate in hippocampal pathways." Advances in biochemical 
psychopharmacology 27: 43-55. 
Strohmeyer, R., Y. Shen and J. Rogers (2000). "Detection of complement alternative pathway 
mRNA and proteins in the Alzheimer’s disease brain." Molecular Brain Research 81(1-2): 7-
18. 
Stutzmann, G. E., I. Smith, A. Caccamo, S. Oddo, F. M. LaFerla and I. Parker (2006). 
"Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, 
and aged Alzheimer's disease mice." Journal of Neuroscience 26(19): 5180-5189. 
Südhof, T. C. (2008). "Neuroligins and neurexins link synaptic function to cognitive disease." 
Nature 455(7215): 903. 
Sun, J.-Y., X.-S. Wu and L.-G. Wu (2002). "Single and multiple vesicle fusion induce 
different rates of endocytosis at a central synapse." Nature 417(6888): 555. 
Sung, S., H. Yang, K. Uryu, E. B. Lee, L. Zhao, D. Shineman, J. Q. Trojanowski, V. M.-Y. 
Lee and D. Pratico (2004). "Modulation of nuclear factor-κB activity by indomethacin 
influences Aβ levels but not Aβ precursor protein metabolism in a model of Alzheimer's 
disease." The American journal of pathology 165(6): 2197-2206. 
Sutinen, E. M., T. Pirttiläˆ, G. Anderson, A. Salminen and J. O. Ojala (2012). "Pro-
inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production 
in human neuron-like cells." Journal of neuroinflammation 9(1): 199. 
Swanson, E., L. Breckenridge, L. McMahon, S. Som, I. McConnell and G. S. Bloom (2017). 
"Extracellular tau oligomers induce invasion of endogenous tau into the somatodendritic 
compartment and axonal transport dysfunction." Journal of Alzheimer's Disease 58(3): 803-
820. 
Sydow, A., A. Van der Jeugd, F. Zheng, T. Ahmed, D. Balschun, O. Petrova, D. Drexler, L. 
Zhou, G. Rune and E. Mandelkow (2011). "Tau-induced defects in synaptic plasticity, 
learning, and memory are reversible in transgenic mice after switching off the toxic Tau 
mutant." Journal of Neuroscience 31(7): 2511-2525. 
Szaniszlo, P., P. German, G. Hajas, D. N. Saenz, M. Kruzel and I. Boldogh (2009). "New 
insights into clinical trial for Colostrinin in Alzheimer's disease." J Nutr Health Aging 13(3): 
235-241. 
Szekely, C., R. Green, J. Breitner, T. Østbye, A. Beiser, M. Corrada, H. Dodge, M. Ganguli, 
C. Kawas and L. Kuller (2008). "No advantage of Aβ42-lowering NSAIDs for prevention of 
Alzheimer dementia in six pooled cohort studies." Neurology 70(24): 2291-2298. 
Szekely, C. and P. Zandi (2010). "Non-steroidal anti-inflammatory drugs and Alzheimer's 
disease: the epidemiological evidence." CNS & Neurological Disorders-Drug Targets 
(Formerly Current Drug Targets-CNS & Neurological Disorders) 9(2): 132-139. 
Tachida, Y., K. Nakagawa, T. Saito, T. C. Saido, T. Honda, Y. Saito, S. Murayama, T. Endo, 
G. Sakaguchi and A. Kato (2008). "Interleukin-­‐1β up-­‐regulates TACE to enhance α-­‐cleavage 
	    	  
167	  	  
of APP in neurons: resulting decrease in Aβ production." Journal of neurochemistry 104(5): 
1387-1393. 
Tai, H.-C., A. Serrano-Pozo, T. Hashimoto, M. P. Frosch, T. L. Spires-Jones and B. T. 
Hyman (2012). "The synaptic accumulation of hyperphosphorylated tau oligomers in 
Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system." The 
American journal of pathology 181(4): 1426-1435. 
Tai, H.-C., A. Serrano-Pozo, T. Hashimoto, M. P. Frosch, T. L. Spires-Jones and B. T. 
Hyman (2012). "The synaptic accumulation of hyperphosphorylated tau oligomers in 
Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system." The 
American journal of pathology 181(4): 1426-1435. 
Tamagno, E., P. Bardini, A. Obbili, A. Vitali, R. Borghi, D. Zaccheo, M. A. Pronzato, O. 
Danni, M. A. Smith and G. Perry (2002). "Oxidative stress increases expression and activity 
of BACE in NT2 neurons." Neurobiology of disease 10(3): 279-288. 
Tampi, R. R. and C. H. van Dyck (2007). "Memantine: efficacy and safety in mild-to-severe 
Alzheimer’s disease." Neuropsychiatric Disease and Treatment 3(2): 245. 
Tan, L., H. Yang, W. Pang, H. Li, W. Liu, S. Sun, N. Song, W. Zhang and Y. Jiang (2017). 
"Investigation on the Role of BDNF in the Benefits of Blueberry Extracts for the 
Improvement of Learning and Memory in Alzheimer’s Disease Mouse Model." Journal of 
Alzheimer's Disease 56(2): 629-640. 
Tan, M.-S., J.-T. Yu, T. Jiang, X.-C. Zhu, H.-S. Guan and L. Tan (2014). "IL12/23 p40 
inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in 
SAMP8 mice." Journal of Alzheimer's Disease 38(3): 633-646. 
Tanila, H., P. Sipilä, M. Shapiro and H. Eichenbaum (1997). "Brain aging: impaired coding of 
novel environmental cues." Journal of Neuroscience 17(13): 5167-5174. 
Taniuchi, N., T. Niidome, Y. Goto, A. Akaike, T. Kihara and H. Sugimoto (2007). 
"Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic 
mice." Neuroreport 18(17): 1801-1805. 
Tanzi, R., R. Moir and S. Wagner (2004). "Clearance of Alzheimer's Aβ peptide: the many 
roads to perdition." Neuron 43(5): 605-608. 
Tarkowski, E., N. Andreasen, A. Tarkowski and K. Blennow (2003). "Intrathecal 
inflammation precedes development of Alzheimer’s disease." Journal of Neurology, 
Neurosurgery & Psychiatry 74(9): 1200-1205. 
Taube, J. and P. A. Schwartzkroin (1988). "Mechanisms of long-term potentiation: 
EPSP/spike dissociation, intradendritic recordings, and glutamate sensitivity." Journal of 
Neuroscience 8(5): 1632-1644. 
Tchélingérian, J. L., F. Le Saux and C. Jacque (1996). "Identification and topography of 
neuronal cell populations expressing; TNFα and IL-­‐1α in response to hippocampal lesion." 
Journal of neuroscience research 43(1): 99-106. 
Terry, R. D., A. Peck, R. DeTeresa, R. Schechter and D. S. Horoupian (1981). "Some 
morphometric aspects of the brain in senile dementia of the Alzheimer type." Annals of 
Neurology: Official Journal of the American Neurological Association and the Child 
Neurology Society 10(2): 184-192. 
Teyler, T. J., R. M. Vardaris, D. Lewis and A. B. Rawitch (1980). "Gonadal steroids: effects 
on excitability of hippocampal pyramidal cells." Science 209(4460): 1017-1018. 
	    	  
168	  	  
Thal, L. J., S. H. Ferris, L. Kirby, G. A. Block, C. R. Lines, E. Yuen, C. Assaid, M. L. Nessly, 
B. A. Norman and C. C. Baranak (2005). "A randomized, double-blind, study of rofecoxib in 
patients with mild cognitive impairment." Neuropsychopharmacology 30(6): 1204. 
Thathiah, A. and B. De Strooper (2011). "The role of G protein-coupled receptors in the 
pathology of Alzheimer's disease." Nature Reviews Neuroscience 12(2): 73. 
Thenmozhi, A. J., T. Manivasagam and M. M. Essa (2016). Role of plant polyphenols in 
Alzheimer’s disease. The Benefits of Natural Products for Neurodegenerative Diseases, 
Springer: 153-171. 
Theunis, C., N. Crespo-Biel, V. Gafner, M. Pihlgren, M. P. López-Deber, P. Reis, D. T. 
Hickman, O. Adolfsson, N. Chuard and D. M. Ndao (2013). "Efficacy and safety of a 
liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model 
tauopathy." PLoS One 8(8): e72301. 
Thomson, C. A., A. McColl, J. Cavanagh and G. J. Graham (2014). "Peripheral inflammation 
is associated with remote global gene expression changes in the brain." Journal of 
neuroinflammation 11(1): 73. 
Tong, L., G. A. Prieto, E. A. Kramár, E. D. Smith, D. H. Cribbs, G. Lynch and C. W. Cotman 
(2012). "Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by 
interleukin-1β via p38 mitogen-activated protein kinase." Journal of Neuroscience 32(49): 
17714-17724. 
Toni, N., E. M. Teng, E. A. Bushong, J. B. Aimone, C. Zhao, A. Consiglio, H. van Praag, M. 
E. Martone, M. H. Ellisman and F. H. Gage (2007). "Synapse formation on neurons born in 
the adult hippocampus." Nature neuroscience 10(6): 727. 
Tooyama, I., H. Kimura, H. Akiyama and P. McGeer (1990). "Reactive microglia express 
class I and class II major histocompatibility complex antigens in Alzheimer's disease." Brain 
research 523(2): 273-280. 
Tremblay, M.-È., B. Stevens, A. Sierra, H. Wake, A. Bessis and A. Nimmerjahn (2011). "The 
role of microglia in the healthy brain." Journal of Neuroscience 31(45): 16064-16069. 
Trommer, B. L., C. Shah, S. H. Yun, G. Gamkrelidze, E. S. Pasternak, W. B. Stine, A. 
Manelli, P. Sullivan, J. F. Pasternak and M. J. LaDu (2005). "ApoE isoform-specific effects 
on LTP: blockade by oligomeric amyloid-β1–42." Neurobiology of disease 18(1): 75-82. 
Trussell, L. O., S. Zhang and I. M. Ramant (1993). "Desensitization of AMPA receptors upon 
multiquantal neurotransmitter release." Neuron 10(6): 1185-1196. 
Tuppo, E. E. and H. R. Arias (2005). "The role of inflammation in Alzheimer's disease." The 
international journal of biochemistry & cell biology 37(2): 289-305. 
Turrigiano, G. G., K. R. Leslie, N. S. Desai, L. C. Rutherford and S. B. Nelson (1998). 
"Activity-dependent scaling of quantal amplitude in neocortical neurons." Nature 391(6670): 
892. 
Tyler, W. J. and L. D. Pozzo-Miller (2001). "BDNF enhances quantal neurotransmitter release 
and increases the number of docked vesicles at the active zones of hippocampal excitatory 
synapses." Journal of Neuroscience 21(12): 4249-4258. 
U Johansson, J., N. S Woodling, J. Shi and K. I Andreasson (2015). "Inflammatory 
cyclooxygenase activity and PGE2 signaling in models of Alzheimer’s disease." Current 
immunology reviews 11(2): 125-131. 
	    	  
169	  	  
Udeochu, J. C., J. M. Shea and S. A. Villeda (2016). "Microglia communication: parallels 
between aging and Alzheimer's disease." Clinical and Experimental Neuroimmunology 7(2): 
114-125. 
Van Dam, D., K. Coen and P. De Deyn (2010). "Ibuprofen modifies cognitive disease 
progression in an Alzheimer’s mouse model." Journal of Psychopharmacology 24(3): 383-388. 
Van de Veerdonk, F. L., M. G. Netea, C. A. Dinarello and L. A. Joosten (2011). 
"Inflammasome activation and IL-1β and IL-18 processing during infection." Trends in 
immunology 32(3): 110-116. 
Van Harreveld, A. and E. Fifkova (1975). "Swelling of dendritic spines in the fascia dentata 
after stimulation of the perforant fibers as a mechanism of post-tetanic potentiation." 
Experimental neurology 49(3): 736-749. 
Varga, E., G. Juhasz, Z. Bozso, B. Penke, L. Fulop and V. Szegedi (2014). "Abeta(1-42) 
enhances neuronal excitability in the CA1 via NR2B subunit-containing NMDA receptors." 
Neural Plast 2014: 584314. 
Varga, E., G. Juhász, Z. Bozsó, B. Penke, L. Fülöp and V. Szegedi (2015). "Amyloid-β 1-42 
Disrupts Synaptic Plasticity by Altering Glutamate Recycling at the Synapse." Journal of 
Alzheimer's Disease 45(2): 449-456. 
Vazdarjanova, A. and J. F. Guzowski (2004). "Differences in hippocampal neuronal 
population responses to modifications of an environmental context: evidence for distinct, yet 
complementary, functions of CA3 and CA1 ensembles." Journal of Neuroscience 24(29): 
6489-6496. 
Vereker, E., E. O'Donnell and M. Lynch (2000). "The inhibitory effect of interleukin-1β on 
long-term potentiation is coupled with increased activity of stress-activated protein kinases." 
Journal of Neuroscience 20(18): 6811-6819. 
Vidensky, S., Y. Zhang, T. Hand, J. Goellner, A. Shaffer, P. Isakson and K. Andreasson 
(2003). "Neuronal overexpression of COX-2 results in dominant production of PGE 2 and 
altered fever response." Neuromolecular medicine 3(1): 15-27. 
Vlad, S. C., D. R. Miller, N. W. Kowall and D. T. Felson (2008). "Protective effects of 
NSAIDs on the development of Alzheimer disease." Neurology 70(19): 1672-1677. 
Vom Berg, J., S. Prokop, K. R. Miller, J. Obst, R. E. Kälin, I. Lopategui-Cabezas, A. Wegner, 
F. Mair, C. G. Schipke and O. Peters (2012). "Inhibition of IL-12/IL-23 signaling reduces 
Alzheimer's disease–like pathology and cognitive decline." Nature medicine 18(12): 1812. 
von Bernhardi, R., G. Ramírez, R. Toro and J. Eugenín (2007). "Pro-inflammatory conditions 
promote neuronal damage mediated by Amyloid Precursor Protein and decrease its 
phagocytosis and degradation by microglial cells in culture." Neurobiology of disease 26(1): 
153-164. 
von Strauss, E., M. Viitanen, D. De Ronchi, B. Winblad and L. Fratiglioni (1999). "Aging and 
the Occurrence of Dementia: Findings From a Population-Based Cohort With a Large Sample 
of Nonagenarians." JAMA Neurology 56(5): 587-592. 
Wadiche, J. I. and C. E. Jahr (2001). "Multivesicular release at climbing fiber-Purkinje cell 
synapses." Neuron 32(2): 301-313. 
Wagner, U., M. Utton, J.-M. Gallo and C. Miller (1996). "Cellular phosphorylation of tau by 
GSK-3 beta influences tau binding to microtubules and microtubule organisation." Journal of 
cell science 109(6): 1537-1543. 
	    	  
170	  	  
Wang, H.-W., J. F. Pasternak, H. Kuo, H. Ristic, M. P. Lambert, B. Chromy, K. L. Viola, W. 
L. Klein, W. B. Stine and G. A. Krafft (2002). "Soluble oligomers of β amyloid (1-42) inhibit 
long-term potentiation but not long-term depression in rat dentate gyrus." Brain research 
924(2): 133-140. 
Wang, J., L. Tan, H.-F. Wang, C.-C. Tan, X.-F. Meng, C. Wang, S.-W. Tang and J.-T. Yu 
(2015). "Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic 
review and meta-analysis." Journal of Alzheimer's Disease 44(2): 385-396. 
Wang, J., H. Tanila, J. Puoliväli, I. Kadish and T. van Groen (2003). "Gender differences in 
the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice." 
Neurobiology of disease 14(3): 318-327. 
Wang, Q., M. J. Rowan and R. Anwyl (2004). "β-amyloid-mediated inhibition of NMDA 
receptor-dependent long-term potentiation induction involves activation of microglia and 
stimulation of inducible nitric oxide synthase and superoxide." Journal of Neuroscience 
24(27): 6049-6056. 
Wang, S., H. Yang, L. Yu, J. Jin, L. Qian, H. Zhao, Y. Xu and X. Zhu (2014). "Oridonin 
attenuates Aβ1–42-induced neuroinflammation and inhibits NF-κB pathway." PloS one 9(8): 
e104745. 
Warren, S. G., A. G. Humphreys, J. M. Juraska and W. T. Greenough (1995). "LTP varies 
across the estrous cycle: enhanced synaptic plasticity in proestrus rats." Brain research 703(1-
2): 26-30. 
Wathey, J. C., W. W. Lytton, J. M. Jester and T. J. Sejnowski (1992). "Computer simulations 
of EPSP-spike (ES) potentiation in hippocampal CA1 pyramidal cells." Journal of 
Neuroscience 12(2): 607-618. 
Watt, A. J., M. C. van Rossum, K. M. MacLeod, S. B. Nelson and G. G. Turrigiano (2000). 
"Activity coregulates quantal AMPA and NMDA currents at neocortical synapses." Neuron 
26(3): 659-670. 
Weggen, S., J. L. Eriksen, P. Das, S. A. Sagi, R. Wang, C. U. Pietrzik, K. A. Findlay, T. E. 
Smith, M. P. Murphy and T. Bulter (2001). "A subset of NSAIDs lower amyloidogenic Aβ42 
independently of cyclooxygenase activity." Nature 414(6860): 212. 
Wei, S.-Q., W. Fraser and Z.-C. Luo (2010). "Inflammatory cytokines and spontaneous 
preterm birth in asymptomatic women: a systematic review." Obstetrics & Gynecology 
116(2): 393-401. 
Welch, J. M., J. Lu, R. M. Rodriguiz, N. C. Trotta, J. Peca, J.-D. Ding, C. Feliciano, M. Chen, 
J. P. Adams and J. Luo (2007). "Cortico-striatal synaptic defects and OCD-like behaviours in 
Sapap3-mutant mice." Nature 448(7156): 894. 
West, M. J., P. D. Coleman, D. G. Flood and J. C. Troncoso (1994). "Differences in the 
pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease." The Lancet 
344(8925): 769-772. 
White, W. F., J. V. Nadler, A. Hamberger, C. W. Cotman and J. T. CUMMINS (1977). 
"Glutamate as transmitter of hippocampal perforant path." Nature 270(5635): 356. 
Willshaw, D. J., O. P. Buneman and H. C. Longuet-Higgins (1969). "Non-holographic 
associative memory." Nature 222(5197): 960. 
Wilson, I. A., S. Ikonen, M. Gallagher, H. Eichenbaum and H. Tanila (2005). "Age-associated 
alterations of hippocampal place cells are subregion specific." J Neurosci 25(29): 6877-6886. 
	    	  
171	  	  
Wilson, I. A., S. Ikonen, I. Gureviciene, R. W. McMahan, M. Gallagher, H. Eichenbaum and 
H. Tanila (2004). "Cognitive aging and the hippocampus: how old rats represent new 
environments." J Neurosci 24(15): 3870-3878. 
Wilson, I. A., S. Ikonen, R. W. McMahan, M. Gallagher, H. Eichenbaum and H. Tanila 
(2003). "Place cell rigidity correlates with impaired spatial learning in aged rats." Neurobiol 
Aging 24(2): 297-305. 
Wischik, C., M. Novak, H. Thøgersen, P. Edwards, M. Runswick, R. Jakes, J. Walker, C. 
Milstein, M. Roth and A. Klug (1988). "Isolation of a fragment of tau derived from the core 
of the paired helical filament of Alzheimer disease." Proceedings of the National Academy of 
Sciences 85(12): 4506-4510. 
Witton, J., J. T. Brown, M. W. Jones and A. D. Randall (2010). "Altered synaptic plasticity in 
the mossy fibre pathway of transgenic mice expressing mutant amyloid precursor protein." 
Molecular brain 3(1): 32. 
Wong, M. and R. L. Moss (1992). "Long-term and short-term electrophysiological effects of 
estrogen on the synaptic properties of hippocampal CA1 neurons." Journal of neuroscience 
12(8): 3217-3225. 
Woodling, N. S., Q. Wang, P. G. Priyam, P. Larkin, J. Shi, J. U. Johansson, I. Zagol-Ikapitte, 
O. Boutaud and K. I. Andreasson (2014). "Suppression of Alzheimer-associated inflammation 
by microglial prostaglandin-E2 EP4 receptor signaling." Journal of Neuroscience 34(17): 
5882-5894. 
Wu, J., R. Anwyl and M. J. Rowan (1995). "beta-Amyloid selectively augments NMDA 
receptor-mediated synaptic transmission in rat hippocampus." Neuroreport 6(17): 2409-2413. 
Wu, J. W., M. Herman, L. Liu, S. Simoes, C. M. Acker, H. Figueroa, J. I. Steinberg, M. 
Margittai, R. Kayed and C. Zurzolo (2013). "Small misfolded Tau species are internalized via 
bulk endocytosis and anterogradely and retrogradely transported in neurons." Journal of 
Biological Chemistry 288(3): 1856-1870. 
Xia, D., C. Li and J. Götz (2015). "Pseudophosphorylation of Tau at distinct epitopes or the 
presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic 
spines." Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852(5): 913-924. 
Xu-Friedman, M. A. and W. G. Regehr (2003). "Ultrastructural contributions to 
desensitization at cerebellar mossy fiber to granule cell synapses." Journal of Neuroscience 
23(6): 2182-2192. 
Yan, R., Q. Fan, J. Zhou and R. Vassar (2016). "Inhibiting BACE1 to reverse synaptic 
dysfunctions in Alzheimer’s disease." Neuroscience & Biobehavioral Reviews 65: 326-340. 
Yang, H. and C. Chen (2008). "Cyclooxygenase-2 in synaptic signaling." Current 
pharmaceutical design 14(14): 1443-1451. 
Yang, J.-T., Z.-J. Wang, H.-Y. Cai, L. Yuan, M.-M. Hu, M.-N. Wu and J.-S. Qi (2018). "Sex 
differences in neuropathology and cognitive behavior in APP/PS1/tau triple-transgenic mouse 
model of Alzheimer’s disease." Neuroscience bulletin 34(5): 736-746. 
Yasojima, K., C. Schwab, E. G. McGeer and P. L. McGeer (1999). "Distribution of 
cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral 
organs." Brain research 830(2): 226-236. 
	    	  
172	  	  
Yasojima, K., C. Schwab, E. G. McGeer and P. L. McGeer (2000). "Human neurons generate 
C-reactive protein and amyloid P: upregulation in Alzheimer’s disease." Brain research 
887(1): 80-89. 
Ye, H., S. Jalini, S. Mylvaganam and P. Carlen (2010). "Activation of large-conductance 
Ca(2+)-activated K(+) channels depresses basal synaptic transmission in the hippocampal 
CA1 area in APP (swe/ind) TgCRND8 mice." Neurobiol Aging 31(4): 591-604. 
Yin, Y., D. Gao, Y. Wang, Z.-H. Wang, X. Wang, J. Ye, D. Wu, L. Fang, G. Pi and Y. Yang 
(2016). "Tau accumulation induces synaptic impairment and memory deficit by calcineurin-
mediated inactivation of nuclear CaMKIV/CREB signaling." Proceedings of the National 
Academy of Sciences 113(26): E3773-E3781. 
Yoshihara, M., A. Ueda, D. Zhang, D. L. Deitcher, T. L. Schwarz and Y. Kidokoro (1999). 
"Selective effects of neuronal-synaptobrevin mutations on transmitter release evoked by 
sustained versus transient Ca2+ increases and by cAMP." Journal of Neuroscience 19(7): 
2432-2441. 
Yun, H.-M., K.-R. Park, E.-C. Kim, S. Kim and J. T. Hong (2015). "Serotonin 6 receptor 
controls Alzheimer’s disease and depression." Oncotarget 6(29): 26716. 
Zhang, G. and R. W. Stackman Jr (2015). "The role of serotonin 5-HT2A receptors in 
memory and cognition." Frontiers in pharmacology 6: 225. 
Zhang, M., J. Li, P. Chakrabarty, B. Bu and I. Vincent (2004). "Cyclin-dependent kinase 
inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor 
defects in Niemann-Pick Type C mice." The American journal of pathology 165(3): 843-853. 
Zhang, W. and D. J. Linden (2003). "The other side of the engram: experience-driven changes 
in neuronal intrinsic excitability." Nat Rev Neurosci 4(11): 885-900. 
Zhang, Y., P. Li, J. Feng and M. Wu (2016). "Dysfunction of NMDA receptors in 
Alzheimer’s disease." Neurological Sciences 37(7): 1039-1047. 
Zhang, Y., L. Shan, Y. Hua, D. Wang, H. Zeng, R. Liu, W. Zhang and Z. Hu (2013). 
"Baicalein selectively induces apoptosis in activated lymphocytes and ameliorates 
concanavalin a-induced hepatitis in mice." PLoS One 8(7): e69592. 
Zhao, J., T. O'Connor and R. Vassar (2011). "The contribution of activated astrocytes to Aβ 
production: implications for Alzheimer's disease pathogenesis." Journal of neuroinflammation 
8(1): 150. 
Zhao, X., L. A. Kotilinek, B. Smith, C. Hlynialuk, K. Zahs, M. Ramsden, J. Cleary and K. H. 
Ashe (2016). "Caspase-2 cleavage of tau reversibly impairs memory." Nature medicine 
22(11): 1268. 
Zhao, Y., C. V. Dayas, H. Aujla, M. A. Baptista, R. Martin-Fardon and F. Weiss (2006). 
"Activation of group II metabotropic glutamate receptors attenuates both stress and cue-
induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala." 
Journal of Neuroscience 26(39): 9967-9974. 
Zhen, G., Y. T. Kim, R.-c. Li, J. Yocum, N. Kapoor, J. Langer, P. Dobrowolski, T. Maruyama, 
S. Narumiya and S. Doré (2012). "PGE2 EP1 receptor exacerbated neurotoxicity in a mouse 
model of cerebral ischemia and Alzheimer's disease." Neurobiology of aging 33(9): 2215-
2219. 
	    	  
173	  	  
Zhou, L., J. McInnes, K. Wierda, M. Holt, A. G. Herrmann, R. J. Jackson, Y.-C. Wang, J. 
Swerts, J. Beyens and K. Miskiewicz (2017). "Tau association with synaptic vesicles causes 
presynaptic dysfunction." Nature communications 8: 15295. 
Zhu, J., Q. Yang, D. Dai and Q. Huang (2013). "X-ray crystal structure of phosphodiesterase 
2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket 
important for selectivity." Journal of the American Chemical Society 135(32): 11708-11711. 
Zhu, M., X. Wang, L. Sun, M. Schultzberg and E. Hjorth (2018). "Can inflammation be 
resolved in Alzheimer’s disease?" Therapeutic advances in neurological disorders 11: 
1756286418791107. 
Zorec, R., A. Horvat, N. Vardjan and A. Verkhratsky (2015). "Memory formation shaped by 
astroglia." Frontiers in integrative neuroscience 9: 56. 
Zucker, R. S. and W. G. Regehr (2002). "Short-term synaptic plasticity." Annual review of 
physiology 64(1): 355-405. 
 
 
 
 
La	  maladie	  d'Alzheimer	  est	  une	  maladie	  neurodégénérative	  dépendante	  de	  l'âge	  qui	  est	  principalement	  caractérisée	  par	  des	  déficits	  cognitifs	  dans	  les	  stades	  précoces	  liés	  à	  un	  dysfonctionnement	  synaptique	  et	  à	  une	  perte	  de	  synapses	  (Selkoe,	  2002;	  Jacobsen	  et	  al.,	  2006;	   Scheff	   et	   al.,	   2006;	   Sheng	   et	   al.,	   2012).	   De	   nombreuses	   études	   de	   la	   littérature	  montrent	   qu'il	   existe	   un	   dimorphisme	   sexuel	   important	   s'exprimant	   par	   un	   dépôt	   de	  plaques	   amyloïdes	   plus	   important	   et	   une	   apparition	   plus	   précoce	   de	   troubles	   de	   la	  mémoire	  chez	  les	  souris	  femelles	  par	  rapport	  aux	  souris	  mâles	  (Gresack	  et	  Frick,	  2003;	  Clinton	  et	  al.,	  2007;	  Taniuchi	  et	  al.,	  2007;	  Gallagher	  et	  al.,	  2013;	  Richetin	  et	  al.,	  2017).	  	  Le	  peptide	  β-­‐amyloïde	  (Aβ)	  revêt	  une	  importance	  primordiale	  dans	  la	  pathogenèse	  de	  la	  maladie	   d'Alzheimer	   (Hardy	   et	  al.,	   1992).	   Dans	   ce	   travail,	   nous	   avons	  montré	   que	   les	  plaques	  Aβ	  apparaissent	  plus	   tôt	  et	  sont	  plus	  nombreuses	  chez	   les	  souris	   femelles	  par	  rapport	   aux	   souris	   mâles	   et	   que	   parallèlement,	   des	   troubles	   cognitifs	   dépendants	   de	  l'hippocampe	   (conditionnement	   de	   la	   peur	   contextuelle	   et	   tâche	   de	   localisation	   de	  l'objet)	  	  apparaissent	  dès	  l'âge	  de	  4	  mois	  chez	  les	  souris	  femelles	  APP	  /	  PS1	  alors	  que	  les	  souris	  mâles	  ne	  montrent	  aucun	  déficits	  jusqu'à	  l'âge	  de	  12	  mois.	  	  	  D'autre	   part,	   de	   nombreux	   travaux	   montrent	   que	   la	   neuroinflammation,	   portée	   par	  l'activation	   des	   cellules	   microgliales,	   des	   astrocytes	   et	   des	   neurones	   à	   proximité	   des	  plaques	   amyloïdes	   (Hoozemans	   et	   al.,	   2008),	   est	   une	   composante	   importante	   de	   la	  maladie	  d'Alzheimer	  notamment	  en	  stimulant	  en	  retour	  la	  production	  d'Aβ	  (Hoshino	  et	  
al.,	  2007,	  2009).	  Dans	  cette	  étude,	  nous	  avons	  montré	  une	  forte	  activation	  des	  astrocytes	  et	  des	  cellules	  de	  la	  microglie	  au	  voisinage	  des	  plaques	  amyloïdes.	  	  Parmi	  les	  molécules	  neuroinflammatoires	  produites	  au	  cours	  de	  la	  maladie	  d'Alzheimer,	  la	  prostaglandine	  E2	  (PGE2)	  joue	  un	  rôle	  majeur	  (Combrinck	  et	  al.,	  2006;	  Wei	  et	  al.,	  2010;	  Shi	   et	   al.,	   2012).	   La	   PGE2	   est	   produite	   à	   partir	   de	   l'acide	   arachidonique	   par	   deux	  enzymes	  limitantes,	  Cox-­‐1	  et	  Cox-­‐2,	  et	  agit	  sur	  quatre	  sous-­‐types	  de	  récepteurs,	  à	  savoir	  EP1,	   EP2,	   EP3	   et	   EP4.	   Dans	   une	   étude	   précédente,	   nous	   avions	   démontré	   que	   la	  Potentialisation	   présynaptique	   à	   Long	   Terme	   (PLT)	   des	   synapses	   fibres	   moussues	   -­‐	  neurones	   CA3	   de	   l'hippocampe	   était	   altérée	   chez	   les	   souris	  mâles	   APP/PS1	   en	   raison	  d'une	  augmentation	  de	  la	  concentration	  hippocampale	  de	  PGE2	  et	  de	  l'engagement	  d'une	  voie	   de	   signalisation	   PGE2-­‐EP3	   (Maingret	   et	   al.,	   2017).	   L'hippocampe	   est	   l'une	   des	  premières	   régions	   du	   cerveau	   touchées	   par	   la	   maladie	   d'Alzheimer	   (Arriagada	   et	   al.,	  1992).	   Dans	   l'hippocampe,	   les	   synapses	   fibres	   moussues	   -­‐	   neurones	   CA3	   sont	   des	  composantes	  importantes	  de	  la	  circuiterie	  excitatrice	  de	  l'hippocampe.	  Ces	  synapses	  ont	  une	   taille	   relativement	   importante	   et	   expriment	   plusieurs	   propriétés	   plastiques	   et	   de	  transmission	   uniques,	   notamment	   la	   facilitation	   par	   stimulation	   pairées,	   la	   facilitation	  fréquence-­‐dépendante	  et	  une	  PLT	  d'origine	  présynaptique.	  Il	  est	  généralement	  accepté	  que	  la	  PLT	  est	  un	  substrat	  moléculaire	  de	  la	  mémoire	  et	  soit	   impliquée	  dans	  le	  codage	  rapide	   de	   nouvelles	   mémoires	   (Kesner,	   2007),	   un	   processus	   mnémonique	  particulièrement	  affecté	  dans	  la	  maladie	  d'Alzheimer.	  Par	  conséquent,	  nous	  avons	  étudié	  la	   PLT	   présynaptique	   aux	   synapses	   fibres	   moussues	   -­‐	   neurones	   CA3	   chez	   les	   souris	  femelles	   APP/PS1	   à	   4	   et	   6	   mois,	   un	   âge	   pour	   lequel	   des	   changements	   cellulaires	   et	  comportementaux	   sont	   déjà	   présents.	   De	  manière	   inattendue,	   la	   PLT	   présynaptique	   à	  cette	  synapse	  n'est	  pas	  altérée	  chez	  les	  souris	  femelles	  APP/PS1.	  	  Ayant	  observé	  un	  dépôt	  accru	  de	  plaques	  amyloïdes	  à	  proximité	  du	  gyrus	  dentelé	  chez	  les	   souris	   femelles	  APP/PS1,	   nous	   avons	   alors	   étudié	   la	   transmission	   synaptique	   et	   la	  
plasticité	   aux	   synapses	   voie	   perforante	   -­‐	   neurones	   granulaires	   du	  gyrus	  dentelé.	  Dans	  l'hippocampe	  de	  rongeur,	  les	  projections	  de	  la	  voie	  perforante	  en	  provenance	  du	  cortex	  entorhinal	  dans	  le	  gyrus	  dentelé	  sont	  impliquées	  dans	  les	  phénomènes	  de	  séparation	  des	  des	   traces	  mnésiques,	   de	   l'information	   spatiale	   et	   du	   codage	   de	   la	  mémoire	   (Rolls	   et	  Kesner,	   2006;	   Leutgeb	   et	  al.,	   2007;	  Hunsaker	   et	  al.,	   2007;	   Sahay	   et	  al.,	   2011).	   La	   voie	  perforante	  est	  subdivisée	  entre	  la	  voie	  latérale	  et	   la	  voie	  médiale	  (McNaughton,	  1980).	  Sur	   la	   base	   de	   l’emplacement	   de	   l’électrode	   de	   stimulation	   et	   des	   critères	  électrophysiologiques	  (facilitation	  vs	  dépression	  de	  stimulations	  pairées),	  il	  est	  possible	  de	   distinguer	   la	   voie	   latérale	   de	   la	   voie	  médiale.	  Nous	   avons	   focalisé	   notre	   étude	   à	   la	  synapse	   voie	   latérale	   -­‐	   neurones	   granulaires	   du	   gyrus	   dentelé	   sur	   les	   souris	   femelles	  sauvages	  vs	  APP/PS1	  âgées	  de	  6	  mois.	  	  	  Nous	   avons	   d’abord	   observé	   que	   la	   facilitation	   par	   stimulations	   pairées	   (plasticité	  présynaptique	   liée	   à	   la	   probabilité	   de	   libération	   du	   neurotransmetteur	   dans	   la	   fente	  synaptique)	  était	  similaire	  pour	  les	  souris	  femelles	  sauvages	  et	  APP/PS1	  à	  6	  mois.	  	  	  La	  relation	  entrée/sortie	  (amplitude	  du	  "Population	  Spike"	  (PS)	  par	  rapport	  à	  l'intensité	  de	  la	  stimulation)	  est	  affectée	  chez	  les	  souris	  APP/PS1	  par	  rapport	  aux	  souris	  sauvages.	  Un	   protocole	   de	   stimulation	   à	   haute	   fréquence	   déclenche	   une	   potentialisation	   à	   long	  terme	   (PLT)	   de	   l'amplitude	   du	   PS	   chez	   les	   souris	   sauvages.	   Cette	   PLT	   est	   totalement	  bloquée	  par	  le	  D-­‐AP5	  (antagoniste	  des	  récepteurs	  NMDA).	  De	  manière	  remarquable,	   la	  PLT	  est	  partiellement	  réduite	  chez	  les	  souris	  femelles	  APP/PS1	  à	  6	  mois.	  Cependant	  ni	  PGE2	  ni	  l’activation	  sélective	  des	  différents	  sous-­‐types	  de	  récepteurs	  EP	  (EP2,	  EP3,	  EP4)	  ne	   réduisent	   la	   PLT	   à	   cette	   synapse	   chez	   les	   souris	   sauvages	   et	   d'autre	   part	   ne	   sont	  impliqués	  dans	  la	  réduction	  de	  la	  PLT	  chez	  les	  souris	  femelles	  APP/PS1	  à	  6	  mois.	  	  	  	  Nous	   avons	   alors	   étudié	   l’hypothèse	  de	   changements	   dans	   les	   propriétés	   intrinsèques	  des	   cellules	   granulaires	   du	  gyrus	  dentelé	   (mécanismes	   non	   synaptiques)	   pouvant	   être	  impliqués	   dans	   la	   réduction	   de	   la	   PLT	   chez	   les	   souris	   femelles	   APP/PS1.	   Pour	   tester	  cette	  hypothèse,	  nous	  avons	  enregistré	  par	  la	  technique	  de	  "patch	  clamp"	  les	  propriétés	  intrinsèques	   des	   cellules	   granulaires	   du	   gyrus	   dentelé.	   Un	   échelon	   de	   potentiel	  dépolarisant	  de	  longue	  durée	  (250	  ms)	  déclenche	  un	  train	  de	  potentiels	  d'action	  (PAs)	  qui	  présente	  un	  plus	  grand	  nombre	  de	  PAs	  pour	  les	  souris	  femelles	  APP/PS1	  par	  rapport	  aux	  souris	  femelles	  sauvages	  ce	  qui	  révèle	  une	  augmentation	  de	  l'excitabilité	  des	  cellules	  granulaires	   du	   gyrus	   dentelé.	  De	   nombreux	   travaux	   font	   état	   d'une	   augmentation	   de	  l'excitabilité	  neuronale	  liée	  à	  une	  accumulation	  d'Aβ	  (Buckner	  et	  al.,	  2005;	  Mintun	  et	  al.,	  2006;	  Seeley	  et	  al.,	  2009;	  Sperling	  et	  al.,	  2009).	  	  Nous	  avons	  également	  caractérisé	  deux	  types	  (type	  1	  et	  type	  2)	  de	  cellules	  granulaires	  du	  gyrus	  dentelé	  en	  fonction	  du	  patron	  de	  décharge	  des	  PAs	  et	  de	  la	  résistance	  d'entrée	  spécifique	  et	  ceci	  pour	  les	  deux	  génotypes	  (sauvage	  vs	  APP/PS1).	  En	  revanche	  d'autres	  propriétés	   intrinsèques	   (potentiel	   membranaire	   de	   repos,	   amplitude	   du	   PA,	   seuil	   de	  déclenchement	   du	   potentiel	   d'action...)	   des	   cellules	   granulaires	   du	   gyrus	   dentelé	   sont	  similaires	  pour	  les	  deux	  génotypes.	  	  Au	  niveau	  synaptique,	  nous	  avons	  étudié	   la	   courbe	  E-­‐S,	  qui	   relie	   la	  pente	  du	  Potentiel	  Excitateur	   Post	   Synaptique	   (PEPS)	   à	   la	   probabilité	   de	   déclenchement	   d'un	   potentiel	  d'action.	  Nous	  n'avons	  observé	  aucune	  modification	  significative	  de	  la	  courbe	  E-­‐S	  entre	  les	   souris	   femelles	   sauvages	   et	   APP/PS1	   qui	   pourrait	   expliquer	   les	   modifications	   de	  
l'excitabilité	  intrinsèque.	  Cependant,	  l'application	  d'une	  stimulation	  haute	  fréquence	  qui	  déclenche	   une	   PLT	   provoque	   un	   déplacement	   de	   la	   courbe	   E-­‐S	   qui	   traduit	   une	  augmentation	   supérieure	   d'excitabilité	   pour	   les	   souris	   femelles	   APP/PS1	   vs	   sauvages.	  Ces	   résultats	   indiquent	   que	   la	   potentialisation	   synaptique	   induit	   un	   changement	  d'excitabilité	   intrinséque	   des	   cellules	   granulaires	   du	   gyrus	   dentelé	   dépendant	   du	  génotype.	  	  Nous	   avons	   donc	   ensuite	   analysé	   la	   possibilité	   que	   l'augmentation	   d'excitabilité	  présentée	  par	  les	  cellules	  granulaires	  du	  gyrus	  dentelé	  puisse	  résulter	  de	  modifications	  de	   l'intégration	   dendritique.	   Une	   façon	   d'étudier	   l'intégration	   dendritique	   consiste	   à	  établir	  le	  rapport	  amplitude/pente	  du	  PEPS	  au	  cours	  des	  deux	  premières	  millisecondes,	  c'est-­‐à-­‐dire	   lorsqu'il	   reflète	   principalement	   la	   composante	   rapide	   de	   la	   transmission	  synaptique	  des	  récepteurs	  AMPA	  (Lopez	  et	  al.,	  2016).	  	  	  Le	   rapport	   amplitude/pente	   PEPS	   est	   similaire	   pour	   les	   deux	   génotypes	   mais	   nous	  avons	  observé	  une	  différence	  significative	  dans	  le	  rapport	  amplitude/pente	  PEPS	  avant	  et	   après	   PLT	   pour	   les	   souris	   femelles	   APP/PS1	   mais	   pas	   pour	   les	   souris	   femelles	  suavages.	  Ces	  résultats	  suggérent	  que	  des	  modifications	  du	  traitement	  dendritique	  des	  entrées	   synaptiques	   dans	   les	   cellules	   granulaires	   du	   gyrus	   dentelé	   chez	   les	   souris	  femelles	  APP/PS1	  pourraient	  soutendrent	  des	  modifications	  de	  l'excitabilité.	  	  	  La	  diminution	  de	  PLT	  observée	  chez	  les	  souris	  femelles	  APP/PS1	  pourrait	  être	  due	  à	  une	  diminution	  de	  la	  probabilité	  de	  libération	  du	  neurotransmetteur,	  à	  une	  diminution	  de	  la	  fiabilité	   ou	   du	   poids	   des	   synapses	   individuelles,	   à	   une	   diminution	   du	   nombre	   de	  synapses	   ou	   de	   récepteurs	   fonctionnels.	   De	   façon	   remarquable	   les	   oligomères	   Aβ	  activent	  une	  voie	  de	  signalisation	  dépendante	  des	  récepteurs	  NMDA	  qui	  conduit	  à	  une	  diminution	   de	   la	   PLT	   hippocampale	   par	   internalisation	   des	   récepteurs	   synaptiques	  AMPA	  et	  NMDA	  (Kamenetz	  et	  al.,	  2003;	  Kessels	  et	  al.,	  2013;	  Snyder	  et	  al.,	  2005	  ).	  Nous	  avons	  donc	  mesuré	  le	  rapport	  AMPA/NMDA	  pour	  évaluer	  cette	  possibilité,	  mais	  n’avons	  observé	  aucun	  changement	  de	  ce	  rapport	  entre	  les	  souris	  femelles	  sauvages	  et	  APP/PS1	  à	  6	  mois.	  	  	  Nous	   avons	   également	   étudié	   les	   courants	   synaptiques	   excitateurs	   miniatures	   des	  cellules	  granulaires.	  Il	  est	  généralement	  décrit	  que	  l’amplitude	  des	  courants	  miniatures	  est	   reliée	  à	  des	  évènements	  postsynaptiques	  quand	   leur	   fréquence	  est	   attribuée	  à	  des	  mécanismes	  présynaptiques	  (Turrigiano	  et	  al.,	  1998;	  Kim	  and	  Tsien,	  2008;	  Ardiles	  et	  al.,	  2012)	   bien	   qu'une	   diminution	   de	   la	   fréquence	   puisse	   également	   être	   liée	   à	   une	  diminution	   du	   nombre	   de	   synapses	   fonctionnelles.	   Les	   résultats	   montrent	   une	  augmentation	  de	  la	  fréquence	  des	  courants	  miniatures	  médiés	  par	  les	  récepteurs	  NMDA	  dans	   les	   cellules	   granulaires	   du	   gyrus	   dentelé	   chez	   les	   souris	   femelles	   APP/PS1	   par	  rapport	  aux	  souris	  femelles	  sauvages.	  Cette	  augmentation	  de	  la	  fréquence	  des	  courants	  miniatures	  NMDA	  pourrait	  être	  due	  à	  un	  nombre	  de	  synapses	  silencieuses	  (c'est	  à	  dire	  dépourvues	   de	   recepteurs	   AMPA)	   supérieur	   chez	   les	   souris	   femelles	   APP/PS1	   par	  rapport	  aux	  souris	  femelles	  sauvages.	  En	  revanche,	  l'amplitude	  des	  courants	  miniatures	  AMPA	  ou	  NMDA	  n'est	  pas	  significativement	  modifié	  par	  le	  génotype.	  	  	  En	  conclusion,	   l'ensemble	  de	  ce	  travail	  montre	  qu'il	  existe	  des	  différences	   importantes	  liées	  au	  sexe	  avec	  un	  dépôt	  plus	   fort	  et	  précoce	  de	  plaques	  amyloïdes,	   	  une	  activation	  gliale	   neuro-­‐inflammatoire	   plus	   importante	   associée	   à	   des	   déficits	   précoces	   de	   la	  
mémoire	  dépendante	  de	  l'hippocampe	  chez	  les	  souris	  femelles	  APP/PS1	  vs	  souris	  mâles	  APP/PS1.	  En	  parallèle	  de	  ces	  altérations	  moléculaires,	  cellulaires	  et	  comportementales,	  nous	  observons	  des	  déficits	  de	  la	  transmission	  et	  de	  la	  plasticité	  synaptique	  à	  la	  synapse	  voie	  perforante	  -­‐	  cellules	  granulaires	  du	  gyrus	  dentelé	  (voie	  d'entrée	  des	  informations	  en	  provenance	  du	  cortex	  entorhinal)	  ainsi	  qu'une	  modification	  des	  propriétés	  intrinséques	  des	  cellules	  granulaires.	  	  	  	  	  
